{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "66edfd29-dde3-44ed-826f-624f69437608",
   "metadata": {},
   "source": [
    "### Using LLamaIndex to Evaluate Correctness"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "6c0cdf15-3a6f-49fa-a6f7-831977284783",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-08-27T19:26:41.021815Z",
     "iopub.status.busy": "2024-08-27T19:26:41.021224Z",
     "iopub.status.idle": "2024-08-27T19:27:04.348183Z",
     "shell.execute_reply": "2024-08-27T19:27:04.346142Z",
     "shell.execute_reply.started": "2024-08-27T19:26:41.021769Z"
    }
   },
   "outputs": [],
   "source": [
    "import os\n",
    "from llama_index.core.evaluation import CorrectnessEvaluator\n",
    "from llama_index.llms.openai import OpenAI\n",
    "import asyncio\n",
    "import pandas as pd\n",
    "import nest_asyncio\n",
    "from tqdm import tqdm\n",
    "import time\n",
    "\n",
    "llm = OpenAI(\"gpt-4o\")\n",
    "evaluator = CorrectnessEvaluator(llm=llm)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "6519ac9c-a714-4328-996b-c3869982a0a0",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-08-27T00:54:39.008638Z",
     "iopub.status.busy": "2024-08-27T00:54:39.007667Z",
     "iopub.status.idle": "2024-08-27T00:54:39.100445Z",
     "shell.execute_reply": "2024-08-27T00:54:39.099720Z",
     "shell.execute_reply.started": "2024-08-27T00:54:39.008589Z"
    },
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pair</th>\n",
       "      <th>subj_name</th>\n",
       "      <th>obj_name</th>\n",
       "      <th>pmid</th>\n",
       "      <th>pmid_text</th>\n",
       "      <th>source</th>\n",
       "      <th>first_year</th>\n",
       "      <th>label</th>\n",
       "      <th>context_pmids</th>\n",
       "      <th>path</th>\n",
       "      <th>llm_response_bl</th>\n",
       "      <th>jaccard_index_score_bl</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>385</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carbopla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3658706', 'C0278579'): ['34345644', '35031...</td>\n",
       "      <td>[C3658706, C0278579, C4724800]</td>\n",
       "      <td>To describe an indirect relationship between p...</td>\n",
       "      <td>0.042857</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carbopla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3658706', 'C4704928'): ['29500171', '28946...</td>\n",
       "      <td>[C3658706, C4704928, C0278579, C4724800]</td>\n",
       "      <td>Based on the provided abstract, an indirect re...</td>\n",
       "      <td>0.032258</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carbopla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3658706', 'C4704928'): ['33983696', '34956...</td>\n",
       "      <td>[C3658706, C4704928, C4724800]</td>\n",
       "      <td>An indirect relationship between pembrolizumab...</td>\n",
       "      <td>0.031250</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carbopla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3658706', 'C1367202'): ['27764796', '28881...</td>\n",
       "      <td>[C3658706, C1367202, C4288736, C4724800]</td>\n",
       "      <td>An indirect relationship between pembrolizumab...</td>\n",
       "      <td>0.029851</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carbopla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3658706', 'C2935436'): ['29881714', '34829...</td>\n",
       "      <td>[C3658706, C2935436, C4288736, C4724800]</td>\n",
       "      <td>An indirect relationship between pembrolizumab...</td>\n",
       "      <td>0.030769</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carbopla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3658706', 'C2982078'): ['30859062'], ('C29...</td>\n",
       "      <td>[C3658706, C2982078, C4288736, C4724800]</td>\n",
       "      <td>An indirect relationship between pembrolizumab...</td>\n",
       "      <td>0.029412</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>383</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Tr...</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3467876', 'C0265325'): ['26141621'], ('C02...</td>\n",
       "      <td>[C3467876, C0265325, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib...</td>\n",
       "      <td>0.028169</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>383</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Tr...</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3467876', 'C2697961'): ['32774277'], ('C26...</td>\n",
       "      <td>[C3467876, C2697961, C0265325, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib...</td>\n",
       "      <td>0.041096</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>383</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Tr...</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C1415138'): ['23432625'], ('C14...</td>\n",
       "      <td>[C3467876, C1415138, C0169658, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib...</td>\n",
       "      <td>0.027778</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>383</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Tr...</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C4519250'): ['33991955'], ('C45...</td>\n",
       "      <td>[C3467876, C4519250, C3853694, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib...</td>\n",
       "      <td>0.028169</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>383</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Tr...</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C1333650'): ['27188223', '24504...</td>\n",
       "      <td>[C3467876, C1333650, C0812222, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib...</td>\n",
       "      <td>0.027027</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382</th>\n",
       "      <td>C3467876 C4086264</td>\n",
       "      <td>entrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Tr...</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3467876', 'C3658706'): ['33657824', '30009...</td>\n",
       "      <td>[C3467876, C3658706, C2697961, C4086264]</td>\n",
       "      <td>An indirect relationship between entrectinib a...</td>\n",
       "      <td>0.028169</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382</th>\n",
       "      <td>C3467876 C4086264</td>\n",
       "      <td>entrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Tr...</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C2743752'): ['27797970'], ('C27...</td>\n",
       "      <td>[C3467876, C2743752, C0812222, C4086264]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.027778</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382</th>\n",
       "      <td>C3467876 C4086264</td>\n",
       "      <td>entrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Tr...</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C0242275'): ['33159968'], ('C02...</td>\n",
       "      <td>[C3467876, C0242275, C0812222, C4086264]</td>\n",
       "      <td>Based on the provided scientific abstracts, an...</td>\n",
       "      <td>0.041667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382</th>\n",
       "      <td>C3467876 C4086264</td>\n",
       "      <td>entrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Tr...</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C0042682'): ['35379272'], ('C00...</td>\n",
       "      <td>[C3467876, C0042682, C0012373, C4086264]</td>\n",
       "      <td>An indirect relationship between entrectinib a...</td>\n",
       "      <td>0.027397</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>380</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Manageme...</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2718773', 'C1609165'): ['32552266', '23729...</td>\n",
       "      <td>[C2718773, C1609165, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab a...</td>\n",
       "      <td>0.038961</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>380</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Manageme...</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2718773', 'C1609165'): ['34698811', '25061...</td>\n",
       "      <td>[C2718773, C1609165, C4044947, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab a...</td>\n",
       "      <td>0.025000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>380</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Manageme...</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2718773', 'C4044947'): ['34868553'], ('C40...</td>\n",
       "      <td>[C2718773, C4044947, C4683810]</td>\n",
       "      <td>Based on the provided scientific abstracts, an...</td>\n",
       "      <td>0.027027</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>380</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Manageme...</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2718773', 'C0674428'): ['19536362'], ('C06...</td>\n",
       "      <td>[C2718773, C0674428, C0028978, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab a...</td>\n",
       "      <td>0.040000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>380</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Manageme...</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2718773', 'C1424250'): ['32623652', '31504...</td>\n",
       "      <td>[C2718773, C1424250, C1335226, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab a...</td>\n",
       "      <td>0.025974</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>380</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Manageme...</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2718773', 'C0010980'): ['29478243'], ('C00...</td>\n",
       "      <td>[C2718773, C0010980, C0026056, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab a...</td>\n",
       "      <td>0.027027</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>379</th>\n",
       "      <td>C2716282 C3886682</td>\n",
       "      <td>gambogenic acid</td>\n",
       "      <td>ACTA2 protein, human</td>\n",
       "      <td>35994849</td>\n",
       "      <td>Gambogenic acid alleviates kidney fibrosis via...</td>\n",
       "      <td>sr_pred_sent_11</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2716282', 'C1172384'): ['34859108', '31579...</td>\n",
       "      <td>[C2716282, C1172384, C3886682]</td>\n",
       "      <td>Based on the provided abstract, we can infer a...</td>\n",
       "      <td>0.027027</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>379</th>\n",
       "      <td>C2716282 C3886682</td>\n",
       "      <td>gambogenic acid</td>\n",
       "      <td>ACTA2 protein, human</td>\n",
       "      <td>35994849</td>\n",
       "      <td>Gambogenic acid alleviates kidney fibrosis via...</td>\n",
       "      <td>sr_pred_sent_11</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2716282', 'C0009968'): ['27036009', '26446...</td>\n",
       "      <td>[C2716282, C0009968, C0291573, C3886682]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.040541</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>379</th>\n",
       "      <td>C2716282 C3886682</td>\n",
       "      <td>gambogenic acid</td>\n",
       "      <td>ACTA2 protein, human</td>\n",
       "      <td>35994849</td>\n",
       "      <td>Gambogenic acid alleviates kidney fibrosis via...</td>\n",
       "      <td>sr_pred_sent_11</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2716282', 'C0055661'): ['26780233', '30634...</td>\n",
       "      <td>[C2716282, C0055661, C0291573, C3886682]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.040541</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>379</th>\n",
       "      <td>C2716282 C3886682</td>\n",
       "      <td>gambogenic acid</td>\n",
       "      <td>ACTA2 protein, human</td>\n",
       "      <td>35994849</td>\n",
       "      <td>Gambogenic acid alleviates kidney fibrosis via...</td>\n",
       "      <td>sr_pred_sent_11</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2716282', 'C1421313'): ['27124181', '28683...</td>\n",
       "      <td>[C2716282, C1421313, C0291573, C3886682]</td>\n",
       "      <td>To describe an indirect relationship between g...</td>\n",
       "      <td>0.066667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>378</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 k...</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2698841', 'C1421500'): ['26885445', '35159...</td>\n",
       "      <td>[C2698841, C1421500, C4053677]</td>\n",
       "      <td>To describe an indirect relationship between A...</td>\n",
       "      <td>0.046512</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>378</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 k...</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2698841', 'C0971285'): ['31832331', '35159...</td>\n",
       "      <td>[C2698841, C0971285, C4053677]</td>\n",
       "      <td>Based on the provided scientific abstracts, an...</td>\n",
       "      <td>0.034884</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>378</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 k...</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2698841', 'C0971285'): ['35159005', '31832...</td>\n",
       "      <td>[C2698841, C0971285, C0290178, C4053677]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.036585</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>378</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 k...</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2698841', 'C1333655'): ['31122263'], ('C13...</td>\n",
       "      <td>[C2698841, C1333655, C0525037, C4053677]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.034884</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>378</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 k...</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2698841', 'C0079419'): ['31227645'], ('C00...</td>\n",
       "      <td>[C2698841, C0079419, C4053677]</td>\n",
       "      <td>An indirect relationship between AZD-1775 and ...</td>\n",
       "      <td>0.024096</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>378</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 k...</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2698841', 'C0249197'): ['24660103'], ('C02...</td>\n",
       "      <td>[C2698841, C0249197, C3853822, C4053677]</td>\n",
       "      <td>Based on the provided scientific abstracts, an...</td>\n",
       "      <td>0.036145</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2316164', 'C0278987'): ['33070053', '34701...</td>\n",
       "      <td>[C2316164, C0278987, C4080091]</td>\n",
       "      <td>To describe an indirect relationship between o...</td>\n",
       "      <td>0.053763</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2316164', 'C0278987'): ['33070053', '34701...</td>\n",
       "      <td>[C2316164, C0278987, C3818721, C4080091]</td>\n",
       "      <td>Based on the provided abstract, an indirect re...</td>\n",
       "      <td>0.023810</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2316164', 'C3818721'): ['32224911', '34810...</td>\n",
       "      <td>[C2316164, C3818721, C4080091]</td>\n",
       "      <td>An indirect relationship between olaparib and ...</td>\n",
       "      <td>0.034091</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2316164', 'C0672708'): ['29902865', '25888...</td>\n",
       "      <td>[C2316164, C0672708, C1420703, C4080091]</td>\n",
       "      <td>An indirect relationship between olaparib and ...</td>\n",
       "      <td>0.022222</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2316164', 'C3501358'): ['31974435', '29575...</td>\n",
       "      <td>[C2316164, C3501358, C0007131, C4080091]</td>\n",
       "      <td>Based on the provided scientific abstract, an ...</td>\n",
       "      <td>0.022222</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorla...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2316164', 'C0000970'): ['34111734'], ('C00...</td>\n",
       "      <td>[C2316164, C0000970, C1333573, C4080091]</td>\n",
       "      <td>An indirect relationship between olaparib and ...</td>\n",
       "      <td>0.021978</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>374</th>\n",
       "      <td>C1456409 C4519220</td>\n",
       "      <td>etravirine</td>\n",
       "      <td>fostemsavir</td>\n",
       "      <td>35315687</td>\n",
       "      <td>Pharmacokinetics of Temsavir, the Active Moiet...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1456409', 'C0292818'): ['25397525', '20236...</td>\n",
       "      <td>[C1456409, C0292818, C0012133, C4519220]</td>\n",
       "      <td>An indirect relationship between etravirine an...</td>\n",
       "      <td>0.035714</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>374</th>\n",
       "      <td>C1456409 C4519220</td>\n",
       "      <td>etravirine</td>\n",
       "      <td>fostemsavir</td>\n",
       "      <td>35315687</td>\n",
       "      <td>Pharmacokinetics of Temsavir, the Active Moiet...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1456409', 'C0027794'): ['25937791'], ('C00...</td>\n",
       "      <td>[C1456409, C0027794, C0001175, C4519220]</td>\n",
       "      <td>An indirect relationship between etravirine an...</td>\n",
       "      <td>0.036585</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>374</th>\n",
       "      <td>C1456409 C4519220</td>\n",
       "      <td>etravirine</td>\n",
       "      <td>fostemsavir</td>\n",
       "      <td>35315687</td>\n",
       "      <td>Pharmacokinetics of Temsavir, the Active Moiet...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1456409', 'C0033308'): ['19088949'], ('C00...</td>\n",
       "      <td>[C1456409, C0033308, C3496793, C4519220]</td>\n",
       "      <td>An indirect relationship between etravirine an...</td>\n",
       "      <td>0.023256</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>374</th>\n",
       "      <td>C1456409 C4519220</td>\n",
       "      <td>etravirine</td>\n",
       "      <td>fostemsavir</td>\n",
       "      <td>35315687</td>\n",
       "      <td>Pharmacokinetics of Temsavir, the Active Moiet...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1456409', 'C1176309'): ['19557204'], ('C11...</td>\n",
       "      <td>[C1456409, C1176309, C0026256, C4519220]</td>\n",
       "      <td>An indirect relationship between etravirine an...</td>\n",
       "      <td>0.060241</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>373</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1453431', 'C0027055'): ['31632535', '33377...</td>\n",
       "      <td>[C1453431, C0027055, C1420201, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.032258</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>373</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1453431', 'C1412622'): ['28747345', '23979...</td>\n",
       "      <td>[C1453431, C1412622, C0027055, C3490348]</td>\n",
       "      <td>To describe an indirect relationship between t...</td>\n",
       "      <td>0.079365</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>373</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1453431', 'C1412617'): ['34112145', '31524...</td>\n",
       "      <td>[C1453431, C1412617, C1420201, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.031746</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>373</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1453431', 'C0054412'): ['32500147', '27872...</td>\n",
       "      <td>[C1453431, C0054412, C0005684, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.031746</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>373</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1453431', 'C0289313'): ['34235122', '29740...</td>\n",
       "      <td>[C1453431, C0289313, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.031746</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>373</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury...</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1453431', 'C1565860'): ['31264128', '29407...</td>\n",
       "      <td>[C1453431, C1565860, C0005684, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.031746</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>370</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic ...</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1425143', 'C4079830'): ['33082322', '32054...</td>\n",
       "      <td>[C1425143, C4079830, C4086509]</td>\n",
       "      <td>Based on the provided abstract, an indirect re...</td>\n",
       "      <td>0.030303</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>370</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic ...</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1425143', 'C1961099'): ['23410974', '25784...</td>\n",
       "      <td>[C1425143, C1961099, C4086509]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.028571</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>370</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic ...</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1425143', 'C4079830'): ['33082322', '32054...</td>\n",
       "      <td>[C1425143, C4079830, C1961099, C4086509]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.057971</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>370</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic ...</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1425143', 'C0049065'): ['32054729'], ('C00...</td>\n",
       "      <td>[C1425143, C0049065, C0020402, C4086509]</td>\n",
       "      <td>Based on the provided abstracts, an indirect r...</td>\n",
       "      <td>0.029412</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>370</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic ...</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1425143', 'C0021246'): ['32833426'], ('C00...</td>\n",
       "      <td>[C1425143, C0021246, C0020402, C4086509]</td>\n",
       "      <td>To describe an indirect relationship between t...</td>\n",
       "      <td>0.027027</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>370</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic ...</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1425143', 'C1417145'): ['34715892'], ('C14...</td>\n",
       "      <td>[C1425143, C1417145, C0020402, C4086509]</td>\n",
       "      <td>To describe an indirect relationship between t...</td>\n",
       "      <td>0.027778</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                  pair             subj_name              obj_name      pmid  \\\n",
       "385  C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "385  C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "385  C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "385  C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "385  C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "385  C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "383  C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "383  C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "383  C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "383  C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "383  C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "382  C3467876 C4086264           entrectinib            dabrafenib  35955671   \n",
       "382  C3467876 C4086264           entrectinib            dabrafenib  35955671   \n",
       "382  C3467876 C4086264           entrectinib            dabrafenib  35955671   \n",
       "382  C3467876 C4086264           entrectinib            dabrafenib  35955671   \n",
       "380  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "380  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "380  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "380  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "380  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "380  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "379  C2716282 C3886682       gambogenic acid  ACTA2 protein, human  35994849   \n",
       "379  C2716282 C3886682       gambogenic acid  ACTA2 protein, human  35994849   \n",
       "379  C2716282 C3886682       gambogenic acid  ACTA2 protein, human  35994849   \n",
       "379  C2716282 C3886682       gambogenic acid  ACTA2 protein, human  35994849   \n",
       "378  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "378  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "378  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "378  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "378  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "378  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "377  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "377  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "377  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "377  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "377  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "377  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "374  C1456409 C4519220            etravirine           fostemsavir  35315687   \n",
       "374  C1456409 C4519220            etravirine           fostemsavir  35315687   \n",
       "374  C1456409 C4519220            etravirine           fostemsavir  35315687   \n",
       "374  C1456409 C4519220            etravirine           fostemsavir  35315687   \n",
       "373  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "373  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "373  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "373  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "373  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "373  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "370  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "370  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "370  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "370  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "370  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "370  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "\n",
       "                                             pmid_text           source  \\\n",
       "385  Tisotumab Vedotin in Combination With Carbopla...       title_cooc   \n",
       "385  Tisotumab Vedotin in Combination With Carbopla...       title_cooc   \n",
       "385  Tisotumab Vedotin in Combination With Carbopla...       title_cooc   \n",
       "385  Tisotumab Vedotin in Combination With Carbopla...       title_cooc   \n",
       "385  Tisotumab Vedotin in Combination With Carbopla...       title_cooc   \n",
       "385  Tisotumab Vedotin in Combination With Carbopla...       title_cooc   \n",
       "383  The Role of Histology-Agnostic Drugs in the Tr...   sr_pred_sent_2   \n",
       "383  The Role of Histology-Agnostic Drugs in the Tr...   sr_pred_sent_2   \n",
       "383  The Role of Histology-Agnostic Drugs in the Tr...   sr_pred_sent_2   \n",
       "383  The Role of Histology-Agnostic Drugs in the Tr...   sr_pred_sent_2   \n",
       "383  The Role of Histology-Agnostic Drugs in the Tr...   sr_pred_sent_2   \n",
       "382  The Role of Histology-Agnostic Drugs in the Tr...   sr_pred_sent_2   \n",
       "382  The Role of Histology-Agnostic Drugs in the Tr...   sr_pred_sent_2   \n",
       "382  The Role of Histology-Agnostic Drugs in the Tr...   sr_pred_sent_2   \n",
       "382  The Role of Histology-Agnostic Drugs in the Tr...   sr_pred_sent_2   \n",
       "380  Targeting Specific Checkpoints in the Manageme...   sr_pred_sent_9   \n",
       "380  Targeting Specific Checkpoints in the Manageme...   sr_pred_sent_9   \n",
       "380  Targeting Specific Checkpoints in the Manageme...   sr_pred_sent_9   \n",
       "380  Targeting Specific Checkpoints in the Manageme...   sr_pred_sent_9   \n",
       "380  Targeting Specific Checkpoints in the Manageme...   sr_pred_sent_9   \n",
       "380  Targeting Specific Checkpoints in the Manageme...   sr_pred_sent_9   \n",
       "379  Gambogenic acid alleviates kidney fibrosis via...  sr_pred_sent_11   \n",
       "379  Gambogenic acid alleviates kidney fibrosis via...  sr_pred_sent_11   \n",
       "379  Gambogenic acid alleviates kidney fibrosis via...  sr_pred_sent_11   \n",
       "379  Gambogenic acid alleviates kidney fibrosis via...  sr_pred_sent_11   \n",
       "378  Polo-like kinase-1, Aurora kinase A and WEE1 k...   sr_pred_sent_5   \n",
       "378  Polo-like kinase-1, Aurora kinase A and WEE1 k...   sr_pred_sent_5   \n",
       "378  Polo-like kinase-1, Aurora kinase A and WEE1 k...   sr_pred_sent_5   \n",
       "378  Polo-like kinase-1, Aurora kinase A and WEE1 k...   sr_pred_sent_5   \n",
       "378  Polo-like kinase-1, Aurora kinase A and WEE1 k...   sr_pred_sent_5   \n",
       "378  Polo-like kinase-1, Aurora kinase A and WEE1 k...   sr_pred_sent_5   \n",
       "377  Rapid and durable response to fifth-line lorla...       title_cooc   \n",
       "377  Rapid and durable response to fifth-line lorla...       title_cooc   \n",
       "377  Rapid and durable response to fifth-line lorla...       title_cooc   \n",
       "377  Rapid and durable response to fifth-line lorla...       title_cooc   \n",
       "377  Rapid and durable response to fifth-line lorla...       title_cooc   \n",
       "377  Rapid and durable response to fifth-line lorla...       title_cooc   \n",
       "374  Pharmacokinetics of Temsavir, the Active Moiet...       title_cooc   \n",
       "374  Pharmacokinetics of Temsavir, the Active Moiet...       title_cooc   \n",
       "374  Pharmacokinetics of Temsavir, the Active Moiet...       title_cooc   \n",
       "374  Pharmacokinetics of Temsavir, the Active Moiet...       title_cooc   \n",
       "373  Empagliflozin alleviates myocardial I/R injury...       title_cooc   \n",
       "373  Empagliflozin alleviates myocardial I/R injury...       title_cooc   \n",
       "373  Empagliflozin alleviates myocardial I/R injury...       title_cooc   \n",
       "373  Empagliflozin alleviates myocardial I/R injury...       title_cooc   \n",
       "373  Empagliflozin alleviates myocardial I/R injury...       title_cooc   \n",
       "373  Empagliflozin alleviates myocardial I/R injury...       title_cooc   \n",
       "370  Idasanutlin and navitoclax induce synergistic ...   sr_pred_sent_4   \n",
       "370  Idasanutlin and navitoclax induce synergistic ...   sr_pred_sent_4   \n",
       "370  Idasanutlin and navitoclax induce synergistic ...   sr_pred_sent_4   \n",
       "370  Idasanutlin and navitoclax induce synergistic ...   sr_pred_sent_4   \n",
       "370  Idasanutlin and navitoclax induce synergistic ...   sr_pred_sent_4   \n",
       "370  Idasanutlin and navitoclax induce synergistic ...   sr_pred_sent_4   \n",
       "\n",
       "    first_year  label                                      context_pmids  \\\n",
       "385       2022      1  {('C3658706', 'C0278579'): ['34345644', '35031...   \n",
       "385       2022      1  {('C3658706', 'C4704928'): ['29500171', '28946...   \n",
       "385       2022      1  {('C3658706', 'C4704928'): ['33983696', '34956...   \n",
       "385       2022      0  {('C3658706', 'C1367202'): ['27764796', '28881...   \n",
       "385       2022      0  {('C3658706', 'C2935436'): ['29881714', '34829...   \n",
       "385       2022      0  {('C3658706', 'C2982078'): ['30859062'], ('C29...   \n",
       "383       2022      1  {('C3467876', 'C0265325'): ['26141621'], ('C02...   \n",
       "383       2022      1  {('C3467876', 'C2697961'): ['32774277'], ('C26...   \n",
       "383       2022      0  {('C3467876', 'C1415138'): ['23432625'], ('C14...   \n",
       "383       2022      0  {('C3467876', 'C4519250'): ['33991955'], ('C45...   \n",
       "383       2022      0  {('C3467876', 'C1333650'): ['27188223', '24504...   \n",
       "382       2022      1  {('C3467876', 'C3658706'): ['33657824', '30009...   \n",
       "382       2022      0  {('C3467876', 'C2743752'): ['27797970'], ('C27...   \n",
       "382       2022      0  {('C3467876', 'C0242275'): ['33159968'], ('C02...   \n",
       "382       2022      0  {('C3467876', 'C0042682'): ['35379272'], ('C00...   \n",
       "380       2022      1  {('C2718773', 'C1609165'): ['32552266', '23729...   \n",
       "380       2022      1  {('C2718773', 'C1609165'): ['34698811', '25061...   \n",
       "380       2022      1  {('C2718773', 'C4044947'): ['34868553'], ('C40...   \n",
       "380       2022      0  {('C2718773', 'C0674428'): ['19536362'], ('C06...   \n",
       "380       2022      0  {('C2718773', 'C1424250'): ['32623652', '31504...   \n",
       "380       2022      0  {('C2718773', 'C0010980'): ['29478243'], ('C00...   \n",
       "379       2022      1  {('C2716282', 'C1172384'): ['34859108', '31579...   \n",
       "379       2022      0  {('C2716282', 'C0009968'): ['27036009', '26446...   \n",
       "379       2022      0  {('C2716282', 'C0055661'): ['26780233', '30634...   \n",
       "379       2022      0  {('C2716282', 'C1421313'): ['27124181', '28683...   \n",
       "378       2022      1  {('C2698841', 'C1421500'): ['26885445', '35159...   \n",
       "378       2022      1  {('C2698841', 'C0971285'): ['31832331', '35159...   \n",
       "378       2022      1  {('C2698841', 'C0971285'): ['35159005', '31832...   \n",
       "378       2022      0  {('C2698841', 'C1333655'): ['31122263'], ('C13...   \n",
       "378       2022      0  {('C2698841', 'C0079419'): ['31227645'], ('C00...   \n",
       "378       2022      0  {('C2698841', 'C0249197'): ['24660103'], ('C02...   \n",
       "377       2022      1  {('C2316164', 'C0278987'): ['33070053', '34701...   \n",
       "377       2022      1  {('C2316164', 'C0278987'): ['33070053', '34701...   \n",
       "377       2022      1  {('C2316164', 'C3818721'): ['32224911', '34810...   \n",
       "377       2022      0  {('C2316164', 'C0672708'): ['29902865', '25888...   \n",
       "377       2022      0  {('C2316164', 'C3501358'): ['31974435', '29575...   \n",
       "377       2022      0  {('C2316164', 'C0000970'): ['34111734'], ('C00...   \n",
       "374       2022      1  {('C1456409', 'C0292818'): ['25397525', '20236...   \n",
       "374       2022      0  {('C1456409', 'C0027794'): ['25937791'], ('C00...   \n",
       "374       2022      0  {('C1456409', 'C0033308'): ['19088949'], ('C00...   \n",
       "374       2022      0  {('C1456409', 'C1176309'): ['19557204'], ('C11...   \n",
       "373       2022      1  {('C1453431', 'C0027055'): ['31632535', '33377...   \n",
       "373       2022      1  {('C1453431', 'C1412622'): ['28747345', '23979...   \n",
       "373       2022      1  {('C1453431', 'C1412617'): ['34112145', '31524...   \n",
       "373       2022      0  {('C1453431', 'C0054412'): ['32500147', '27872...   \n",
       "373       2022      0  {('C1453431', 'C0289313'): ['34235122', '29740...   \n",
       "373       2022      0  {('C1453431', 'C1565860'): ['31264128', '29407...   \n",
       "370       2023      1  {('C1425143', 'C4079830'): ['33082322', '32054...   \n",
       "370       2023      1  {('C1425143', 'C1961099'): ['23410974', '25784...   \n",
       "370       2023      1  {('C1425143', 'C4079830'): ['33082322', '32054...   \n",
       "370       2023      0  {('C1425143', 'C0049065'): ['32054729'], ('C00...   \n",
       "370       2023      0  {('C1425143', 'C0021246'): ['32833426'], ('C00...   \n",
       "370       2023      0  {('C1425143', 'C1417145'): ['34715892'], ('C14...   \n",
       "\n",
       "                                         path  \\\n",
       "385            [C3658706, C0278579, C4724800]   \n",
       "385  [C3658706, C4704928, C0278579, C4724800]   \n",
       "385            [C3658706, C4704928, C4724800]   \n",
       "385  [C3658706, C1367202, C4288736, C4724800]   \n",
       "385  [C3658706, C2935436, C4288736, C4724800]   \n",
       "385  [C3658706, C2982078, C4288736, C4724800]   \n",
       "383            [C3467876, C0265325, C4524315]   \n",
       "383  [C3467876, C2697961, C0265325, C4524315]   \n",
       "383  [C3467876, C1415138, C0169658, C4524315]   \n",
       "383  [C3467876, C4519250, C3853694, C4524315]   \n",
       "383  [C3467876, C1333650, C0812222, C4524315]   \n",
       "382  [C3467876, C3658706, C2697961, C4086264]   \n",
       "382  [C3467876, C2743752, C0812222, C4086264]   \n",
       "382  [C3467876, C0242275, C0812222, C4086264]   \n",
       "382  [C3467876, C0042682, C0012373, C4086264]   \n",
       "380            [C2718773, C1609165, C4683810]   \n",
       "380  [C2718773, C1609165, C4044947, C4683810]   \n",
       "380            [C2718773, C4044947, C4683810]   \n",
       "380  [C2718773, C0674428, C0028978, C4683810]   \n",
       "380  [C2718773, C1424250, C1335226, C4683810]   \n",
       "380  [C2718773, C0010980, C0026056, C4683810]   \n",
       "379            [C2716282, C1172384, C3886682]   \n",
       "379  [C2716282, C0009968, C0291573, C3886682]   \n",
       "379  [C2716282, C0055661, C0291573, C3886682]   \n",
       "379  [C2716282, C1421313, C0291573, C3886682]   \n",
       "378            [C2698841, C1421500, C4053677]   \n",
       "378            [C2698841, C0971285, C4053677]   \n",
       "378  [C2698841, C0971285, C0290178, C4053677]   \n",
       "378  [C2698841, C1333655, C0525037, C4053677]   \n",
       "378            [C2698841, C0079419, C4053677]   \n",
       "378  [C2698841, C0249197, C3853822, C4053677]   \n",
       "377            [C2316164, C0278987, C4080091]   \n",
       "377  [C2316164, C0278987, C3818721, C4080091]   \n",
       "377            [C2316164, C3818721, C4080091]   \n",
       "377  [C2316164, C0672708, C1420703, C4080091]   \n",
       "377  [C2316164, C3501358, C0007131, C4080091]   \n",
       "377  [C2316164, C0000970, C1333573, C4080091]   \n",
       "374  [C1456409, C0292818, C0012133, C4519220]   \n",
       "374  [C1456409, C0027794, C0001175, C4519220]   \n",
       "374  [C1456409, C0033308, C3496793, C4519220]   \n",
       "374  [C1456409, C1176309, C0026256, C4519220]   \n",
       "373  [C1453431, C0027055, C1420201, C3490348]   \n",
       "373  [C1453431, C1412622, C0027055, C3490348]   \n",
       "373  [C1453431, C1412617, C1420201, C3490348]   \n",
       "373  [C1453431, C0054412, C0005684, C3490348]   \n",
       "373            [C1453431, C0289313, C3490348]   \n",
       "373  [C1453431, C1565860, C0005684, C3490348]   \n",
       "370            [C1425143, C4079830, C4086509]   \n",
       "370            [C1425143, C1961099, C4086509]   \n",
       "370  [C1425143, C4079830, C1961099, C4086509]   \n",
       "370  [C1425143, C0049065, C0020402, C4086509]   \n",
       "370  [C1425143, C0021246, C0020402, C4086509]   \n",
       "370  [C1425143, C1417145, C0020402, C4086509]   \n",
       "\n",
       "                                       llm_response_bl  jaccard_index_score_bl  \n",
       "385  To describe an indirect relationship between p...                0.042857  \n",
       "385  Based on the provided abstract, an indirect re...                0.032258  \n",
       "385  An indirect relationship between pembrolizumab...                0.031250  \n",
       "385  An indirect relationship between pembrolizumab...                0.029851  \n",
       "385  An indirect relationship between pembrolizumab...                0.030769  \n",
       "385  An indirect relationship between pembrolizumab...                0.029412  \n",
       "383  An indirect relationship between larotrectinib...                0.028169  \n",
       "383  An indirect relationship between larotrectinib...                0.041096  \n",
       "383  An indirect relationship between larotrectinib...                0.027778  \n",
       "383  An indirect relationship between larotrectinib...                0.028169  \n",
       "383  An indirect relationship between larotrectinib...                0.027027  \n",
       "382  An indirect relationship between entrectinib a...                0.028169  \n",
       "382  Based on the provided abstracts, an indirect r...                0.027778  \n",
       "382  Based on the provided scientific abstracts, an...                0.041667  \n",
       "382  An indirect relationship between entrectinib a...                0.027397  \n",
       "380  An indirect relationship between canakinumab a...                0.038961  \n",
       "380  An indirect relationship between canakinumab a...                0.025000  \n",
       "380  Based on the provided scientific abstracts, an...                0.027027  \n",
       "380  An indirect relationship between canakinumab a...                0.040000  \n",
       "380  An indirect relationship between canakinumab a...                0.025974  \n",
       "380  An indirect relationship between canakinumab a...                0.027027  \n",
       "379  Based on the provided abstract, we can infer a...                0.027027  \n",
       "379  Based on the provided abstracts, an indirect r...                0.040541  \n",
       "379  Based on the provided abstracts, an indirect r...                0.040541  \n",
       "379  To describe an indirect relationship between g...                0.066667  \n",
       "378  To describe an indirect relationship between A...                0.046512  \n",
       "378  Based on the provided scientific abstracts, an...                0.034884  \n",
       "378  Based on the provided abstracts, an indirect r...                0.036585  \n",
       "378  Based on the provided abstracts, an indirect r...                0.034884  \n",
       "378  An indirect relationship between AZD-1775 and ...                0.024096  \n",
       "378  Based on the provided scientific abstracts, an...                0.036145  \n",
       "377  To describe an indirect relationship between o...                0.053763  \n",
       "377  Based on the provided abstract, an indirect re...                0.023810  \n",
       "377  An indirect relationship between olaparib and ...                0.034091  \n",
       "377  An indirect relationship between olaparib and ...                0.022222  \n",
       "377  Based on the provided scientific abstract, an ...                0.022222  \n",
       "377  An indirect relationship between olaparib and ...                0.021978  \n",
       "374  An indirect relationship between etravirine an...                0.035714  \n",
       "374  An indirect relationship between etravirine an...                0.036585  \n",
       "374  An indirect relationship between etravirine an...                0.023256  \n",
       "374  An indirect relationship between etravirine an...                0.060241  \n",
       "373  Based on the provided abstracts, an indirect r...                0.032258  \n",
       "373  To describe an indirect relationship between t...                0.079365  \n",
       "373  Based on the provided abstracts, an indirect r...                0.031746  \n",
       "373  Based on the provided abstracts, an indirect r...                0.031746  \n",
       "373  Based on the provided abstracts, an indirect r...                0.031746  \n",
       "373  Based on the provided abstracts, an indirect r...                0.031746  \n",
       "370  Based on the provided abstract, an indirect re...                0.030303  \n",
       "370  Based on the provided abstracts, an indirect r...                0.028571  \n",
       "370  Based on the provided abstracts, an indirect r...                0.057971  \n",
       "370  Based on the provided abstracts, an indirect r...                0.029412  \n",
       "370  To describe an indirect relationship between t...                0.027027  \n",
       "370  To describe an indirect relationship between t...                0.027778  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filtered_df = pd.read_pickle('filtered_df.pkl')\n",
    "filtered_df"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "db9f81a5-87f7-4964-8d90-c7edb93a00c4",
   "metadata": {},
   "source": [
    "### Batched Correctness Evaluator:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "ab6611bd-f748-42b6-9000-8d79118e67b8",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-08-27T02:18:31.587639Z",
     "iopub.status.busy": "2024-08-27T02:18:31.587008Z",
     "iopub.status.idle": "2024-08-27T02:19:52.815567Z",
     "shell.execute_reply": "2024-08-27T02:19:52.814687Z",
     "shell.execute_reply.started": "2024-08-27T02:18:31.587593Z"
    },
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Processing Batches: 100%|| 11/11 [01:21<00:00,  7.37s/it]\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pair</th>\n",
       "      <th>subj_name</th>\n",
       "      <th>obj_name</th>\n",
       "      <th>pmid</th>\n",
       "      <th>pmid_text</th>\n",
       "      <th>source</th>\n",
       "      <th>first_year</th>\n",
       "      <th>label</th>\n",
       "      <th>context_pmids</th>\n",
       "      <th>path</th>\n",
       "      <th>llm_response_bl</th>\n",
       "      <th>jaccard_index_score_bl</th>\n",
       "      <th>EvalCorrectness_score_bl</th>\n",
       "      <th>EvalCorrectness_feedback_bl</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade &gt;=3 adverse events (&gt;=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none &gt;=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3658706', 'C0278579'): ['34345644', '35031189', '29666026', '32740092'], ('C0278579', 'C4724800'): ['35277279']}</td>\n",
       "      <td>[C3658706, C0278579, C4724800]</td>\n",
       "      <td>To describe an indirect relationship between pembrolizumab and tisotumab vedotin based on the provided scientific abstract, we can focus on the context of their use in treating recurrent cervical cancer and the potential for complementary or sequential therapeutic strategies. Heres a detailed description:\\n\\n---\\n\\n**Indirect Relationship Between Pembrolizumab and Tisotumab Vedotin in Recurrent Cervical Cancer**\\n\\nPembrolizumab, an anti-PD-1 therapy, has shown promise in treating advanced or recurrent PD-L1 positive cervical cancer, with a subset of patients deriving durable clinical benefits. In a retrospective cohort study of 14 patients with recurrent or metastatic cervical cancer treated with pembrolizumab, the objective response rate was 21%, with a durable clinical benefit rate of 36%. Key factors associated with improved response included metastatic spread limited to the lung and/or lymph nodes and higher tumor mutational burden.\\n\\nTisotumab vedotin, an antibody-drug conjugate targeting tissue factor, represents another therapeutic option for cervical cancer. While the abstract does not provide specific data on tisotumab vedotin, its mechanism of action and clinical application suggest it could be used in patients who do not respond to or progress after pembrolizumab treatment.\\n\\nThe indirect relationship between pembrolizumab and tisotumab vedotin can be understood in the context of their complementary roles in the treatment landscape of recurrent cervical cancer. Pembrolizumab may be particularly beneficial for patients with specific clinicopathologic features, such as higher tumor mutational burden and limited metastatic spread. For patients who do not achieve a durable response with pembrolizumab, tisotumab vedotin offers an alternative therapeutic approach, potentially targeting different aspects of tumor biology.\\n\\nIn summary, while pembrolizumab and tisotumab vedotin are distinct therapies with different mechanisms of action, their indirect relationship lies in their sequential or combined use to optimize treatment outcomes for patients with recurrent cervical cancer. Identifying biomarkers and clinical features that predict response to each therapy can help tailor treatment strategies and improve patient outcomes.\\n\\n---\\n\\nThis description highlights how pembrolizumab and tisotumab vedotin might be used in a complementary manner, addressing different patient needs and potentially improving overall treatment efficacy in recurrent cervical cancer.</td>\n",
       "      <td>0.042857</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant to the user query and provides a detailed description of the indirect relationship between pembrolizumab and tisotumab vedotin. However, it introduces additional information not present in the provided abstract, such as a retrospective cohort study of pembrolizumab, which may not be directly related to the context given. The answer could be more concise and focused on the specific study mentioned in the reference.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade &gt;=3 adverse events (&gt;=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none &gt;=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3658706', 'C4704928'): ['29500171', '28946123', '34956447', '33983696', '34829916', '33324546', '33852056', '34424404', '33767972', '30844889'], ('C4704928', 'C0278579'): ['35277279'], ('C0278579', 'C4724800'): ['35277279']}</td>\n",
       "      <td>[C3658706, C4704928, C0278579, C4724800]</td>\n",
       "      <td>Based on the provided abstract, an indirect relationship between pembrolizumab and tisotumab vedotin in the context of metastatic triple negative breast cancer (TNBC) can be described as follows:\\n\\nPembrolizumab is mentioned in the context of recent advances in the treatment of metastatic TNBC, particularly in combination with chemotherapy for patients with programmed death-ligand 1 (PD-L1) positive tumors. The abstract highlights that pembrolizumab, when combined with chemotherapy, has shown improved progression-free survival (PFS) in this patient population.\\n\\nTisotumab vedotin, although not explicitly mentioned in the abstract, falls under the category of antibody-drug conjugates (ADCs), which are identified as an area of therapeutic interest for metastatic TNBC. ADCs are a class of targeted cancer therapies that deliver cytotoxic agents directly to cancer cells, thereby minimizing damage to normal cells.\\n\\nThe indirect relationship between pembrolizumab and tisotumab vedotin can be inferred through their roles in the evolving landscape of metastatic TNBC treatment. Both agents represent different therapeutic strategies aimed at improving outcomes for patients with this aggressive cancer type. Pembrolizumab, an immune checkpoint inhibitor, enhances the body's immune response against cancer cells, while tisotumab vedotin, as an ADC, targets and delivers cytotoxic agents to cancer cells.\\n\\nIn summary, the indirect relationship between pembrolizumab and tisotumab vedotin in metastatic TNBC is that they are both part of the broader spectrum of emerging therapeutic options being explored to improve patient outcomes. Pembrolizumab is part of the immunotherapy approach, while tisotumab vedotin represents the targeted therapy approach using ADCs. Both strategies are being investigated to address the unmet needs in the treatment of metastatic TNBC.</td>\n",
       "      <td>0.032258</td>\n",
       "      <td>1.0</td>\n",
       "      <td>The generated answer is not relevant to the user query. The user asked about the relationship between pembrolizumab and tisotumab vedotin in the context of the provided scientific abstracts, which focus on recurrent or metastatic cervical cancer, not metastatic triple negative breast cancer (TNBC). The generated answer incorrectly discusses TNBC and does not address the specific context given in the abstracts.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade &gt;=3 adverse events (&gt;=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none &gt;=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3658706', 'C4704928'): ['33983696', '34956447', '28749907', '33852056'], ('C4704928', 'C4724800'): ['35277279', '36046840', '30126944']}</td>\n",
       "      <td>[C3658706, C4704928, C4724800]</td>\n",
       "      <td>An indirect relationship between pembrolizumab and tisotumab vedotin can be described through their roles in the evolving landscape of cancer treatment, particularly in the context of metastatic triple-negative breast cancer (mTNBC).\\n\\nPembrolizumab is an immunotherapy agent that has been approved for use in combination with chemotherapy for PD-L1-positive mTNBC. It works by targeting the PD-1/PD-L1 pathway, thereby enhancing the immune system's ability to recognize and attack cancer cells. This represents a significant advancement in the treatment of mTNBC, which traditionally has had limited therapeutic options and poor outcomes.\\n\\nOn the other hand, tisotumab vedotin is an antibody-drug conjugate (ADC) that is being explored for its potential in treating various cancers. While the abstract does not specifically mention tisotumab vedotin, it does highlight the approval and promise of other ADCs, such as sacituzumab govitecan, in the treatment of mTNBC. ADCs like tisotumab vedotin combine the targeting capabilities of monoclonal antibodies with the potent cell-killing ability of cytotoxic drugs, offering a novel approach to cancer therapy.\\n\\nThe indirect relationship between pembrolizumab and tisotumab vedotin lies in their shared goal of improving cancer treatment outcomes through innovative mechanisms. Both represent different but complementary strategies in the broader context of precision medicine and targeted therapies for cancer. Pembrolizumab enhances the immune response against cancer cells, while ADCs like tisotumab vedotin deliver targeted cytotoxic effects. Together, these advancements contribute to a more comprehensive and effective approach to managing challenging cancers such as mTNBC.</td>\n",
       "      <td>0.031250</td>\n",
       "      <td>1.0</td>\n",
       "      <td>The generated answer is not relevant to the user query. The user asked for a description of the indirect relationship between pembrolizumab and tisotumab vedotin based on the provided scientific abstracts, which focus on recurrent or metastatic cervical cancer. Instead, the generated answer discusses metastatic triple-negative breast cancer (mTNBC) and does not address the specific context or content of the provided abstracts.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade &gt;=3 adverse events (&gt;=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none &gt;=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3658706', 'C1367202'): ['27764796', '28881222', '26513491', '32128919', '32774137', '31442816', '29143108'], ('C1367202', 'C4288736'): ['31098752'], ('C4288736', 'C4724800'): ['36046840']}</td>\n",
       "      <td>[C3658706, C1367202, C4288736, C4724800]</td>\n",
       "      <td>An indirect relationship between pembrolizumab and tisotumab vedotin can be inferred from the provided scientific abstracts through their shared context of cancer treatment and the potential for adverse effects, particularly ocular toxicities.\\n\\n1. **Pembrolizumab and Age-Related Efficacy in Metastatic Melanoma**:\\n   - The first abstract discusses the efficacy of pembrolizumab, an anti-PD1 immune checkpoint inhibitor, in treating metastatic melanoma. It highlights that patients aged between 70 and 80 years have better overall survival and progression-free survival compared to younger patients. The study also notes that age-related immune dysfunction (ARID) does not negatively impact the efficacy of pembrolizumab in these patients. However, it cautions about the higher risk of serious immune-related adverse events in elderly patients.\\n\\n2. **Ocular Toxicities of Chemotherapeutic Agents**:\\n   - The second abstract focuses on the ocular toxicities associated with various chemotherapeutic agents, including both traditional and novel therapies. It reports a range of ocular side effects in cancer patients, emphasizing the need for ophthalmologists to manage these potential toxicities. Specific examples of ocular toxicities are provided for several drugs, although pembrolizumab is not mentioned directly.\\n\\n**Indirect Relationship**:\\n- **Shared Context of Cancer Treatment**: Both pembrolizumab and tisotumab vedotin are used in the treatment of cancer. Pembrolizumab is an immune checkpoint inhibitor used for metastatic melanoma, while tisotumab vedotin is an antibody-drug conjugate used in other cancer types.\\n- **Potential for Adverse Effects**: The second abstract underscores the importance of monitoring and managing adverse effects, particularly ocular toxicities, in patients undergoing cancer treatment with various chemotherapeutic agents. While pembrolizumab is not specifically mentioned in the context of ocular toxicities, the general concern about adverse effects in cancer therapies is relevant.\\n- **Age and Comorbidities**: The first abstract highlights that older patients (70-80 years) have better outcomes with pembrolizumab but also face higher risks of serious adverse events. This consideration is important for clinicians when deciding on treatment plans, including the use of other chemotherapeutic agents like tisotumab vedotin, which may also have age-related implications and potential toxicities.\\n\\nIn summary, the indirect relationship between pembrolizumab and tisotumab vedotin is established through their roles in cancer treatment, the shared concern for managing adverse effects, and the consideration of patient age and comorbidities in treatment efficacy and safety.</td>\n",
       "      <td>0.029851</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer attempts to establish an indirect relationship between pembrolizumab and tisotumab vedotin but introduces unrelated abstracts about pembrolizumab in metastatic melanoma and ocular toxicities of chemotherapeutic agents, which are not relevant to the provided context. The reference answer specifically discusses a study involving both drugs in the context of cervical cancer treatment, making the generated answer less relevant and somewhat incorrect.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade &gt;=3 adverse events (&gt;=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none &gt;=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3658706', 'C2935436'): ['29881714', '34829916'], ('C2935436', 'C4288736'): ['32618744', '29116596'], ('C4288736', 'C4724800'): ['36046840']}</td>\n",
       "      <td>[C3658706, C2935436, C4288736, C4724800]</td>\n",
       "      <td>An indirect relationship between pembrolizumab and tisotumab vedotin can be described through their roles in the broader landscape of cancer treatment, particularly focusing on their mechanisms and therapeutic contexts.\\n\\nPembrolizumab is an immune checkpoint inhibitor (ICI) that has shown promising efficacy in the treatment of triple-negative breast cancer (TNBC) and other cancers by targeting the PD-1/PD-L1 pathway to enhance the immune system's ability to fight cancer cells. It represents a significant advancement in immunotherapy, particularly for cancers that are immunogenic, such as certain subtypes of breast cancer.\\n\\nOn the other hand, tisotumab vedotin is an antibody-drug conjugate (ADC) designed to deliver a cytotoxic agent specifically to cancer cells. ADCs like tisotumab vedotin consist of a monoclonal antibody linked to a cytotoxic drug, which is released inside the cancer cell upon internalization, leading to cell death. This targeted approach aims to minimize damage to healthy cells and improve the therapeutic index.\\n\\nThe indirect relationship between pembrolizumab and tisotumab vedotin lies in their complementary roles in the evolving field of cancer therapy. Both represent innovative strategies to improve cancer treatment outcomes but operate through different mechanisms. Pembrolizumab enhances the immune response against cancer cells, while tisotumab vedotin directly delivers cytotoxic agents to kill cancer cells. \\n\\nMoreover, both therapies are part of a broader trend towards personalized and targeted cancer treatments. The success and limitations of each approach highlight the need for combination strategies and the development of new therapeutic modalities to overcome resistance mechanisms and improve patient outcomes. For instance, combining ICIs like pembrolizumab with ADCs like tisotumab vedotin could potentially enhance the efficacy of treatment by simultaneously boosting the immune response and directly targeting cancer cells.\\n\\nIn summary, while pembrolizumab and tisotumab vedotin are not directly related, they are part of a complementary and evolving therapeutic landscape in oncology, where the integration of different modalities holds promise for more effective and personalized cancer treatments.</td>\n",
       "      <td>0.030769</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer provides a general overview of pembrolizumab and tisotumab vedotin, describing their mechanisms and roles in cancer treatment. However, it does not specifically address the indirect relationship between the two drugs in the context of the provided scientific abstracts. The reference answer focuses on their combined use in a specific study, which is not mentioned in the generated answer. This makes the generated answer less relevant and somewhat off-topic.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>C3658706 C4724800</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>tisotumab vedotin</td>\n",
       "      <td>37651655</td>\n",
       "      <td>Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade &gt;=3 adverse events (&gt;=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none &gt;=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3658706', 'C2982078'): ['30859062'], ('C2982078', 'C4288736'): ['29300693'], ('C4288736', 'C4724800'): ['36046840']}</td>\n",
       "      <td>[C3658706, C2982078, C4288736, C4724800]</td>\n",
       "      <td>An indirect relationship between pembrolizumab and tisotumab vedotin can be inferred from the provided scientific abstracts through their shared context within the broader field of antibody therapeutics, particularly in cancer treatment.\\n\\n1. **Pembrolizumab Context**: The first abstract discusses the use of pembrolizumab, an anti-PD-1 antibody, in treating a patient with advanced lung squamous cell carcinoma. Pembrolizumab is highlighted for its role in reducing tumor size in a patient with high PD-L1 expression. This abstract also mentions the use of benralizumab, another antibody therapeutic, for managing severe asthma in the same patient, illustrating the intersection of different antibody treatments in complex clinical scenarios.\\n\\n2. **Tisotumab Vedotin Context**: The second abstract, while not mentioning tisotumab vedotin directly, provides a comprehensive overview of the landscape of antibody therapeutics as of 2018. It lists various antibodies approved or under regulatory review, including those for cancer indications. Among the cancer-targeting antibodies mentioned are several antibody-drug conjugates (ADCs) like glembatumumab vedotin and mirvetuximab soravtansine, which share a similar mechanism of action with tisotumab vedotin. Tisotumab vedotin, although not explicitly listed, belongs to the same class of ADCs, which are designed to deliver cytotoxic agents directly to cancer cells.\\n\\n**Indirect Relationship**:\\n- **Shared Therapeutic Class**: Both pembrolizumab and tisotumab vedotin are part of the expanding arsenal of antibody-based therapies used in oncology. Pembrolizumab is an immune checkpoint inhibitor, while tisotumab vedotin is an ADC. They represent different strategies within the same therapeutic domain aimed at targeting cancer cells.\\n- **Clinical Development and Approval**: The second abstract highlights the rapid development and approval of various antibody therapeutics, including those for cancer. This context underscores the dynamic and interconnected nature of antibody drug development, where pembrolizumab and tisotumab vedotin are part of a broader trend of innovative cancer treatments.\\n- **Mechanistic Diversity**: The abstracts collectively illustrate the diversity of mechanisms by which antibody therapeutics can act. Pembrolizumab modulates the immune response to target cancer cells, while ADCs like tisotumab vedotin deliver cytotoxic agents directly to cancer cells. This diversity is crucial for addressing different types of cancer and patient needs.\\n\\nIn summary, the indirect relationship between pembrolizumab and tisotumab vedotin is rooted in their roles within the evolving field of antibody therapeutics for cancer treatment. They exemplify different but complementary approaches to leveraging antibodies in oncology, contributing to the broader narrative of innovation and clinical application in this area.</td>\n",
       "      <td>0.029412</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is relevant to the user query but contains inaccuracies and lacks specificity. It incorrectly references abstracts that are not provided and does not directly address the relationship between pembrolizumab and tisotumab vedotin as described in the given context. The reference answer provides a clear and specific connection within the context of a clinical study, which the generated answer fails to capture accurately.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3467876', 'C0265325'): ['26141621'], ('C0265325', 'C4524315'): ['31705130', '32755482', '34285720']}</td>\n",
       "      <td>[C3467876, C0265325, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib and dabrafenib can be described based on their roles in different cancer treatment contexts and their involvement in combination therapies with other agents. Heres a detailed description:\\n\\n1. **Different Cancer Types**: Larotrectinib is highlighted in the context of metastatic pancreatic cancer, specifically for patients with TRK alterations. It is recommended as a targeted therapy option following first-line treatment. On the other hand, dabrafenib is discussed in the context of metastatic melanoma, particularly for patients with BRAF V600E/K mutations. This indicates that larotrectinib and dabrafenib are used to treat different types of cancers based on specific genetic mutations.\\n\\n2. **Combination Therapies**: Both drugs are part of combination therapy strategies, but with different partners and for different purposes. Dabrafenib is combined with trametinib (a MEK inhibitor) to improve outcomes in melanoma patients with BRAF mutations. This combination has shown positive results in clinical trials. Larotrectinib, while not discussed in combination with other drugs in the provided abstract, is part of updated guidelines for treating metastatic pancreatic cancer, suggesting its use in a targeted therapy approach based on genetic profiling.\\n\\n3. **Targeted Therapy**: Both larotrectinib and dabrafenib are targeted therapies, but they target different genetic alterations. Larotrectinib targets TRK gene fusions, while dabrafenib targets BRAF V600 mutations. This highlights their roles in precision medicine, where treatments are tailored based on specific genetic characteristics of the tumor.\\n\\n4. **Clinical Trials and Guidelines**: The abstracts mention clinical trials and guideline updates involving both drugs. Dabrafenib is part of ongoing research in combination with other agents like trametinib and durvolumab for melanoma. Larotrectinib is included in updated ASCO guidelines for second-line therapy in metastatic pancreatic cancer, emphasizing the importance of genetic testing to identify suitable patients for this treatment.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib lies in their shared role as targeted therapies used in precision medicine, their involvement in combination treatment strategies, and their inclusion in clinical guidelines for different types of cancer based on specific genetic mutations.</td>\n",
       "      <td>0.028169</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is relevant to the user query but contains several inaccuracies and misinterpretations. For instance, it incorrectly states that larotrectinib is used for metastatic pancreatic cancer, whereas the reference context mentions its use for tumors with NTRK fusions. Additionally, the generated answer does not accurately reflect the context provided in the reference answer, which focuses on histology-agnostic indications and the specific genetic mutations targeted by these drugs.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3467876', 'C2697961'): ['32774277'], ('C2697961', 'C0265325'): ['26141621'], ('C0265325', 'C4524315'): ['34285720']}</td>\n",
       "      <td>[C3467876, C2697961, C0265325, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib and dabrafenib can be described based on their roles in targeted cancer therapies, as highlighted in the provided scientific abstracts. Both drugs are used to treat cancers with specific genetic mutations, although they target different mutations and types of cancer.\\n\\n1. **Targeted Therapy for Specific Mutations**:\\n   - **Larotrectinib**: Approved for treating tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusions, regardless of the tumor's location in the body. This broad approval is based on the presence of a specific genetic alteration rather than the type of cancer.\\n   - **Dabrafenib**: Used in combination with trametinib to treat melanoma with BRAF V600E/K mutations. This combination targets a specific mutation commonly found in melanoma and other cancers.\\n\\n2. **Mechanism of Action**:\\n   - **Larotrectinib**: Inhibits TRK fusion proteins, which are the result of NTRK gene fusions. These proteins drive cancer cell growth and survival.\\n   - **Dabrafenib**: Inhibits the BRAF V600E/K mutant protein, which is part of the MAPK/ERK signaling pathway that promotes cell division and survival in melanoma.\\n\\n3. **Clinical Context and Use**:\\n   - **Larotrectinib**: Highlighted in the context of metastatic pancreatic adenocarcinoma (PDAC) as a treatment option for patients with NTRK gene fusions. This underscores its role in precision medicine, where treatment is tailored based on genetic profiling of tumors.\\n   - **Dabrafenib**: Discussed in the context of melanoma treatment, particularly in combination with trametinib, to improve progression-free survival in patients with BRAF V600E/K mutations. This combination therapy is part of a broader strategy to enhance treatment efficacy through targeted approaches.\\n\\n4. **Emerging Trends in Oncology**:\\n   - Both abstracts emphasize the growing importance of combination therapies and the use of targeted agents in oncology. While larotrectinib and dabrafenib are not used together, they represent the broader trend of using molecular profiling to guide treatment decisions and improve patient outcomes.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib lies in their shared role in the paradigm of targeted cancer therapy. Both drugs exemplify the shift towards precision medicine, where treatments are increasingly based on specific genetic alterations within tumors, leading to more personalized and effective cancer care.</td>\n",
       "      <td>0.041096</td>\n",
       "      <td>4.0</td>\n",
       "      <td>The generated answer is relevant and mostly correct. It accurately describes the indirect relationship between larotrectinib and dabrafenib by focusing on their roles in targeted cancer therapies and their mechanisms of action. However, it introduces some additional context not directly mentioned in the provided abstract, such as the mention of metastatic pancreatic adenocarcinoma (PDAC), which could be seen as slightly extraneous. Overall, the answer is comprehensive and well-explained.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C1415138'): ['23432625'], ('C1415138', 'C0169658'): ['32269842'], ('C0169658', 'C4524315'): ['33792431']}</td>\n",
       "      <td>[C3467876, C1415138, C0169658, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib and dabrafenib can be described through their involvement in targeted cancer therapies, albeit for different types of mutations and cancers. Heres a detailed explanation based on the provided abstracts:\\n\\n1. **Larotrectinib**:\\n   - **Context**: Larotrectinib is a TRK inhibitor used in the treatment of cancers with NTRK gene fusions. In the provided abstract, it was used to treat a patient with basaloid squamous cell carcinoma (BSCC) of the uterine cervix, which harbored an NTRK2 fusion.\\n   - **Mechanism**: Larotrectinib targets TRK fusion proteins, which are the result of NTRK gene fusions, leading to the inhibition of tumor growth driven by these fusions.\\n\\n2. **Dabrafenib**:\\n   - **Context**: Dabrafenib is a BRAF inhibitor used primarily in the treatment of melanoma with BRAF mutations. The abstract discusses its use in combination with trametinib, a MEK inhibitor, for treating BRAF-mutant melanoma.\\n   - **Mechanism**: Dabrafenib targets the BRAF V600E mutation, which is a driver mutation in the MAPK pathway, leading to the inhibition of tumor growth driven by this mutation.\\n\\n### Indirect Relationship:\\n\\n- **Targeted Therapy**: Both larotrectinib and dabrafenib are part of the broader category of targeted cancer therapies. They are designed to inhibit specific molecular targets that drive cancer growth, albeit different targets (NTRK fusions for larotrectinib and BRAF mutations for dabrafenib).\\n  \\n- **Molecular Pathways**: While larotrectinib targets the TRK pathway, dabrafenib targets the MAPK pathway. These pathways are distinct but represent the concept of targeting specific molecular abnormalities in cancer cells.\\n\\n- **Genetic Characterization**: The use of next-generation sequencing (NGS) in both contexts highlights the importance of genetic characterization in identifying actionable mutations or fusions. For instance, the identification of NTRK2 fusion in the BSCC case led to the use of larotrectinib, while the identification of BRAF mutations in melanoma patients leads to the use of dabrafenib.\\n\\n- **Clinical Application**: Both drugs exemplify the shift towards personalized medicine in oncology, where treatment is tailored based on the genetic profile of the tumor. This approach is evident in the use of larotrectinib for NTRK fusion-positive cancers and dabrafenib for BRAF-mutant melanomas.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib lies in their roles as targeted therapies for specific genetic alterations in different cancers. They both underscore the importance of molecular diagnostics in guiding treatment decisions, although they act on different molecular targets and pathways.</td>\n",
       "      <td>0.027778</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the indirect relationship between larotrectinib and dabrafenib. However, it contains inaccuracies and extraneous information not directly supported by the provided abstract. For instance, the abstract does not mention the use of larotrectinib in basaloid squamous cell carcinoma (BSCC) of the uterine cervix or the specific mechanisms of action for each drug. The generated answer also introduces additional context not present in the abstract, which could lead to confusion.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C4519250'): ['33991955'], ('C4519250', 'C3853694'): ['34434895'], ('C3853694', 'C4524315'): ['34041811', '31571972']}</td>\n",
       "      <td>[C3467876, C4519250, C3853694, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib and dabrafenib can be described based on their roles in targeted cancer therapies and their inclusion in studies focusing on different types of cancers and therapeutic strategies.\\n\\n1. **Targeted Cancer Therapies**: Both larotrectinib and dabrafenib are targeted cancer therapies, but they act on different molecular targets. Larotrectinib is a TRK inhibitor used primarily for cancers with NTRK gene fusions, while dabrafenib is a BRAF inhibitor used for cancers with BRAF V600E mutations. Despite targeting different pathways, both drugs exemplify the shift towards personalized medicine in oncology, where treatments are tailored based on specific genetic mutations or alterations in the tumor.\\n\\n2. **Therapeutic Drug Monitoring (TDM)**: The first abstract discusses the development of an LC-MS/MS method for the simultaneous quantification of 12 tyrosine kinase inhibitors (TKIs), including dabrafenib, in human plasma for therapeutic drug monitoring (TDM) in non-small cell lung cancer (NSCLC) patients. Although larotrectinib is not mentioned in this study, the focus on TDM highlights the importance of monitoring drug levels to optimize efficacy and safety, a principle that is also relevant to the use of larotrectinib in clinical practice.\\n\\n3. **Combination Therapies and Resistance**: The second abstract explores the use of Xihuang Pill (XHW) to enhance the efficacy of anlotinib in lung cancer, addressing issues of drug resistance and side effects. While neither larotrectinib nor dabrafenib is directly involved in this study, the concept of using combination therapies to overcome resistance and improve outcomes is a common theme in cancer treatment. Both larotrectinib and dabrafenib may be part of similar combination strategies in their respective indications.\\n\\n4. **Personalized Treatment in Thyroid Cancer**: The third abstract discusses personalized treatment options for thyroid cancer, mentioning larotrectinib as a TRK inhibitor used based on specific genetic information. This personalized approach is also applicable to dabrafenib, which is used for thyroid cancers with BRAF mutations. The emphasis on genetic profiling and targeted therapies underscores the broader context in which both drugs operate, even though they are used for different genetic targets and cancer types.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib can be described through their roles in the paradigm of personalized cancer treatment, the importance of therapeutic drug monitoring, and the strategies to overcome drug resistance and improve efficacy through combination therapies. Both drugs are part of the broader landscape of targeted therapies that are tailored based on the genetic characteristics of the tumor, highlighting the ongoing evolution in cancer treatment.</td>\n",
       "      <td>0.028169</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the indirect relationship between larotrectinib and dabrafenib. However, it introduces additional contexts and abstracts that were not part of the original user query, which could lead to confusion. The core explanation about their roles in targeted cancer therapies and personalized medicine is correct, but the inclusion of unrelated studies and concepts slightly detracts from the clarity and focus of the response.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>C3467876 C4524315</td>\n",
       "      <td>larotrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C1333650'): ['27188223', '24504448'], ('C1333650', 'C0812222'): ['23222563', '18948082'], ('C0812222', 'C4524315'): ['34340207']}</td>\n",
       "      <td>[C3467876, C1333650, C0812222, C4524315]</td>\n",
       "      <td>An indirect relationship between larotrectinib and dabrafenib can be described through their involvement in different but potentially intersecting pathways and mechanisms of resistance in cancer treatment. Heres a detailed explanation based on the provided abstracts:\\n\\n1. **Mechanisms of Resistance and Pathways**:\\n   - **Dabrafenib**: This drug is a BRAF inhibitor used in treating melanomas with BRAF(V600) mutations. Resistance to dabrafenib can occur through mutations in other genes such as GNAQ and PTEN, which sustain MAPK signaling and activate the PI3K/AKT pathway, respectively.\\n   - **Larotrectinib**: This drug is an NTRK inhibitor used in treating cancers with NTRK gene fusions, such as pleomorphic liposarcoma of the uterus. The case study shows that larotrectinib was effective after other treatments, including entrectinib and pazopanib, failed.\\n\\n2. **Pathway Intersections**:\\n   - Both abstracts mention the involvement of the MAPK pathway. In the context of dabrafenib, resistance is mediated through sustained MAPK signaling due to GNAQ mutations. In the context of uveal melanoma, the MAPK pathway is disrupted due to GNAQ/11 mutations.\\n   - The PI3K/AKT pathway is also a common theme. Resistance to dabrafenib involves activation of this pathway through PTEN mutations, and the uveal melanoma abstract mentions PTEN mutations disrupting the PI3K/AKT pathway.\\n\\n3. **Genetic Testing and Targeted Therapy**:\\n   - The importance of genetic testing is highlighted in both contexts. For dabrafenib, understanding the genetic mutations (GNAQ and PTEN) that cause resistance can guide combination therapies. For larotrectinib, identifying NTRK gene fusions through genetic testing allows for targeted therapy.\\n   - The case study of larotrectinib emphasizes the need for genetic testing in rare cancers like pleomorphic liposarcoma of the uterus to identify actionable mutations for targeted therapy.\\n\\n4. **Therapeutic Implications**:\\n   - The resistance mechanisms to dabrafenib suggest that combination therapies targeting both the MAPK and PI3K/AKT pathways could be effective. This aligns with the broader strategy of using targeted therapies based on specific genetic alterations.\\n   - Larotrectinibs success in treating a patient with an NTRK3 fusion after other treatments failed underscores the potential of targeted therapies in overcoming resistance and achieving better outcomes.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib lies in their roles in targeted cancer therapy, addressing different genetic mutations and pathways. Both drugs highlight the importance of understanding the genetic landscape of tumors to overcome resistance and improve treatment efficacy. While they target different mutations (NTRK fusions for larotrectinib and BRAF mutations for dabrafenib), the underlying principle of using genetic information to guide therapy connects their use in personalized medicine.</td>\n",
       "      <td>0.027027</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the indirect relationship between larotrectinib and dabrafenib, focusing on their roles in targeted cancer therapy and mechanisms of resistance. However, it introduces additional information not directly derived from the provided abstract, such as specific resistance mechanisms and pathways, which may not be entirely accurate or necessary. The answer could be more concise and directly tied to the provided context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>C3467876 C4086264</td>\n",
       "      <td>entrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C3467876', 'C3658706'): ['33657824', '30009647', '24928310', '27188223'], ('C3658706', 'C2697961'): ['28614138', '29561296', '31118140', '26353041'], ('C2697961', 'C4086264'): ['33846488', '33353026', '31862477']}</td>\n",
       "      <td>[C3467876, C3658706, C2697961, C4086264]</td>\n",
       "      <td>An indirect relationship between entrectinib and dabrafenib can be described based on their roles in targeted cancer therapies, particularly in the context of treating malignancies with specific genetic mutations. Heres a detailed explanation:\\n\\n1. **Targeted Therapies for Specific Mutations**:\\n   - **Dabrafenib**: This drug is a BRAF inhibitor used in combination with trametinib (a MEK inhibitor) for treating malignant melanoma with a proven BRAF mutation. It is part of the targeted therapy regimen for melanoma patients, as highlighted in the first abstract.\\n   - **Entrectinib**: This drug targets oncogenic fusion genes, specifically ROS1 and NTRK fusions, and is used in treating pediatric high-grade gliomas (pHGG) with these genetic alterations, as described in the third abstract.\\n\\n2. **Mechanism of Action**:\\n   - Both drugs are kinase inhibitors but target different pathways. Dabrafenib inhibits the BRAF kinase, which is part of the MAPK/ERK pathway, while entrectinib inhibits TRK and ROS1 kinases, which are involved in different signaling pathways.\\n\\n3. **Combination Therapies**:\\n   - The abstracts mention the use of combination therapies to enhance treatment efficacy. Dabrafenib is often combined with trametinib to target both BRAF and MEK pathways in melanoma.\\n   - Entrectinib is shown to potentially work synergistically with other treatments like radiotherapy, intrathecal chemotherapy, and MEK inhibitors (e.g., trametinib) in treating pHGG.\\n\\n4. **Clinical Context and Treatment Challenges**:\\n   - The first abstract discusses the challenges and considerations in treating malignant melanoma, including the failure of adjuvant therapies and the need for alternative treatments upon relapse.\\n   - The third abstract provides insights into the treatment of pHGG with entrectinib, emphasizing the importance of combination therapies and the potential for enhanced antitumor effects.\\n\\n5. **Indirect Relationship**:\\n   - The indirect relationship between entrectinib and dabrafenib lies in their shared context of being part of targeted cancer therapies that require precise identification of genetic mutations for effective treatment.\\n   - Both drugs are used in combination with other therapies to improve outcomes, although they target different genetic alterations and cancer types.\\n   - The use of trametinib in combination with both dabrafenib (for melanoma) and entrectinib (for pHGG) suggests a common strategy of targeting multiple pathways to overcome resistance and enhance therapeutic efficacy.\\n\\nIn summary, while entrectinib and dabrafenib are not directly related in terms of their specific targets or cancer types, they share an indirect relationship through their roles in the broader landscape of targeted cancer therapies, the use of combination treatments, and the strategic approach to overcoming treatment resistance in genetically defined malignancies.</td>\n",
       "      <td>0.028169</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the indirect relationship between entrectinib and dabrafenib in the context of targeted cancer therapies. However, it introduces additional contexts and abstracts not mentioned in the user query or reference answer, which could lead to confusion. The core points about their roles in targeted therapies and combination treatments are correct, but the answer could be more concise and focused on the provided context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>C3467876 C4086264</td>\n",
       "      <td>entrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C2743752'): ['27797970'], ('C2743752', 'C0812222'): ['24281001'], ('C0812222', 'C4086264'): ['34340207']}</td>\n",
       "      <td>[C3467876, C2743752, C0812222, C4086264]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between entrectinib and dabrafenib can be described through their roles in cancer treatment, particularly in the context of overcoming drug resistance and targeting specific genetic mutations.\\n\\n1. **Mechanisms of Action and Resistance**:\\n   - **Dabrafenib**: This drug is a BRAF inhibitor used to target hyperactive MAPK signaling in cancers with BRAF mutations. However, resistance to dabrafenib often develops due to adaptive rewiring of intracellular signaling and nonmutational drug tolerance, as described in the first abstract. This resistance can be mediated by external signaling from the tumor microenvironment or the selection of drug-tolerant cell phenotypes.\\n   - **Entrectinib**: This drug is a receptor tyrosine kinase (RTK) inhibitor that targets NTRK gene fusions, among others. The third abstract describes a case where entrectinib was used to treat a patient with a rare uterine cancer harboring an IQGAP-NTRK3 gene fusion. Although the patient initially showed progression on entrectinib, the case highlights the importance of genetic testing and targeted therapy in managing cancer.\\n\\n2. **Combination Therapies and Overcoming Resistance**:\\n   - The first abstract discusses the potential of combining MAPK pathway inhibitors like dabrafenib with other agents, such as RTK inhibitors, to overcome early drug tolerance. This suggests that combining dabrafenib with drugs like entrectinib could be a strategy to prevent or delay resistance by targeting multiple pathways simultaneously.\\n   - The second abstract on HDAC inhibitors (HDACi) like vorinostat and entinostat also touches on the importance of combination treatments to enhance anticancer effects. Although not directly related to dabrafenib or entrectinib, it underscores the broader theme of using combination therapies to improve treatment outcomes.\\n\\n3. **Genetic Mutations and Targeted Therapy**:\\n   - Both abstracts highlight the significance of genetic mutations in determining the effectiveness of targeted therapies. Dabrafenib is effective in cancers with BRAF mutations, while entrectinib targets cancers with NTRK gene fusions. The third abstract emphasizes the need for genetic testing to identify actionable mutations and tailor treatment accordingly.\\n\\nIn summary, the indirect relationship between entrectinib and dabrafenib can be described through their roles in targeted cancer therapy, the challenges of drug resistance, and the potential benefits of combination treatments. Both drugs are part of a broader strategy to personalize cancer treatment based on genetic mutations and to overcome resistance mechanisms by targeting multiple pathways.</td>\n",
       "      <td>0.027778</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the indirect relationship between entrectinib and dabrafenib in the context of cancer treatment. However, it introduces information not present in the provided abstract, such as specific mechanisms of resistance and combination therapies, which may not be directly supported by the given context. This inclusion of extraneous details affects the precision and correctness of the answer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>C3467876 C4086264</td>\n",
       "      <td>entrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C0242275'): ['33159968'], ('C0242275', 'C0812222'): ['24799378', '24194188', '29297949', '12588705', '11278558', '25145657', '15110188', '30514153'], ('C0812222', 'C4086264'): ['34340207']}</td>\n",
       "      <td>[C3467876, C0242275, C0812222, C4086264]</td>\n",
       "      <td>Based on the provided scientific abstracts, an indirect relationship between entrectinib and dabrafenib can be described through their involvement in pathways related to receptor tyrosine kinases (RTKs) and their roles in cancer treatment resistance mechanisms.\\n\\n1. **Dabrafenib and Resistance Mechanisms:**\\n   - Dabrafenib is a selective BRAF inhibitor used in the treatment of metastatic melanoma, particularly targeting the BRAF(V600E) mutation.\\n   - Resistance to dabrafenib can occur through various mechanisms, including the activation of multiple RTKs such as EGFR. The loss of ACK1, a protein kinase that modulates EGFR turnover, has been shown to upregulate EGFR and mediate resistance to BRAF inhibitors like dabrafenib.\\n\\n2. **Entrectinib and RTK Inhibition:**\\n   - Entrectinib is a targeted therapy that inhibits TRK (tropomyosin receptor kinase) fusion proteins, which are a type of RTK. It is used in cancers with NTRK gene fusions.\\n   - In the context of the provided abstract, entrectinib was used to treat a patient with pleomorphic liposarcoma of the uterus harboring an IQGAP-NTRK3 gene fusion. Although the patient initially showed progression, the case highlights the role of RTK inhibitors in targeted cancer therapy.\\n\\n3. **Indirect Relationship:**\\n   - The indirect relationship between entrectinib and dabrafenib lies in their shared involvement in targeting RTKs, albeit different ones (EGFR for dabrafenib resistance and TRK for entrectinib efficacy).\\n   - Both drugs are part of the broader strategy of using targeted therapies to overcome specific genetic alterations in cancer. Resistance mechanisms to one RTK-targeting drug (e.g., dabrafenib) can involve the upregulation of other RTKs (e.g., EGFR), which might be targeted by different inhibitors (e.g., gefitinib for EGFR).\\n   - This interplay suggests that understanding the network of RTKs and their role in drug resistance and efficacy is crucial for developing effective combination therapies and overcoming resistance in cancer treatment.\\n\\nIn summary, the indirect relationship between entrectinib and dabrafenib is rooted in their roles in targeting different RTKs involved in cancer progression and resistance mechanisms. Both drugs exemplify the importance of RTK inhibition in personalized cancer therapy, highlighting the need for comprehensive genetic testing and tailored treatment strategies.</td>\n",
       "      <td>0.041667</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant to the user query and provides a detailed explanation of the indirect relationship between entrectinib and dabrafenib through their involvement in receptor tyrosine kinases (RTKs) and cancer treatment resistance mechanisms. However, it introduces additional context not directly derived from the provided abstract, such as specific resistance mechanisms and case studies, which may not be entirely accurate or necessary. The core idea is correct, but the answer could be more concise and directly tied to the provided abstract.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>C3467876 C4086264</td>\n",
       "      <td>entrectinib</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>35955671</td>\n",
       "      <td>The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.</td>\n",
       "      <td>sr_pred_sent_2</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C3467876', 'C0042682'): ['35379272'], ('C0042682', 'C0012373'): ['4006044'], ('C0012373', 'C4086264'): ['34495458']}</td>\n",
       "      <td>[C3467876, C0042682, C0012373, C4086264]</td>\n",
       "      <td>An indirect relationship between entrectinib and dabrafenib can be inferred from the provided scientific abstracts through the common involvement of cytochrome P450 (CYP) enzymes, particularly CYP3A4, in their pharmacokinetics and potential drug-drug interactions.\\n\\n1. **Entrectinib and CYP3A4 Modulation**: The second abstract discusses how entrectinib, a selective inhibitor of ROS1/TRK/ALK kinases, is predominantly metabolized by CYP3A4. The pharmacokinetics of entrectinib and its active metabolite M5 are significantly affected by CYP3A4 inhibitors and inducers. For instance, co-administration with CYP3A4 inhibitors like verapamil and diltiazem can increase entrectinib exposure, while CYP3A4 inducers can decrease its exposure.\\n\\n2. **Calcium Channel Blockers and Antitumor Agents**: The first abstract highlights the potentiation of antitumor agents by calcium channel blockers (e.g., verapamil, diltiazem). These calcium channel blockers can enhance the efficacy of various chemotherapeutic agents, potentially through mechanisms involving drug transport and metabolism.\\n\\n3. **Dabrafenib and CYP3A4**: Although not explicitly mentioned in the provided abstracts, dabrafenib is known from other literature to be metabolized by CYP3A4 and CYP2C8. Therefore, its pharmacokinetics can also be influenced by CYP3A4 inhibitors and inducers.\\n\\nGiven these points, the indirect relationship between entrectinib and dabrafenib can be described as follows:\\n\\n- **Common Pathway of Metabolism**: Both entrectinib and dabrafenib are metabolized by CYP3A4. Therefore, any drug that modulates CYP3A4 activity (such as calcium channel blockers like verapamil and diltiazem) can potentially affect the pharmacokinetics of both drugs.\\n  \\n- **Potential for Drug-Drug Interactions**: The use of CYP3A4 inhibitors or inducers can alter the exposure and efficacy of both entrectinib and dabrafenib. For example, co-administration with a CYP3A4 inhibitor could increase the plasma levels of both drugs, potentially leading to enhanced efficacy or increased toxicity.\\n\\n- **Therapeutic Implications**: Understanding the role of CYP3A4 in the metabolism of both drugs can help in making informed decisions about their co-administration with other medications, particularly those that are known CYP3A4 modulators. This can optimize therapeutic outcomes and minimize adverse effects.\\n\\nIn summary, the indirect relationship between entrectinib and dabrafenib is primarily mediated through their shared metabolic pathway involving CYP3A4, which can be influenced by other drugs such as calcium channel blockers.</td>\n",
       "      <td>0.027397</td>\n",
       "      <td>1.0</td>\n",
       "      <td>The generated answer is not relevant to the user query. The user asked for a description of the indirect relationship between entrectinib and dabrafenib based on the provided scientific abstracts. However, the generated answer discusses the involvement of cytochrome P450 (CYP) enzymes, which is not mentioned in the provided abstract. The reference answer focuses on the histology-agnostic indications and the genomic alterations targeted by these drugs, which is the relevant context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2718773', 'C1609165'): ['32552266', '23729309', '32193746', '25218736', '26048626', '24129147', '23172748'], ('C1609165', 'C4683810'): ['34160250']}</td>\n",
       "      <td>[C2718773, C1609165, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab and zanubrutinib can be inferred from the contexts provided by the two scientific abstracts, despite the fact that the studies focus on different diseases and mechanisms.\\n\\n1. **Canakinumab in Systemic Juvenile Idiopathic Arthritis (sJIA)**:\\n   - Canakinumab is an IL-1 inhibitor used to treat systemic juvenile idiopathic arthritis (sJIA).\\n   - The study demonstrates its efficacy in reducing corticosteroid use and achieving significant clinical responses in Japanese patients with sJIA.\\n   - The safety profile includes common adverse events such as infections and serious adverse events, including potential cases of macrophage activation syndrome.\\n\\n2. **Zanubrutinib in SARS-CoV-2 Spike Protein-Induced Endothelial Dysfunction**:\\n   - Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor.\\n   - The study shows that zanubrutinib can inhibit inflammatory receptor signaling, reducing cellular senescence markers and reactive oxygen species (ROS) generation in endothelial cells exposed to SARS-CoV-2 spike protein.\\n   - This inhibition also prevents the expression of endothelial adhesion molecules and leukocyte attachment, which are associated with microvascular complications in COVID-19.\\n\\n### Indirect Relationship:\\n\\n- **Common Pathways and Inflammatory Mechanisms**:\\n  - Both canakinumab and zanubrutinib are involved in modulating inflammatory pathways. Canakinumab targets IL-1, a cytokine involved in inflammatory responses, while zanubrutinib inhibits BTK, a key enzyme in B-cell receptor signaling and inflammatory processes.\\n  - The SARS-CoV-2 study highlights the role of inflammatory cytokines (e.g., IL-6) and the potential for BTK inhibitors like zanubrutinib to mitigate inflammation and cellular senescence. This suggests a broader context where inflammatory modulation is crucial in disease management.\\n\\n- **Potential Overlapping Therapeutic Implications**:\\n  - While canakinumab is used for sJIA and zanubrutinib for conditions involving BTK pathways, both drugs could theoretically be explored for their anti-inflammatory properties in other diseases characterized by excessive inflammation.\\n  - For instance, the modulation of inflammatory pathways by canakinumab might have implications in conditions where IL-1 plays a role, potentially overlapping with the inflammatory pathways influenced by BTK inhibitors like zanubrutinib.\\n\\n- **Shared Adverse Events and Safety Considerations**:\\n  - Both drugs have safety profiles that include risks of infections, which is a common concern in immunomodulatory therapies. This shared aspect underscores the importance of monitoring and managing infections in patients receiving these treatments.\\n\\nIn summary, the indirect relationship between canakinumab and zanubrutinib lies in their roles in modulating inflammatory pathways and their potential overlapping therapeutic implications in managing diseases characterized by inflammation. Both drugs, while targeting different specific mechanisms, contribute to the broader understanding of inflammation and its management in various clinical contexts.</td>\n",
       "      <td>0.038961</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the indirect relationship between canakinumab and zanubrutinib. However, it introduces additional contexts not present in the reference answer, such as the use of canakinumab in systemic juvenile idiopathic arthritis (sJIA) and zanubrutinib in endothelial dysfunction, which are not directly related to the provided context of SARS-CoV-2-induced cytokine storm. This makes the answer somewhat less focused and introduces potential inaccuracies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2718773', 'C1609165'): ['34698811', '25061259', '33683393', '32449926', '26628580', '32322121', '29110911'], ('C1609165', 'C4044947'): ['34729893', '33455920', '34488083', '33519271', '33595833', '32550671', '34826840'], ('C4044947', 'C4683810'): ['33539089']}</td>\n",
       "      <td>[C2718773, C1609165, C4044947, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab and zanubrutinib can be inferred from the contexts provided in the scientific abstracts through their roles in treating different conditions and their involvement in broader therapeutic strategies.\\n\\n1. **Canakinumab**: This is a biologic agent mentioned in the context of treating Blau syndrome (BS), a rare auto-inflammatory granulomatous disease. Canakinumab is a monoclonal antibody targeting interleukin-1, used in cases where other treatments, such as glucocorticoids and other biologics, have failed. The abstract highlights its use among other biologics like Etanercept, Infliximab, Adalimumab, and Anakinra for refractory BS cases.\\n\\n2. **Zanubrutinib**: This is a kinase inhibitor discussed in the context of managing viral infections, particularly COVID-19. Zanubrutinib, along with other kinase inhibitors like baricitinib and ruxolitinib, is being repurposed for its antiviral properties. Kinase inhibitors target host cellular proteins essential for viral replication, offering a broad-spectrum antiviral approach.\\n\\nThe indirect relationship between canakinumab and zanubrutinib lies in their shared characteristic of being part of advanced therapeutic strategies involving monoclonal antibodies and kinase inhibitors, respectively. Both are used in the context of treating complex diseases where traditional therapies may not suffice. While canakinumab is used for its anti-inflammatory properties in auto-inflammatory conditions like BS, zanubrutinib is explored for its potential in managing viral infections through kinase inhibition.\\n\\nIn summary, the indirect relationship is established through their roles in modern therapeutic approaches for difficult-to-treat conditions, highlighting the evolving landscape of targeted therapies in both auto-inflammatory diseases and viral infections.</td>\n",
       "      <td>0.025000</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a reasonable explanation of the indirect relationship between canakinumab and zanubrutinib. However, it contains inaccuracies and lacks clarity in connecting the two drugs specifically within the context of the provided scientific abstracts. The reference answer clearly links both drugs to the management of SARS-CoV-2-induced cytokine storm, which is not adequately addressed in the generated answer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2718773', 'C4044947'): ['34868553'], ('C4044947', 'C4683810'): ['33539089']}</td>\n",
       "      <td>[C2718773, C4044947, C4683810]</td>\n",
       "      <td>Based on the provided scientific abstracts, an indirect relationship between canakinumab and zanubrutinib can be described as follows:\\n\\nCanakinumab is a monoclonal antibody that targets interleukin-1 (IL-1) and is primarily used for its anti-inflammatory properties in conditions such as rheumatoid arthritis and other inflammatory diseases. It is not directly mentioned in the context of antiviral therapies or kinase inhibition.\\n\\nZanubrutinib, on the other hand, is a Bruton tyrosine kinase (BTK) inhibitor that is being investigated for its potential antiviral properties, particularly in the context of COVID-19. Kinase inhibitors like zanubrutinib are being repurposed for viral infections due to their ability to interfere with host cellular proteins that viruses depend on for their life cycle.\\n\\nThe indirect relationship between canakinumab and zanubrutinib lies in their potential roles in managing inflammatory responses and viral infections, respectively. While canakinumab addresses inflammation by targeting cytokines, zanubrutinib targets kinases involved in viral replication and immune response modulation. Both drugs, although different in their primary mechanisms and indications, may contribute to a broader therapeutic strategy in managing diseases that involve both inflammation and viral infections, such as COVID-19.</td>\n",
       "      <td>0.027027</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and correctly identifies the roles of canakinumab and zanubrutinib in managing inflammation and viral infections, respectively. However, it contains inaccuracies and omissions. The reference answer specifically mentions that both drugs are beneficial in managing SARS-CoV-2-induced cytokine storm by reducing proinflammatory cytokines and improving respiratory function. The generated answer does not fully capture this context and incorrectly states that canakinumab is not mentioned in antiviral therapies, which is misleading given the reference's context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2718773', 'C0674428'): ['19536362'], ('C0674428', 'C0028978'): ['22862307', '27566010'], ('C0028978', 'C4683810'): ['33336408']}</td>\n",
       "      <td>[C2718773, C0674428, C0028978, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab and zanubrutinib can be inferred through their respective interactions with cytochrome P450 (CYP) enzymes and drug transporter proteins, as described in the provided abstracts.\\n\\n1. **Canakinumab Context**: The first abstract lists canakinumab among various drugs in a broad overview of clinical trials. While it does not provide specific details about canakinumab's pharmacokinetics or interactions, it is known from other sources that canakinumab is an interleukin-1 inhibitor used primarily for its anti-inflammatory properties.\\n\\n2. **Zanubrutinib Context**: The third abstract specifically evaluates the drug interaction potential of zanubrutinib with various CYP enzymes and drug transporter proteins. Zanubrutinib was shown to have minimal or no effect on CYP2C9, BCRP, and P-gp, but it decreased the systemic exposure of CYP3A and CYP2C19 substrates.\\n\\n3. **Indirect Relationship**: The indirect relationship between canakinumab and zanubrutinib can be understood through their potential interactions with the CYP enzyme system. While canakinumab itself is not directly mentioned to interact with CYP enzymes in the provided abstracts, the fact that zanubrutinib affects CYP3A and CYP2C19 substrates suggests that if canakinumab were to be co-administered with drugs metabolized by these enzymes, there could be potential pharmacokinetic interactions. For instance, if canakinumab were to be used in a patient already taking zanubrutinib, the altered activity of CYP3A and CYP2C19 by zanubrutinib could potentially affect the metabolism of other co-administered drugs, leading to changes in their efficacy or toxicity.\\n\\nIn summary, the indirect relationship between canakinumab and zanubrutinib is mediated through their interactions with the CYP enzyme system, particularly CYP3A and CYP2C19, which could influence the pharmacokinetics of other drugs metabolized by these enzymes when both drugs are part of a broader therapeutic regimen.</td>\n",
       "      <td>0.040000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>The generated answer is not relevant to the user query. The user asked for a description of an indirect relationship between canakinumab and zanubrutinib based on the provided scientific abstracts, which focus on their roles in managing SARS-CoV-2-induced cytokine storm. The generated answer incorrectly discusses their interactions with cytochrome P450 enzymes and drug transporter proteins, which are not mentioned in the provided context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2718773', 'C1424250'): ['32623652', '31504417', '21967869', '33883388', '30930410', '31755287', '34784874', '34650351', '21356079'], ('C1424250', 'C1335226'): ['32552384', '30619256', '31408184', '34535969', '30783801', '31993418', '32671674', '25418813', '33042144'], ('C1335226', 'C4683810'): ['31028669', '34248972']}</td>\n",
       "      <td>[C2718773, C1424250, C1335226, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab and zanubrutinib can be inferred through their respective roles in treating different conditions that involve immune system dysregulation. \\n\\nCanakinumab is an interleukin-1 beta antibody used to treat Muckle-Wells syndrome, a type of Cryopyrin-associated periodic fever syndrome (CAPS) caused by mutations in the NLRP3 gene. This condition is characterized by an overproduction of interleukin-1, leading to inflammatory symptoms. The efficacy of canakinumab in treating Muckle-Wells syndrome highlights its role in modulating the immune response by targeting specific cytokines involved in inflammation.\\n\\nOn the other hand, zanubrutinib is a second-generation Bruton's tyrosine kinase inhibitor (BTKi) used in the treatment of chronic lymphocytic leukemia (CLL). BTK inhibitors like zanubrutinib work by targeting the B-cell receptor signaling pathway, which is crucial for the survival and proliferation of malignant B cells in CLL. By inhibiting BTK, zanubrutinib helps to control the growth of these cancerous cells.\\n\\nThe indirect relationship between canakinumab and zanubrutinib lies in their shared goal of modulating the immune system, albeit through different mechanisms and for different diseases. Canakinumab targets cytokine signaling to reduce inflammation in autoinflammatory conditions, while zanubrutinib targets kinase signaling to inhibit the proliferation of malignant B cells in hematologic malignancies. Both drugs exemplify the broader therapeutic strategy of targeting specific components of the immune system to treat diseases characterized by immune dysregulation.</td>\n",
       "      <td>0.025974</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is somewhat relevant but does not directly address the specific context provided in the scientific abstract. The abstract focuses on the role of canakinumab and zanubrutinib in managing SARS-CoV-2-induced cytokine storm, while the generated answer discusses their roles in treating other conditions. The connection to the cytokine storm and COVID-19 context is missing, leading to a lack of full correctness.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>C2718773 C4683810</td>\n",
       "      <td>canakinumab</td>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>35454970</td>\n",
       "      <td>Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.</td>\n",
       "      <td>sr_pred_sent_9</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2718773', 'C0010980'): ['29478243'], ('C0010980', 'C0026056'): ['21342112', '34078115'], ('C0026056', 'C4683810'): ['33336408', '33687157']}</td>\n",
       "      <td>[C2718773, C0010980, C0026056, C4683810]</td>\n",
       "      <td>An indirect relationship between canakinumab and zanubrutinib can be inferred through their interactions with the cytochrome P450 (CYP) enzyme system, which plays a crucial role in drug metabolism.\\n\\n1. **Canakinumab and CYP Metabolism**: The first abstract mentions that canakinumab, a biologic used in the treatment of pyoderma gangrenosum (PG), is part of a broader category of biologics that can influence drug metabolism through the CYP system. Specifically, the second abstract discusses how biological drugs, including IL-6 inhibitors, can significantly alter the metabolism of drugs processed by CYP enzymes. Although canakinumab itself is not explicitly mentioned in the second abstract, it is reasonable to consider that, as a biologic, it might have similar effects on CYP-mediated drug metabolism.\\n\\n2. **Zanubrutinib and CYP Metabolism**: The third abstract focuses on zanubrutinib, a small-molecule drug used in B-cell malignancies, and its interactions with the CYP3A enzyme. The PBPK model developed for zanubrutinib shows that its exposure can be significantly affected by CYP3A inhibitors and inducers. Additionally, zanubrutinib can act as a perpetrator in drug-drug interactions (DDIs) involving CYP3A4, CYP2C8, and CYP2B6 substrates.\\n\\n3. **Connecting the Dots**: Given that both canakinumab and zanubrutinib interact with the CYP enzyme system, albeit in different capacities, an indirect relationship can be established. Canakinumab, as a biologic, may alter the metabolism of drugs processed by CYP enzymes, potentially affecting the pharmacokinetics of zanubrutinib if used concurrently. Conversely, zanubrutinib's role as a CYP3A substrate and its potential to influence the metabolism of other drugs could be impacted by the presence of canakinumab or similar biologics that modulate CYP activity.\\n\\nIn summary, the indirect relationship between canakinumab and zanubrutinib is mediated through their respective influences on the CYP enzyme system, which could lead to altered drug metabolism and potential drug-drug interactions when these agents are used together.</td>\n",
       "      <td>0.027027</td>\n",
       "      <td>1.0</td>\n",
       "      <td>The generated answer is not relevant to the user query. The user asked for a description of an indirect relationship between canakinumab and zanubrutinib based on the provided scientific abstracts, which focus on their roles in managing SARS-CoV-2-induced cytokine storm. The generated answer instead discusses their interactions with the cytochrome P450 enzyme system, which is not mentioned in the provided context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>C2716282 C3886682</td>\n",
       "      <td>gambogenic acid</td>\n",
       "      <td>ACTA2 protein, human</td>\n",
       "      <td>35994849</td>\n",
       "      <td>Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. Epigenetics regulating gene expression plays important role in kidney fibrosis. Natural products originating from diverse sources including plants and microorganisms are capable to influence epigenetic modifications. Gambogenic acid (GNA) is a caged xanthone extracted from gamboge resin, exudation of Garcinia hanburyi Hook.f., and the effect of GNA on kidney fibrosis with its underlying mechanism on epigenetics remains unknown. This study aimed to explore the role of GNA against kidney fibrogenesis by histone methylation mediating gene expression. Two experimental mice of unilateral ureteral obstruction (UUO) and folic acid (FA) were given two dosages of GNA (3 and 6 mg/kg/d). TGF-beta1 was used to stimulate mouse tubular epithelial (TCMK-1) cells and siRNAs were transfected to verify the underlying mechanisms of GNA. Histological changes were evaluated by HE, MASSON stainings, immunohistochemistry and immunofluorescence. Western blot and qPCR were used to measure protein/gene transcription levels. GNA dose-dependently alleviated UUO-induced kidney fibrosis and FA-induced kidney early fibrosis, indicated by the pathology and fibrotic factor changes (alpha-SMA, collagen I, collagen VI, and fibronectin). Mechanically, GNA reduced enhancer of zeste homolog 2 (EZH2) and H3K27me3, promoted Smad7 transcription, and inhibited TGF-beta/Smad3 fibrotic signaling in injured kidneys. Moreover, with TGF-beta1-induced EZH2 increasing, GNA suppressed alpha-SMA, fibronectin and collagen levels in tubular epithelial TCMK-1 cells. Although partially decreasing EZH2, GNA did not influence fibrotic signaling in Smad7 siRNA-transfected TCMK-1 cells. Epigenetic inhibition of EZH2 by GNA ameliorated kidney fibrogenesis via regulating Smad7-meidated TGF-beta/Smad3 signaling.</td>\n",
       "      <td>sr_pred_sent_11</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2716282', 'C1172384'): ['34859108', '31579944', '32041748', '31128153'], ('C1172384', 'C3886682'): ['28320739']}</td>\n",
       "      <td>[C2716282, C1172384, C3886682]</td>\n",
       "      <td>Based on the provided abstract, we can infer an indirect relationship between gambogenic acid (GNA) and the ACTA2 protein in humans through the following chain of interactions:\\n\\n1. **Gambogenic Acid (GNA) and EZH2**: GNA is identified as a novel agent that covalently binds to the EZH2 protein, specifically at the Cys668 site within the EZH2-SET domain. This binding triggers the degradation of EZH2 through CHIP-mediated ubiquitination.\\n\\n2. **EZH2 and Tumor Suppressor Genes**: EZH2 is a critical oncogene involved in the suppression of tumor suppressor genes through its role in the polycomb repressor complex 2 (PRC2). The degradation of EZH2 by GNA leads to the reactivation of these PRC2-silenced tumor suppressor genes.\\n\\n3. **Tumor Suppressor Genes and ACTA2**: While the abstract does not directly mention ACTA2, it is known from other scientific literature that ACTA2 (alpha-smooth muscle actin) can be involved in various cellular processes, including those related to tumor suppression and cellular differentiation. The reactivation of tumor suppressor genes could potentially influence the expression or activity of ACTA2, given its role in cellular structure and function.\\n\\nTherefore, the indirect relationship can be summarized as follows:\\n\\n- **Gambogenic Acid (GNA)** binds to and degrades **EZH2**.\\n- The degradation of **EZH2** leads to the reactivation of **PRC2-silenced tumor suppressor genes**.\\n- The reactivation of these tumor suppressor genes may influence the expression or activity of **ACTA2**.\\n\\nIn conclusion, the indirect relationship between gambogenic acid and the ACTA2 protein in humans is mediated through the degradation of EZH2 and the subsequent reactivation of tumor suppressor genes, which could potentially affect ACTA2 expression or function.</td>\n",
       "      <td>0.027027</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is somewhat relevant but contains inaccuracies and speculative connections not supported by the provided abstract. The abstract focuses on the role of GNA in kidney fibrosis through epigenetic inhibition of EZH2 and regulation of Smad7-dependent mechanisms, without mentioning tumor suppressor genes or CHIP-mediated ubiquitination. The connection to ACTA2 (alpha-SMA) is not clearly established in the generated answer, making it partially correct but largely speculative.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>C2716282 C3886682</td>\n",
       "      <td>gambogenic acid</td>\n",
       "      <td>ACTA2 protein, human</td>\n",
       "      <td>35994849</td>\n",
       "      <td>Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. Epigenetics regulating gene expression plays important role in kidney fibrosis. Natural products originating from diverse sources including plants and microorganisms are capable to influence epigenetic modifications. Gambogenic acid (GNA) is a caged xanthone extracted from gamboge resin, exudation of Garcinia hanburyi Hook.f., and the effect of GNA on kidney fibrosis with its underlying mechanism on epigenetics remains unknown. This study aimed to explore the role of GNA against kidney fibrogenesis by histone methylation mediating gene expression. Two experimental mice of unilateral ureteral obstruction (UUO) and folic acid (FA) were given two dosages of GNA (3 and 6 mg/kg/d). TGF-beta1 was used to stimulate mouse tubular epithelial (TCMK-1) cells and siRNAs were transfected to verify the underlying mechanisms of GNA. Histological changes were evaluated by HE, MASSON stainings, immunohistochemistry and immunofluorescence. Western blot and qPCR were used to measure protein/gene transcription levels. GNA dose-dependently alleviated UUO-induced kidney fibrosis and FA-induced kidney early fibrosis, indicated by the pathology and fibrotic factor changes (alpha-SMA, collagen I, collagen VI, and fibronectin). Mechanically, GNA reduced enhancer of zeste homolog 2 (EZH2) and H3K27me3, promoted Smad7 transcription, and inhibited TGF-beta/Smad3 fibrotic signaling in injured kidneys. Moreover, with TGF-beta1-induced EZH2 increasing, GNA suppressed alpha-SMA, fibronectin and collagen levels in tubular epithelial TCMK-1 cells. Although partially decreasing EZH2, GNA did not influence fibrotic signaling in Smad7 siRNA-transfected TCMK-1 cells. Epigenetic inhibition of EZH2 by GNA ameliorated kidney fibrogenesis via regulating Smad7-meidated TGF-beta/Smad3 signaling.</td>\n",
       "      <td>sr_pred_sent_11</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2716282', 'C0009968'): ['27036009', '26446519', '34135753', '22879914', '33744278'], ('C0009968', 'C0291573'): ['28350998', '30556269', '18381230', '32080790', '30366095'], ('C0291573', 'C3886682'): ['24427275', '30125771', '24460340', '28382147', '25087947']}</td>\n",
       "      <td>[C2716282, C0009968, C0291573, C3886682]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between gambogenic acid and the ACTA2 protein (alpha smooth muscle actin, alphaSMA) in humans can be described as follows:\\n\\n1. **Gambogenic Acid and Apoptosis in Cancer Cells**:\\n   - Gambogenic acid has been shown to induce apoptosis in breast cancer cells (MDA-MB-231) through both death receptor and mitochondrial pathways. This involves the upregulation of pro-apoptotic proteins such as Bax and cleaved caspase-3, -8, and -9, and the downregulation of the anti-apoptotic protein Bcl-2.\\n\\n2. **ACTA2 (alphaSMA) and Myofibroblasts**:\\n   - ACTA2 is a marker for myofibroblasts, which are distinct from normal fibroblasts. Myofibroblasts play a role in tissue remodeling and fibrosis and are characterized by the expression of alphaSMA. TGFbeta is known to increase the expression of alphaSMA in skin fibroblasts, indicating its role in the activation of fibroblasts to myofibroblasts.\\n\\n3. **Indirect Relationship**:\\n   - While the abstracts do not directly link gambogenic acid to ACTA2, an indirect relationship can be inferred through the broader context of apoptosis and cell differentiation. Gambogenic acid induces apoptosis in cancer cells, which could potentially affect the tumor microenvironment, including the behavior of myofibroblasts.\\n   - Myofibroblasts, marked by ACTA2 expression, are involved in the tumor microenvironment and can influence tumor progression. The apoptosis of cancer cells induced by gambogenic acid might indirectly impact the activity and presence of myofibroblasts in the tumor stroma.\\n   - Additionally, the modulation of apoptosis-related pathways by gambogenic acid could intersect with pathways that regulate myofibroblast differentiation and function, although this specific interaction is not detailed in the provided abstracts.\\n\\nIn summary, the indirect relationship between gambogenic acid and ACTA2 protein in humans can be conceptualized through the impact of gambogenic acid on cancer cell apoptosis, which may subsequently influence the tumor microenvironment and the role of myofibroblasts characterized by ACTA2 expression.</td>\n",
       "      <td>0.040541</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer attempts to describe an indirect relationship between gambogenic acid and ACTA2 protein but introduces unrelated information about apoptosis in cancer cells, which is not relevant to the provided context about kidney fibrosis. The reference answer focuses on the role of gambogenic acid in kidney fibrosis through epigenetic mechanisms involving EZH2 and Smad7, which is more pertinent. The generated answer lacks relevance and accuracy in this context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>C2716282 C3886682</td>\n",
       "      <td>gambogenic acid</td>\n",
       "      <td>ACTA2 protein, human</td>\n",
       "      <td>35994849</td>\n",
       "      <td>Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. Epigenetics regulating gene expression plays important role in kidney fibrosis. Natural products originating from diverse sources including plants and microorganisms are capable to influence epigenetic modifications. Gambogenic acid (GNA) is a caged xanthone extracted from gamboge resin, exudation of Garcinia hanburyi Hook.f., and the effect of GNA on kidney fibrosis with its underlying mechanism on epigenetics remains unknown. This study aimed to explore the role of GNA against kidney fibrogenesis by histone methylation mediating gene expression. Two experimental mice of unilateral ureteral obstruction (UUO) and folic acid (FA) were given two dosages of GNA (3 and 6 mg/kg/d). TGF-beta1 was used to stimulate mouse tubular epithelial (TCMK-1) cells and siRNAs were transfected to verify the underlying mechanisms of GNA. Histological changes were evaluated by HE, MASSON stainings, immunohistochemistry and immunofluorescence. Western blot and qPCR were used to measure protein/gene transcription levels. GNA dose-dependently alleviated UUO-induced kidney fibrosis and FA-induced kidney early fibrosis, indicated by the pathology and fibrotic factor changes (alpha-SMA, collagen I, collagen VI, and fibronectin). Mechanically, GNA reduced enhancer of zeste homolog 2 (EZH2) and H3K27me3, promoted Smad7 transcription, and inhibited TGF-beta/Smad3 fibrotic signaling in injured kidneys. Moreover, with TGF-beta1-induced EZH2 increasing, GNA suppressed alpha-SMA, fibronectin and collagen levels in tubular epithelial TCMK-1 cells. Although partially decreasing EZH2, GNA did not influence fibrotic signaling in Smad7 siRNA-transfected TCMK-1 cells. Epigenetic inhibition of EZH2 by GNA ameliorated kidney fibrogenesis via regulating Smad7-meidated TGF-beta/Smad3 signaling.</td>\n",
       "      <td>sr_pred_sent_11</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2716282', 'C0055661'): ['26780233', '30634545', '26297989', '29987200', '28565752', '30225683', '26062793', '30866863'], ('C0055661', 'C0291573'): ['27347080', '18590707', '15555556', '22574207', '27329777', '29805643', '24019108', '35301625'], ('C0291573', 'C3886682'): ['25087947', '30125771', '24427275', '30592285', '22222560', '22007630', '28382147', '24460340']}</td>\n",
       "      <td>[C2716282, C0055661, C0291573, C3886682]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between gambogenic acid and the ACTA2 protein (which encodes alpha-smooth muscle actin, alpha-SMA) in humans can be described as follows:\\n\\n1. **Gambogenic Acid and Apoptosis in Cancer Cells**:\\n   - The first abstract discusses the effects of gambogenic acid on breast cancer cells, specifically the MDA-MB-231 cell line. Gambogenic acid induces apoptosis through both death receptor and mitochondrial pathways, involving proteins such as Fas, cleaved caspase-3, -8, -9, Bax, and Bcl-2. However, this study does not directly mention ACTA2 or alpha-SMA.\\n\\n2. **Chrysin and ACTA2 in Diabetic Kidney Disease**:\\n   - The second abstract focuses on the effects of chrysin on mesangial cells exposed to advanced glycation end products (AGE) and in diabetic kidneys. Chrysin reduces the induction of alpha-SMA (encoded by ACTA2) in mesangial cells and diabetic kidney tissues, indicating its role in blocking mesangial proliferation and actin cytoskeleton formation.\\n\\n3. **Connecting the Dots**:\\n   - While the two studies do not directly link gambogenic acid to ACTA2, they provide a context for understanding potential indirect relationships. Gambogenic acid is shown to have anti-cancer properties by inducing apoptosis in breast cancer cells, while chrysin affects actin dynamics and alpha-SMA expression in mesangial cells.\\n   - Both compounds influence cellular pathways that could intersect. For instance, the apoptosis pathways modulated by gambogenic acid might indirectly affect actin cytoskeleton dynamics, as apoptosis often involves cytoskeletal reorganization.\\n   - Similarly, the modulation of actin dynamics and alpha-SMA by chrysin in mesangial cells suggests that compounds affecting apoptosis and cell proliferation (like gambogenic acid) could also impact actin-related proteins, including ACTA2, in different cellular contexts.\\n\\nIn summary, while there is no direct evidence linking gambogenic acid to ACTA2 in the provided abstracts, the indirect relationship can be inferred through the broader context of cellular pathways involving apoptosis, actin dynamics, and protein expression modulation. Gambogenic acid's role in inducing apoptosis might intersect with pathways that also regulate actin cytoskeleton and alpha-SMA expression, as seen with chrysin in mesangial cells.</td>\n",
       "      <td>0.040541</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer attempts to describe an indirect relationship between gambogenic acid and ACTA2 protein by discussing apoptosis and actin dynamics. However, it introduces unrelated studies about chrysin and cancer cells, which are not relevant to the provided context about kidney fibrosis and epigenetic regulation. The answer lacks direct relevance and coherence with the given abstracts, leading to a score of 2.0.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>C2716282 C3886682</td>\n",
       "      <td>gambogenic acid</td>\n",
       "      <td>ACTA2 protein, human</td>\n",
       "      <td>35994849</td>\n",
       "      <td>Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. Epigenetics regulating gene expression plays important role in kidney fibrosis. Natural products originating from diverse sources including plants and microorganisms are capable to influence epigenetic modifications. Gambogenic acid (GNA) is a caged xanthone extracted from gamboge resin, exudation of Garcinia hanburyi Hook.f., and the effect of GNA on kidney fibrosis with its underlying mechanism on epigenetics remains unknown. This study aimed to explore the role of GNA against kidney fibrogenesis by histone methylation mediating gene expression. Two experimental mice of unilateral ureteral obstruction (UUO) and folic acid (FA) were given two dosages of GNA (3 and 6 mg/kg/d). TGF-beta1 was used to stimulate mouse tubular epithelial (TCMK-1) cells and siRNAs were transfected to verify the underlying mechanisms of GNA. Histological changes were evaluated by HE, MASSON stainings, immunohistochemistry and immunofluorescence. Western blot and qPCR were used to measure protein/gene transcription levels. GNA dose-dependently alleviated UUO-induced kidney fibrosis and FA-induced kidney early fibrosis, indicated by the pathology and fibrotic factor changes (alpha-SMA, collagen I, collagen VI, and fibronectin). Mechanically, GNA reduced enhancer of zeste homolog 2 (EZH2) and H3K27me3, promoted Smad7 transcription, and inhibited TGF-beta/Smad3 fibrotic signaling in injured kidneys. Moreover, with TGF-beta1-induced EZH2 increasing, GNA suppressed alpha-SMA, fibronectin and collagen levels in tubular epithelial TCMK-1 cells. Although partially decreasing EZH2, GNA did not influence fibrotic signaling in Smad7 siRNA-transfected TCMK-1 cells. Epigenetic inhibition of EZH2 by GNA ameliorated kidney fibrogenesis via regulating Smad7-meidated TGF-beta/Smad3 signaling.</td>\n",
       "      <td>sr_pred_sent_11</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2716282', 'C1421313'): ['27124181', '28683125', '32240652'], ('C1421313', 'C0291573'): ['29858912', '35689706', '35656450', '28875237', '19610036', '23099053', '32454192', '28089824', '22502613'], ('C0291573', 'C3886682'): ['24460340', '28382147', '22222560', '22007630', '33624779', '30592285', '25087947', '24427275', '30125771']}</td>\n",
       "      <td>[C2716282, C1421313, C0291573, C3886682]</td>\n",
       "      <td>To describe an indirect relationship between gambogenic acid and the ACTA2 protein (also known as alpha-smooth muscle actin or SMA) in humans, we need to identify a chain of interactions or effects that connect these two entities based on the provided abstracts.\\n\\n1. **Gambogenic Acid and Apoptosis**:\\n   - The third abstract discusses the effects of gambogenic acid on breast cancer cells, highlighting its role in inducing apoptosis. Gambogenic acid increases the expression of apoptosis-related proteins such as cleaved caspase-3, -8, -9, and Bax, while decreasing the anti-apoptotic protein Bcl-2. This suggests that gambogenic acid promotes apoptosis through both death receptor and mitochondrial pathways.\\n\\n2. **Caspase-3 and Apoptosis**:\\n   - The second abstract focuses on a fluorescence-quenching-based assay for detecting caspase-3 activity, which is a key mediator of apoptosis. Caspase-3 is activated during apoptosis and is involved in the cleavage of various cellular proteins, leading to cell death.\\n\\n3. **Prostaglandin E2 (PGE2) and ACTA2**:\\n   - The first abstract describes the role of PGE2 in regulating inflammation, fibrosis, and adipose tissue remodeling in obese human adipose tissue. PGE2 is shown to reduce the expression of fibrogenic genes, including Col1alpha1, Col1alpha2, and ACTA2 (SMA), in differentiated adipocytes exposed to TGF-beta. This indicates that PGE2 can down-regulate ACTA2 expression, which is associated with fibrosis and inflammation.\\n\\n4. **Connecting the Dots**:\\n   - While the abstracts do not directly link gambogenic acid to ACTA2, we can infer an indirect relationship through the following chain of interactions:\\n     - Gambogenic acid induces apoptosis in cancer cells by activating caspase-3.\\n     - Caspase-3, as a key mediator of apoptosis, can influence various cellular processes, including inflammation and fibrosis.\\n     - PGE2, which is involved in the regulation of inflammation and fibrosis, can down-regulate ACTA2 expression in adipocytes.\\n     - Therefore, if gambogenic acid influences the levels of PGE2 or the activity of caspase-3 in a broader biological context, it could indirectly affect the expression of ACTA2.\\n\\nIn summary, the indirect relationship between gambogenic acid and ACTA2 protein in humans can be described as follows: Gambogenic acid induces apoptosis through the activation of caspase-3. Caspase-3, being a central player in apoptosis, may influence inflammatory and fibrotic processes. PGE2, which regulates inflammation and fibrosis, can down-regulate ACTA2 expression. Thus, through a cascade of apoptotic and inflammatory pathways, gambogenic acid may indirectly impact the expression of ACTA2.</td>\n",
       "      <td>0.066667</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer attempts to establish an indirect relationship between gambogenic acid and ACTA2 protein by connecting multiple biological pathways. However, it introduces information not present in the provided abstract, such as the role of PGE2 and caspase-3, which are not mentioned in the context. This makes the answer speculative and not fully grounded in the given context, leading to inaccuracies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2698841', 'C1421500'): ['26885445', '35159005'], ('C1421500', 'C4053677'): ['31222885', '27318641', '31703356', '35173547', '28790110', '30068368', '27304454', '28208168']}</td>\n",
       "      <td>[C2698841, C1421500, C4053677]</td>\n",
       "      <td>To describe an indirect relationship between AZD-1775 and Volasertib based on the provided scientific abstracts, you would need to identify the key points from each abstract that suggest a connection between the two drugs, even if they are not directly compared or studied together. Heres a structured approach to synthesizing the information:\\n\\n1. **Mechanism of Action**:\\n   - **AZD-1775**: This drug is a Wee1 kinase inhibitor. Wee1 kinase is involved in the regulation of the G2/M checkpoint in the cell cycle. By inhibiting Wee1, AZD-1775 forces cells with DNA damage to enter mitosis prematurely, leading to cell death, particularly in cancer cells with defective p53.\\n   - **Volasertib**: This drug is a Polo-like kinase 1 (Plk1) inhibitor. Plk1 is crucial for various stages of mitosis, including spindle formation and cytokinesis. Inhibiting Plk1 disrupts mitotic progression and can lead to cell death.\\n\\n2. **Cell Cycle and Cancer Therapy**:\\n   - Both drugs target key regulators of the cell cycle, albeit at different points. AZD-1775 affects the G2/M checkpoint, while Volasertib impacts mitotic progression. This suggests that both drugs aim to exploit the vulnerabilities of cancer cells during cell division.\\n\\n3. **Therapeutic Context**:\\n   - **AZD-1775**: Often used in combination with DNA-damaging agents (like chemotherapy) to enhance their efficacy by preventing cancer cells from repairing DNA damage before mitosis.\\n   - **Volasertib**: Can be used as a monotherapy or in combination with other agents to disrupt mitosis in cancer cells.\\n\\n4. **Potential Synergy**:\\n   - Given their mechanisms, there is a potential for a synergistic effect if both drugs were used in combination. AZD-1775 could force cells into mitosis with damaged DNA, while Volasertib could then inhibit the mitotic process, leading to enhanced cell death.\\n\\n5. **Research Implications**:\\n   - Studies might explore the sequential or combined use of these drugs to maximize cancer cell kill rates. For instance, pre-treating with AZD-1775 to accumulate cells in a vulnerable state followed by Volasertib to disrupt mitosis could be a potential therapeutic strategy.\\n\\n6. **Clinical Trials and Studies**:\\n   - If abstracts mention clinical trials or studies involving these drugs, they might provide insights into their efficacy, safety, and potential combinatory use. For example, if one abstract discusses the success of AZD-1775 in a specific cancer type, and another highlights Volasertibs effectiveness in the same or similar context, this could suggest an indirect relationship worth exploring further.\\n\\n### Example Description:\\n\\n\"AZD-1775 and Volasertib exhibit an indirect relationship through their complementary mechanisms of action targeting different phases of the cell cycle in cancer therapy. AZD-1775, a Wee1 kinase inhibitor, disrupts the G2/M checkpoint, forcing cells with DNA damage into mitosis prematurely. Volasertib, a Polo-like kinase 1 inhibitor, interferes with mitotic progression. This suggests a potential synergistic effect where AZD-1775-induced premature mitosis could be further exploited by Volasertibs inhibition of mitotic processes, leading to enhanced cancer cell death. This indirect relationship highlights a promising area for combinatory therapeutic strategies in oncology.\"\\n\\nThis description synthesizes the key points from the abstracts to explain how the two drugs might be related indirectly through their effects on the cell cycle and potential for combined use in cancer treatment.</td>\n",
       "      <td>0.046512</td>\n",
       "      <td>4.0</td>\n",
       "      <td>The generated answer is relevant and provides a comprehensive explanation of the indirect relationship between AZD-1775 and Volasertib. It accurately describes the mechanisms of action of both drugs, their roles in cancer therapy, and the potential for synergistic effects. However, it is somewhat verbose and could be more concise.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2698841', 'C0971285'): ['31832331', '35159005', '28482026', '32735909', '35637734'], ('C0971285', 'C4053677'): ['30755439']}</td>\n",
       "      <td>[C2698841, C0971285, C4053677]</td>\n",
       "      <td>Based on the provided scientific abstracts, an indirect relationship between AZD-1775 (adavosertib) and Volasertib can be described through their respective roles in targeting different components of the cell cycle machinery, which can be exploited for cancer therapy.\\n\\n1. **AZD-1775 (Adavosertib)**: This is a WEE1 inhibitor. WEE1 is a kinase that plays a crucial role in the G2-M checkpoint by inhibiting CDK1, thereby preventing cells with DNA damage from entering mitosis. Inhibition of WEE1 by AZD-1775 forces cells to prematurely enter mitosis, leading to mitotic catastrophe, especially in cells with defective p53, such as HPV-negative HNSCC.\\n\\n2. **Volasertib**: This is an inhibitor of Polo-like kinase 1 (PLK1), another key regulator of mitosis. PLK1 is involved in various stages of mitotic progression, including spindle formation, chromosome segregation, and cytokinesis. Inhibition of PLK1 by Volasertib disrupts these processes, leading to mitotic arrest and cell death.\\n\\n**Indirect Relationship**:\\n- Both AZD-1775 and Volasertib target different kinases that are crucial for the proper progression of the cell cycle, particularly mitosis.\\n- The abstract describes a synergistic antitumor effect when combining AURKA inhibition (alisertib) with WEE1 inhibition (AZD-1775), suggesting that disrupting multiple points of cell cycle regulation can be an effective therapeutic strategy.\\n- Although Volasertib is not directly mentioned in the abstract, its role as a PLK1 inhibitor suggests that it could potentially be combined with other cell cycle inhibitors like AZD-1775 to achieve similar synergistic effects. Both drugs disrupt mitotic processes but at different regulatory points, which could lead to enhanced antitumor activity.\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib lies in their complementary mechanisms of action in disrupting cell cycle progression, particularly mitosis, which can be exploited for synergistic cancer therapy.</td>\n",
       "      <td>0.034884</td>\n",
       "      <td>4.0</td>\n",
       "      <td>The generated answer is relevant and mostly correct. It accurately describes the roles of AZD-1775 and Volasertib in targeting different components of the cell cycle and explains their potential synergistic effects in cancer therapy. However, it introduces some extraneous information (e.g., mentioning HPV-negative HNSCC) that is not directly related to the provided context. Additionally, it does not explicitly mention the combination of Volasertib and AZD-1775 as described in the reference answer, which slightly detracts from its completeness.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2698841', 'C0971285'): ['35159005', '31832331'], ('C0971285', 'C0290178'): ['32231069', '27249336'], ('C0290178', 'C4053677'): ['29954437', '31200459']}</td>\n",
       "      <td>[C2698841, C0971285, C0290178, C4053677]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between AZD-1775 and Volasertib can be described through their respective targets and the downstream effects on cell cycle regulation and mitosis.\\n\\n1. **AZD-1775 and Wee1 Inhibition**:\\n   - AZD-1775 is primarily an inhibitor of Wee1 kinase at therapeutically relevant concentrations.\\n   - Wee1 kinase inhibits cyclin-dependent kinase 1 (Cdk1) by phosphorylating it, which prevents cells from entering mitosis with incompletely replicated or damaged DNA.\\n   - Inhibition of Wee1 by AZD-1775 leads to the acceleration of mitosis onset, overriding the DNA replication checkpoint, and hastening Plk1-dependent phosphorylation.\\n\\n2. **Volasertib and Plk1 Inhibition**:\\n   - Volasertib is a known inhibitor of Polo-like kinase 1 (Plk1).\\n   - Plk1 is crucial for various stages of mitosis, including the activation of Cdk1 and the progression through mitosis.\\n   - Inhibition of Plk1 by Volasertib would therefore slow down or halt mitotic progression, contrasting with the effects of Wee1 inhibition by AZD-1775.\\n\\n3. **Indirect Relationship**:\\n   - Although AZD-1775 primarily targets Wee1, it has been shown to inhibit Plk1 in vitro, though not at clinically relevant concentrations.\\n   - The primary action of AZD-1775 is to promote mitotic entry by inhibiting Wee1, which indirectly affects Plk1 activity by hastening Plk1-dependent phosphorylation events.\\n   - Volasertib directly inhibits Plk1, leading to a direct suppression of mitotic progression.\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib can be understood through their effects on the cell cycle and mitosis. AZD-1775, by inhibiting Wee1, indirectly influences Plk1 activity and mitotic progression, while Volasertib directly inhibits Plk1. This relationship highlights the interconnected roles of Wee1 and Plk1 in cell cycle regulation and the potential for combined therapeutic strategies targeting these kinases.</td>\n",
       "      <td>0.036585</td>\n",
       "      <td>4.0</td>\n",
       "      <td>The generated answer is relevant and mostly correct, providing a detailed explanation of the indirect relationship between AZD-1775 and Volasertib through their effects on cell cycle regulation and mitosis. However, it could be more concise and directly tied to the specific context of the provided abstracts, which focus on the combination therapy in chronic myeloid leukemia (CML).</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2698841', 'C1333655'): ['31122263'], ('C1333655', 'C0525037'): ['14971655', '26518708', '15637593', '25187435', '1990262', '33976322', '16022731'], ('C0525037', 'C4053677'): ['28619757', '34277427', '32565737', '32012873', '30755439', '27939202']}</td>\n",
       "      <td>[C2698841, C1333655, C0525037, C4053677]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between AZD-1775 (adavosertib) and Volasertib can be described through their involvement in targeting different components of the cell cycle and mitotic checkpoints, which are crucial for cancer cell survival and proliferation.\\n\\n1. **AZD-1775 (Adavosertib)**:\\n   - **Mechanism of Action**: AZD-1775 is a WEE1 inhibitor. WEE1 is a kinase that regulates the G2/M checkpoint by inhibiting CDK1, thus preventing cells with DNA damage from entering mitosis.\\n   - **Context**: In the context of HPV-negative head and neck squamous cell carcinoma (HNSCC), AZD-1775 promotes M-phase entry, leading to mitotic catastrophe and apoptosis when combined with CHK1/2 inhibitors. This combination is particularly effective in cells with compromised G1/S checkpoints due to TP53 and CDKN2A mutations.\\n\\n2. **Volasertib**:\\n   - **Mechanism of Action**: Volasertib is a Polo-like kinase 1 (PLK1) inhibitor. PLK1 is essential for various stages of mitosis, including spindle formation, chromosome segregation, and cytokinesis.\\n   - **Context**: In chronic myeloid leukemia (CML), Volasertib targets the AURKA-PLK1-FOXM1 axis, which is hyper-activated due to BCR-ABL1 tyrosine kinase activity. Inhibition of this axis can lead to increased expression of GADD45a, a DNA damage-inducible gene that inhibits AURKA, thereby promoting apoptosis and potentially eradicating leukemic cells.\\n\\n**Indirect Relationship**:\\n- **Common Pathways**: Both AZD-1775 and Volasertib target key regulators of the cell cycle and mitosis, albeit at different points. AZD-1775 affects the G2/M checkpoint by inhibiting WEE1, while Volasertib targets PLK1, a critical kinase for mitotic progression.\\n- **DNA Damage Response**: Both drugs indirectly influence the DNA damage response. AZD-1775, by promoting mitotic entry in the presence of DNA damage, and Volasertib, by disrupting mitotic processes and potentially increasing GADD45a expression, which is involved in the DNA damage response.\\n- **Therapeutic Potential**: The inhibition of these pathways can lead to synthetic lethality in cancer cells that rely on these checkpoints due to other genetic deficiencies (e.g., TP53 mutations in HNSCC or BCR-ABL1 activity in CML).\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib lies in their shared goal of disrupting cell cycle regulation and mitotic checkpoints to induce cancer cell death, albeit through different molecular targets and mechanisms. This convergence on cell cycle disruption highlights their potential complementary roles in cancer therapy.</td>\n",
       "      <td>0.034884</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the mechanisms of action for both AZD-1775 and Volasertib. However, it introduces additional contexts (e.g., HPV-negative head and neck squamous cell carcinoma) that are not present in the provided abstract, leading to some inaccuracies. The core idea of the indirect relationship through cell cycle disruption is correct, but the extraneous details and slight deviations from the provided context reduce the overall accuracy.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2698841', 'C0079419'): ['31227645'], ('C0079419', 'C4053677'): ['30679201']}</td>\n",
       "      <td>[C2698841, C0079419, C4053677]</td>\n",
       "      <td>An indirect relationship between AZD-1775 and Volasertib can be described through their respective mechanisms of action and their effects on p53-related pathways in different types of cancer.\\n\\n1. **Mechanism of Action**:\\n   - **AZD-1775**: This is a WEE1 kinase inhibitor. WEE1 is a key regulator of the G2/M checkpoint in the cell cycle, and its inhibition leads to mitotic entry with damaged DNA, particularly in p53-deficient cells. This results in increased replication stress, mitotic deregulation, and ultimately cell death.\\n   - **Volasertib**: This is a Polo-like kinase 1 (PLK1) inhibitor. PLK1 is crucial for various stages of mitosis, and its inhibition leads to cell-cycle arrest and apoptosis. In B-cell acute lymphoblastic leukemia (B-ALL), PLK1 inhibition results in p53 stabilization and cell death.\\n\\n2. **p53 Pathway**:\\n   - Both drugs indirectly affect the p53 pathway, albeit in different contexts and cancer types.\\n   - **AZD-1775**: In p53-deficient head and neck cancer cells, the absence of functional p53 exacerbates the effects of WEE1 inhibition, leading to increased replication stress and mitotic errors, which the cells cannot properly repair, resulting in cell death.\\n   - **Volasertib**: In B-ALL, PLK1 inhibition leads to p53 stabilization and upregulation of pro-apoptotic factors like BAX, promoting cell death. This effect is seen even in the presence of functional p53, as PLK1 inhibition directly influences p53 activity.\\n\\n3. **Therapeutic Implications**:\\n   - Both drugs are being explored for their potential in treating cancers with specific genetic backgrounds.\\n   - **AZD-1775**: Its efficacy is being tested in p53-deficient head and neck squamous cell carcinoma, where the lack of p53 makes the cells more susceptible to the replication stress and mitotic errors induced by WEE1 inhibition.\\n   - **Volasertib**: Its efficacy is being tested in B-ALL, particularly in high-risk subtypes like Philadelphia-like ALL, where PLK1 inhibition can lead to p53 stabilization and apoptosis.\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib lies in their shared impact on the p53 pathway, albeit through different mechanisms and in different cancer types. AZD-1775 exploits the vulnerabilities of p53-deficient cells by inducing replication stress and mitotic errors, while Volasertib stabilizes p53 by inhibiting PLK1, leading to cell death in B-ALL. Both drugs highlight the therapeutic potential of targeting cell cycle regulators in cancers with specific genetic alterations.</td>\n",
       "      <td>0.024096</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is somewhat relevant but contains inaccuracies and lacks direct connection to the provided context. The reference answer focuses on the combination of AZD-1775 and Volasertib in treating chronic myeloid leukemia (CML) and their effects on DNA damage and apoptosis. The generated answer, however, discusses the mechanisms of action of AZD-1775 and Volasertib in different cancer types and their impact on the p53 pathway, which is not directly related to the context provided.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>C2698841 C4053677</td>\n",
       "      <td>AZD-1775</td>\n",
       "      <td>Volasertib</td>\n",
       "      <td>35992847</td>\n",
       "      <td>Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.</td>\n",
       "      <td>sr_pred_sent_5</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2698841', 'C0249197'): ['24660103'], ('C0249197', 'C3853822'): ['30979737', '28663582', '35619220', '30872077'], ('C3853822', 'C4053677'): ['28619757']}</td>\n",
       "      <td>[C2698841, C0249197, C3853822, C4053677]</td>\n",
       "      <td>Based on the provided scientific abstracts, an indirect relationship between AZD-1775 and Volasertib can be described through their respective interactions with other agents that influence cell cycle regulation and DNA damage response in cancer cells.\\n\\n1. **Volasertib and Sepantronium**: The first abstract describes how Volasertib, a PLK1 inhibitor, synergizes with Sepantronium, a DNA-damaging agent, to inhibit the growth of non-small cell lung cancer (NSCLC) cell lines. Sepantronium enhances the anti-neoplastic effects of Volasertib by preventing the accumulation of survivin and cyclin B, inducing cell cycle arrest, and causing DNA damage. This combination effectively disrupts the cell cycle and enhances cancer cell lethality.\\n\\n2. **AZD-1775 and Palbociclib**: The second abstract discusses how AZD-1775, a Wee1 kinase inhibitor, works synergistically with Palbociclib, a CDK4/6 inhibitor, to sensitize Rb-positive sarcoma cells to cell cycle arrest and subsequent treatment. Palbociclib induces a reversible G1 phase arrest, making the cells more susceptible to agents like AZD-1775 that act preferentially in the S-G2 phase. This combination strategy is shown to be effective in both in vitro and in vivo models.\\n\\n**Indirect Relationship**:\\n- **Cell Cycle Modulation**: Both AZD-1775 and Volasertib are involved in disrupting the cell cycle, albeit at different phases. Volasertib targets PLK1, which is crucial for mitotic progression, while AZD-1775 inhibits Wee1 kinase, which regulates the G2/M checkpoint.\\n- **Synergistic Combinations**: Both drugs are part of combination therapies that enhance their efficacy. Volasertib's synergy with Sepantronium involves DNA damage and cell cycle arrest, while AZD-1775's synergy with Palbociclib involves sensitizing cells to S-G2 phase agents following G1 arrest.\\n- **DNA Damage Response**: The combination of Sepantronium with Volasertib leads to DNA damage and cell cycle disruption, similar to how AZD-1775, when combined with Palbociclib, exploits cell cycle vulnerabilities to enhance treatment efficacy.\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib is established through their roles in cell cycle regulation and their use in combination therapies that enhance the efficacy of cancer treatments by exploiting cell cycle vulnerabilities and inducing DNA damage responses.</td>\n",
       "      <td>0.036145</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is somewhat relevant but contains inaccuracies and lacks direct connection to the provided context. The reference answer focuses on the combination of AZD-1775 and Volasertib in the context of chronic myeloid leukemia (CML) and their role in overcoming tyrosine kinase inhibitor resistance. The generated answer, however, introduces unrelated agents (Sepantronium and Palbociclib) and discusses different cancer types (NSCLC and sarcoma), which diverges from the specific context of CML provided in the reference. This makes the generated answer less accurate and relevant.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2316164', 'C0278987'): ['33070053', '34701460', '35511434'], ('C0278987', 'C4080091'): ['34626769', '33776691', '33569330', '33091333', '30394941', '30786826', '35307611', '32974130']}</td>\n",
       "      <td>[C2316164, C0278987, C4080091]</td>\n",
       "      <td>To describe an indirect relationship between olaparib and lorlatinib based on scientific abstracts, you would need to identify the key points from each abstract that connect the two drugs through intermediary factors such as biological pathways, mechanisms of action, or clinical outcomes. Heres a structured approach to formulating such a description:\\n\\n1. **Identify the Mechanisms of Action:**\\n   - **Olaparib:** This is a PARP inhibitor used primarily in the treatment of cancers with BRCA1/2 mutations. It works by inhibiting the PARP enzyme, which is involved in DNA repair, thereby leading to the accumulation of DNA damage and cancer cell death.\\n   - **Lorlatinib:** This is an ALK and ROS1 tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations. It works by inhibiting the activity of these kinases, which are involved in cell growth and survival.\\n\\n2. **Identify Common Pathways or Biological Processes:**\\n   - Both drugs are involved in targeting specific genetic mutations or alterations in cancer cells.\\n   - Both drugs ultimately aim to induce cancer cell death, albeit through different mechanisms (DNA damage for olaparib and kinase inhibition for lorlatinib).\\n\\n3. **Identify Potential Intermediary Factors:**\\n   - **Genetic Mutations:** Both drugs may be used in cancers with specific genetic backgrounds. For instance, a patient with a BRCA mutation (targeted by olaparib) might also have an ALK or ROS1 mutation (targeted by lorlatinib).\\n   - **Combination Therapies:** There might be ongoing research or clinical trials exploring the combination of PARP inhibitors with tyrosine kinase inhibitors to enhance therapeutic efficacy or overcome resistance.\\n\\n4. **Clinical Outcomes and Research Context:**\\n   - Research might be exploring the sequential use of these drugs in patients who develop resistance to one therapy.\\n   - Studies might be investigating the broader genetic landscape of cancers to identify patients who could benefit from both therapies.\\n\\n### Example Description:\\n\\nBased on the provided scientific abstracts, an indirect relationship between olaparib and lorlatinib can be described through their roles in targeted cancer therapy. Olaparib, a PARP inhibitor, is primarily used to treat cancers with BRCA1/2 mutations by exploiting the defective DNA repair mechanisms in these cancer cells. On the other hand, lorlatinib is a tyrosine kinase inhibitor targeting ALK and ROS1 mutations, commonly used in non-small cell lung cancer (NSCLC).\\n\\nThe indirect relationship between these two drugs may be mediated through the genetic landscape of the tumors they target. For instance, a subset of patients with complex genetic profiles might harbor both BRCA mutations and ALK/ROS1 alterations, making them potential candidates for sequential or combination therapy involving both olaparib and lorlatinib. Additionally, ongoing research might be investigating the synergistic effects of combining PARP inhibitors with tyrosine kinase inhibitors to overcome resistance mechanisms and improve clinical outcomes.\\n\\nIn summary, while olaparib and lorlatinib target different molecular pathways, their indirect relationship is rooted in the genetic complexities of cancer and the evolving strategies in precision oncology to tailor treatments based on specific genetic alterations.</td>\n",
       "      <td>0.053763</td>\n",
       "      <td>4.0</td>\n",
       "      <td>The generated answer is relevant and provides a structured approach to describing the indirect relationship between olaparib and lorlatinib. It correctly identifies the mechanisms of action, common pathways, intermediary factors, and clinical outcomes. However, it could be more concise and directly reference the specific case report mentioned in the reference answer to strengthen the connection.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2316164', 'C0278987'): ['33070053', '34701460', '35511434'], ('C0278987', 'C3818721'): ['27401242', '26361725', '28404761', '28729021', '34626769', '30251885', '31906956', '25888090'], ('C3818721', 'C4080091'): ['31331844', '31857951', '35250311', '31943796', '31354290', '29799091', '33449423', '30737231']}</td>\n",
       "      <td>[C2316164, C0278987, C3818721, C4080091]</td>\n",
       "      <td>Based on the provided abstract, an indirect relationship between olaparib and lorlatinib can be described as follows:\\n\\nOlaparib and lorlatinib are both targeted therapies used in the treatment of different types of cancer. Olaparib is a PARP inhibitor primarily used for treating certain types of ovarian, breast, pancreatic, and prostate cancers, particularly those with BRCA mutations. Lorlatinib, on the other hand, is an ALK inhibitor used for treating ALK-positive non-small cell lung cancer (NSCLC), including cases with brain metastases.\\n\\nThe abstract focuses on a Bayesian network meta-analysis comparing the efficacy of various treatments for ALK-positive, brain metastatic NSCLC, highlighting lorlatinib as one of the top-ranking treatments for progression-free survival (PFS) and objective response rate (ORR) in these patients. It also mentions that lorlatinib is recommended as a second-line treatment after alectinib, especially in cases of drug resistance.\\n\\nThe indirect relationship between olaparib and lorlatinib can be understood in the context of their roles in targeted cancer therapy. Both drugs represent advancements in personalized medicine, targeting specific genetic mutations or alterations in cancer cells. While they are used for different cancer types and target different molecular pathways, their development and use reflect a broader trend in oncology towards precision medicine, where treatments are tailored based on the genetic profile of the tumor.\\n\\nIn summary, the indirect relationship between olaparib and lorlatinib lies in their shared role as targeted therapies in the evolving landscape of cancer treatment, each addressing specific genetic vulnerabilities in different types of cancer.</td>\n",
       "      <td>0.023810</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is somewhat relevant but contains significant inaccuracies and lacks specificity. It incorrectly describes the abstract's content, mentioning a Bayesian network meta-analysis which is not present in the provided abstract. Additionally, it fails to accurately capture the specific context of the indirect relationship between olaparib and lorlatinib as described in the reference answer. The reference answer provides a detailed case study, while the generated answer gives a general overview of the drugs without addressing the specific case or the indirect relationship in the context of the provided abstract.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C2316164', 'C3818721'): ['32224911', '34810199'], ('C3818721', 'C4080091'): ['34820326', '31616158', '29458783', '32974130', '30786826', '33449423', '33776703', '30662002', '31857953', '34418561']}</td>\n",
       "      <td>[C2316164, C3818721, C4080091]</td>\n",
       "      <td>An indirect relationship between olaparib and lorlatinib can be inferred from the contexts provided in the scientific abstracts, even though the two drugs are not directly compared or studied together.\\n\\n1. **Olaparib Context**: In the first abstract, olaparib is mentioned as a less effective treatment compared to the combination of ceritinib and dasatinib in a case of osteosarcoma with lung metastases. This suggests that olaparib, a PARP inhibitor, was considered for its potential therapeutic effects but was found to be less effective in this specific context.\\n\\n2. **Lorlatinib Context**: The second abstract discusses lorlatinib, a selective inhibitor of ALK and ROS1 tyrosine kinases, used for treating ALK-positive metastatic non-small cell lung cancer (NSCLC). The pharmacokinetics of lorlatinib are well-characterized, and it is used following progression on other ALK inhibitors like crizotinib, alectinib, or ceritinib.\\n\\n3. **Indirect Relationship via Ceritinib**: The indirect relationship between olaparib and lorlatinib can be established through ceritinib. Ceritinib is a common link between the two abstracts:\\n   - In the first abstract, ceritinib is part of a combination therapy (with dasatinib) that was more effective than olaparib in treating osteosarcoma.\\n   - In the second abstract, ceritinib is mentioned as a prior ALK inhibitor therapy before lorlatinib is administered for NSCLC.\\n\\n4. **Therapeutic Pathways and Indications**: Both olaparib and lorlatinib are used in cancer treatment, but they target different pathways and types of cancer. Olaparib is a PARP inhibitor used primarily in cancers with BRCA mutations, while lorlatinib targets ALK and ROS1 in NSCLC. The indirect relationship is highlighted by the fact that ceritinib, which is relevant in both contexts, serves as a bridge between the two drugs.\\n\\nIn summary, the indirect relationship between olaparib and lorlatinib is mediated through ceritinib, which is a common factor in the treatment protocols discussed in the abstracts. While olaparib and lorlatinib are used for different cancer types and mechanisms, ceritinib's involvement in both contexts provides a link between them.</td>\n",
       "      <td>0.034091</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer attempts to establish an indirect relationship between olaparib and lorlatinib through ceritinib, but it misinterprets the context of the provided abstracts. The reference answer clearly describes a direct combination therapy involving both olaparib and lorlatinib in a specific case of metastatic lung adenocarcinoma. The generated answer's focus on ceritinib as a bridge is incorrect and irrelevant to the actual relationship described in the reference.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2316164', 'C0672708'): ['29902865', '25888415'], ('C0672708', 'C1420703'): ['23484070'], ('C1420703', 'C4080091'): ['34059352', '34157012']}</td>\n",
       "      <td>[C2316164, C0672708, C1420703, C4080091]</td>\n",
       "      <td>An indirect relationship between olaparib and lorlatinib can be described through their respective roles in targeting different molecular pathways in cancer treatment, as inferred from the provided scientific abstracts.\\n\\n1. **Olaparib and DNA Repair Pathways in TNBC**:\\n   - Olaparib is a PARP inhibitor used in the treatment of triple-negative breast cancer (TNBC), particularly in BRCA-mutated cells. It works by inhibiting the PARP enzyme, which is crucial for repairing single-strand DNA breaks. When combined with histone deacetylase inhibitors (HDACi), olaparib shows enhanced efficacy by further disrupting DNA repair mechanisms, leading to increased DNA damage and cell death in TNBC cells.\\n\\n2. **Lorlatinib and Tyrosine Kinase Inhibitors in IMT**:\\n   - Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 fusions, which are common in inflammatory myofibroblastic tumors (IMTs). It is particularly effective in cases where resistance to first and second-generation TKIs, such as crizotinib, has developed. Lorlatinib's mechanism involves inhibiting the signaling pathways driven by these oncogenic fusions, thereby controlling tumor growth and metastasis.\\n\\n**Indirect Relationship**:\\n- The indirect relationship between olaparib and lorlatinib lies in their shared goal of targeting specific molecular abnormalities in cancer cells, albeit through different mechanisms and in different types of cancers. Olaparib focuses on impairing DNA repair pathways in TNBC, especially in BRCA-mutated cells, while lorlatinib targets tyrosine kinase signaling pathways in IMTs with ROS1 fusions.\\n- Both drugs exemplify the precision medicine approach, where treatments are tailored based on the molecular characteristics of the tumor. This highlights the broader strategy of using targeted therapies to exploit specific vulnerabilities in cancer cells, whether through disrupting DNA repair (olaparib) or inhibiting oncogenic signaling (lorlatinib).\\n\\nIn summary, while olaparib and lorlatinib do not directly interact or target the same pathways, they are both part of the evolving landscape of targeted cancer therapies that aim to improve outcomes by focusing on the unique molecular features of different cancers.</td>\n",
       "      <td>0.022222</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer provides a general explanation of the mechanisms of olaparib and lorlatinib but does not directly address the specific context provided by the scientific abstracts. It introduces unrelated information about TNBC and IMT, which is not relevant to the ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma case discussed in the reference. The answer lacks focus on the specific indirect relationship highlighted in the provided context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2316164', 'C3501358'): ['31974435', '29575238'], ('C3501358', 'C0007131'): ['25214559', '30663221', '34921994', '33434619'], ('C0007131', 'C4080091'): ['35431862', '32069373', '34820326', '33298467']}</td>\n",
       "      <td>[C2316164, C3501358, C0007131, C4080091]</td>\n",
       "      <td>Based on the provided scientific abstract, an indirect relationship between olaparib and lorlatinib can be described through their respective interactions with other drugs and their roles in cancer treatment. Heres a detailed explanation:\\n\\n1. **Olaparib and Ibrutinib in Mantle Cell Lymphoma (MCL):**\\n   - Olaparib is a PARP inhibitor that targets tumor cells with deficiencies in single-strand DNA break repair.\\n   - Ibrutinib is a B cell targeting agent used as a second-line therapy for MCL.\\n   - The combination of olaparib and ibrutinib has been shown to significantly inhibit MCL cell growth more effectively than either drug alone, through mechanisms such as increased apoptosis, cell death, and cell cycle arrest.\\n\\n2. **Lorlatinib in Cancer Treatment:**\\n   - Although lorlatinib is not mentioned in the provided abstract, it is known to be a third-generation ALK and ROS1 tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations.\\n\\n3. **Indirect Relationship:**\\n   - The indirect relationship between olaparib and lorlatinib can be inferred through their shared context in cancer treatment and their interactions with other drugs.\\n   - Both olaparib and lorlatinib are used in targeted cancer therapies, albeit for different types of cancer and genetic contexts.\\n   - The combination strategy involving olaparib and ibrutinib in MCL suggests a broader principle of using drug combinations to enhance therapeutic efficacy and overcome resistance, which is a common challenge in cancer treatment, including in the context where lorlatinib is used.\\n   - While olaparib is combined with ibrutinib to target MCL, lorlatinib might be combined with other agents to target NSCLC, reflecting a similar therapeutic strategy of using drug combinations to improve outcomes.\\n\\nIn summary, the indirect relationship between olaparib and lorlatinib is characterized by their roles in targeted cancer therapies and the principle of using drug combinations to enhance treatment efficacy and manage drug resistance. This relationship is contextual and based on their respective interactions with other drugs in the treatment of different cancers.</td>\n",
       "      <td>0.022222</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is somewhat relevant but contains significant inaccuracies and irrelevant information. The user query specifically asks about the indirect relationship between olaparib and lorlatinib in the context of the provided scientific abstract, which discusses their combined use in treating a specific case of metastatic lung adenocarcinoma. The generated answer incorrectly introduces ibrutinib and mantle cell lymphoma, which are not mentioned in the provided abstract, leading to confusion and a lack of focus on the actual context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>C2316164 C4080091</td>\n",
       "      <td>olaparib</td>\n",
       "      <td>lorlatinib</td>\n",
       "      <td>35324529</td>\n",
       "      <td>Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C2316164', 'C0000970'): ['34111734'], ('C0000970', 'C1333573'): ['23220477', '31428698'], ('C1333573', 'C4080091'): ['30459283']}</td>\n",
       "      <td>[C2316164, C0000970, C1333573, C4080091]</td>\n",
       "      <td>An indirect relationship between olaparib and lorlatinib can be inferred through their involvement in overlapping biological pathways and the use of similar analytical techniques for their study, as described in the provided scientific abstracts.\\n\\n1. **Analytical Techniques**: Both olaparib and lorlatinib are small molecule drugs that can be quantified using high-performance liquid chromatography mass spectrometry (LC-MS/MS). The first abstract describes a generic LC-MS/MS assay platform developed for the bioanalysis of small molecule drugs, including olaparib. This platform could potentially be adapted for the quantitation of lorlatinib as well, given its applicability to a range of small molecule compounds.\\n\\n2. **Biological Pathways**: The third abstract discusses the role of the Akt-FoxO3 signaling pathway in neuroblastoma cells treated with lorlatinib, an ALK-targeting tyrosine kinase inhibitor (TKI). The second abstract highlights the involvement of the Akt-FoxO3 pathway in reproductive aging due to in utero exposure to acetaminophen and ibuprofen. Although olaparib is not directly mentioned in these contexts, it is known to be a PARP inhibitor used in cancer therapy, and its effects could intersect with pathways involving DNA damage response and cell survival, potentially linking it indirectly to the Akt-FoxO3 pathway.\\n\\n3. **Pharmacological Context**: Both olaparib and lorlatinib are used in cancer treatment, albeit for different types of cancer (olaparib for BRCA-mutated cancers and lorlatinib for ALK-positive cancers). The study of their pharmacology and mechanisms of action often involves similar cellular and molecular techniques, such as proteomics and phosphoproteomics, as described in the third abstract for lorlatinib.\\n\\nIn summary, the indirect relationship between olaparib and lorlatinib can be described through their shared use of advanced analytical techniques for bioanalysis and their potential involvement in overlapping signaling pathways related to cell survival and cancer therapy.</td>\n",
       "      <td>0.021978</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer attempts to describe an indirect relationship between olaparib and lorlatinib but introduces irrelevant information about analytical techniques and pathways not directly related to the provided context. The reference answer focuses on a specific case report and clinical evidence, which the generated answer fails to address adequately.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>C1456409 C4519220</td>\n",
       "      <td>etravirine</td>\n",
       "      <td>fostemsavir</td>\n",
       "      <td>35315687</td>\n",
       "      <td>Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Fostemsavir is a prodrug of temsavir, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells with demonstrated efficacy in phase 2 and 3. Temsavir is a P-glycoprotein and breast cancer resistance protein (BCRP) substrate; its metabolism is mediated by esterase and CYP3A4 enzymes. Drugs that induce or inhibit CYP3A, P-glycoprotein, and BCRP may affect temsavir concentrations. Understanding potential drug-drug interactions (DDIs) following fostemsavir coadministration with antiretrovirals approved for HIV-1-infected treatment-experienced patients, including darunavir plus cobicistat (DRV/c) or DRV plus low-dose ritonavir (DRV/r) and etravirine, is clinically relevant. Open-label, single-sequence, multiple-dose, multicohort DDI studies were conducted in healthy participants (n = 46; n = 32). The primary objective was to assess the effects of DRV/r, etravirine, DRV/r plus etravirine, cobicistat, and DRV/c on temsavir systemic exposures; safety was a secondary objective. Compared with fostemsavir alone, coadministration with DRV/r increased the temsavir maximum observed plasma concentration (Cmax), area under the concentration-time curve in one dosing interval (AUCtau), and plasma trough concentration (Ctau) by 52%, 63%, and 88%, respectively, while etravirine decreased the temsavir Cmax, AUCtau, and Ctau by  50% each. DRV/r plus etravirine increased the temsavir Cmax, AUCtau, and Ctau by 53%, 34%, and 33%, respectively. Compared with fostemsavir alone, coadministration with cobicistat increased the temsavir Cmax, AUCtau, and Ctau by 71%, 93%, and 136%, respectively; DRV/c increased the temsavir Cmax, AUCtau, and Ctau by 79%, 97%, and 124%, respectively. Fostemsavir with all combinations was generally well tolerated. No dose adjustment is required for fostemsavir when coadministered with strong CYP3A inhibitors, P-glycoprotein inhibitors, and modest inducers, including regimens with DRV/r, DRV/c, cobicistat, etravirine, and DRV/r plus etravirine based on the therapeutic margin for temsavir (ClinicalTrials.gov registration no. NCT02063360 and NCT02277600).</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1456409', 'C0292818'): ['25397525', '20236784', '25350959', '22378681', '25585528', '19275497', '18567574', '21852713'], ('C0292818', 'C0012133'): ['16685132', '16220085', '9443665', '15807718', '26855245', '16563858', '18567912', '11312622'], ('C0012133', 'C4519220'): ['34459470']}</td>\n",
       "      <td>[C1456409, C0292818, C0012133, C4519220]</td>\n",
       "      <td>An indirect relationship between etravirine and fostemsavir can be inferred from the contexts provided in the scientific abstracts, primarily through their roles in the management of HIV and their interactions with other drugs.\\n\\n1. **Mechanism and Use in HIV Treatment**:\\n   - **Etravirine**: Etravirine is a next-generation nonnucleoside reverse-transcriptase inhibitor (NNRTI) used in patients who have experienced virologic failure with previous NNRTI-containing regimens. It is effective against both wild-type and NNRTI-resistant strains of HIV.\\n   - **Fostemsavir**: Although not detailed in the provided abstracts, fostemsavir is known to be an attachment inhibitor used in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.\\n\\n2. **Drug-Drug Interactions**:\\n   - **Etravirine**: The abstract mentions that etravirine is metabolized by cytochrome P450 isoenzymes, leading to significant drug-drug interactions (DDIs) with several other medications, including antiretrovirals like fosamprenavir and high-dose ritonavir.\\n   - **Fostemsavir**: The third abstract highlights that newer antiretrovirals, including fostemsavir, have reduced DDI potential compared to older NNRTIs and boosted ARVs. This suggests that fostemsavir may be a preferable option in patients where DDIs are a concern.\\n\\n3. **Clinical Management and Considerations**:\\n   - The third abstract emphasizes the importance of managing DDIs in contemporary antiretroviral therapy, especially in older patients with polypharmacy. It suggests strategies such as switching to ARVs with less DDI potential, which could include transitioning from etravirine to fostemsavir in certain clinical scenarios.\\n\\n4. **Indirect Relationship**:\\n   - The indirect relationship between etravirine and fostemsavir is primarily through their roles in the evolving landscape of HIV treatment. While etravirine is effective for patients with NNRTI resistance, its potential for DDIs may limit its use in complex treatment regimens. Fostemsavir, with its reduced DDI potential, represents an alternative for patients who require a regimen with fewer interactions, particularly in the context of polypharmacy and comorbid conditions.\\n\\nIn summary, the indirect relationship between etravirine and fostemsavir is characterized by their respective places in HIV treatment strategies, particularly concerning drug-drug interactions. Etravirine's higher potential for DDIs may lead clinicians to consider fostemsavir as a safer alternative in patients with complex medication regimens.</td>\n",
       "      <td>0.035714</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the indirect relationship between etravirine and fostemsavir, focusing on their roles in HIV treatment and drug-drug interactions. However, it contains some inaccuracies and assumptions not directly supported by the provided abstract, such as the specific mention of fosamprenavir and high-dose ritonavir, and the generalization about fostemsavir's reduced DDI potential. These inaccuracies slightly detract from the overall correctness of the answer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>C1456409 C4519220</td>\n",
       "      <td>etravirine</td>\n",
       "      <td>fostemsavir</td>\n",
       "      <td>35315687</td>\n",
       "      <td>Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Fostemsavir is a prodrug of temsavir, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells with demonstrated efficacy in phase 2 and 3. Temsavir is a P-glycoprotein and breast cancer resistance protein (BCRP) substrate; its metabolism is mediated by esterase and CYP3A4 enzymes. Drugs that induce or inhibit CYP3A, P-glycoprotein, and BCRP may affect temsavir concentrations. Understanding potential drug-drug interactions (DDIs) following fostemsavir coadministration with antiretrovirals approved for HIV-1-infected treatment-experienced patients, including darunavir plus cobicistat (DRV/c) or DRV plus low-dose ritonavir (DRV/r) and etravirine, is clinically relevant. Open-label, single-sequence, multiple-dose, multicohort DDI studies were conducted in healthy participants (n = 46; n = 32). The primary objective was to assess the effects of DRV/r, etravirine, DRV/r plus etravirine, cobicistat, and DRV/c on temsavir systemic exposures; safety was a secondary objective. Compared with fostemsavir alone, coadministration with DRV/r increased the temsavir maximum observed plasma concentration (Cmax), area under the concentration-time curve in one dosing interval (AUCtau), and plasma trough concentration (Ctau) by 52%, 63%, and 88%, respectively, while etravirine decreased the temsavir Cmax, AUCtau, and Ctau by  50% each. DRV/r plus etravirine increased the temsavir Cmax, AUCtau, and Ctau by 53%, 34%, and 33%, respectively. Compared with fostemsavir alone, coadministration with cobicistat increased the temsavir Cmax, AUCtau, and Ctau by 71%, 93%, and 136%, respectively; DRV/c increased the temsavir Cmax, AUCtau, and Ctau by 79%, 97%, and 124%, respectively. Fostemsavir with all combinations was generally well tolerated. No dose adjustment is required for fostemsavir when coadministered with strong CYP3A inhibitors, P-glycoprotein inhibitors, and modest inducers, including regimens with DRV/r, DRV/c, cobicistat, etravirine, and DRV/r plus etravirine based on the therapeutic margin for temsavir (ClinicalTrials.gov registration no. NCT02063360 and NCT02277600).</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1456409', 'C0027794'): ['25937791'], ('C0027794', 'C0001175'): ['30934067', '24036558', '20007668', '27571699', '31987053'], ('C0001175', 'C4519220'): ['33128903', '29689540', '34176425', '35338549', '32464638']}</td>\n",
       "      <td>[C1456409, C0027794, C0001175, C4519220]</td>\n",
       "      <td>An indirect relationship between etravirine and fostemsavir can be described through their roles in the treatment of HIV-1 infection, particularly in the context of drug resistance and treatment-experienced patients.\\n\\n1. **Etravirine**:\\n   - **Class and Use**: Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1. It is particularly noted for its efficacy in patients who have developed resistance to other NNRTIs, such as efavirenz.\\n   - **Patient Population**: Etravirine is not yet approved for use in children under the age of 6 years but is considered for use in patients who have developed resistance to first-line NNRTIs.\\n   - **Mechanism of Action**: Etravirine works by inhibiting the reverse transcriptase enzyme, which is crucial for the replication of HIV-1.\\n\\n2. **Fostemsavir**:\\n   - **Class and Use**: Fostemsavir is a prodrug of temsavir, an HIV-1 attachment inhibitor. It is indicated for heavily treatment-experienced individuals with multidrug-resistant HIV-1.\\n   - **Patient Population**: Fostemsavir is used in patients who have limited treatment options due to extensive drug resistance, including those who have failed multiple antiretroviral therapies.\\n   - **Mechanism of Action**: Fostemsavir works by preventing the attachment of HIV-1 to host cells, thereby inhibiting the virus's ability to enter and infect these cells.\\n\\n**Indirect Relationship**:\\n- **Drug Resistance**: Both etravirine and fostemsavir are used in the context of drug resistance, albeit at different stages and for different patient populations. Etravirine is used when resistance to first-line NNRTIs like efavirenz has developed, while fostemsavir is used in heavily treatment-experienced patients with multidrug-resistant HIV-1.\\n- **Treatment Options**: Etravirine may be part of an optimized background therapy for patients who are also candidates for fostemsavir. In heavily treatment-experienced individuals, a combination of drugs, including NNRTIs like etravirine and attachment inhibitors like fostemsavir, may be necessary to achieve virological suppression.\\n- **Clinical Outcomes**: Both drugs aim to improve clinical outcomes in patients with limited treatment options due to resistance. Etravirine helps maintain NNRTI activity in the presence of resistance mutations, while fostemsavir provides an alternative mechanism of action to combat multidrug-resistant HIV-1.\\n\\nIn summary, the indirect relationship between etravirine and fostemsavir lies in their complementary roles in managing HIV-1 infection in patients with drug resistance. Etravirine addresses resistance to NNRTIs, while fostemsavir offers a treatment option for those with extensive multidrug resistance, potentially including resistance to NNRTIs like etravirine.</td>\n",
       "      <td>0.036585</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the roles of etravirine and fostemsavir in HIV-1 treatment, highlighting their use in drug-resistant cases. However, it lacks specific details from the provided scientific abstract, such as the pharmacokinetic interactions between etravirine and fostemsavir, which are crucial for a complete understanding of their indirect relationship.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>C1456409 C4519220</td>\n",
       "      <td>etravirine</td>\n",
       "      <td>fostemsavir</td>\n",
       "      <td>35315687</td>\n",
       "      <td>Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Fostemsavir is a prodrug of temsavir, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells with demonstrated efficacy in phase 2 and 3. Temsavir is a P-glycoprotein and breast cancer resistance protein (BCRP) substrate; its metabolism is mediated by esterase and CYP3A4 enzymes. Drugs that induce or inhibit CYP3A, P-glycoprotein, and BCRP may affect temsavir concentrations. Understanding potential drug-drug interactions (DDIs) following fostemsavir coadministration with antiretrovirals approved for HIV-1-infected treatment-experienced patients, including darunavir plus cobicistat (DRV/c) or DRV plus low-dose ritonavir (DRV/r) and etravirine, is clinically relevant. Open-label, single-sequence, multiple-dose, multicohort DDI studies were conducted in healthy participants (n = 46; n = 32). The primary objective was to assess the effects of DRV/r, etravirine, DRV/r plus etravirine, cobicistat, and DRV/c on temsavir systemic exposures; safety was a secondary objective. Compared with fostemsavir alone, coadministration with DRV/r increased the temsavir maximum observed plasma concentration (Cmax), area under the concentration-time curve in one dosing interval (AUCtau), and plasma trough concentration (Ctau) by 52%, 63%, and 88%, respectively, while etravirine decreased the temsavir Cmax, AUCtau, and Ctau by  50% each. DRV/r plus etravirine increased the temsavir Cmax, AUCtau, and Ctau by 53%, 34%, and 33%, respectively. Compared with fostemsavir alone, coadministration with cobicistat increased the temsavir Cmax, AUCtau, and Ctau by 71%, 93%, and 136%, respectively; DRV/c increased the temsavir Cmax, AUCtau, and Ctau by 79%, 97%, and 124%, respectively. Fostemsavir with all combinations was generally well tolerated. No dose adjustment is required for fostemsavir when coadministered with strong CYP3A inhibitors, P-glycoprotein inhibitors, and modest inducers, including regimens with DRV/r, DRV/c, cobicistat, etravirine, and DRV/r plus etravirine based on the therapeutic margin for temsavir (ClinicalTrials.gov registration no. NCT02063360 and NCT02277600).</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1456409', 'C0033308'): ['19088949'], ('C0033308', 'C3496793'): ['30273606', '31017696', '27816190', '32824674', '25649766', '34208290', '30770950'], ('C3496793', 'C4519220'): ['33547469']}</td>\n",
       "      <td>[C1456409, C0033308, C3496793, C4519220]</td>\n",
       "      <td>An indirect relationship between etravirine and fostemsavir can be inferred based on their roles in the treatment of HIV-1 infection, as described in the provided scientific abstracts. Heres a detailed explanation:\\n\\n1. **Etravirine**:\\n   - **Context**: Etravirine is mentioned in the context of a guide to recent clinical trials, indicating its ongoing relevance in drug discovery and development.\\n   - **Role**: Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is particularly useful for patients who have developed resistance to first-generation NNRTIs.\\n\\n2. **Fostemsavir**:\\n   - **Context**: Fostemsavir is highlighted in a review focusing on its pharmacology, pharmacokinetics, and clinical efficacy in the management of HIV-1 infection.\\n   - **Role**: Fostemsavir is a prodrug of temsavir, an oral attachment inhibitor that prevents HIV-1 from entering host cells. It is approved for use in combination with other antiretroviral agents for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.\\n\\n3. **Indirect Relationship**:\\n   - **Combination Therapy**: Both etravirine and fostemsavir are used in combination with other antiretroviral agents to manage HIV-1 infection. This suggests that they may be part of overlapping treatment regimens, especially in patients with multidrug-resistant HIV-1.\\n   - **Treatment of Resistant HIV-1**: Etravirine is effective for patients who have developed resistance to other NNRTIs, while fostemsavir is used for patients with multidrug-resistant HIV-1 who have limited treatment options. This indicates that both drugs are crucial for managing complex cases of HIV-1 where resistance to standard therapies is an issue.\\n   - **Mechanism of Action**: While etravirine works by inhibiting the reverse transcriptase enzyme, fostemsavir prevents the virus from attaching to and entering host cells. Their different mechanisms of action make them complementary in a combination therapy setting, potentially enhancing overall treatment efficacy.\\n\\nIn summary, the indirect relationship between etravirine and fostemsavir lies in their complementary roles in combination antiretroviral therapy for HIV-1 infection, particularly in patients with drug-resistant strains. Both drugs are part of the therapeutic arsenal aimed at achieving viral suppression in challenging cases, albeit through different mechanisms of action.</td>\n",
       "      <td>0.023256</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the roles of etravirine and fostemsavir in HIV-1 treatment. However, it lacks specific details from the provided scientific abstract, such as the pharmacokinetic interactions between etravirine and fostemsavir. The answer correctly identifies the indirect relationship through their use in combination therapy but misses the specific impact of etravirine on temsavir concentrations, which is crucial for a complete understanding.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>C1456409 C4519220</td>\n",
       "      <td>etravirine</td>\n",
       "      <td>fostemsavir</td>\n",
       "      <td>35315687</td>\n",
       "      <td>Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Fostemsavir is a prodrug of temsavir, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells with demonstrated efficacy in phase 2 and 3. Temsavir is a P-glycoprotein and breast cancer resistance protein (BCRP) substrate; its metabolism is mediated by esterase and CYP3A4 enzymes. Drugs that induce or inhibit CYP3A, P-glycoprotein, and BCRP may affect temsavir concentrations. Understanding potential drug-drug interactions (DDIs) following fostemsavir coadministration with antiretrovirals approved for HIV-1-infected treatment-experienced patients, including darunavir plus cobicistat (DRV/c) or DRV plus low-dose ritonavir (DRV/r) and etravirine, is clinically relevant. Open-label, single-sequence, multiple-dose, multicohort DDI studies were conducted in healthy participants (n = 46; n = 32). The primary objective was to assess the effects of DRV/r, etravirine, DRV/r plus etravirine, cobicistat, and DRV/c on temsavir systemic exposures; safety was a secondary objective. Compared with fostemsavir alone, coadministration with DRV/r increased the temsavir maximum observed plasma concentration (Cmax), area under the concentration-time curve in one dosing interval (AUCtau), and plasma trough concentration (Ctau) by 52%, 63%, and 88%, respectively, while etravirine decreased the temsavir Cmax, AUCtau, and Ctau by  50% each. DRV/r plus etravirine increased the temsavir Cmax, AUCtau, and Ctau by 53%, 34%, and 33%, respectively. Compared with fostemsavir alone, coadministration with cobicistat increased the temsavir Cmax, AUCtau, and Ctau by 71%, 93%, and 136%, respectively; DRV/c increased the temsavir Cmax, AUCtau, and Ctau by 79%, 97%, and 124%, respectively. Fostemsavir with all combinations was generally well tolerated. No dose adjustment is required for fostemsavir when coadministered with strong CYP3A inhibitors, P-glycoprotein inhibitors, and modest inducers, including regimens with DRV/r, DRV/c, cobicistat, etravirine, and DRV/r plus etravirine based on the therapeutic margin for temsavir (ClinicalTrials.gov registration no. NCT02063360 and NCT02277600).</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1456409', 'C1176309'): ['19557204'], ('C1176309', 'C0026256'): ['27631436'], ('C0026256', 'C4519220'): ['33547469']}</td>\n",
       "      <td>[C1456409, C1176309, C0026256, C4519220]</td>\n",
       "      <td>An indirect relationship between etravirine and fostemsavir can be described through their shared context within the broader landscape of HIV-1 treatment and their potential interactions with other drugs used in this therapeutic area.\\n\\n1. **Shared Therapeutic Context**: Both etravirine and fostemsavir are antiretroviral agents used in the treatment of HIV-1 infection. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while fostemsavir is an attachment inhibitor. They are both part of the arsenal of drugs used to manage HIV-1, particularly in patients with multidrug-resistant strains of the virus.\\n\\n2. **Drug Interaction Considerations**: The abstracts highlight the importance of understanding drug interactions in HIV treatment. Fostemsavir's metabolism can be significantly affected by strong CYP3A inducers, including mitotane, which is mentioned in the context of another study. This is relevant because etravirine, like fostemsavir, is also metabolized by the cytochrome P-450 system, specifically CYP3A4. Therefore, the presence of strong CYP3A inducers could potentially affect the pharmacokinetics and efficacy of both drugs.\\n\\n3. **Clinical Trial Context**: Both drugs are mentioned in the context of clinical trials. Etravirine is listed among various drugs in a broad clinical trial gateway, indicating its ongoing evaluation and use in different therapeutic regimens. Fostemsavir, on the other hand, is discussed in detail regarding its clinical efficacy and safety in phase 2 and phase 3 trials. This shared context of clinical evaluation underscores their roles in evolving HIV treatment strategies.\\n\\n4. **Potential for Combination Therapy**: While the abstracts do not directly link etravirine and fostemsavir, the broader context of HIV treatment often involves combination therapy to achieve viral suppression. Understanding the pharmacological profiles and potential interactions of these drugs is crucial for optimizing treatment regimens, especially in heavily treatment-experienced patients.\\n\\nIn summary, the indirect relationship between etravirine and fostemsavir can be described through their roles in HIV-1 treatment, the importance of considering drug interactions, their evaluation in clinical trials, and the potential for their use in combination therapy to manage multidrug-resistant HIV-1 infections.</td>\n",
       "      <td>0.060241</td>\n",
       "      <td>4.0</td>\n",
       "      <td>The generated answer is relevant and mostly correct. It accurately describes the indirect relationship between etravirine and fostemsavir by discussing their roles in HIV-1 treatment, drug interaction considerations, clinical trial contexts, and potential for combination therapy. However, it could be more concise and directly reference specific findings from the provided abstract, such as the specific effects of etravirine on temsavir concentrations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1453431', 'C0027055'): ['31632535', '33377581', '33083461', '27246989', '26604691', '34530090', '30066841', '34119533', '34391873'], ('C0027055', 'C1420201'): ['30992077', '30873553', '30847415', '33483761', '32194159'], ('C1420201', 'C3490348'): ['33846238', '27009625', '35126806', '34137526', '25301180', '33899306', '30097993', '34753480', '28440590']}</td>\n",
       "      <td>[C1453431, C0027055, C1420201, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following chain of associations:\\n\\n1. **BECN1 and Myocardial Ischemia/Reperfusion Injury (MI/RI) in Diabetic Mice:**\\n   - The first abstract discusses the role of BECN1 (Beclin1) in the context of myocardial ischemia/reperfusion injury (MI/RI) in diabetic mice. It highlights that diabetes exacerbates MI/RI, which is associated with increased levels of HMGB1 and autophagy-related proteins, including Beclin1. Inhibition of HMGB1 reduces myocardial damage and autophagy markers, suggesting that Beclin1 is involved in the autophagic response to MI/RI in diabetic conditions.\\n\\n2. **Empagliflozin and Myocardial Infarct Size Reduction:**\\n   - The second abstract focuses on the cardioprotective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, in reducing myocardial infarct size in preclinical animal models of MI/RI. The meta-analysis indicates that SGLT2 inhibitors significantly reduce myocardial infarct size, with a more pronounced effect in diabetic animals.\\n\\n3. **Linking the Two Contexts:**\\n   - While the first abstract does not directly mention empagliflozin, it establishes a connection between autophagy (involving Beclin1) and myocardial injury in diabetic conditions.\\n   - The second abstract, on the other hand, demonstrates that empagliflozin, an SGLT2 inhibitor, has a cardioprotective effect in reducing myocardial infarct size, particularly in diabetic models.\\n\\n### Indirect Relationship Description:\\nEmpagliflozin, an SGLT2 inhibitor, has been shown to reduce myocardial infarct size in preclinical models of myocardial ischemia/reperfusion injury, with a more significant effect observed in diabetic animals. This cardioprotective effect may be indirectly related to the modulation of autophagy pathways, as suggested by the first abstract. In diabetic conditions, myocardial injury is associated with increased autophagy, involving proteins such as BECN1 (Beclin1). Inhibition of HMGB1, which reduces autophagy and myocardial damage, implies that autophagy plays a critical role in the exacerbation of myocardial injury in diabetes. Therefore, it is plausible that empagliflozin's cardioprotective effects might involve modulation of autophagy pathways, potentially affecting proteins like BECN1, although this specific mechanism requires further investigation.\\n\\nIn summary, the indirect relationship between BECN1 and empagliflozin can be inferred through their respective roles in autophagy and myocardial protection in diabetic conditions, suggesting a potential mechanistic link that warrants further exploration.</td>\n",
       "      <td>0.032258</td>\n",
       "      <td>4.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the indirect relationship between BECN1 protein and empagliflozin. It correctly identifies the role of BECN1 in autophagy and myocardial injury and links it to the cardioprotective effects of empagliflozin. However, it could be more concise and focused, as some parts are slightly repetitive and could be streamlined for clarity.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1453431', 'C1412622'): ['28747345', '23979425'], ('C1412622', 'C0027055'): ['30880910', '30728891'], ('C0027055', 'C3490348'): ['33738012', '33953281']}</td>\n",
       "      <td>[C1453431, C1412622, C0027055, C3490348]</td>\n",
       "      <td>To describe an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin, we can draw connections based on the roles of autophagy, ER stress, and cardioprotection mechanisms discussed in the provided abstracts.\\n\\n1. **BECN1 and Autophagy**:\\n   - The first abstract highlights the role of BECN1 (Beclin1) in autophagy, particularly in the context of neuroprotection against ethanol-induced neurodegeneration. It shows that higher expression of autophagy-related genes, including BECN1, is associated with reduced vulnerability to ethanol-induced apoptosis in the developing brain.\\n\\n2. **ER Stress and Cardioprotection**:\\n   - The second abstract discusses how Ginkgolide B (GB) ameliorates myocardial ischemia-reperfusion (I/R) injury by inhibiting ER stress-induced apoptosis. It mentions key proteins involved in ER stress (p-PERK, p-IRE1alpha, ATF6) and suggests that reducing ER stress can protect against myocardial injury.\\n\\n3. **Empagliflozin and Cardioprotection**:\\n   - The third abstract focuses on the cardioprotective effects of empagliflozin (EMPA) in the context of myocardial I/R injury. It indicates that EMPA reduces infarct size and improves left ventricular function, potentially through mechanisms involving enhanced mitochondrial respiration and modulated myocardial metabolism.\\n\\n### Indirect Relationship:\\n\\n- **Autophagy and ER Stress**:\\n  - Both autophagy and ER stress are crucial cellular processes that help manage cellular stress and maintain homeostasis. BECN1 is a key regulator of autophagy, which can interact with pathways involved in ER stress. The inhibition of ER stress, as seen with GB, can reduce apoptosis and protect cells, a mechanism that might also involve autophagy regulation.\\n\\n- **Empagliflozin and Cellular Stress Pathways**:\\n  - While the exact mechanism of empagliflozin's cardioprotective effects is not fully understood, it is suggested to involve improved mitochondrial function and metabolic modulation. Given that mitochondrial health is closely linked to both autophagy and ER stress responses, it is plausible that empagliflozin indirectly influences these pathways.\\n\\n- **Connecting the Dots**:\\n  - Although the abstracts do not directly link BECN1 and empagliflozin, we can infer an indirect relationship through the shared involvement in cellular stress responses. BECN1's role in autophagy could intersect with the pathways influenced by empagliflozin, particularly in the context of reducing cellular stress and apoptosis during myocardial injury.\\n\\n### Summary:\\n\\nThe indirect relationship between BECN1 protein and empagliflozin can be described as follows: BECN1 is a key regulator of autophagy, a process that helps mitigate cellular stress and apoptosis. Empagliflozin, a cardioprotective agent, appears to enhance mitochondrial function and modulate metabolism, potentially influencing cellular stress pathways. While not directly connected, both BECN1 and empagliflozin contribute to cellular resilience against stress, suggesting that empagliflozin's cardioprotective effects might involve mechanisms that intersect with autophagy and ER stress pathways regulated by BECN1.</td>\n",
       "      <td>0.079365</td>\n",
       "      <td>4.0</td>\n",
       "      <td>The generated answer is relevant and provides a comprehensive explanation of the indirect relationship between BECN1 protein and empagliflozin. It correctly identifies the roles of autophagy, ER stress, and cardioprotection mechanisms, and logically connects these processes to describe the indirect relationship. However, the answer could be more concise and focused on the specific context provided by the abstracts.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1453431', 'C1412617'): ['34112145', '31524237'], ('C1412617', 'C1420201'): ['31285506'], ('C1420201', 'C3490348'): ['35287171', '29693360']}</td>\n",
       "      <td>[C1453431, C1412617, C1420201, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following connections:\\n\\n1. **BECN1 and ER Stress/Autophagy in DLBCL**:\\n   - The first abstract discusses the role of Beclin1 (BECN1) in autophagy within the context of diffuse large B-cell lymphoma (DLBCL). It highlights that overexpression of LINC00963 leads to increased levels of Beclin1, which is associated with autophagy. This process is part of the cellular response to endoplasmic reticulum (ER) stress, as indicated by the upregulation of UPR (unfolded protein response) sensors like GRP78, p-IRE1, and spliced XBP-1 (XBP1(s)).\\n\\n2. **ER Stress and Dapagliflozin**:\\n   - The second abstract focuses on dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and its role in mitigating ER stress-mediated apoptosis in renal cells and diabetic nephropathy (DN). Dapagliflozin regulates the elf2alpha-ATF4-CHOP pathway, which is a part of the ER stress response.\\n\\n3. **Empagliflozin and Dapagliflozin**:\\n   - Although the second abstract specifically mentions dapagliflozin, it is part of the same class of drugs as empagliflozin (both are SGLT2 inhibitors). These drugs share similar mechanisms of action, including the potential to modulate ER stress.\\n\\n### Indirect Relationship Description:\\n\\nEmpagliflozin, like dapagliflozin, is an SGLT2 inhibitor that may influence ER stress pathways. The regulation of ER stress is crucial in various cellular processes, including autophagy, where Beclin1 (BECN1) plays a significant role. In the context of DLBCL, Beclin1 is upregulated as part of the autophagy response to ER stress, mediated by the LINC00963/miR-320a/XBP1 axis. Given that dapagliflozin has been shown to mitigate ER stress-mediated apoptosis, it is plausible that empagliflozin could have similar effects. Therefore, the indirect relationship between BECN1 and empagliflozin can be inferred through their respective roles in ER stress and autophagy pathways, suggesting that empagliflozin might influence autophagy-related proteins like Beclin1 by modulating ER stress responses.</td>\n",
       "      <td>0.031746</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a detailed explanation of the indirect relationship between BECN1 protein and empagliflozin. However, it introduces information about dapagliflozin and DLBCL, which are not mentioned in the provided context. This additional information, while related, may confuse the user and detracts from the direct connection between BECN1 and empagliflozin as described in the reference answer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1453431', 'C0054412'): ['32500147', '27872163', '33127495'], ('C0054412', 'C0005684'): ['7729958', '6680725', '1804290', '14555400'], ('C0005684', 'C3490348'): ['28725912', '24348059', '27486640', '31426529', '25554069', '33552467', '31741440', '30972917']}</td>\n",
       "      <td>[C1453431, C0054412, C0005684, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following connections:\\n\\n1. **Cadmium Exposure and BECN1**: The first abstract discusses the effects of cadmium (Cd) on rat ovarian granulosa cells (OGCs). It highlights that cadmium exposure increases apoptosis but does not affect autophagy, as indicated by unchanged levels of autophagic markers such as BECN1 (Beclin1). This suggests that BECN1 is not directly involved in the apoptotic response to cadmium in this context.\\n\\n2. **Cadmium and Metallothionein**: The second abstract explores the effects of cadmium on human urothelial cells, showing that cadmium exposure increases the expression of metallothionein (MT) genes and proteins. This indicates a cellular response to cadmium toxicity, which is consistent with the findings in the first abstract regarding cadmium's cytotoxic effects.\\n\\n3. **Empagliflozin and Cardiovascular Effects**: The third abstract focuses on empagliflozin, a drug used to treat type 2 diabetes. It highlights that empagliflozin reduces overall mortality in patients with type 2 diabetes, primarily by reducing cardiovascular mortality, particularly heart failure. This effect is attributed to empagliflozin's diuretic action rather than its glucose-lowering effect.\\n\\n### Indirect Relationship:\\n\\n- **Cadmium and Cellular Stress**: Both abstracts involving cadmium exposure (first and second) indicate that cadmium induces cellular stress responses, including apoptosis and increased metallothionein expression. These responses are part of the broader cellular mechanisms to counteract cadmium toxicity.\\n\\n- **Empagliflozin and Cellular Stress**: While the third abstract does not directly mention cadmium or BECN1, it discusses empagliflozin's effects on cardiovascular health, which can be influenced by cellular stress and damage mechanisms. Empagliflozin's ability to reduce heart failure and mortality might be indirectly related to its effects on cellular stress pathways, which could overlap with pathways affected by cadmium exposure.\\n\\n- **Potential Overlapping Pathways**: Although BECN1 is not directly implicated in the response to cadmium in the first abstract, it is a known autophagic marker. Autophagy and apoptosis are interconnected processes, and cellular stress responses often involve a balance between these pathways. Empagliflozin's cardiovascular benefits might involve modulation of cellular stress pathways, potentially intersecting with mechanisms involving BECN1, even if not directly mentioned.\\n\\nIn summary, the indirect relationship between BECN1 and empagliflozin can be conceptualized through their respective roles in cellular stress responses. Cadmium exposure affects apoptosis and metallothionein expression, while empagliflozin impacts cardiovascular health, potentially through mechanisms involving cellular stress and damage pathways. Although BECN1 is not directly altered by cadmium in the provided context, its role in autophagy links it to broader cellular stress responses that could intersect with the effects of empagliflozin.</td>\n",
       "      <td>0.031746</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer attempts to describe an indirect relationship between BECN1 and empagliflozin but introduces irrelevant information about cadmium exposure, which is not mentioned in the provided context. The reference answer focuses on the role of empagliflozin in inhibiting ER stress-induced autophagy via the PERK/ATF4/Beclin1 pathway, which is directly relevant to the query. The generated answer's inclusion of cadmium-related studies detracts from its relevance and correctness.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1453431', 'C0289313'): ['34235122', '29740932'], ('C0289313', 'C3490348'): ['29520964', '30767126']}</td>\n",
       "      <td>[C1453431, C0289313, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following connections:\\n\\n1. **BECN1 and Autophagy in Microglia**:\\n   - The first abstract discusses how antagonizing peroxisome proliferator-activated receptor gamma (PPAR) promotes autophagy in microglia via the LKB1-AMPK signaling pathway. This process involves the upregulation of autophagy-related proteins, including Beclin1 (BECN1), which is crucial for the formation of autophagosomes.\\n\\n2. **Empagliflozin and Heart Failure in T2DM**:\\n   - The second abstract highlights the role of empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, in reducing heart failure (HF) hospitalization in patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease. While the abstract does not directly mention autophagy or BECN1, it indicates the therapeutic benefits of empagliflozin in managing HF in T2DM patients.\\n\\n3. **Connecting the Dots**:\\n   - Although the abstracts do not directly link BECN1 and empagliflozin, an indirect relationship can be inferred through the broader context of autophagy and cardiovascular health. Autophagy, regulated by proteins like BECN1, plays a significant role in cellular homeostasis and has been implicated in various diseases, including neuroinflammation and cardiovascular conditions.\\n   - Empagliflozin's benefits in reducing HF hospitalization may involve mechanisms that indirectly affect autophagy pathways. For instance, improved cardiovascular health and reduced HF could potentially influence systemic inflammation and cellular stress responses, which are known to interact with autophagy processes.\\n\\nIn summary, the indirect relationship between BECN1 and empagliflozin can be described as follows: BECN1 is involved in autophagy regulation, which is crucial for cellular health and has implications in diseases like neuroinflammation and cardiovascular conditions. Empagliflozin, while primarily used to manage T2DM and reduce HF hospitalization, may exert its beneficial effects through mechanisms that could indirectly influence autophagy pathways, thereby connecting it to the role of BECN1 in maintaining cellular homeostasis.</td>\n",
       "      <td>0.031746</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer attempts to establish an indirect relationship between BECN1 and empagliflozin but introduces unrelated contexts (microglia and PPAR) that are not present in the provided abstracts. The reference answer directly links empagliflozin to the inhibition of the PERK/ATF4/Beclin1 pathway, which is relevant to the user query. The generated answer is partially relevant but contains inaccuracies and extraneous information.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>C1453431 C3490348</td>\n",
       "      <td>BECN1 protein, human</td>\n",
       "      <td>empagliflozin</td>\n",
       "      <td>35400245</td>\n",
       "      <td>Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.</td>\n",
       "      <td>title_cooc</td>\n",
       "      <td>2022</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1453431', 'C1565860'): ['31264128', '29407824', '31632535', '30873010', '25303541', '29864907'], ('C1565860', 'C0005684'): ['29422113', '32992651', '15870865', '20428812', '24612661', '24964787'], ('C0005684', 'C3490348'): ['27486640', '31426529', '32704566', '32271194', '33552467', '24348059']}</td>\n",
       "      <td>[C1453431, C1565860, C0005684, C3490348]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following connections:\\n\\n1. **BECN1 and Autophagy**: The first abstract discusses the role of BECN1 in the autophagy pathway. It highlights that PM2.5 exposure in zebrafish embryos leads to increased expression of autophagy-related genes, including BECN1 (Beclin1). This suggests that BECN1 is involved in the cellular response to stress and toxicity, particularly through the autophagy pathway.\\n\\n2. **Empagliflozin and Cardiovascular Health**: The third abstract focuses on empagliflozin, a drug used to treat type 2 diabetes. It mentions that empagliflozin has a beneficial effect on reducing cardiovascular mortality, particularly heart failure, in patients with a history of cardiovascular disorders. This effect is attributed to its diuretic action rather than its glucose-lowering properties.\\n\\n3. **Linking Autophagy and Cardiovascular Health**: While the abstracts do not directly connect BECN1 and empagliflozin, there is a potential indirect link through the broader context of autophagy and cardiovascular health. Autophagy, regulated by proteins like BECN1, plays a crucial role in maintaining cellular homeostasis and responding to stress. Dysregulation of autophagy has been implicated in various cardiovascular diseases, including heart failure.\\n\\n4. **Potential Mechanistic Insights**: Given that empagliflozin reduces heart failure and that autophagy is involved in cardiovascular health, it is plausible that the beneficial effects of empagliflozin on heart failure might involve modulation of autophagy pathways. Although the exact mechanisms are not detailed in the abstracts, it is conceivable that empagliflozin could influence autophagy-related processes, potentially involving BECN1, to exert its cardioprotective effects.\\n\\nIn summary, the indirect relationship between BECN1 and empagliflozin can be described through the role of BECN1 in autophagy and the potential involvement of autophagy in the cardiovascular benefits observed with empagliflozin treatment. Further research would be needed to elucidate the precise mechanisms linking these two factors.</td>\n",
       "      <td>0.031746</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is relevant to the user query and attempts to describe an indirect relationship between BECN1 and empagliflozin. However, it contains inaccuracies and lacks clarity. The reference answer specifically mentions the PERK/ATF4/Beclin1 pathway and the role of empagliflozin in inhibiting ER stress-induced autophagy, which is not clearly articulated in the generated answer. The generated answer also introduces unrelated information about PM2.5 exposure and zebrafish embryos, which is not relevant to the context provided.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1425143', 'C4079830'): ['33082322', '32054729'], ('C4079830', 'C4086509'): ['28915653', '29768700', '34101461', '27353420', '35233509', '28914567', '33850004']}</td>\n",
       "      <td>[C1425143, C4079830, C4086509]</td>\n",
       "      <td>Based on the provided abstract, an indirect relationship between the BBC3 gene and Idasanutlin can be described as follows:\\n\\nThe BBC3 gene encodes the protein PUMA (p53 upregulated modulator of apoptosis), which plays a crucial role in the apoptosis pathway. In the context of resistance to FGFR1 inhibitors in leukemia/lymphoma, downregulation of PUMA has been identified as a key factor. This downregulation is associated with sustained Akt activation and the sequestration of inactivated p-Foxo3a in the cytoplasm, leading to compromised PUMA activation and suppression of apoptosis.\\n\\nIdasanutlin is a small molecule inhibitor of MDM2, which is known to activate the p53 pathway. Since PUMA is a downstream target of p53, activation of p53 by Idasanutlin could potentially upregulate PUMA expression. Therefore, although the abstract does not directly mention Idasanutlin, the relationship can be inferred through the p53 pathway. By activating p53, Idasanutlin could counteract the downregulation of PUMA, thereby restoring apoptosis in FGFR1 inhibitor-resistant cells.\\n\\nIn summary, the indirect relationship between BBC3 (PUMA) and Idasanutlin is mediated through the p53 pathway. Idasanutlin, by inhibiting MDM2 and activating p53, could potentially upregulate PUMA, thereby overcoming resistance mechanisms that involve PUMA downregulation.</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is somewhat relevant but contains inaccuracies and extraneous information. It incorrectly introduces FGFR1 inhibitors and resistance mechanisms not mentioned in the provided abstract. While it correctly identifies the role of Idasanutlin in activating the p53 pathway and the potential upregulation of BBC3 (PUMA), it fails to accurately describe the context given in the abstract, which focuses on T-ALL and the combination treatment with navitoclax.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1425143', 'C1961099'): ['23410974', '25784680', '19737931'], ('C1961099', 'C4086509'): ['34465864']}</td>\n",
       "      <td>[C1425143, C1961099, C4086509]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between the BBC3 gene and Idasanutlin can be described through their involvement in the apoptotic pathways and leukemia progression mechanisms.\\n\\n1. **BBC3 (Puma) and Apoptosis in Leukemia:**\\n   - The first abstract discusses how the induction of BBC3 (Puma) sensitizes human leukemia cells to apoptosis. Specifically, the expression of p16(INK4A) leads to the induction of BBC3/Puma, which promotes apoptosis by altering the balance of pro- and anti-apoptotic BCL2 proteins. This suggests that BBC3 plays a crucial role in mediating apoptosis in leukemia cells.\\n\\n2. **Idasanutlin and MDM2 Inhibition:**\\n   - The second abstract focuses on the role of PHF6 and JAK3 mutations in T-cell acute lymphoblastic leukemia (T-ALL) progression. It highlights that the combination of a JAK3 inhibitor (tofacitinib) and an MDM2 inhibitor (idasanutlin) can reduce leukemia burden in a mouse model. The MDM2 inhibitor Idasanutlin works by inhibiting the MDM2 protein, which is a negative regulator of the p53 tumor suppressor pathway.\\n\\n3. **Connecting the Dots:**\\n   - Although BBC3 and Idasanutlin are not directly mentioned together, they are both involved in pathways that regulate apoptosis and leukemia progression. BBC3/Puma is a pro-apoptotic protein that is regulated by p53, a pathway that is negatively regulated by MDM2. Idasanutlin, by inhibiting MDM2, can enhance p53 activity, potentially leading to increased expression of pro-apoptotic genes like BBC3/Puma.\\n   - Therefore, the indirect relationship can be described as follows: Idasanutlin, by inhibiting MDM2, can enhance p53 activity, which in turn can lead to the induction of pro-apoptotic genes such as BBC3/Puma. This suggests that Idasanutlin may indirectly influence the expression of BBC3/Puma through the p53 pathway, contributing to increased apoptosis in leukemia cells.\\n\\nIn summary, the indirect relationship between BBC3 and Idasanutlin is mediated through the p53 pathway, where Idasanutlin's inhibition of MDM2 can lead to increased p53 activity and subsequent induction of BBC3/Puma, promoting apoptosis in leukemia cells.</td>\n",
       "      <td>0.028571</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and provides a reasonable explanation of the indirect relationship between BBC3 and Idasanutlin through the p53 pathway. However, it introduces additional abstracts and information not present in the reference answer, which may confuse the user. The core idea is correct, but the answer could be more concise and focused on the provided context.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>1</td>\n",
       "      <td>{('C1425143', 'C4079830'): ['33082322', '32054729'], ('C4079830', 'C1961099'): ['33970999', '29854301', '32733662', '32970500', '30225152', '28074072'], ('C1961099', 'C4086509'): ['34465864']}</td>\n",
       "      <td>[C1425143, C4079830, C1961099, C4086509]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between the BBC3 gene and Idasanutlin can be described through the involvement of the p53 pathway and apoptosis regulation mechanisms in leukemia.\\n\\n1. **BBC3 Gene (PUMA) and Apoptosis Regulation:**\\n   - The first abstract discusses the role of PUMA (encoded by the BBC3 gene) in mediating apoptosis in the context of resistance to FGFR1 inhibitors in leukemia. It highlights that downregulation of PUMA leads to resistance by preventing apoptosis, which is a crucial cell death pathway. PUMA is a pro-apoptotic protein that promotes cell death by targeting Bcl2, and its suppression results in increased survival of leukemic cells.\\n\\n2. **Idasanutlin and MDM2 Inhibition:**\\n   - The third abstract mentions Idasanutlin as an MDM2 inhibitor used in combination therapy to reduce leukemia burden in T-ALL with PHF6 and JAK3 mutations. MDM2 is a negative regulator of the p53 tumor suppressor protein. By inhibiting MDM2, Idasanutlin stabilizes and activates p53, leading to increased apoptosis in cancer cells.\\n\\n3. **Connecting the Dots:**\\n   - The indirect relationship between BBC3 (PUMA) and Idasanutlin can be inferred through their common involvement in the p53-mediated apoptosis pathway. PUMA is a downstream target of p53 and is upregulated in response to p53 activation. Idasanutlin, by inhibiting MDM2, enhances p53 activity, which in turn can lead to increased expression of PUMA, promoting apoptosis in leukemic cells.\\n\\nIn summary, the indirect relationship between the BBC3 gene and Idasanutlin is mediated through the p53 pathway. Idasanutlin enhances p53 activity by inhibiting MDM2, which can lead to the upregulation of PUMA (encoded by BBC3), thereby promoting apoptosis in leukemia cells. This connection underscores the potential therapeutic synergy in targeting both MDM2 and apoptotic pathways in leukemia treatment.</td>\n",
       "      <td>0.057971</td>\n",
       "      <td>4.0</td>\n",
       "      <td>The generated answer accurately describes the indirect relationship between the BBC3 gene and Idasanutlin through the p53 pathway and apoptosis regulation mechanisms in leukemia. It correctly identifies the role of PUMA (encoded by BBC3) and the effect of Idasanutlin as an MDM2 inhibitor. However, the answer could be more concise and directly tied to the specific abstracts provided.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1425143', 'C0049065'): ['32054729'], ('C0049065', 'C0020402'): ['25696830', '26858356', '15561675', '25931013', '24163393', '16859388', '26783435', '11001887', '12010787'], ('C0020402', 'C4086509'): ['33936902', '34933330', '30543590']}</td>\n",
       "      <td>[C1425143, C0049065, C0020402, C4086509]</td>\n",
       "      <td>Based on the provided abstracts, an indirect relationship between the BBC3 gene (also known as PUMA) and Idasanutlin can be described through the following connections:\\n\\n1. **BBC3 (PUMA) and Apoptosis in AML**: The first abstract discusses the role of BBC3 (PUMA) in acute myeloid leukemia (AML) cells. It highlights that the combination of venetoclax (a BCL-2 inhibitor) and 5-azacitidine (5-Aza, a hypomethylating agent) induces apoptosis in AML cells. This apoptosis is mediated through the integrated stress response (ISR) pathway, which leads to the induction of proapoptotic proteins such as NOXA and PUMA. The study shows that PUMA plays a significant role in the synergistic effect of venetoclax and 5-Aza in killing AML cells.\\n\\n2. **Idasanutlin and MDM2 Inhibition**: Although Idasanutlin is not directly mentioned in the provided abstracts, it is known from other literature that Idasanutlin is an MDM2 inhibitor. MDM2 inhibitors, like Idasanutlin, activate the p53 pathway by preventing MDM2 from degrading p53. Activation of p53 can lead to the transcription of several proapoptotic genes, including BBC3 (PUMA).\\n\\n3. **Indirect Relationship**: The indirect relationship between BBC3 and Idasanutlin can be inferred through the p53 pathway. Idasanutlin, by inhibiting MDM2, stabilizes and activates p53. Activated p53 can then induce the expression of proapoptotic genes such as BBC3 (PUMA). Therefore, while the first abstract does not mention Idasanutlin, it provides context on the role of PUMA in apoptosis, which can be linked to Idasanutlin through the p53 activation pathway.\\n\\nIn summary, the indirect relationship between BBC3 (PUMA) and Idasanutlin is mediated through the p53 pathway. Idasanutlin, as an MDM2 inhibitor, activates p53, which in turn can induce the expression of PUMA, thereby promoting apoptosis in cancer cells.</td>\n",
       "      <td>0.029412</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is somewhat relevant but contains inaccuracies and extraneous information. It incorrectly references AML and venetoclax, which are not mentioned in the provided abstract. The correct context involves T-ALL and the combination of idasanutlin with navitoclax, not venetoclax. The explanation of the indirect relationship through the p53 pathway is correct but muddled by the incorrect references.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1425143', 'C0021246'): ['32833426'], ('C0021246', 'C0020402'): ['8450970', '2838255', '2752516', '9389508', '28614773', '1724341', '8708984'], ('C0020402', 'C4086509'): ['33936902', '34933330', '30543590']}</td>\n",
       "      <td>[C1425143, C0021246, C0020402, C4086509]</td>\n",
       "      <td>To describe an indirect relationship between the BBC3 gene and Idasanutlin using the provided scientific abstracts, we need to identify the relevant pathways and mechanisms that connect these entities, even if they are not directly mentioned together in the abstracts.\\n\\n1. **BBC3 Gene (Puma)**:\\n   - The first abstract discusses the role of adropin in a rotenone-induced Parkinson's disease (PD) model and its associated gastric ulcer. It mentions that adropin affects the apoptotic P53/Puma (BBC3) pathways. Puma (BBC3) is a pro-apoptotic gene regulated by the tumor suppressor protein p53, which is involved in apoptosis.\\n\\n2. **Idasanutlin**:\\n   - Although Idasanutlin is not mentioned in the abstracts, it is known from other scientific literature that Idasanutlin is an MDM2 antagonist. MDM2 is a negative regulator of p53, and by inhibiting MDM2, Idasanutlin can increase p53 activity, leading to enhanced expression of p53 target genes, including BBC3 (Puma).\\n\\n3. **Indirect Relationship**:\\n   - The first abstract indicates that the P53/Puma pathway is involved in the neuroprotective and gastroprotective effects observed in the PD model. Specifically, adropin helps restore the balance between pro-survival PI3K/Akt/murine double minute 2 (MDM2) signals and apoptotic P53/Puma pathways.\\n   - Since Idasanutlin inhibits MDM2, it would lead to increased p53 activity and subsequently upregulate Puma (BBC3). This suggests that Idasanutlin could potentially influence the same apoptotic pathways involving Puma (BBC3) as described in the context of the PD model treated with adropin.\\n\\nTherefore, the indirect relationship between the BBC3 gene and Idasanutlin can be described as follows:\\n\\n**Description**:\\nThe BBC3 gene, also known as Puma, is a pro-apoptotic gene regulated by the tumor suppressor protein p53. In the context of Parkinson's disease and associated gastric ulcers, the P53/Puma pathway plays a crucial role in mediating apoptosis. Adropin has been shown to modulate this pathway, restoring the balance between pro-survival and apoptotic signals. Idasanutlin, an MDM2 antagonist, indirectly influences the BBC3 gene by inhibiting MDM2, thereby enhancing p53 activity and increasing the expression of p53 target genes, including BBC3. This suggests that Idasanutlin could potentially affect the same apoptotic pathways involving Puma (BBC3) as those modulated by adropin in the PD model.</td>\n",
       "      <td>0.027027</td>\n",
       "      <td>2.0</td>\n",
       "      <td>The generated answer is somewhat relevant but contains significant inaccuracies and irrelevant information. The user query specifically asks for a description of the indirect relationship between the BBC3 gene and Idasanutlin based on the provided scientific abstracts. However, the generated answer introduces unrelated information about Parkinson's disease and adropin, which is not mentioned in the provided context. The correct relationship should focus on the role of Idasanutlin as an MDM2 inhibitor that upregulates BBC3 in the context of T-cell acute lymphoblastic leukemia, as described in the reference answer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>C1425143 C4086509</td>\n",
       "      <td>BBC3 gene</td>\n",
       "      <td>Idasanutlin</td>\n",
       "      <td>37838759</td>\n",
       "      <td>Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.</td>\n",
       "      <td>sr_pred_sent_4</td>\n",
       "      <td>2023</td>\n",
       "      <td>0</td>\n",
       "      <td>{('C1425143', 'C1417145'): ['34715892'], ('C1417145', 'C0020402'): ['32765515'], ('C0020402', 'C4086509'): ['33936902', '34933330', '30543590']}</td>\n",
       "      <td>[C1425143, C1417145, C0020402, C4086509]</td>\n",
       "      <td>To describe an indirect relationship between the BBC3 gene and Idasanutlin based on the provided scientific abstracts, we need to identify the pathways and interactions that connect these two entities through intermediary processes or molecules.\\n\\n1. **BBC3 Gene Context**:\\n   - The first abstract discusses the role of the BBC3 gene in cancer-related processes. BBC3 (also known as PUMA) is involved in \"Evading apoptosis\" and \"Genomic instability,\" which are critical pathways in cancer development. The abstract mentions that BBC3 is dysregulated in the context of Mitchell-Riley syndrome (MRS), which can lead to cancer predisposition.\\n\\n2. **Idasanutlin Context**:\\n   - Although Idasanutlin is not directly mentioned in the abstracts, it is known from other sources that Idasanutlin is a small molecule inhibitor of MDM2, which is a negative regulator of the p53 tumor suppressor pathway. By inhibiting MDM2, Idasanutlin activates p53, leading to cell cycle arrest and apoptosis in cancer cells.\\n\\n3. **Connecting Pathways**:\\n   - **p53 Pathway**: Both BBC3 and Idasanutlin are connected through the p53 pathway. BBC3 is a pro-apoptotic gene that is transcriptionally activated by p53. When p53 is activated, it can induce the expression of BBC3, leading to apoptosis.\\n   - **MDM2 Inhibition**: Idasanutlin inhibits MDM2, thereby preventing the degradation of p53. This results in increased levels of active p53, which can then promote the expression of pro-apoptotic genes like BBC3.\\n\\n4. **Indirect Relationship**:\\n   - The indirect relationship between BBC3 and Idasanutlin can be described as follows: Idasanutlin inhibits MDM2, leading to the stabilization and activation of p53. Activated p53, in turn, induces the expression of BBC3, which promotes apoptosis. Therefore, Idasanutlin indirectly influences the activity of BBC3 through the p53-mediated apoptotic pathway.\\n\\nIn summary, the indirect relationship between the BBC3 gene and Idasanutlin is mediated through the p53 pathway. Idasanutlin stabilizes and activates p53 by inhibiting MDM2, and active p53 then upregulates BBC3, leading to apoptosis. This connection highlights the role of Idasanutlin in potentially enhancing the pro-apoptotic effects of BBC3 in cancer cells.</td>\n",
       "      <td>0.027778</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The generated answer is relevant and correctly identifies the indirect relationship between BBC3 and Idasanutlin through the p53 pathway. However, it introduces some extraneous information not directly related to the provided abstract, such as Mitchell-Riley syndrome, which is not mentioned in the reference context. This inclusion of unrelated details slightly detracts from the clarity and focus of the answer.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                 pair             subj_name              obj_name      pmid  \\\n",
       "0   C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "1   C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "2   C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "3   C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "4   C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "5   C3658706 C4724800         pembrolizumab     tisotumab vedotin  37651655   \n",
       "6   C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "7   C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "8   C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "9   C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "10  C3467876 C4524315         larotrectinib            dabrafenib  35955671   \n",
       "11  C3467876 C4086264           entrectinib            dabrafenib  35955671   \n",
       "12  C3467876 C4086264           entrectinib            dabrafenib  35955671   \n",
       "13  C3467876 C4086264           entrectinib            dabrafenib  35955671   \n",
       "14  C3467876 C4086264           entrectinib            dabrafenib  35955671   \n",
       "15  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "16  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "17  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "18  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "19  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "20  C2718773 C4683810           canakinumab          zanubrutinib  35454970   \n",
       "21  C2716282 C3886682       gambogenic acid  ACTA2 protein, human  35994849   \n",
       "22  C2716282 C3886682       gambogenic acid  ACTA2 protein, human  35994849   \n",
       "23  C2716282 C3886682       gambogenic acid  ACTA2 protein, human  35994849   \n",
       "24  C2716282 C3886682       gambogenic acid  ACTA2 protein, human  35994849   \n",
       "25  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "26  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "27  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "28  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "29  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "30  C2698841 C4053677              AZD-1775            Volasertib  35992847   \n",
       "31  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "32  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "33  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "34  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "35  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "36  C2316164 C4080091              olaparib            lorlatinib  35324529   \n",
       "37  C1456409 C4519220            etravirine           fostemsavir  35315687   \n",
       "38  C1456409 C4519220            etravirine           fostemsavir  35315687   \n",
       "39  C1456409 C4519220            etravirine           fostemsavir  35315687   \n",
       "40  C1456409 C4519220            etravirine           fostemsavir  35315687   \n",
       "41  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "42  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "43  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "44  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "45  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "46  C1453431 C3490348  BECN1 protein, human         empagliflozin  35400245   \n",
       "47  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "48  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "49  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "50  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "51  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "52  C1425143 C4086509             BBC3 gene           Idasanutlin  37838759   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               pmid_text  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                      Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade >=3 adverse events (>=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none >=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.    \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                      Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade >=3 adverse events (>=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none >=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.    \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                      Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade >=3 adverse events (>=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none >=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.    \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                      Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade >=3 adverse events (>=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none >=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.    \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                      Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade >=3 adverse events (>=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none >=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.    \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                      Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade >=3 adverse events (>=15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none >=15%, arm E). TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.    \n",
       "6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.    \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.    \n",
       "8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.    \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.    \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.    \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.    \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.    \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.    \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembrolizumab (both for tumors with the mismatch-repair deficiency (dMMR)/high microsatellite instability (MSI-H) phenotype and for those with the high tumor mutational burden (TMB-H) phenotype), dostarlimab (for dMMR tumors), larotrectinib and entrectinib (for tumors harboring neurotrophic tyrosine receptor kinase (NTRK) fusions), and the combination of dabrafenib plus trametinib (for BRAF V600E-mutated tumors). The genomic alterations targeted by these antineoplastic agents are rare in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, only a small number of mCRPC patients were enrolled in the clinical trials that led to the approval of the above-mentioned drugs. Therefore, we critically reviewed the literature on the efficacy of histology-agnostic drugs in mCRPC patients. Although the available evidence derives from retrospective studies and case reports, our results confirmed the efficacy of pembrolizumab in dMMR/MSI-H mCRPC. In contrast, few data are available for dostarlimab, larotrectinib, entrectinib, and dabrafenib-trametinib in this subset of patients. Large, multi-institutional registries aimed at collecting real-world data are needed to better comprehend the role of tissue-agnostic drugs in mCRPC patients.    \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.    \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.    \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.    \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.    \n",
       "19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.    \n",
       "20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.    \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. Epigenetics regulating gene expression plays important role in kidney fibrosis. Natural products originating from diverse sources including plants and microorganisms are capable to influence epigenetic modifications. Gambogenic acid (GNA) is a caged xanthone extracted from gamboge resin, exudation of Garcinia hanburyi Hook.f., and the effect of GNA on kidney fibrosis with its underlying mechanism on epigenetics remains unknown. This study aimed to explore the role of GNA against kidney fibrogenesis by histone methylation mediating gene expression. Two experimental mice of unilateral ureteral obstruction (UUO) and folic acid (FA) were given two dosages of GNA (3 and 6 mg/kg/d). TGF-beta1 was used to stimulate mouse tubular epithelial (TCMK-1) cells and siRNAs were transfected to verify the underlying mechanisms of GNA. Histological changes were evaluated by HE, MASSON stainings, immunohistochemistry and immunofluorescence. Western blot and qPCR were used to measure protein/gene transcription levels. GNA dose-dependently alleviated UUO-induced kidney fibrosis and FA-induced kidney early fibrosis, indicated by the pathology and fibrotic factor changes (alpha-SMA, collagen I, collagen VI, and fibronectin). Mechanically, GNA reduced enhancer of zeste homolog 2 (EZH2) and H3K27me3, promoted Smad7 transcription, and inhibited TGF-beta/Smad3 fibrotic signaling in injured kidneys. Moreover, with TGF-beta1-induced EZH2 increasing, GNA suppressed alpha-SMA, fibronectin and collagen levels in tubular epithelial TCMK-1 cells. Although partially decreasing EZH2, GNA did not influence fibrotic signaling in Smad7 siRNA-transfected TCMK-1 cells. Epigenetic inhibition of EZH2 by GNA ameliorated kidney fibrogenesis via regulating Smad7-meidated TGF-beta/Smad3 signaling.    \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. Epigenetics regulating gene expression plays important role in kidney fibrosis. Natural products originating from diverse sources including plants and microorganisms are capable to influence epigenetic modifications. Gambogenic acid (GNA) is a caged xanthone extracted from gamboge resin, exudation of Garcinia hanburyi Hook.f., and the effect of GNA on kidney fibrosis with its underlying mechanism on epigenetics remains unknown. This study aimed to explore the role of GNA against kidney fibrogenesis by histone methylation mediating gene expression. Two experimental mice of unilateral ureteral obstruction (UUO) and folic acid (FA) were given two dosages of GNA (3 and 6 mg/kg/d). TGF-beta1 was used to stimulate mouse tubular epithelial (TCMK-1) cells and siRNAs were transfected to verify the underlying mechanisms of GNA. Histological changes were evaluated by HE, MASSON stainings, immunohistochemistry and immunofluorescence. Western blot and qPCR were used to measure protein/gene transcription levels. GNA dose-dependently alleviated UUO-induced kidney fibrosis and FA-induced kidney early fibrosis, indicated by the pathology and fibrotic factor changes (alpha-SMA, collagen I, collagen VI, and fibronectin). Mechanically, GNA reduced enhancer of zeste homolog 2 (EZH2) and H3K27me3, promoted Smad7 transcription, and inhibited TGF-beta/Smad3 fibrotic signaling in injured kidneys. Moreover, with TGF-beta1-induced EZH2 increasing, GNA suppressed alpha-SMA, fibronectin and collagen levels in tubular epithelial TCMK-1 cells. Although partially decreasing EZH2, GNA did not influence fibrotic signaling in Smad7 siRNA-transfected TCMK-1 cells. Epigenetic inhibition of EZH2 by GNA ameliorated kidney fibrogenesis via regulating Smad7-meidated TGF-beta/Smad3 signaling.    \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. Epigenetics regulating gene expression plays important role in kidney fibrosis. Natural products originating from diverse sources including plants and microorganisms are capable to influence epigenetic modifications. Gambogenic acid (GNA) is a caged xanthone extracted from gamboge resin, exudation of Garcinia hanburyi Hook.f., and the effect of GNA on kidney fibrosis with its underlying mechanism on epigenetics remains unknown. This study aimed to explore the role of GNA against kidney fibrogenesis by histone methylation mediating gene expression. Two experimental mice of unilateral ureteral obstruction (UUO) and folic acid (FA) were given two dosages of GNA (3 and 6 mg/kg/d). TGF-beta1 was used to stimulate mouse tubular epithelial (TCMK-1) cells and siRNAs were transfected to verify the underlying mechanisms of GNA. Histological changes were evaluated by HE, MASSON stainings, immunohistochemistry and immunofluorescence. Western blot and qPCR were used to measure protein/gene transcription levels. GNA dose-dependently alleviated UUO-induced kidney fibrosis and FA-induced kidney early fibrosis, indicated by the pathology and fibrotic factor changes (alpha-SMA, collagen I, collagen VI, and fibronectin). Mechanically, GNA reduced enhancer of zeste homolog 2 (EZH2) and H3K27me3, promoted Smad7 transcription, and inhibited TGF-beta/Smad3 fibrotic signaling in injured kidneys. Moreover, with TGF-beta1-induced EZH2 increasing, GNA suppressed alpha-SMA, fibronectin and collagen levels in tubular epithelial TCMK-1 cells. Although partially decreasing EZH2, GNA did not influence fibrotic signaling in Smad7 siRNA-transfected TCMK-1 cells. Epigenetic inhibition of EZH2 by GNA ameliorated kidney fibrogenesis via regulating Smad7-meidated TGF-beta/Smad3 signaling.    \n",
       "24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. Epigenetics regulating gene expression plays important role in kidney fibrosis. Natural products originating from diverse sources including plants and microorganisms are capable to influence epigenetic modifications. Gambogenic acid (GNA) is a caged xanthone extracted from gamboge resin, exudation of Garcinia hanburyi Hook.f., and the effect of GNA on kidney fibrosis with its underlying mechanism on epigenetics remains unknown. This study aimed to explore the role of GNA against kidney fibrogenesis by histone methylation mediating gene expression. Two experimental mice of unilateral ureteral obstruction (UUO) and folic acid (FA) were given two dosages of GNA (3 and 6 mg/kg/d). TGF-beta1 was used to stimulate mouse tubular epithelial (TCMK-1) cells and siRNAs were transfected to verify the underlying mechanisms of GNA. Histological changes were evaluated by HE, MASSON stainings, immunohistochemistry and immunofluorescence. Western blot and qPCR were used to measure protein/gene transcription levels. GNA dose-dependently alleviated UUO-induced kidney fibrosis and FA-induced kidney early fibrosis, indicated by the pathology and fibrotic factor changes (alpha-SMA, collagen I, collagen VI, and fibronectin). Mechanically, GNA reduced enhancer of zeste homolog 2 (EZH2) and H3K27me3, promoted Smad7 transcription, and inhibited TGF-beta/Smad3 fibrotic signaling in injured kidneys. Moreover, with TGF-beta1-induced EZH2 increasing, GNA suppressed alpha-SMA, fibronectin and collagen levels in tubular epithelial TCMK-1 cells. Although partially decreasing EZH2, GNA did not influence fibrotic signaling in Smad7 siRNA-transfected TCMK-1 cells. Epigenetic inhibition of EZH2 by GNA ameliorated kidney fibrogenesis via regulating Smad7-meidated TGF-beta/Smad3 signaling.    \n",
       "25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.    \n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.    \n",
       "27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.    \n",
       "28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.    \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.    \n",
       "30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker gammaH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.    \n",
       "31                                                                                                                                                                                                                                                                                                                                                                                                                       Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.    \n",
       "32                                                                                                                                                                                                                                                                                                                                                                                                                       Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.    \n",
       "33                                                                                                                                                                                                                                                                                                                                                                                                                       Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.    \n",
       "34                                                                                                                                                                                                                                                                                                                                                                                                                       Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.    \n",
       "35                                                                                                                                                                                                                                                                                                                                                                                                                       Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.    \n",
       "36                                                                                                                                                                                                                                                                                                                                                                                                                       Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Treatment options for heavily treated anaplastic lymphona kinase (ALK )-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 ( BRCA1/2 )-mutated patients in a few tumor types. There have been a trial and two case reports of an olaparib-containing regimen in treating epidermal growth factor receptor (EGFR)-positive or driver-negative NSCLC. We report a case of a 27-year-old female nonsmoker diagnosed with ALK -rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified. After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months. Shortly after progression, the patient was admitted to the ICU due to critically severe stenosis caused by a tracheal mass and soon relieved by embolization and stenting. Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK -positive, g BRCA -mutated metastatic NSCLC. Together with previous reports in EGFR -positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2 -mutated NSCLC.    \n",
       "37  Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Fostemsavir is a prodrug of temsavir, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells with demonstrated efficacy in phase 2 and 3. Temsavir is a P-glycoprotein and breast cancer resistance protein (BCRP) substrate; its metabolism is mediated by esterase and CYP3A4 enzymes. Drugs that induce or inhibit CYP3A, P-glycoprotein, and BCRP may affect temsavir concentrations. Understanding potential drug-drug interactions (DDIs) following fostemsavir coadministration with antiretrovirals approved for HIV-1-infected treatment-experienced patients, including darunavir plus cobicistat (DRV/c) or DRV plus low-dose ritonavir (DRV/r) and etravirine, is clinically relevant. Open-label, single-sequence, multiple-dose, multicohort DDI studies were conducted in healthy participants (n = 46; n = 32). The primary objective was to assess the effects of DRV/r, etravirine, DRV/r plus etravirine, cobicistat, and DRV/c on temsavir systemic exposures; safety was a secondary objective. Compared with fostemsavir alone, coadministration with DRV/r increased the temsavir maximum observed plasma concentration (Cmax), area under the concentration-time curve in one dosing interval (AUCtau), and plasma trough concentration (Ctau) by 52%, 63%, and 88%, respectively, while etravirine decreased the temsavir Cmax, AUCtau, and Ctau by  50% each. DRV/r plus etravirine increased the temsavir Cmax, AUCtau, and Ctau by 53%, 34%, and 33%, respectively. Compared with fostemsavir alone, coadministration with cobicistat increased the temsavir Cmax, AUCtau, and Ctau by 71%, 93%, and 136%, respectively; DRV/c increased the temsavir Cmax, AUCtau, and Ctau by 79%, 97%, and 124%, respectively. Fostemsavir with all combinations was generally well tolerated. No dose adjustment is required for fostemsavir when coadministered with strong CYP3A inhibitors, P-glycoprotein inhibitors, and modest inducers, including regimens with DRV/r, DRV/c, cobicistat, etravirine, and DRV/r plus etravirine based on the therapeutic margin for temsavir (ClinicalTrials.gov registration no. NCT02063360 and NCT02277600).    \n",
       "38  Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Fostemsavir is a prodrug of temsavir, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells with demonstrated efficacy in phase 2 and 3. Temsavir is a P-glycoprotein and breast cancer resistance protein (BCRP) substrate; its metabolism is mediated by esterase and CYP3A4 enzymes. Drugs that induce or inhibit CYP3A, P-glycoprotein, and BCRP may affect temsavir concentrations. Understanding potential drug-drug interactions (DDIs) following fostemsavir coadministration with antiretrovirals approved for HIV-1-infected treatment-experienced patients, including darunavir plus cobicistat (DRV/c) or DRV plus low-dose ritonavir (DRV/r) and etravirine, is clinically relevant. Open-label, single-sequence, multiple-dose, multicohort DDI studies were conducted in healthy participants (n = 46; n = 32). The primary objective was to assess the effects of DRV/r, etravirine, DRV/r plus etravirine, cobicistat, and DRV/c on temsavir systemic exposures; safety was a secondary objective. Compared with fostemsavir alone, coadministration with DRV/r increased the temsavir maximum observed plasma concentration (Cmax), area under the concentration-time curve in one dosing interval (AUCtau), and plasma trough concentration (Ctau) by 52%, 63%, and 88%, respectively, while etravirine decreased the temsavir Cmax, AUCtau, and Ctau by  50% each. DRV/r plus etravirine increased the temsavir Cmax, AUCtau, and Ctau by 53%, 34%, and 33%, respectively. Compared with fostemsavir alone, coadministration with cobicistat increased the temsavir Cmax, AUCtau, and Ctau by 71%, 93%, and 136%, respectively; DRV/c increased the temsavir Cmax, AUCtau, and Ctau by 79%, 97%, and 124%, respectively. Fostemsavir with all combinations was generally well tolerated. No dose adjustment is required for fostemsavir when coadministered with strong CYP3A inhibitors, P-glycoprotein inhibitors, and modest inducers, including regimens with DRV/r, DRV/c, cobicistat, etravirine, and DRV/r plus etravirine based on the therapeutic margin for temsavir (ClinicalTrials.gov registration no. NCT02063360 and NCT02277600).    \n",
       "39  Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Fostemsavir is a prodrug of temsavir, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells with demonstrated efficacy in phase 2 and 3. Temsavir is a P-glycoprotein and breast cancer resistance protein (BCRP) substrate; its metabolism is mediated by esterase and CYP3A4 enzymes. Drugs that induce or inhibit CYP3A, P-glycoprotein, and BCRP may affect temsavir concentrations. Understanding potential drug-drug interactions (DDIs) following fostemsavir coadministration with antiretrovirals approved for HIV-1-infected treatment-experienced patients, including darunavir plus cobicistat (DRV/c) or DRV plus low-dose ritonavir (DRV/r) and etravirine, is clinically relevant. Open-label, single-sequence, multiple-dose, multicohort DDI studies were conducted in healthy participants (n = 46; n = 32). The primary objective was to assess the effects of DRV/r, etravirine, DRV/r plus etravirine, cobicistat, and DRV/c on temsavir systemic exposures; safety was a secondary objective. Compared with fostemsavir alone, coadministration with DRV/r increased the temsavir maximum observed plasma concentration (Cmax), area under the concentration-time curve in one dosing interval (AUCtau), and plasma trough concentration (Ctau) by 52%, 63%, and 88%, respectively, while etravirine decreased the temsavir Cmax, AUCtau, and Ctau by  50% each. DRV/r plus etravirine increased the temsavir Cmax, AUCtau, and Ctau by 53%, 34%, and 33%, respectively. Compared with fostemsavir alone, coadministration with cobicistat increased the temsavir Cmax, AUCtau, and Ctau by 71%, 93%, and 136%, respectively; DRV/c increased the temsavir Cmax, AUCtau, and Ctau by 79%, 97%, and 124%, respectively. Fostemsavir with all combinations was generally well tolerated. No dose adjustment is required for fostemsavir when coadministered with strong CYP3A inhibitors, P-glycoprotein inhibitors, and modest inducers, including regimens with DRV/r, DRV/c, cobicistat, etravirine, and DRV/r plus etravirine based on the therapeutic margin for temsavir (ClinicalTrials.gov registration no. NCT02063360 and NCT02277600).    \n",
       "40  Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Fostemsavir is a prodrug of temsavir, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells with demonstrated efficacy in phase 2 and 3. Temsavir is a P-glycoprotein and breast cancer resistance protein (BCRP) substrate; its metabolism is mediated by esterase and CYP3A4 enzymes. Drugs that induce or inhibit CYP3A, P-glycoprotein, and BCRP may affect temsavir concentrations. Understanding potential drug-drug interactions (DDIs) following fostemsavir coadministration with antiretrovirals approved for HIV-1-infected treatment-experienced patients, including darunavir plus cobicistat (DRV/c) or DRV plus low-dose ritonavir (DRV/r) and etravirine, is clinically relevant. Open-label, single-sequence, multiple-dose, multicohort DDI studies were conducted in healthy participants (n = 46; n = 32). The primary objective was to assess the effects of DRV/r, etravirine, DRV/r plus etravirine, cobicistat, and DRV/c on temsavir systemic exposures; safety was a secondary objective. Compared with fostemsavir alone, coadministration with DRV/r increased the temsavir maximum observed plasma concentration (Cmax), area under the concentration-time curve in one dosing interval (AUCtau), and plasma trough concentration (Ctau) by 52%, 63%, and 88%, respectively, while etravirine decreased the temsavir Cmax, AUCtau, and Ctau by  50% each. DRV/r plus etravirine increased the temsavir Cmax, AUCtau, and Ctau by 53%, 34%, and 33%, respectively. Compared with fostemsavir alone, coadministration with cobicistat increased the temsavir Cmax, AUCtau, and Ctau by 71%, 93%, and 136%, respectively; DRV/c increased the temsavir Cmax, AUCtau, and Ctau by 79%, 97%, and 124%, respectively. Fostemsavir with all combinations was generally well tolerated. No dose adjustment is required for fostemsavir when coadministered with strong CYP3A inhibitors, P-glycoprotein inhibitors, and modest inducers, including regimens with DRV/r, DRV/c, cobicistat, etravirine, and DRV/r plus etravirine based on the therapeutic margin for temsavir (ClinicalTrials.gov registration no. NCT02063360 and NCT02277600).    \n",
       "41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.    \n",
       "42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.    \n",
       "43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.    \n",
       "44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.    \n",
       "45                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.    \n",
       "46                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway. To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin in alleviating myocardial ischaemia-reperfusion (I/R) injury. A mouse model of I/R injury and H2O2-induced H9C2 cell model were established. The expressions of Bcl-2, Bax, LC3, Beclin1, GRP78, CHOP, PERK, ATF4, ATF6, IREalpha and P62 were examined by western blot, immunofluorescence or immunohistochemistry staining, respectively. The cardiac function was measured by echocardiography, TCC staining, lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity. Cell apoptosis was analysed by TUNEL, Annexin V/propidium iodide (PI) staining and caspase 3 and 9 activities. CCK-8 assay was used for analysing cell viability. PBA, TUDC and 3-MA were utilised for blocking ER stress and autophagy, respectively. Empagliflozin suppressed myocardial I/R injury in vivo and H2O2-induced cardiomyocyte apoptosis in vitro. Blockade of ER stress and autophagy inhibited H2O2-induced cardiomyocyte apoptosis. ER stress activated autophagy through the PERK signalling in H2O2-treated H9C2 cells. Empagliflozin suppressed ER stress-induced autophagy by inhibiting the PERK/ATF4/Beclin1 signalling. H2O2 and I/R-induced cardiomyocyte apoptosis was restrained by empagliflozin through inhibition of ER stress-induced autophagy. Empagliflozin suppressed ER stress-induced autophagy via suppressing the PERK/ATF4/Beclin1 signalling, thus alleviating myocardial I/R injury and cardiomyocyte apoptosis.    \n",
       "47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.    \n",
       "48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.    \n",
       "49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.    \n",
       "50                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.    \n",
       "51                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.    \n",
       "52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.    \n",
       "\n",
       "             source first_year  label  \\\n",
       "0        title_cooc       2022      1   \n",
       "1        title_cooc       2022      1   \n",
       "2        title_cooc       2022      1   \n",
       "3        title_cooc       2022      0   \n",
       "4        title_cooc       2022      0   \n",
       "5        title_cooc       2022      0   \n",
       "6    sr_pred_sent_2       2022      1   \n",
       "7    sr_pred_sent_2       2022      1   \n",
       "8    sr_pred_sent_2       2022      0   \n",
       "9    sr_pred_sent_2       2022      0   \n",
       "10   sr_pred_sent_2       2022      0   \n",
       "11   sr_pred_sent_2       2022      1   \n",
       "12   sr_pred_sent_2       2022      0   \n",
       "13   sr_pred_sent_2       2022      0   \n",
       "14   sr_pred_sent_2       2022      0   \n",
       "15   sr_pred_sent_9       2022      1   \n",
       "16   sr_pred_sent_9       2022      1   \n",
       "17   sr_pred_sent_9       2022      1   \n",
       "18   sr_pred_sent_9       2022      0   \n",
       "19   sr_pred_sent_9       2022      0   \n",
       "20   sr_pred_sent_9       2022      0   \n",
       "21  sr_pred_sent_11       2022      1   \n",
       "22  sr_pred_sent_11       2022      0   \n",
       "23  sr_pred_sent_11       2022      0   \n",
       "24  sr_pred_sent_11       2022      0   \n",
       "25   sr_pred_sent_5       2022      1   \n",
       "26   sr_pred_sent_5       2022      1   \n",
       "27   sr_pred_sent_5       2022      1   \n",
       "28   sr_pred_sent_5       2022      0   \n",
       "29   sr_pred_sent_5       2022      0   \n",
       "30   sr_pred_sent_5       2022      0   \n",
       "31       title_cooc       2022      1   \n",
       "32       title_cooc       2022      1   \n",
       "33       title_cooc       2022      1   \n",
       "34       title_cooc       2022      0   \n",
       "35       title_cooc       2022      0   \n",
       "36       title_cooc       2022      0   \n",
       "37       title_cooc       2022      1   \n",
       "38       title_cooc       2022      0   \n",
       "39       title_cooc       2022      0   \n",
       "40       title_cooc       2022      0   \n",
       "41       title_cooc       2022      1   \n",
       "42       title_cooc       2022      1   \n",
       "43       title_cooc       2022      1   \n",
       "44       title_cooc       2022      0   \n",
       "45       title_cooc       2022      0   \n",
       "46       title_cooc       2022      0   \n",
       "47   sr_pred_sent_4       2023      1   \n",
       "48   sr_pred_sent_4       2023      1   \n",
       "49   sr_pred_sent_4       2023      1   \n",
       "50   sr_pred_sent_4       2023      0   \n",
       "51   sr_pred_sent_4       2023      0   \n",
       "52   sr_pred_sent_4       2023      0   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                           context_pmids  \\\n",
       "0                                                                                                                                                                                                                                                                   {('C3658706', 'C0278579'): ['34345644', '35031189', '29666026', '32740092'], ('C0278579', 'C4724800'): ['35277279']}   \n",
       "1                                                                                                                                                   {('C3658706', 'C4704928'): ['29500171', '28946123', '34956447', '33983696', '34829916', '33324546', '33852056', '34424404', '33767972', '30844889'], ('C4704928', 'C0278579'): ['35277279'], ('C0278579', 'C4724800'): ['35277279']}   \n",
       "2                                                                                                                                                                                                                                           {('C3658706', 'C4704928'): ['33983696', '34956447', '28749907', '33852056'], ('C4704928', 'C4724800'): ['35277279', '36046840', '30126944']}   \n",
       "3                                                                                                                                                                                       {('C3658706', 'C1367202'): ['27764796', '28881222', '26513491', '32128919', '32774137', '31442816', '29143108'], ('C1367202', 'C4288736'): ['31098752'], ('C4288736', 'C4724800'): ['36046840']}   \n",
       "4                                                                                                                                                                                                                                       {('C3658706', 'C2935436'): ['29881714', '34829916'], ('C2935436', 'C4288736'): ['32618744', '29116596'], ('C4288736', 'C4724800'): ['36046840']}   \n",
       "5                                                                                                                                                                                                                                                               {('C3658706', 'C2982078'): ['30859062'], ('C2982078', 'C4288736'): ['29300693'], ('C4288736', 'C4724800'): ['36046840']}   \n",
       "6                                                                                                                                                                                                                                                                               {('C3467876', 'C0265325'): ['26141621'], ('C0265325', 'C4524315'): ['31705130', '32755482', '34285720']}   \n",
       "7                                                                                                                                                                                                                                                               {('C3467876', 'C2697961'): ['32774277'], ('C2697961', 'C0265325'): ['26141621'], ('C0265325', 'C4524315'): ['34285720']}   \n",
       "8                                                                                                                                                                                                                                                               {('C3467876', 'C1415138'): ['23432625'], ('C1415138', 'C0169658'): ['32269842'], ('C0169658', 'C4524315'): ['33792431']}   \n",
       "9                                                                                                                                                                                                                                                   {('C3467876', 'C4519250'): ['33991955'], ('C4519250', 'C3853694'): ['34434895'], ('C3853694', 'C4524315'): ['34041811', '31571972']}   \n",
       "10                                                                                                                                                                                                                                      {('C3467876', 'C1333650'): ['27188223', '24504448'], ('C1333650', 'C0812222'): ['23222563', '18948082'], ('C0812222', 'C4524315'): ['34340207']}   \n",
       "11                                                                                                                                                              {('C3467876', 'C3658706'): ['33657824', '30009647', '24928310', '27188223'], ('C3658706', 'C2697961'): ['28614138', '29561296', '31118140', '26353041'], ('C2697961', 'C4086264'): ['33846488', '33353026', '31862477']}   \n",
       "12                                                                                                                                                                                                                                                              {('C3467876', 'C2743752'): ['27797970'], ('C2743752', 'C0812222'): ['24281001'], ('C0812222', 'C4086264'): ['34340207']}   \n",
       "13                                                                                                                                                                          {('C3467876', 'C0242275'): ['33159968'], ('C0242275', 'C0812222'): ['24799378', '24194188', '29297949', '12588705', '11278558', '25145657', '15110188', '30514153'], ('C0812222', 'C4086264'): ['34340207']}   \n",
       "14                                                                                                                                                                                                                                                               {('C3467876', 'C0042682'): ['35379272'], ('C0042682', 'C0012373'): ['4006044'], ('C0012373', 'C4086264'): ['34495458']}   \n",
       "15                                                                                                                                                                                                                              {('C2718773', 'C1609165'): ['32552266', '23729309', '32193746', '25218736', '26048626', '24129147', '23172748'], ('C1609165', 'C4683810'): ['34160250']}   \n",
       "16                                                                                                              {('C2718773', 'C1609165'): ['34698811', '25061259', '33683393', '32449926', '26628580', '32322121', '29110911'], ('C1609165', 'C4044947'): ['34729893', '33455920', '34488083', '33519271', '33595833', '32550671', '34826840'], ('C4044947', 'C4683810'): ['33539089']}   \n",
       "17                                                                                                                                                                                                                                                                                                      {('C2718773', 'C4044947'): ['34868553'], ('C4044947', 'C4683810'): ['33539089']}   \n",
       "18                                                                                                                                                                                                                                                  {('C2718773', 'C0674428'): ['19536362'], ('C0674428', 'C0028978'): ['22862307', '27566010'], ('C0028978', 'C4683810'): ['33336408']}   \n",
       "19                                                  {('C2718773', 'C1424250'): ['32623652', '31504417', '21967869', '33883388', '30930410', '31755287', '34784874', '34650351', '21356079'], ('C1424250', 'C1335226'): ['32552384', '30619256', '31408184', '34535969', '30783801', '31993418', '32671674', '25418813', '33042144'], ('C1335226', 'C4683810'): ['31028669', '34248972']}   \n",
       "20                                                                                                                                                                                                                                      {('C2718773', 'C0010980'): ['29478243'], ('C0010980', 'C0026056'): ['21342112', '34078115'], ('C0026056', 'C4683810'): ['33336408', '33687157']}   \n",
       "21                                                                                                                                                                                                                                                                  {('C2716282', 'C1172384'): ['34859108', '31579944', '32041748', '31128153'], ('C1172384', 'C3886682'): ['28320739']}   \n",
       "22                                                                                                              {('C2716282', 'C0009968'): ['27036009', '26446519', '34135753', '22879914', '33744278'], ('C0009968', 'C0291573'): ['28350998', '30556269', '18381230', '32080790', '30366095'], ('C0291573', 'C3886682'): ['24427275', '30125771', '24460340', '28382147', '25087947']}   \n",
       "23  {('C2716282', 'C0055661'): ['26780233', '30634545', '26297989', '29987200', '28565752', '30225683', '26062793', '30866863'], ('C0055661', 'C0291573'): ['27347080', '18590707', '15555556', '22574207', '27329777', '29805643', '24019108', '35301625'], ('C0291573', 'C3886682'): ['25087947', '30125771', '24427275', '30592285', '22222560', '22007630', '28382147', '24460340']}   \n",
       "24                                      {('C2716282', 'C1421313'): ['27124181', '28683125', '32240652'], ('C1421313', 'C0291573'): ['29858912', '35689706', '35656450', '28875237', '19610036', '23099053', '32454192', '28089824', '22502613'], ('C0291573', 'C3886682'): ['24460340', '28382147', '22222560', '22007630', '33624779', '30592285', '25087947', '24427275', '30125771']}   \n",
       "25                                                                                                                                                                                                      {('C2698841', 'C1421500'): ['26885445', '35159005'], ('C1421500', 'C4053677'): ['31222885', '27318641', '31703356', '35173547', '28790110', '30068368', '27304454', '28208168']}   \n",
       "26                                                                                                                                                                                                                                                      {('C2698841', 'C0971285'): ['31832331', '35159005', '28482026', '32735909', '35637734'], ('C0971285', 'C4053677'): ['30755439']}   \n",
       "27                                                                                                                                                                                                                          {('C2698841', 'C0971285'): ['35159005', '31832331'], ('C0971285', 'C0290178'): ['32231069', '27249336'], ('C0290178', 'C4053677'): ['29954437', '31200459']}   \n",
       "28                                                                                                                           {('C2698841', 'C1333655'): ['31122263'], ('C1333655', 'C0525037'): ['14971655', '26518708', '15637593', '25187435', '1990262', '33976322', '16022731'], ('C0525037', 'C4053677'): ['28619757', '34277427', '32565737', '32012873', '30755439', '27939202']}   \n",
       "29                                                                                                                                                                                                                                                                                                      {('C2698841', 'C0079419'): ['31227645'], ('C0079419', 'C4053677'): ['30679201']}   \n",
       "30                                                                                                                                                                                                                          {('C2698841', 'C0249197'): ['24660103'], ('C0249197', 'C3853822'): ['30979737', '28663582', '35619220', '30872077'], ('C3853822', 'C4053677'): ['28619757']}   \n",
       "31                                                                                                                                                                                          {('C2316164', 'C0278987'): ['33070053', '34701460', '35511434'], ('C0278987', 'C4080091'): ['34626769', '33776691', '33569330', '33091333', '30394941', '30786826', '35307611', '32974130']}   \n",
       "32                                                              {('C2316164', 'C0278987'): ['33070053', '34701460', '35511434'], ('C0278987', 'C3818721'): ['27401242', '26361725', '28404761', '28729021', '34626769', '30251885', '31906956', '25888090'], ('C3818721', 'C4080091'): ['31331844', '31857951', '35250311', '31943796', '31354290', '29799091', '33449423', '30737231']}   \n",
       "33                                                                                                                                                                              {('C2316164', 'C3818721'): ['32224911', '34810199'], ('C3818721', 'C4080091'): ['34820326', '31616158', '29458783', '32974130', '30786826', '33449423', '33776703', '30662002', '31857953', '34418561']}   \n",
       "34                                                                                                                                                                                                                                      {('C2316164', 'C0672708'): ['29902865', '25888415'], ('C0672708', 'C1420703'): ['23484070'], ('C1420703', 'C4080091'): ['34059352', '34157012']}   \n",
       "35                                                                                                                                                                          {('C2316164', 'C3501358'): ['31974435', '29575238'], ('C3501358', 'C0007131'): ['25214559', '30663221', '34921994', '33434619'], ('C0007131', 'C4080091'): ['35431862', '32069373', '34820326', '33298467']}   \n",
       "36                                                                                                                                                                                                                                                  {('C2316164', 'C0000970'): ['34111734'], ('C0000970', 'C1333573'): ['23220477', '31428698'], ('C1333573', 'C4080091'): ['30459283']}   \n",
       "37                                                                                       {('C1456409', 'C0292818'): ['25397525', '20236784', '25350959', '22378681', '25585528', '19275497', '18567574', '21852713'], ('C0292818', 'C0012133'): ['16685132', '16220085', '9443665', '15807718', '26855245', '16563858', '18567912', '11312622'], ('C0012133', 'C4519220'): ['34459470']}   \n",
       "38                                                                                                                                                              {('C1456409', 'C0027794'): ['25937791'], ('C0027794', 'C0001175'): ['30934067', '24036558', '20007668', '27571699', '31987053'], ('C0001175', 'C4519220'): ['33128903', '29689540', '34176425', '35338549', '32464638']}   \n",
       "39                                                                                                                                                                                      {('C1456409', 'C0033308'): ['19088949'], ('C0033308', 'C3496793'): ['30273606', '31017696', '27816190', '32824674', '25649766', '34208290', '30770950'], ('C3496793', 'C4519220'): ['33547469']}   \n",
       "40                                                                                                                                                                                                                                                              {('C1456409', 'C1176309'): ['19557204'], ('C1176309', 'C0026256'): ['27631436'], ('C0026256', 'C4519220'): ['33547469']}   \n",
       "41              {('C1453431', 'C0027055'): ['31632535', '33377581', '33083461', '27246989', '26604691', '34530090', '30066841', '34119533', '34391873'], ('C0027055', 'C1420201'): ['30992077', '30873553', '30847415', '33483761', '32194159'], ('C1420201', 'C3490348'): ['33846238', '27009625', '35126806', '34137526', '25301180', '33899306', '30097993', '34753480', '28440590']}   \n",
       "42                                                                                                                                                                                                                          {('C1453431', 'C1412622'): ['28747345', '23979425'], ('C1412622', 'C0027055'): ['30880910', '30728891'], ('C0027055', 'C3490348'): ['33738012', '33953281']}   \n",
       "43                                                                                                                                                                                                                                      {('C1453431', 'C1412617'): ['34112145', '31524237'], ('C1412617', 'C1420201'): ['31285506'], ('C1420201', 'C3490348'): ['35287171', '29693360']}   \n",
       "44                                                                                                                 {('C1453431', 'C0054412'): ['32500147', '27872163', '33127495'], ('C0054412', 'C0005684'): ['7729958', '6680725', '1804290', '14555400'], ('C0005684', 'C3490348'): ['28725912', '24348059', '27486640', '31426529', '25554069', '33552467', '31741440', '30972917']}   \n",
       "45                                                                                                                                                                                                                                                                              {('C1453431', 'C0289313'): ['34235122', '29740932'], ('C0289313', 'C3490348'): ['29520964', '30767126']}   \n",
       "46                                                                          {('C1453431', 'C1565860'): ['31264128', '29407824', '31632535', '30873010', '25303541', '29864907'], ('C1565860', 'C0005684'): ['29422113', '32992651', '15870865', '20428812', '24612661', '24964787'], ('C0005684', 'C3490348'): ['27486640', '31426529', '32704566', '32271194', '33552467', '24348059']}   \n",
       "47                                                                                                                                                                                                                  {('C1425143', 'C4079830'): ['33082322', '32054729'], ('C4079830', 'C4086509'): ['28915653', '29768700', '34101461', '27353420', '35233509', '28914567', '33850004']}   \n",
       "48                                                                                                                                                                                                                                                                              {('C1425143', 'C1961099'): ['23410974', '25784680', '19737931'], ('C1961099', 'C4086509'): ['34465864']}   \n",
       "49                                                                                                                                                                                      {('C1425143', 'C4079830'): ['33082322', '32054729'], ('C4079830', 'C1961099'): ['33970999', '29854301', '32733662', '32970500', '30225152', '28074072'], ('C1961099', 'C4086509'): ['34465864']}   \n",
       "50                                                                                                                                      {('C1425143', 'C0049065'): ['32054729'], ('C0049065', 'C0020402'): ['25696830', '26858356', '15561675', '25931013', '24163393', '16859388', '26783435', '11001887', '12010787'], ('C0020402', 'C4086509'): ['33936902', '34933330', '30543590']}   \n",
       "51                                                                                                                                                                    {('C1425143', 'C0021246'): ['32833426'], ('C0021246', 'C0020402'): ['8450970', '2838255', '2752516', '9389508', '28614773', '1724341', '8708984'], ('C0020402', 'C4086509'): ['33936902', '34933330', '30543590']}   \n",
       "52                                                                                                                                                                                                                                      {('C1425143', 'C1417145'): ['34715892'], ('C1417145', 'C0020402'): ['32765515'], ('C0020402', 'C4086509'): ['33936902', '34933330', '30543590']}   \n",
       "\n",
       "                                        path  \\\n",
       "0             [C3658706, C0278579, C4724800]   \n",
       "1   [C3658706, C4704928, C0278579, C4724800]   \n",
       "2             [C3658706, C4704928, C4724800]   \n",
       "3   [C3658706, C1367202, C4288736, C4724800]   \n",
       "4   [C3658706, C2935436, C4288736, C4724800]   \n",
       "5   [C3658706, C2982078, C4288736, C4724800]   \n",
       "6             [C3467876, C0265325, C4524315]   \n",
       "7   [C3467876, C2697961, C0265325, C4524315]   \n",
       "8   [C3467876, C1415138, C0169658, C4524315]   \n",
       "9   [C3467876, C4519250, C3853694, C4524315]   \n",
       "10  [C3467876, C1333650, C0812222, C4524315]   \n",
       "11  [C3467876, C3658706, C2697961, C4086264]   \n",
       "12  [C3467876, C2743752, C0812222, C4086264]   \n",
       "13  [C3467876, C0242275, C0812222, C4086264]   \n",
       "14  [C3467876, C0042682, C0012373, C4086264]   \n",
       "15            [C2718773, C1609165, C4683810]   \n",
       "16  [C2718773, C1609165, C4044947, C4683810]   \n",
       "17            [C2718773, C4044947, C4683810]   \n",
       "18  [C2718773, C0674428, C0028978, C4683810]   \n",
       "19  [C2718773, C1424250, C1335226, C4683810]   \n",
       "20  [C2718773, C0010980, C0026056, C4683810]   \n",
       "21            [C2716282, C1172384, C3886682]   \n",
       "22  [C2716282, C0009968, C0291573, C3886682]   \n",
       "23  [C2716282, C0055661, C0291573, C3886682]   \n",
       "24  [C2716282, C1421313, C0291573, C3886682]   \n",
       "25            [C2698841, C1421500, C4053677]   \n",
       "26            [C2698841, C0971285, C4053677]   \n",
       "27  [C2698841, C0971285, C0290178, C4053677]   \n",
       "28  [C2698841, C1333655, C0525037, C4053677]   \n",
       "29            [C2698841, C0079419, C4053677]   \n",
       "30  [C2698841, C0249197, C3853822, C4053677]   \n",
       "31            [C2316164, C0278987, C4080091]   \n",
       "32  [C2316164, C0278987, C3818721, C4080091]   \n",
       "33            [C2316164, C3818721, C4080091]   \n",
       "34  [C2316164, C0672708, C1420703, C4080091]   \n",
       "35  [C2316164, C3501358, C0007131, C4080091]   \n",
       "36  [C2316164, C0000970, C1333573, C4080091]   \n",
       "37  [C1456409, C0292818, C0012133, C4519220]   \n",
       "38  [C1456409, C0027794, C0001175, C4519220]   \n",
       "39  [C1456409, C0033308, C3496793, C4519220]   \n",
       "40  [C1456409, C1176309, C0026256, C4519220]   \n",
       "41  [C1453431, C0027055, C1420201, C3490348]   \n",
       "42  [C1453431, C1412622, C0027055, C3490348]   \n",
       "43  [C1453431, C1412617, C1420201, C3490348]   \n",
       "44  [C1453431, C0054412, C0005684, C3490348]   \n",
       "45            [C1453431, C0289313, C3490348]   \n",
       "46  [C1453431, C1565860, C0005684, C3490348]   \n",
       "47            [C1425143, C4079830, C4086509]   \n",
       "48            [C1425143, C1961099, C4086509]   \n",
       "49  [C1425143, C4079830, C1961099, C4086509]   \n",
       "50  [C1425143, C0049065, C0020402, C4086509]   \n",
       "51  [C1425143, C0021246, C0020402, C4086509]   \n",
       "52  [C1425143, C1417145, C0020402, C4086509]   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               llm_response_bl  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               To describe an indirect relationship between pembrolizumab and tisotumab vedotin based on the provided scientific abstract, we can focus on the context of their use in treating recurrent cervical cancer and the potential for complementary or sequential therapeutic strategies. Heres a detailed description:\\n\\n---\\n\\n**Indirect Relationship Between Pembrolizumab and Tisotumab Vedotin in Recurrent Cervical Cancer**\\n\\nPembrolizumab, an anti-PD-1 therapy, has shown promise in treating advanced or recurrent PD-L1 positive cervical cancer, with a subset of patients deriving durable clinical benefits. In a retrospective cohort study of 14 patients with recurrent or metastatic cervical cancer treated with pembrolizumab, the objective response rate was 21%, with a durable clinical benefit rate of 36%. Key factors associated with improved response included metastatic spread limited to the lung and/or lymph nodes and higher tumor mutational burden.\\n\\nTisotumab vedotin, an antibody-drug conjugate targeting tissue factor, represents another therapeutic option for cervical cancer. While the abstract does not provide specific data on tisotumab vedotin, its mechanism of action and clinical application suggest it could be used in patients who do not respond to or progress after pembrolizumab treatment.\\n\\nThe indirect relationship between pembrolizumab and tisotumab vedotin can be understood in the context of their complementary roles in the treatment landscape of recurrent cervical cancer. Pembrolizumab may be particularly beneficial for patients with specific clinicopathologic features, such as higher tumor mutational burden and limited metastatic spread. For patients who do not achieve a durable response with pembrolizumab, tisotumab vedotin offers an alternative therapeutic approach, potentially targeting different aspects of tumor biology.\\n\\nIn summary, while pembrolizumab and tisotumab vedotin are distinct therapies with different mechanisms of action, their indirect relationship lies in their sequential or combined use to optimize treatment outcomes for patients with recurrent cervical cancer. Identifying biomarkers and clinical features that predict response to each therapy can help tailor treatment strategies and improve patient outcomes.\\n\\n---\\n\\nThis description highlights how pembrolizumab and tisotumab vedotin might be used in a complementary manner, addressing different patient needs and potentially improving overall treatment efficacy in recurrent cervical cancer.   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Based on the provided abstract, an indirect relationship between pembrolizumab and tisotumab vedotin in the context of metastatic triple negative breast cancer (TNBC) can be described as follows:\\n\\nPembrolizumab is mentioned in the context of recent advances in the treatment of metastatic TNBC, particularly in combination with chemotherapy for patients with programmed death-ligand 1 (PD-L1) positive tumors. The abstract highlights that pembrolizumab, when combined with chemotherapy, has shown improved progression-free survival (PFS) in this patient population.\\n\\nTisotumab vedotin, although not explicitly mentioned in the abstract, falls under the category of antibody-drug conjugates (ADCs), which are identified as an area of therapeutic interest for metastatic TNBC. ADCs are a class of targeted cancer therapies that deliver cytotoxic agents directly to cancer cells, thereby minimizing damage to normal cells.\\n\\nThe indirect relationship between pembrolizumab and tisotumab vedotin can be inferred through their roles in the evolving landscape of metastatic TNBC treatment. Both agents represent different therapeutic strategies aimed at improving outcomes for patients with this aggressive cancer type. Pembrolizumab, an immune checkpoint inhibitor, enhances the body's immune response against cancer cells, while tisotumab vedotin, as an ADC, targets and delivers cytotoxic agents to cancer cells.\\n\\nIn summary, the indirect relationship between pembrolizumab and tisotumab vedotin in metastatic TNBC is that they are both part of the broader spectrum of emerging therapeutic options being explored to improve patient outcomes. Pembrolizumab is part of the immunotherapy approach, while tisotumab vedotin represents the targeted therapy approach using ADCs. Both strategies are being investigated to address the unmet needs in the treatment of metastatic TNBC.   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         An indirect relationship between pembrolizumab and tisotumab vedotin can be described through their roles in the evolving landscape of cancer treatment, particularly in the context of metastatic triple-negative breast cancer (mTNBC).\\n\\nPembrolizumab is an immunotherapy agent that has been approved for use in combination with chemotherapy for PD-L1-positive mTNBC. It works by targeting the PD-1/PD-L1 pathway, thereby enhancing the immune system's ability to recognize and attack cancer cells. This represents a significant advancement in the treatment of mTNBC, which traditionally has had limited therapeutic options and poor outcomes.\\n\\nOn the other hand, tisotumab vedotin is an antibody-drug conjugate (ADC) that is being explored for its potential in treating various cancers. While the abstract does not specifically mention tisotumab vedotin, it does highlight the approval and promise of other ADCs, such as sacituzumab govitecan, in the treatment of mTNBC. ADCs like tisotumab vedotin combine the targeting capabilities of monoclonal antibodies with the potent cell-killing ability of cytotoxic drugs, offering a novel approach to cancer therapy.\\n\\nThe indirect relationship between pembrolizumab and tisotumab vedotin lies in their shared goal of improving cancer treatment outcomes through innovative mechanisms. Both represent different but complementary strategies in the broader context of precision medicine and targeted therapies for cancer. Pembrolizumab enhances the immune response against cancer cells, while ADCs like tisotumab vedotin deliver targeted cytotoxic effects. Together, these advancements contribute to a more comprehensive and effective approach to managing challenging cancers such as mTNBC.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     An indirect relationship between pembrolizumab and tisotumab vedotin can be inferred from the provided scientific abstracts through their shared context of cancer treatment and the potential for adverse effects, particularly ocular toxicities.\\n\\n1. **Pembrolizumab and Age-Related Efficacy in Metastatic Melanoma**:\\n   - The first abstract discusses the efficacy of pembrolizumab, an anti-PD1 immune checkpoint inhibitor, in treating metastatic melanoma. It highlights that patients aged between 70 and 80 years have better overall survival and progression-free survival compared to younger patients. The study also notes that age-related immune dysfunction (ARID) does not negatively impact the efficacy of pembrolizumab in these patients. However, it cautions about the higher risk of serious immune-related adverse events in elderly patients.\\n\\n2. **Ocular Toxicities of Chemotherapeutic Agents**:\\n   - The second abstract focuses on the ocular toxicities associated with various chemotherapeutic agents, including both traditional and novel therapies. It reports a range of ocular side effects in cancer patients, emphasizing the need for ophthalmologists to manage these potential toxicities. Specific examples of ocular toxicities are provided for several drugs, although pembrolizumab is not mentioned directly.\\n\\n**Indirect Relationship**:\\n- **Shared Context of Cancer Treatment**: Both pembrolizumab and tisotumab vedotin are used in the treatment of cancer. Pembrolizumab is an immune checkpoint inhibitor used for metastatic melanoma, while tisotumab vedotin is an antibody-drug conjugate used in other cancer types.\\n- **Potential for Adverse Effects**: The second abstract underscores the importance of monitoring and managing adverse effects, particularly ocular toxicities, in patients undergoing cancer treatment with various chemotherapeutic agents. While pembrolizumab is not specifically mentioned in the context of ocular toxicities, the general concern about adverse effects in cancer therapies is relevant.\\n- **Age and Comorbidities**: The first abstract highlights that older patients (70-80 years) have better outcomes with pembrolizumab but also face higher risks of serious adverse events. This consideration is important for clinicians when deciding on treatment plans, including the use of other chemotherapeutic agents like tisotumab vedotin, which may also have age-related implications and potential toxicities.\\n\\nIn summary, the indirect relationship between pembrolizumab and tisotumab vedotin is established through their roles in cancer treatment, the shared concern for managing adverse effects, and the consideration of patient age and comorbidities in treatment efficacy and safety.   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               An indirect relationship between pembrolizumab and tisotumab vedotin can be described through their roles in the broader landscape of cancer treatment, particularly focusing on their mechanisms and therapeutic contexts.\\n\\nPembrolizumab is an immune checkpoint inhibitor (ICI) that has shown promising efficacy in the treatment of triple-negative breast cancer (TNBC) and other cancers by targeting the PD-1/PD-L1 pathway to enhance the immune system's ability to fight cancer cells. It represents a significant advancement in immunotherapy, particularly for cancers that are immunogenic, such as certain subtypes of breast cancer.\\n\\nOn the other hand, tisotumab vedotin is an antibody-drug conjugate (ADC) designed to deliver a cytotoxic agent specifically to cancer cells. ADCs like tisotumab vedotin consist of a monoclonal antibody linked to a cytotoxic drug, which is released inside the cancer cell upon internalization, leading to cell death. This targeted approach aims to minimize damage to healthy cells and improve the therapeutic index.\\n\\nThe indirect relationship between pembrolizumab and tisotumab vedotin lies in their complementary roles in the evolving field of cancer therapy. Both represent innovative strategies to improve cancer treatment outcomes but operate through different mechanisms. Pembrolizumab enhances the immune response against cancer cells, while tisotumab vedotin directly delivers cytotoxic agents to kill cancer cells. \\n\\nMoreover, both therapies are part of a broader trend towards personalized and targeted cancer treatments. The success and limitations of each approach highlight the need for combination strategies and the development of new therapeutic modalities to overcome resistance mechanisms and improve patient outcomes. For instance, combining ICIs like pembrolizumab with ADCs like tisotumab vedotin could potentially enhance the efficacy of treatment by simultaneously boosting the immune response and directly targeting cancer cells.\\n\\nIn summary, while pembrolizumab and tisotumab vedotin are not directly related, they are part of a complementary and evolving therapeutic landscape in oncology, where the integration of different modalities holds promise for more effective and personalized cancer treatments.   \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          An indirect relationship between pembrolizumab and tisotumab vedotin can be inferred from the provided scientific abstracts through their shared context within the broader field of antibody therapeutics, particularly in cancer treatment.\\n\\n1. **Pembrolizumab Context**: The first abstract discusses the use of pembrolizumab, an anti-PD-1 antibody, in treating a patient with advanced lung squamous cell carcinoma. Pembrolizumab is highlighted for its role in reducing tumor size in a patient with high PD-L1 expression. This abstract also mentions the use of benralizumab, another antibody therapeutic, for managing severe asthma in the same patient, illustrating the intersection of different antibody treatments in complex clinical scenarios.\\n\\n2. **Tisotumab Vedotin Context**: The second abstract, while not mentioning tisotumab vedotin directly, provides a comprehensive overview of the landscape of antibody therapeutics as of 2018. It lists various antibodies approved or under regulatory review, including those for cancer indications. Among the cancer-targeting antibodies mentioned are several antibody-drug conjugates (ADCs) like glembatumumab vedotin and mirvetuximab soravtansine, which share a similar mechanism of action with tisotumab vedotin. Tisotumab vedotin, although not explicitly listed, belongs to the same class of ADCs, which are designed to deliver cytotoxic agents directly to cancer cells.\\n\\n**Indirect Relationship**:\\n- **Shared Therapeutic Class**: Both pembrolizumab and tisotumab vedotin are part of the expanding arsenal of antibody-based therapies used in oncology. Pembrolizumab is an immune checkpoint inhibitor, while tisotumab vedotin is an ADC. They represent different strategies within the same therapeutic domain aimed at targeting cancer cells.\\n- **Clinical Development and Approval**: The second abstract highlights the rapid development and approval of various antibody therapeutics, including those for cancer. This context underscores the dynamic and interconnected nature of antibody drug development, where pembrolizumab and tisotumab vedotin are part of a broader trend of innovative cancer treatments.\\n- **Mechanistic Diversity**: The abstracts collectively illustrate the diversity of mechanisms by which antibody therapeutics can act. Pembrolizumab modulates the immune response to target cancer cells, while ADCs like tisotumab vedotin deliver cytotoxic agents directly to cancer cells. This diversity is crucial for addressing different types of cancer and patient needs.\\n\\nIn summary, the indirect relationship between pembrolizumab and tisotumab vedotin is rooted in their roles within the evolving field of antibody therapeutics for cancer treatment. They exemplify different but complementary approaches to leveraging antibodies in oncology, contributing to the broader narrative of innovation and clinical application in this area.   \n",
       "6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           An indirect relationship between larotrectinib and dabrafenib can be described based on their roles in different cancer treatment contexts and their involvement in combination therapies with other agents. Heres a detailed description:\\n\\n1. **Different Cancer Types**: Larotrectinib is highlighted in the context of metastatic pancreatic cancer, specifically for patients with TRK alterations. It is recommended as a targeted therapy option following first-line treatment. On the other hand, dabrafenib is discussed in the context of metastatic melanoma, particularly for patients with BRAF V600E/K mutations. This indicates that larotrectinib and dabrafenib are used to treat different types of cancers based on specific genetic mutations.\\n\\n2. **Combination Therapies**: Both drugs are part of combination therapy strategies, but with different partners and for different purposes. Dabrafenib is combined with trametinib (a MEK inhibitor) to improve outcomes in melanoma patients with BRAF mutations. This combination has shown positive results in clinical trials. Larotrectinib, while not discussed in combination with other drugs in the provided abstract, is part of updated guidelines for treating metastatic pancreatic cancer, suggesting its use in a targeted therapy approach based on genetic profiling.\\n\\n3. **Targeted Therapy**: Both larotrectinib and dabrafenib are targeted therapies, but they target different genetic alterations. Larotrectinib targets TRK gene fusions, while dabrafenib targets BRAF V600 mutations. This highlights their roles in precision medicine, where treatments are tailored based on specific genetic characteristics of the tumor.\\n\\n4. **Clinical Trials and Guidelines**: The abstracts mention clinical trials and guideline updates involving both drugs. Dabrafenib is part of ongoing research in combination with other agents like trametinib and durvolumab for melanoma. Larotrectinib is included in updated ASCO guidelines for second-line therapy in metastatic pancreatic cancer, emphasizing the importance of genetic testing to identify suitable patients for this treatment.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib lies in their shared role as targeted therapies used in precision medicine, their involvement in combination treatment strategies, and their inclusion in clinical guidelines for different types of cancer based on specific genetic mutations.   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                An indirect relationship between larotrectinib and dabrafenib can be described based on their roles in targeted cancer therapies, as highlighted in the provided scientific abstracts. Both drugs are used to treat cancers with specific genetic mutations, although they target different mutations and types of cancer.\\n\\n1. **Targeted Therapy for Specific Mutations**:\\n   - **Larotrectinib**: Approved for treating tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusions, regardless of the tumor's location in the body. This broad approval is based on the presence of a specific genetic alteration rather than the type of cancer.\\n   - **Dabrafenib**: Used in combination with trametinib to treat melanoma with BRAF V600E/K mutations. This combination targets a specific mutation commonly found in melanoma and other cancers.\\n\\n2. **Mechanism of Action**:\\n   - **Larotrectinib**: Inhibits TRK fusion proteins, which are the result of NTRK gene fusions. These proteins drive cancer cell growth and survival.\\n   - **Dabrafenib**: Inhibits the BRAF V600E/K mutant protein, which is part of the MAPK/ERK signaling pathway that promotes cell division and survival in melanoma.\\n\\n3. **Clinical Context and Use**:\\n   - **Larotrectinib**: Highlighted in the context of metastatic pancreatic adenocarcinoma (PDAC) as a treatment option for patients with NTRK gene fusions. This underscores its role in precision medicine, where treatment is tailored based on genetic profiling of tumors.\\n   - **Dabrafenib**: Discussed in the context of melanoma treatment, particularly in combination with trametinib, to improve progression-free survival in patients with BRAF V600E/K mutations. This combination therapy is part of a broader strategy to enhance treatment efficacy through targeted approaches.\\n\\n4. **Emerging Trends in Oncology**:\\n   - Both abstracts emphasize the growing importance of combination therapies and the use of targeted agents in oncology. While larotrectinib and dabrafenib are not used together, they represent the broader trend of using molecular profiling to guide treatment decisions and improve patient outcomes.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib lies in their shared role in the paradigm of targeted cancer therapy. Both drugs exemplify the shift towards precision medicine, where treatments are increasingly based on specific genetic alterations within tumors, leading to more personalized and effective cancer care.   \n",
       "8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               An indirect relationship between larotrectinib and dabrafenib can be described through their involvement in targeted cancer therapies, albeit for different types of mutations and cancers. Heres a detailed explanation based on the provided abstracts:\\n\\n1. **Larotrectinib**:\\n   - **Context**: Larotrectinib is a TRK inhibitor used in the treatment of cancers with NTRK gene fusions. In the provided abstract, it was used to treat a patient with basaloid squamous cell carcinoma (BSCC) of the uterine cervix, which harbored an NTRK2 fusion.\\n   - **Mechanism**: Larotrectinib targets TRK fusion proteins, which are the result of NTRK gene fusions, leading to the inhibition of tumor growth driven by these fusions.\\n\\n2. **Dabrafenib**:\\n   - **Context**: Dabrafenib is a BRAF inhibitor used primarily in the treatment of melanoma with BRAF mutations. The abstract discusses its use in combination with trametinib, a MEK inhibitor, for treating BRAF-mutant melanoma.\\n   - **Mechanism**: Dabrafenib targets the BRAF V600E mutation, which is a driver mutation in the MAPK pathway, leading to the inhibition of tumor growth driven by this mutation.\\n\\n### Indirect Relationship:\\n\\n- **Targeted Therapy**: Both larotrectinib and dabrafenib are part of the broader category of targeted cancer therapies. They are designed to inhibit specific molecular targets that drive cancer growth, albeit different targets (NTRK fusions for larotrectinib and BRAF mutations for dabrafenib).\\n  \\n- **Molecular Pathways**: While larotrectinib targets the TRK pathway, dabrafenib targets the MAPK pathway. These pathways are distinct but represent the concept of targeting specific molecular abnormalities in cancer cells.\\n\\n- **Genetic Characterization**: The use of next-generation sequencing (NGS) in both contexts highlights the importance of genetic characterization in identifying actionable mutations or fusions. For instance, the identification of NTRK2 fusion in the BSCC case led to the use of larotrectinib, while the identification of BRAF mutations in melanoma patients leads to the use of dabrafenib.\\n\\n- **Clinical Application**: Both drugs exemplify the shift towards personalized medicine in oncology, where treatment is tailored based on the genetic profile of the tumor. This approach is evident in the use of larotrectinib for NTRK fusion-positive cancers and dabrafenib for BRAF-mutant melanomas.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib lies in their roles as targeted therapies for specific genetic alterations in different cancers. They both underscore the importance of molecular diagnostics in guiding treatment decisions, although they act on different molecular targets and pathways.   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              An indirect relationship between larotrectinib and dabrafenib can be described based on their roles in targeted cancer therapies and their inclusion in studies focusing on different types of cancers and therapeutic strategies.\\n\\n1. **Targeted Cancer Therapies**: Both larotrectinib and dabrafenib are targeted cancer therapies, but they act on different molecular targets. Larotrectinib is a TRK inhibitor used primarily for cancers with NTRK gene fusions, while dabrafenib is a BRAF inhibitor used for cancers with BRAF V600E mutations. Despite targeting different pathways, both drugs exemplify the shift towards personalized medicine in oncology, where treatments are tailored based on specific genetic mutations or alterations in the tumor.\\n\\n2. **Therapeutic Drug Monitoring (TDM)**: The first abstract discusses the development of an LC-MS/MS method for the simultaneous quantification of 12 tyrosine kinase inhibitors (TKIs), including dabrafenib, in human plasma for therapeutic drug monitoring (TDM) in non-small cell lung cancer (NSCLC) patients. Although larotrectinib is not mentioned in this study, the focus on TDM highlights the importance of monitoring drug levels to optimize efficacy and safety, a principle that is also relevant to the use of larotrectinib in clinical practice.\\n\\n3. **Combination Therapies and Resistance**: The second abstract explores the use of Xihuang Pill (XHW) to enhance the efficacy of anlotinib in lung cancer, addressing issues of drug resistance and side effects. While neither larotrectinib nor dabrafenib is directly involved in this study, the concept of using combination therapies to overcome resistance and improve outcomes is a common theme in cancer treatment. Both larotrectinib and dabrafenib may be part of similar combination strategies in their respective indications.\\n\\n4. **Personalized Treatment in Thyroid Cancer**: The third abstract discusses personalized treatment options for thyroid cancer, mentioning larotrectinib as a TRK inhibitor used based on specific genetic information. This personalized approach is also applicable to dabrafenib, which is used for thyroid cancers with BRAF mutations. The emphasis on genetic profiling and targeted therapies underscores the broader context in which both drugs operate, even though they are used for different genetic targets and cancer types.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib can be described through their roles in the paradigm of personalized cancer treatment, the importance of therapeutic drug monitoring, and the strategies to overcome drug resistance and improve efficacy through combination therapies. Both drugs are part of the broader landscape of targeted therapies that are tailored based on the genetic characteristics of the tumor, highlighting the ongoing evolution in cancer treatment.   \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        An indirect relationship between larotrectinib and dabrafenib can be described through their involvement in different but potentially intersecting pathways and mechanisms of resistance in cancer treatment. Heres a detailed explanation based on the provided abstracts:\\n\\n1. **Mechanisms of Resistance and Pathways**:\\n   - **Dabrafenib**: This drug is a BRAF inhibitor used in treating melanomas with BRAF(V600) mutations. Resistance to dabrafenib can occur through mutations in other genes such as GNAQ and PTEN, which sustain MAPK signaling and activate the PI3K/AKT pathway, respectively.\\n   - **Larotrectinib**: This drug is an NTRK inhibitor used in treating cancers with NTRK gene fusions, such as pleomorphic liposarcoma of the uterus. The case study shows that larotrectinib was effective after other treatments, including entrectinib and pazopanib, failed.\\n\\n2. **Pathway Intersections**:\\n   - Both abstracts mention the involvement of the MAPK pathway. In the context of dabrafenib, resistance is mediated through sustained MAPK signaling due to GNAQ mutations. In the context of uveal melanoma, the MAPK pathway is disrupted due to GNAQ/11 mutations.\\n   - The PI3K/AKT pathway is also a common theme. Resistance to dabrafenib involves activation of this pathway through PTEN mutations, and the uveal melanoma abstract mentions PTEN mutations disrupting the PI3K/AKT pathway.\\n\\n3. **Genetic Testing and Targeted Therapy**:\\n   - The importance of genetic testing is highlighted in both contexts. For dabrafenib, understanding the genetic mutations (GNAQ and PTEN) that cause resistance can guide combination therapies. For larotrectinib, identifying NTRK gene fusions through genetic testing allows for targeted therapy.\\n   - The case study of larotrectinib emphasizes the need for genetic testing in rare cancers like pleomorphic liposarcoma of the uterus to identify actionable mutations for targeted therapy.\\n\\n4. **Therapeutic Implications**:\\n   - The resistance mechanisms to dabrafenib suggest that combination therapies targeting both the MAPK and PI3K/AKT pathways could be effective. This aligns with the broader strategy of using targeted therapies based on specific genetic alterations.\\n   - Larotrectinibs success in treating a patient with an NTRK3 fusion after other treatments failed underscores the potential of targeted therapies in overcoming resistance and achieving better outcomes.\\n\\nIn summary, the indirect relationship between larotrectinib and dabrafenib lies in their roles in targeted cancer therapy, addressing different genetic mutations and pathways. Both drugs highlight the importance of understanding the genetic landscape of tumors to overcome resistance and improve treatment efficacy. While they target different mutations (NTRK fusions for larotrectinib and BRAF mutations for dabrafenib), the underlying principle of using genetic information to guide therapy connects their use in personalized medicine.   \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    An indirect relationship between entrectinib and dabrafenib can be described based on their roles in targeted cancer therapies, particularly in the context of treating malignancies with specific genetic mutations. Heres a detailed explanation:\\n\\n1. **Targeted Therapies for Specific Mutations**:\\n   - **Dabrafenib**: This drug is a BRAF inhibitor used in combination with trametinib (a MEK inhibitor) for treating malignant melanoma with a proven BRAF mutation. It is part of the targeted therapy regimen for melanoma patients, as highlighted in the first abstract.\\n   - **Entrectinib**: This drug targets oncogenic fusion genes, specifically ROS1 and NTRK fusions, and is used in treating pediatric high-grade gliomas (pHGG) with these genetic alterations, as described in the third abstract.\\n\\n2. **Mechanism of Action**:\\n   - Both drugs are kinase inhibitors but target different pathways. Dabrafenib inhibits the BRAF kinase, which is part of the MAPK/ERK pathway, while entrectinib inhibits TRK and ROS1 kinases, which are involved in different signaling pathways.\\n\\n3. **Combination Therapies**:\\n   - The abstracts mention the use of combination therapies to enhance treatment efficacy. Dabrafenib is often combined with trametinib to target both BRAF and MEK pathways in melanoma.\\n   - Entrectinib is shown to potentially work synergistically with other treatments like radiotherapy, intrathecal chemotherapy, and MEK inhibitors (e.g., trametinib) in treating pHGG.\\n\\n4. **Clinical Context and Treatment Challenges**:\\n   - The first abstract discusses the challenges and considerations in treating malignant melanoma, including the failure of adjuvant therapies and the need for alternative treatments upon relapse.\\n   - The third abstract provides insights into the treatment of pHGG with entrectinib, emphasizing the importance of combination therapies and the potential for enhanced antitumor effects.\\n\\n5. **Indirect Relationship**:\\n   - The indirect relationship between entrectinib and dabrafenib lies in their shared context of being part of targeted cancer therapies that require precise identification of genetic mutations for effective treatment.\\n   - Both drugs are used in combination with other therapies to improve outcomes, although they target different genetic alterations and cancer types.\\n   - The use of trametinib in combination with both dabrafenib (for melanoma) and entrectinib (for pHGG) suggests a common strategy of targeting multiple pathways to overcome resistance and enhance therapeutic efficacy.\\n\\nIn summary, while entrectinib and dabrafenib are not directly related in terms of their specific targets or cancer types, they share an indirect relationship through their roles in the broader landscape of targeted cancer therapies, the use of combination treatments, and the strategic approach to overcoming treatment resistance in genetically defined malignancies.   \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Based on the provided abstracts, an indirect relationship between entrectinib and dabrafenib can be described through their roles in cancer treatment, particularly in the context of overcoming drug resistance and targeting specific genetic mutations.\\n\\n1. **Mechanisms of Action and Resistance**:\\n   - **Dabrafenib**: This drug is a BRAF inhibitor used to target hyperactive MAPK signaling in cancers with BRAF mutations. However, resistance to dabrafenib often develops due to adaptive rewiring of intracellular signaling and nonmutational drug tolerance, as described in the first abstract. This resistance can be mediated by external signaling from the tumor microenvironment or the selection of drug-tolerant cell phenotypes.\\n   - **Entrectinib**: This drug is a receptor tyrosine kinase (RTK) inhibitor that targets NTRK gene fusions, among others. The third abstract describes a case where entrectinib was used to treat a patient with a rare uterine cancer harboring an IQGAP-NTRK3 gene fusion. Although the patient initially showed progression on entrectinib, the case highlights the importance of genetic testing and targeted therapy in managing cancer.\\n\\n2. **Combination Therapies and Overcoming Resistance**:\\n   - The first abstract discusses the potential of combining MAPK pathway inhibitors like dabrafenib with other agents, such as RTK inhibitors, to overcome early drug tolerance. This suggests that combining dabrafenib with drugs like entrectinib could be a strategy to prevent or delay resistance by targeting multiple pathways simultaneously.\\n   - The second abstract on HDAC inhibitors (HDACi) like vorinostat and entinostat also touches on the importance of combination treatments to enhance anticancer effects. Although not directly related to dabrafenib or entrectinib, it underscores the broader theme of using combination therapies to improve treatment outcomes.\\n\\n3. **Genetic Mutations and Targeted Therapy**:\\n   - Both abstracts highlight the significance of genetic mutations in determining the effectiveness of targeted therapies. Dabrafenib is effective in cancers with BRAF mutations, while entrectinib targets cancers with NTRK gene fusions. The third abstract emphasizes the need for genetic testing to identify actionable mutations and tailor treatment accordingly.\\n\\nIn summary, the indirect relationship between entrectinib and dabrafenib can be described through their roles in targeted cancer therapy, the challenges of drug resistance, and the potential benefits of combination treatments. Both drugs are part of a broader strategy to personalize cancer treatment based on genetic mutations and to overcome resistance mechanisms by targeting multiple pathways.   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Based on the provided scientific abstracts, an indirect relationship between entrectinib and dabrafenib can be described through their involvement in pathways related to receptor tyrosine kinases (RTKs) and their roles in cancer treatment resistance mechanisms.\\n\\n1. **Dabrafenib and Resistance Mechanisms:**\\n   - Dabrafenib is a selective BRAF inhibitor used in the treatment of metastatic melanoma, particularly targeting the BRAF(V600E) mutation.\\n   - Resistance to dabrafenib can occur through various mechanisms, including the activation of multiple RTKs such as EGFR. The loss of ACK1, a protein kinase that modulates EGFR turnover, has been shown to upregulate EGFR and mediate resistance to BRAF inhibitors like dabrafenib.\\n\\n2. **Entrectinib and RTK Inhibition:**\\n   - Entrectinib is a targeted therapy that inhibits TRK (tropomyosin receptor kinase) fusion proteins, which are a type of RTK. It is used in cancers with NTRK gene fusions.\\n   - In the context of the provided abstract, entrectinib was used to treat a patient with pleomorphic liposarcoma of the uterus harboring an IQGAP-NTRK3 gene fusion. Although the patient initially showed progression, the case highlights the role of RTK inhibitors in targeted cancer therapy.\\n\\n3. **Indirect Relationship:**\\n   - The indirect relationship between entrectinib and dabrafenib lies in their shared involvement in targeting RTKs, albeit different ones (EGFR for dabrafenib resistance and TRK for entrectinib efficacy).\\n   - Both drugs are part of the broader strategy of using targeted therapies to overcome specific genetic alterations in cancer. Resistance mechanisms to one RTK-targeting drug (e.g., dabrafenib) can involve the upregulation of other RTKs (e.g., EGFR), which might be targeted by different inhibitors (e.g., gefitinib for EGFR).\\n   - This interplay suggests that understanding the network of RTKs and their role in drug resistance and efficacy is crucial for developing effective combination therapies and overcoming resistance in cancer treatment.\\n\\nIn summary, the indirect relationship between entrectinib and dabrafenib is rooted in their roles in targeting different RTKs involved in cancer progression and resistance mechanisms. Both drugs exemplify the importance of RTK inhibition in personalized cancer therapy, highlighting the need for comprehensive genetic testing and tailored treatment strategies.   \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              An indirect relationship between entrectinib and dabrafenib can be inferred from the provided scientific abstracts through the common involvement of cytochrome P450 (CYP) enzymes, particularly CYP3A4, in their pharmacokinetics and potential drug-drug interactions.\\n\\n1. **Entrectinib and CYP3A4 Modulation**: The second abstract discusses how entrectinib, a selective inhibitor of ROS1/TRK/ALK kinases, is predominantly metabolized by CYP3A4. The pharmacokinetics of entrectinib and its active metabolite M5 are significantly affected by CYP3A4 inhibitors and inducers. For instance, co-administration with CYP3A4 inhibitors like verapamil and diltiazem can increase entrectinib exposure, while CYP3A4 inducers can decrease its exposure.\\n\\n2. **Calcium Channel Blockers and Antitumor Agents**: The first abstract highlights the potentiation of antitumor agents by calcium channel blockers (e.g., verapamil, diltiazem). These calcium channel blockers can enhance the efficacy of various chemotherapeutic agents, potentially through mechanisms involving drug transport and metabolism.\\n\\n3. **Dabrafenib and CYP3A4**: Although not explicitly mentioned in the provided abstracts, dabrafenib is known from other literature to be metabolized by CYP3A4 and CYP2C8. Therefore, its pharmacokinetics can also be influenced by CYP3A4 inhibitors and inducers.\\n\\nGiven these points, the indirect relationship between entrectinib and dabrafenib can be described as follows:\\n\\n- **Common Pathway of Metabolism**: Both entrectinib and dabrafenib are metabolized by CYP3A4. Therefore, any drug that modulates CYP3A4 activity (such as calcium channel blockers like verapamil and diltiazem) can potentially affect the pharmacokinetics of both drugs.\\n  \\n- **Potential for Drug-Drug Interactions**: The use of CYP3A4 inhibitors or inducers can alter the exposure and efficacy of both entrectinib and dabrafenib. For example, co-administration with a CYP3A4 inhibitor could increase the plasma levels of both drugs, potentially leading to enhanced efficacy or increased toxicity.\\n\\n- **Therapeutic Implications**: Understanding the role of CYP3A4 in the metabolism of both drugs can help in making informed decisions about their co-administration with other medications, particularly those that are known CYP3A4 modulators. This can optimize therapeutic outcomes and minimize adverse effects.\\n\\nIn summary, the indirect relationship between entrectinib and dabrafenib is primarily mediated through their shared metabolic pathway involving CYP3A4, which can be influenced by other drugs such as calcium channel blockers.   \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                     An indirect relationship between canakinumab and zanubrutinib can be inferred from the contexts provided by the two scientific abstracts, despite the fact that the studies focus on different diseases and mechanisms.\\n\\n1. **Canakinumab in Systemic Juvenile Idiopathic Arthritis (sJIA)**:\\n   - Canakinumab is an IL-1 inhibitor used to treat systemic juvenile idiopathic arthritis (sJIA).\\n   - The study demonstrates its efficacy in reducing corticosteroid use and achieving significant clinical responses in Japanese patients with sJIA.\\n   - The safety profile includes common adverse events such as infections and serious adverse events, including potential cases of macrophage activation syndrome.\\n\\n2. **Zanubrutinib in SARS-CoV-2 Spike Protein-Induced Endothelial Dysfunction**:\\n   - Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor.\\n   - The study shows that zanubrutinib can inhibit inflammatory receptor signaling, reducing cellular senescence markers and reactive oxygen species (ROS) generation in endothelial cells exposed to SARS-CoV-2 spike protein.\\n   - This inhibition also prevents the expression of endothelial adhesion molecules and leukocyte attachment, which are associated with microvascular complications in COVID-19.\\n\\n### Indirect Relationship:\\n\\n- **Common Pathways and Inflammatory Mechanisms**:\\n  - Both canakinumab and zanubrutinib are involved in modulating inflammatory pathways. Canakinumab targets IL-1, a cytokine involved in inflammatory responses, while zanubrutinib inhibits BTK, a key enzyme in B-cell receptor signaling and inflammatory processes.\\n  - The SARS-CoV-2 study highlights the role of inflammatory cytokines (e.g., IL-6) and the potential for BTK inhibitors like zanubrutinib to mitigate inflammation and cellular senescence. This suggests a broader context where inflammatory modulation is crucial in disease management.\\n\\n- **Potential Overlapping Therapeutic Implications**:\\n  - While canakinumab is used for sJIA and zanubrutinib for conditions involving BTK pathways, both drugs could theoretically be explored for their anti-inflammatory properties in other diseases characterized by excessive inflammation.\\n  - For instance, the modulation of inflammatory pathways by canakinumab might have implications in conditions where IL-1 plays a role, potentially overlapping with the inflammatory pathways influenced by BTK inhibitors like zanubrutinib.\\n\\n- **Shared Adverse Events and Safety Considerations**:\\n  - Both drugs have safety profiles that include risks of infections, which is a common concern in immunomodulatory therapies. This shared aspect underscores the importance of monitoring and managing infections in patients receiving these treatments.\\n\\nIn summary, the indirect relationship between canakinumab and zanubrutinib lies in their roles in modulating inflammatory pathways and their potential overlapping therapeutic implications in managing diseases characterized by inflammation. Both drugs, while targeting different specific mechanisms, contribute to the broader understanding of inflammation and its management in various clinical contexts.   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       An indirect relationship between canakinumab and zanubrutinib can be inferred from the contexts provided in the scientific abstracts through their roles in treating different conditions and their involvement in broader therapeutic strategies.\\n\\n1. **Canakinumab**: This is a biologic agent mentioned in the context of treating Blau syndrome (BS), a rare auto-inflammatory granulomatous disease. Canakinumab is a monoclonal antibody targeting interleukin-1, used in cases where other treatments, such as glucocorticoids and other biologics, have failed. The abstract highlights its use among other biologics like Etanercept, Infliximab, Adalimumab, and Anakinra for refractory BS cases.\\n\\n2. **Zanubrutinib**: This is a kinase inhibitor discussed in the context of managing viral infections, particularly COVID-19. Zanubrutinib, along with other kinase inhibitors like baricitinib and ruxolitinib, is being repurposed for its antiviral properties. Kinase inhibitors target host cellular proteins essential for viral replication, offering a broad-spectrum antiviral approach.\\n\\nThe indirect relationship between canakinumab and zanubrutinib lies in their shared characteristic of being part of advanced therapeutic strategies involving monoclonal antibodies and kinase inhibitors, respectively. Both are used in the context of treating complex diseases where traditional therapies may not suffice. While canakinumab is used for its anti-inflammatory properties in auto-inflammatory conditions like BS, zanubrutinib is explored for its potential in managing viral infections through kinase inhibition.\\n\\nIn summary, the indirect relationship is established through their roles in modern therapeutic approaches for difficult-to-treat conditions, highlighting the evolving landscape of targeted therapies in both auto-inflammatory diseases and viral infections.   \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Based on the provided scientific abstracts, an indirect relationship between canakinumab and zanubrutinib can be described as follows:\\n\\nCanakinumab is a monoclonal antibody that targets interleukin-1 (IL-1) and is primarily used for its anti-inflammatory properties in conditions such as rheumatoid arthritis and other inflammatory diseases. It is not directly mentioned in the context of antiviral therapies or kinase inhibition.\\n\\nZanubrutinib, on the other hand, is a Bruton tyrosine kinase (BTK) inhibitor that is being investigated for its potential antiviral properties, particularly in the context of COVID-19. Kinase inhibitors like zanubrutinib are being repurposed for viral infections due to their ability to interfere with host cellular proteins that viruses depend on for their life cycle.\\n\\nThe indirect relationship between canakinumab and zanubrutinib lies in their potential roles in managing inflammatory responses and viral infections, respectively. While canakinumab addresses inflammation by targeting cytokines, zanubrutinib targets kinases involved in viral replication and immune response modulation. Both drugs, although different in their primary mechanisms and indications, may contribute to a broader therapeutic strategy in managing diseases that involve both inflammation and viral infections, such as COVID-19.   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              An indirect relationship between canakinumab and zanubrutinib can be inferred through their respective interactions with cytochrome P450 (CYP) enzymes and drug transporter proteins, as described in the provided abstracts.\\n\\n1. **Canakinumab Context**: The first abstract lists canakinumab among various drugs in a broad overview of clinical trials. While it does not provide specific details about canakinumab's pharmacokinetics or interactions, it is known from other sources that canakinumab is an interleukin-1 inhibitor used primarily for its anti-inflammatory properties.\\n\\n2. **Zanubrutinib Context**: The third abstract specifically evaluates the drug interaction potential of zanubrutinib with various CYP enzymes and drug transporter proteins. Zanubrutinib was shown to have minimal or no effect on CYP2C9, BCRP, and P-gp, but it decreased the systemic exposure of CYP3A and CYP2C19 substrates.\\n\\n3. **Indirect Relationship**: The indirect relationship between canakinumab and zanubrutinib can be understood through their potential interactions with the CYP enzyme system. While canakinumab itself is not directly mentioned to interact with CYP enzymes in the provided abstracts, the fact that zanubrutinib affects CYP3A and CYP2C19 substrates suggests that if canakinumab were to be co-administered with drugs metabolized by these enzymes, there could be potential pharmacokinetic interactions. For instance, if canakinumab were to be used in a patient already taking zanubrutinib, the altered activity of CYP3A and CYP2C19 by zanubrutinib could potentially affect the metabolism of other co-administered drugs, leading to changes in their efficacy or toxicity.\\n\\nIn summary, the indirect relationship between canakinumab and zanubrutinib is mediated through their interactions with the CYP enzyme system, particularly CYP3A and CYP2C19, which could influence the pharmacokinetics of other drugs metabolized by these enzymes when both drugs are part of a broader therapeutic regimen.   \n",
       "19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     An indirect relationship between canakinumab and zanubrutinib can be inferred through their respective roles in treating different conditions that involve immune system dysregulation. \\n\\nCanakinumab is an interleukin-1 beta antibody used to treat Muckle-Wells syndrome, a type of Cryopyrin-associated periodic fever syndrome (CAPS) caused by mutations in the NLRP3 gene. This condition is characterized by an overproduction of interleukin-1, leading to inflammatory symptoms. The efficacy of canakinumab in treating Muckle-Wells syndrome highlights its role in modulating the immune response by targeting specific cytokines involved in inflammation.\\n\\nOn the other hand, zanubrutinib is a second-generation Bruton's tyrosine kinase inhibitor (BTKi) used in the treatment of chronic lymphocytic leukemia (CLL). BTK inhibitors like zanubrutinib work by targeting the B-cell receptor signaling pathway, which is crucial for the survival and proliferation of malignant B cells in CLL. By inhibiting BTK, zanubrutinib helps to control the growth of these cancerous cells.\\n\\nThe indirect relationship between canakinumab and zanubrutinib lies in their shared goal of modulating the immune system, albeit through different mechanisms and for different diseases. Canakinumab targets cytokine signaling to reduce inflammation in autoinflammatory conditions, while zanubrutinib targets kinase signaling to inhibit the proliferation of malignant B cells in hematologic malignancies. Both drugs exemplify the broader therapeutic strategy of targeting specific components of the immune system to treat diseases characterized by immune dysregulation.   \n",
       "20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           An indirect relationship between canakinumab and zanubrutinib can be inferred through their interactions with the cytochrome P450 (CYP) enzyme system, which plays a crucial role in drug metabolism.\\n\\n1. **Canakinumab and CYP Metabolism**: The first abstract mentions that canakinumab, a biologic used in the treatment of pyoderma gangrenosum (PG), is part of a broader category of biologics that can influence drug metabolism through the CYP system. Specifically, the second abstract discusses how biological drugs, including IL-6 inhibitors, can significantly alter the metabolism of drugs processed by CYP enzymes. Although canakinumab itself is not explicitly mentioned in the second abstract, it is reasonable to consider that, as a biologic, it might have similar effects on CYP-mediated drug metabolism.\\n\\n2. **Zanubrutinib and CYP Metabolism**: The third abstract focuses on zanubrutinib, a small-molecule drug used in B-cell malignancies, and its interactions with the CYP3A enzyme. The PBPK model developed for zanubrutinib shows that its exposure can be significantly affected by CYP3A inhibitors and inducers. Additionally, zanubrutinib can act as a perpetrator in drug-drug interactions (DDIs) involving CYP3A4, CYP2C8, and CYP2B6 substrates.\\n\\n3. **Connecting the Dots**: Given that both canakinumab and zanubrutinib interact with the CYP enzyme system, albeit in different capacities, an indirect relationship can be established. Canakinumab, as a biologic, may alter the metabolism of drugs processed by CYP enzymes, potentially affecting the pharmacokinetics of zanubrutinib if used concurrently. Conversely, zanubrutinib's role as a CYP3A substrate and its potential to influence the metabolism of other drugs could be impacted by the presence of canakinumab or similar biologics that modulate CYP activity.\\n\\nIn summary, the indirect relationship between canakinumab and zanubrutinib is mediated through their respective influences on the CYP enzyme system, which could lead to altered drug metabolism and potential drug-drug interactions when these agents are used together.   \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Based on the provided abstract, we can infer an indirect relationship between gambogenic acid (GNA) and the ACTA2 protein in humans through the following chain of interactions:\\n\\n1. **Gambogenic Acid (GNA) and EZH2**: GNA is identified as a novel agent that covalently binds to the EZH2 protein, specifically at the Cys668 site within the EZH2-SET domain. This binding triggers the degradation of EZH2 through CHIP-mediated ubiquitination.\\n\\n2. **EZH2 and Tumor Suppressor Genes**: EZH2 is a critical oncogene involved in the suppression of tumor suppressor genes through its role in the polycomb repressor complex 2 (PRC2). The degradation of EZH2 by GNA leads to the reactivation of these PRC2-silenced tumor suppressor genes.\\n\\n3. **Tumor Suppressor Genes and ACTA2**: While the abstract does not directly mention ACTA2, it is known from other scientific literature that ACTA2 (alpha-smooth muscle actin) can be involved in various cellular processes, including those related to tumor suppression and cellular differentiation. The reactivation of tumor suppressor genes could potentially influence the expression or activity of ACTA2, given its role in cellular structure and function.\\n\\nTherefore, the indirect relationship can be summarized as follows:\\n\\n- **Gambogenic Acid (GNA)** binds to and degrades **EZH2**.\\n- The degradation of **EZH2** leads to the reactivation of **PRC2-silenced tumor suppressor genes**.\\n- The reactivation of these tumor suppressor genes may influence the expression or activity of **ACTA2**.\\n\\nIn conclusion, the indirect relationship between gambogenic acid and the ACTA2 protein in humans is mediated through the degradation of EZH2 and the subsequent reactivation of tumor suppressor genes, which could potentially affect ACTA2 expression or function.   \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Based on the provided abstracts, an indirect relationship between gambogenic acid and the ACTA2 protein (alpha smooth muscle actin, alphaSMA) in humans can be described as follows:\\n\\n1. **Gambogenic Acid and Apoptosis in Cancer Cells**:\\n   - Gambogenic acid has been shown to induce apoptosis in breast cancer cells (MDA-MB-231) through both death receptor and mitochondrial pathways. This involves the upregulation of pro-apoptotic proteins such as Bax and cleaved caspase-3, -8, and -9, and the downregulation of the anti-apoptotic protein Bcl-2.\\n\\n2. **ACTA2 (alphaSMA) and Myofibroblasts**:\\n   - ACTA2 is a marker for myofibroblasts, which are distinct from normal fibroblasts. Myofibroblasts play a role in tissue remodeling and fibrosis and are characterized by the expression of alphaSMA. TGFbeta is known to increase the expression of alphaSMA in skin fibroblasts, indicating its role in the activation of fibroblasts to myofibroblasts.\\n\\n3. **Indirect Relationship**:\\n   - While the abstracts do not directly link gambogenic acid to ACTA2, an indirect relationship can be inferred through the broader context of apoptosis and cell differentiation. Gambogenic acid induces apoptosis in cancer cells, which could potentially affect the tumor microenvironment, including the behavior of myofibroblasts.\\n   - Myofibroblasts, marked by ACTA2 expression, are involved in the tumor microenvironment and can influence tumor progression. The apoptosis of cancer cells induced by gambogenic acid might indirectly impact the activity and presence of myofibroblasts in the tumor stroma.\\n   - Additionally, the modulation of apoptosis-related pathways by gambogenic acid could intersect with pathways that regulate myofibroblast differentiation and function, although this specific interaction is not detailed in the provided abstracts.\\n\\nIn summary, the indirect relationship between gambogenic acid and ACTA2 protein in humans can be conceptualized through the impact of gambogenic acid on cancer cell apoptosis, which may subsequently influence the tumor microenvironment and the role of myofibroblasts characterized by ACTA2 expression.   \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Based on the provided abstracts, an indirect relationship between gambogenic acid and the ACTA2 protein (which encodes alpha-smooth muscle actin, alpha-SMA) in humans can be described as follows:\\n\\n1. **Gambogenic Acid and Apoptosis in Cancer Cells**:\\n   - The first abstract discusses the effects of gambogenic acid on breast cancer cells, specifically the MDA-MB-231 cell line. Gambogenic acid induces apoptosis through both death receptor and mitochondrial pathways, involving proteins such as Fas, cleaved caspase-3, -8, -9, Bax, and Bcl-2. However, this study does not directly mention ACTA2 or alpha-SMA.\\n\\n2. **Chrysin and ACTA2 in Diabetic Kidney Disease**:\\n   - The second abstract focuses on the effects of chrysin on mesangial cells exposed to advanced glycation end products (AGE) and in diabetic kidneys. Chrysin reduces the induction of alpha-SMA (encoded by ACTA2) in mesangial cells and diabetic kidney tissues, indicating its role in blocking mesangial proliferation and actin cytoskeleton formation.\\n\\n3. **Connecting the Dots**:\\n   - While the two studies do not directly link gambogenic acid to ACTA2, they provide a context for understanding potential indirect relationships. Gambogenic acid is shown to have anti-cancer properties by inducing apoptosis in breast cancer cells, while chrysin affects actin dynamics and alpha-SMA expression in mesangial cells.\\n   - Both compounds influence cellular pathways that could intersect. For instance, the apoptosis pathways modulated by gambogenic acid might indirectly affect actin cytoskeleton dynamics, as apoptosis often involves cytoskeletal reorganization.\\n   - Similarly, the modulation of actin dynamics and alpha-SMA by chrysin in mesangial cells suggests that compounds affecting apoptosis and cell proliferation (like gambogenic acid) could also impact actin-related proteins, including ACTA2, in different cellular contexts.\\n\\nIn summary, while there is no direct evidence linking gambogenic acid to ACTA2 in the provided abstracts, the indirect relationship can be inferred through the broader context of cellular pathways involving apoptosis, actin dynamics, and protein expression modulation. Gambogenic acid's role in inducing apoptosis might intersect with pathways that also regulate actin cytoskeleton and alpha-SMA expression, as seen with chrysin in mesangial cells.   \n",
       "24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        To describe an indirect relationship between gambogenic acid and the ACTA2 protein (also known as alpha-smooth muscle actin or SMA) in humans, we need to identify a chain of interactions or effects that connect these two entities based on the provided abstracts.\\n\\n1. **Gambogenic Acid and Apoptosis**:\\n   - The third abstract discusses the effects of gambogenic acid on breast cancer cells, highlighting its role in inducing apoptosis. Gambogenic acid increases the expression of apoptosis-related proteins such as cleaved caspase-3, -8, -9, and Bax, while decreasing the anti-apoptotic protein Bcl-2. This suggests that gambogenic acid promotes apoptosis through both death receptor and mitochondrial pathways.\\n\\n2. **Caspase-3 and Apoptosis**:\\n   - The second abstract focuses on a fluorescence-quenching-based assay for detecting caspase-3 activity, which is a key mediator of apoptosis. Caspase-3 is activated during apoptosis and is involved in the cleavage of various cellular proteins, leading to cell death.\\n\\n3. **Prostaglandin E2 (PGE2) and ACTA2**:\\n   - The first abstract describes the role of PGE2 in regulating inflammation, fibrosis, and adipose tissue remodeling in obese human adipose tissue. PGE2 is shown to reduce the expression of fibrogenic genes, including Col1alpha1, Col1alpha2, and ACTA2 (SMA), in differentiated adipocytes exposed to TGF-beta. This indicates that PGE2 can down-regulate ACTA2 expression, which is associated with fibrosis and inflammation.\\n\\n4. **Connecting the Dots**:\\n   - While the abstracts do not directly link gambogenic acid to ACTA2, we can infer an indirect relationship through the following chain of interactions:\\n     - Gambogenic acid induces apoptosis in cancer cells by activating caspase-3.\\n     - Caspase-3, as a key mediator of apoptosis, can influence various cellular processes, including inflammation and fibrosis.\\n     - PGE2, which is involved in the regulation of inflammation and fibrosis, can down-regulate ACTA2 expression in adipocytes.\\n     - Therefore, if gambogenic acid influences the levels of PGE2 or the activity of caspase-3 in a broader biological context, it could indirectly affect the expression of ACTA2.\\n\\nIn summary, the indirect relationship between gambogenic acid and ACTA2 protein in humans can be described as follows: Gambogenic acid induces apoptosis through the activation of caspase-3. Caspase-3, being a central player in apoptosis, may influence inflammatory and fibrotic processes. PGE2, which regulates inflammation and fibrosis, can down-regulate ACTA2 expression. Thus, through a cascade of apoptotic and inflammatory pathways, gambogenic acid may indirectly impact the expression of ACTA2.   \n",
       "25  To describe an indirect relationship between AZD-1775 and Volasertib based on the provided scientific abstracts, you would need to identify the key points from each abstract that suggest a connection between the two drugs, even if they are not directly compared or studied together. Heres a structured approach to synthesizing the information:\\n\\n1. **Mechanism of Action**:\\n   - **AZD-1775**: This drug is a Wee1 kinase inhibitor. Wee1 kinase is involved in the regulation of the G2/M checkpoint in the cell cycle. By inhibiting Wee1, AZD-1775 forces cells with DNA damage to enter mitosis prematurely, leading to cell death, particularly in cancer cells with defective p53.\\n   - **Volasertib**: This drug is a Polo-like kinase 1 (Plk1) inhibitor. Plk1 is crucial for various stages of mitosis, including spindle formation and cytokinesis. Inhibiting Plk1 disrupts mitotic progression and can lead to cell death.\\n\\n2. **Cell Cycle and Cancer Therapy**:\\n   - Both drugs target key regulators of the cell cycle, albeit at different points. AZD-1775 affects the G2/M checkpoint, while Volasertib impacts mitotic progression. This suggests that both drugs aim to exploit the vulnerabilities of cancer cells during cell division.\\n\\n3. **Therapeutic Context**:\\n   - **AZD-1775**: Often used in combination with DNA-damaging agents (like chemotherapy) to enhance their efficacy by preventing cancer cells from repairing DNA damage before mitosis.\\n   - **Volasertib**: Can be used as a monotherapy or in combination with other agents to disrupt mitosis in cancer cells.\\n\\n4. **Potential Synergy**:\\n   - Given their mechanisms, there is a potential for a synergistic effect if both drugs were used in combination. AZD-1775 could force cells into mitosis with damaged DNA, while Volasertib could then inhibit the mitotic process, leading to enhanced cell death.\\n\\n5. **Research Implications**:\\n   - Studies might explore the sequential or combined use of these drugs to maximize cancer cell kill rates. For instance, pre-treating with AZD-1775 to accumulate cells in a vulnerable state followed by Volasertib to disrupt mitosis could be a potential therapeutic strategy.\\n\\n6. **Clinical Trials and Studies**:\\n   - If abstracts mention clinical trials or studies involving these drugs, they might provide insights into their efficacy, safety, and potential combinatory use. For example, if one abstract discusses the success of AZD-1775 in a specific cancer type, and another highlights Volasertibs effectiveness in the same or similar context, this could suggest an indirect relationship worth exploring further.\\n\\n### Example Description:\\n\\n\"AZD-1775 and Volasertib exhibit an indirect relationship through their complementary mechanisms of action targeting different phases of the cell cycle in cancer therapy. AZD-1775, a Wee1 kinase inhibitor, disrupts the G2/M checkpoint, forcing cells with DNA damage into mitosis prematurely. Volasertib, a Polo-like kinase 1 inhibitor, interferes with mitotic progression. This suggests a potential synergistic effect where AZD-1775-induced premature mitosis could be further exploited by Volasertibs inhibition of mitotic processes, leading to enhanced cancer cell death. This indirect relationship highlights a promising area for combinatory therapeutic strategies in oncology.\"\\n\\nThis description synthesizes the key points from the abstracts to explain how the two drugs might be related indirectly through their effects on the cell cycle and potential for combined use in cancer treatment.   \n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Based on the provided scientific abstracts, an indirect relationship between AZD-1775 (adavosertib) and Volasertib can be described through their respective roles in targeting different components of the cell cycle machinery, which can be exploited for cancer therapy.\\n\\n1. **AZD-1775 (Adavosertib)**: This is a WEE1 inhibitor. WEE1 is a kinase that plays a crucial role in the G2-M checkpoint by inhibiting CDK1, thereby preventing cells with DNA damage from entering mitosis. Inhibition of WEE1 by AZD-1775 forces cells to prematurely enter mitosis, leading to mitotic catastrophe, especially in cells with defective p53, such as HPV-negative HNSCC.\\n\\n2. **Volasertib**: This is an inhibitor of Polo-like kinase 1 (PLK1), another key regulator of mitosis. PLK1 is involved in various stages of mitotic progression, including spindle formation, chromosome segregation, and cytokinesis. Inhibition of PLK1 by Volasertib disrupts these processes, leading to mitotic arrest and cell death.\\n\\n**Indirect Relationship**:\\n- Both AZD-1775 and Volasertib target different kinases that are crucial for the proper progression of the cell cycle, particularly mitosis.\\n- The abstract describes a synergistic antitumor effect when combining AURKA inhibition (alisertib) with WEE1 inhibition (AZD-1775), suggesting that disrupting multiple points of cell cycle regulation can be an effective therapeutic strategy.\\n- Although Volasertib is not directly mentioned in the abstract, its role as a PLK1 inhibitor suggests that it could potentially be combined with other cell cycle inhibitors like AZD-1775 to achieve similar synergistic effects. Both drugs disrupt mitotic processes but at different regulatory points, which could lead to enhanced antitumor activity.\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib lies in their complementary mechanisms of action in disrupting cell cycle progression, particularly mitosis, which can be exploited for synergistic cancer therapy.   \n",
       "27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Based on the provided abstracts, an indirect relationship between AZD-1775 and Volasertib can be described through their respective targets and the downstream effects on cell cycle regulation and mitosis.\\n\\n1. **AZD-1775 and Wee1 Inhibition**:\\n   - AZD-1775 is primarily an inhibitor of Wee1 kinase at therapeutically relevant concentrations.\\n   - Wee1 kinase inhibits cyclin-dependent kinase 1 (Cdk1) by phosphorylating it, which prevents cells from entering mitosis with incompletely replicated or damaged DNA.\\n   - Inhibition of Wee1 by AZD-1775 leads to the acceleration of mitosis onset, overriding the DNA replication checkpoint, and hastening Plk1-dependent phosphorylation.\\n\\n2. **Volasertib and Plk1 Inhibition**:\\n   - Volasertib is a known inhibitor of Polo-like kinase 1 (Plk1).\\n   - Plk1 is crucial for various stages of mitosis, including the activation of Cdk1 and the progression through mitosis.\\n   - Inhibition of Plk1 by Volasertib would therefore slow down or halt mitotic progression, contrasting with the effects of Wee1 inhibition by AZD-1775.\\n\\n3. **Indirect Relationship**:\\n   - Although AZD-1775 primarily targets Wee1, it has been shown to inhibit Plk1 in vitro, though not at clinically relevant concentrations.\\n   - The primary action of AZD-1775 is to promote mitotic entry by inhibiting Wee1, which indirectly affects Plk1 activity by hastening Plk1-dependent phosphorylation events.\\n   - Volasertib directly inhibits Plk1, leading to a direct suppression of mitotic progression.\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib can be understood through their effects on the cell cycle and mitosis. AZD-1775, by inhibiting Wee1, indirectly influences Plk1 activity and mitotic progression, while Volasertib directly inhibits Plk1. This relationship highlights the interconnected roles of Wee1 and Plk1 in cell cycle regulation and the potential for combined therapeutic strategies targeting these kinases.   \n",
       "28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Based on the provided abstracts, an indirect relationship between AZD-1775 (adavosertib) and Volasertib can be described through their involvement in targeting different components of the cell cycle and mitotic checkpoints, which are crucial for cancer cell survival and proliferation.\\n\\n1. **AZD-1775 (Adavosertib)**:\\n   - **Mechanism of Action**: AZD-1775 is a WEE1 inhibitor. WEE1 is a kinase that regulates the G2/M checkpoint by inhibiting CDK1, thus preventing cells with DNA damage from entering mitosis.\\n   - **Context**: In the context of HPV-negative head and neck squamous cell carcinoma (HNSCC), AZD-1775 promotes M-phase entry, leading to mitotic catastrophe and apoptosis when combined with CHK1/2 inhibitors. This combination is particularly effective in cells with compromised G1/S checkpoints due to TP53 and CDKN2A mutations.\\n\\n2. **Volasertib**:\\n   - **Mechanism of Action**: Volasertib is a Polo-like kinase 1 (PLK1) inhibitor. PLK1 is essential for various stages of mitosis, including spindle formation, chromosome segregation, and cytokinesis.\\n   - **Context**: In chronic myeloid leukemia (CML), Volasertib targets the AURKA-PLK1-FOXM1 axis, which is hyper-activated due to BCR-ABL1 tyrosine kinase activity. Inhibition of this axis can lead to increased expression of GADD45a, a DNA damage-inducible gene that inhibits AURKA, thereby promoting apoptosis and potentially eradicating leukemic cells.\\n\\n**Indirect Relationship**:\\n- **Common Pathways**: Both AZD-1775 and Volasertib target key regulators of the cell cycle and mitosis, albeit at different points. AZD-1775 affects the G2/M checkpoint by inhibiting WEE1, while Volasertib targets PLK1, a critical kinase for mitotic progression.\\n- **DNA Damage Response**: Both drugs indirectly influence the DNA damage response. AZD-1775, by promoting mitotic entry in the presence of DNA damage, and Volasertib, by disrupting mitotic processes and potentially increasing GADD45a expression, which is involved in the DNA damage response.\\n- **Therapeutic Potential**: The inhibition of these pathways can lead to synthetic lethality in cancer cells that rely on these checkpoints due to other genetic deficiencies (e.g., TP53 mutations in HNSCC or BCR-ABL1 activity in CML).\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib lies in their shared goal of disrupting cell cycle regulation and mitotic checkpoints to induce cancer cell death, albeit through different molecular targets and mechanisms. This convergence on cell cycle disruption highlights their potential complementary roles in cancer therapy.   \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      An indirect relationship between AZD-1775 and Volasertib can be described through their respective mechanisms of action and their effects on p53-related pathways in different types of cancer.\\n\\n1. **Mechanism of Action**:\\n   - **AZD-1775**: This is a WEE1 kinase inhibitor. WEE1 is a key regulator of the G2/M checkpoint in the cell cycle, and its inhibition leads to mitotic entry with damaged DNA, particularly in p53-deficient cells. This results in increased replication stress, mitotic deregulation, and ultimately cell death.\\n   - **Volasertib**: This is a Polo-like kinase 1 (PLK1) inhibitor. PLK1 is crucial for various stages of mitosis, and its inhibition leads to cell-cycle arrest and apoptosis. In B-cell acute lymphoblastic leukemia (B-ALL), PLK1 inhibition results in p53 stabilization and cell death.\\n\\n2. **p53 Pathway**:\\n   - Both drugs indirectly affect the p53 pathway, albeit in different contexts and cancer types.\\n   - **AZD-1775**: In p53-deficient head and neck cancer cells, the absence of functional p53 exacerbates the effects of WEE1 inhibition, leading to increased replication stress and mitotic errors, which the cells cannot properly repair, resulting in cell death.\\n   - **Volasertib**: In B-ALL, PLK1 inhibition leads to p53 stabilization and upregulation of pro-apoptotic factors like BAX, promoting cell death. This effect is seen even in the presence of functional p53, as PLK1 inhibition directly influences p53 activity.\\n\\n3. **Therapeutic Implications**:\\n   - Both drugs are being explored for their potential in treating cancers with specific genetic backgrounds.\\n   - **AZD-1775**: Its efficacy is being tested in p53-deficient head and neck squamous cell carcinoma, where the lack of p53 makes the cells more susceptible to the replication stress and mitotic errors induced by WEE1 inhibition.\\n   - **Volasertib**: Its efficacy is being tested in B-ALL, particularly in high-risk subtypes like Philadelphia-like ALL, where PLK1 inhibition can lead to p53 stabilization and apoptosis.\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib lies in their shared impact on the p53 pathway, albeit through different mechanisms and in different cancer types. AZD-1775 exploits the vulnerabilities of p53-deficient cells by inducing replication stress and mitotic errors, while Volasertib stabilizes p53 by inhibiting PLK1, leading to cell death in B-ALL. Both drugs highlight the therapeutic potential of targeting cell cycle regulators in cancers with specific genetic alterations.   \n",
       "30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Based on the provided scientific abstracts, an indirect relationship between AZD-1775 and Volasertib can be described through their respective interactions with other agents that influence cell cycle regulation and DNA damage response in cancer cells.\\n\\n1. **Volasertib and Sepantronium**: The first abstract describes how Volasertib, a PLK1 inhibitor, synergizes with Sepantronium, a DNA-damaging agent, to inhibit the growth of non-small cell lung cancer (NSCLC) cell lines. Sepantronium enhances the anti-neoplastic effects of Volasertib by preventing the accumulation of survivin and cyclin B, inducing cell cycle arrest, and causing DNA damage. This combination effectively disrupts the cell cycle and enhances cancer cell lethality.\\n\\n2. **AZD-1775 and Palbociclib**: The second abstract discusses how AZD-1775, a Wee1 kinase inhibitor, works synergistically with Palbociclib, a CDK4/6 inhibitor, to sensitize Rb-positive sarcoma cells to cell cycle arrest and subsequent treatment. Palbociclib induces a reversible G1 phase arrest, making the cells more susceptible to agents like AZD-1775 that act preferentially in the S-G2 phase. This combination strategy is shown to be effective in both in vitro and in vivo models.\\n\\n**Indirect Relationship**:\\n- **Cell Cycle Modulation**: Both AZD-1775 and Volasertib are involved in disrupting the cell cycle, albeit at different phases. Volasertib targets PLK1, which is crucial for mitotic progression, while AZD-1775 inhibits Wee1 kinase, which regulates the G2/M checkpoint.\\n- **Synergistic Combinations**: Both drugs are part of combination therapies that enhance their efficacy. Volasertib's synergy with Sepantronium involves DNA damage and cell cycle arrest, while AZD-1775's synergy with Palbociclib involves sensitizing cells to S-G2 phase agents following G1 arrest.\\n- **DNA Damage Response**: The combination of Sepantronium with Volasertib leads to DNA damage and cell cycle disruption, similar to how AZD-1775, when combined with Palbociclib, exploits cell cycle vulnerabilities to enhance treatment efficacy.\\n\\nIn summary, the indirect relationship between AZD-1775 and Volasertib is established through their roles in cell cycle regulation and their use in combination therapies that enhance the efficacy of cancer treatments by exploiting cell cycle vulnerabilities and inducing DNA damage responses.   \n",
       "31                                                                                                                                                            To describe an indirect relationship between olaparib and lorlatinib based on scientific abstracts, you would need to identify the key points from each abstract that connect the two drugs through intermediary factors such as biological pathways, mechanisms of action, or clinical outcomes. Heres a structured approach to formulating such a description:\\n\\n1. **Identify the Mechanisms of Action:**\\n   - **Olaparib:** This is a PARP inhibitor used primarily in the treatment of cancers with BRCA1/2 mutations. It works by inhibiting the PARP enzyme, which is involved in DNA repair, thereby leading to the accumulation of DNA damage and cancer cell death.\\n   - **Lorlatinib:** This is an ALK and ROS1 tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations. It works by inhibiting the activity of these kinases, which are involved in cell growth and survival.\\n\\n2. **Identify Common Pathways or Biological Processes:**\\n   - Both drugs are involved in targeting specific genetic mutations or alterations in cancer cells.\\n   - Both drugs ultimately aim to induce cancer cell death, albeit through different mechanisms (DNA damage for olaparib and kinase inhibition for lorlatinib).\\n\\n3. **Identify Potential Intermediary Factors:**\\n   - **Genetic Mutations:** Both drugs may be used in cancers with specific genetic backgrounds. For instance, a patient with a BRCA mutation (targeted by olaparib) might also have an ALK or ROS1 mutation (targeted by lorlatinib).\\n   - **Combination Therapies:** There might be ongoing research or clinical trials exploring the combination of PARP inhibitors with tyrosine kinase inhibitors to enhance therapeutic efficacy or overcome resistance.\\n\\n4. **Clinical Outcomes and Research Context:**\\n   - Research might be exploring the sequential use of these drugs in patients who develop resistance to one therapy.\\n   - Studies might be investigating the broader genetic landscape of cancers to identify patients who could benefit from both therapies.\\n\\n### Example Description:\\n\\nBased on the provided scientific abstracts, an indirect relationship between olaparib and lorlatinib can be described through their roles in targeted cancer therapy. Olaparib, a PARP inhibitor, is primarily used to treat cancers with BRCA1/2 mutations by exploiting the defective DNA repair mechanisms in these cancer cells. On the other hand, lorlatinib is a tyrosine kinase inhibitor targeting ALK and ROS1 mutations, commonly used in non-small cell lung cancer (NSCLC).\\n\\nThe indirect relationship between these two drugs may be mediated through the genetic landscape of the tumors they target. For instance, a subset of patients with complex genetic profiles might harbor both BRCA mutations and ALK/ROS1 alterations, making them potential candidates for sequential or combination therapy involving both olaparib and lorlatinib. Additionally, ongoing research might be investigating the synergistic effects of combining PARP inhibitors with tyrosine kinase inhibitors to overcome resistance mechanisms and improve clinical outcomes.\\n\\nIn summary, while olaparib and lorlatinib target different molecular pathways, their indirect relationship is rooted in the genetic complexities of cancer and the evolving strategies in precision oncology to tailor treatments based on specific genetic alterations.   \n",
       "32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Based on the provided abstract, an indirect relationship between olaparib and lorlatinib can be described as follows:\\n\\nOlaparib and lorlatinib are both targeted therapies used in the treatment of different types of cancer. Olaparib is a PARP inhibitor primarily used for treating certain types of ovarian, breast, pancreatic, and prostate cancers, particularly those with BRCA mutations. Lorlatinib, on the other hand, is an ALK inhibitor used for treating ALK-positive non-small cell lung cancer (NSCLC), including cases with brain metastases.\\n\\nThe abstract focuses on a Bayesian network meta-analysis comparing the efficacy of various treatments for ALK-positive, brain metastatic NSCLC, highlighting lorlatinib as one of the top-ranking treatments for progression-free survival (PFS) and objective response rate (ORR) in these patients. It also mentions that lorlatinib is recommended as a second-line treatment after alectinib, especially in cases of drug resistance.\\n\\nThe indirect relationship between olaparib and lorlatinib can be understood in the context of their roles in targeted cancer therapy. Both drugs represent advancements in personalized medicine, targeting specific genetic mutations or alterations in cancer cells. While they are used for different cancer types and target different molecular pathways, their development and use reflect a broader trend in oncology towards precision medicine, where treatments are tailored based on the genetic profile of the tumor.\\n\\nIn summary, the indirect relationship between olaparib and lorlatinib lies in their shared role as targeted therapies in the evolving landscape of cancer treatment, each addressing specific genetic vulnerabilities in different types of cancer.   \n",
       "33                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                An indirect relationship between olaparib and lorlatinib can be inferred from the contexts provided in the scientific abstracts, even though the two drugs are not directly compared or studied together.\\n\\n1. **Olaparib Context**: In the first abstract, olaparib is mentioned as a less effective treatment compared to the combination of ceritinib and dasatinib in a case of osteosarcoma with lung metastases. This suggests that olaparib, a PARP inhibitor, was considered for its potential therapeutic effects but was found to be less effective in this specific context.\\n\\n2. **Lorlatinib Context**: The second abstract discusses lorlatinib, a selective inhibitor of ALK and ROS1 tyrosine kinases, used for treating ALK-positive metastatic non-small cell lung cancer (NSCLC). The pharmacokinetics of lorlatinib are well-characterized, and it is used following progression on other ALK inhibitors like crizotinib, alectinib, or ceritinib.\\n\\n3. **Indirect Relationship via Ceritinib**: The indirect relationship between olaparib and lorlatinib can be established through ceritinib. Ceritinib is a common link between the two abstracts:\\n   - In the first abstract, ceritinib is part of a combination therapy (with dasatinib) that was more effective than olaparib in treating osteosarcoma.\\n   - In the second abstract, ceritinib is mentioned as a prior ALK inhibitor therapy before lorlatinib is administered for NSCLC.\\n\\n4. **Therapeutic Pathways and Indications**: Both olaparib and lorlatinib are used in cancer treatment, but they target different pathways and types of cancer. Olaparib is a PARP inhibitor used primarily in cancers with BRCA mutations, while lorlatinib targets ALK and ROS1 in NSCLC. The indirect relationship is highlighted by the fact that ceritinib, which is relevant in both contexts, serves as a bridge between the two drugs.\\n\\nIn summary, the indirect relationship between olaparib and lorlatinib is mediated through ceritinib, which is a common factor in the treatment protocols discussed in the abstracts. While olaparib and lorlatinib are used for different cancer types and mechanisms, ceritinib's involvement in both contexts provides a link between them.   \n",
       "34                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     An indirect relationship between olaparib and lorlatinib can be described through their respective roles in targeting different molecular pathways in cancer treatment, as inferred from the provided scientific abstracts.\\n\\n1. **Olaparib and DNA Repair Pathways in TNBC**:\\n   - Olaparib is a PARP inhibitor used in the treatment of triple-negative breast cancer (TNBC), particularly in BRCA-mutated cells. It works by inhibiting the PARP enzyme, which is crucial for repairing single-strand DNA breaks. When combined with histone deacetylase inhibitors (HDACi), olaparib shows enhanced efficacy by further disrupting DNA repair mechanisms, leading to increased DNA damage and cell death in TNBC cells.\\n\\n2. **Lorlatinib and Tyrosine Kinase Inhibitors in IMT**:\\n   - Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 fusions, which are common in inflammatory myofibroblastic tumors (IMTs). It is particularly effective in cases where resistance to first and second-generation TKIs, such as crizotinib, has developed. Lorlatinib's mechanism involves inhibiting the signaling pathways driven by these oncogenic fusions, thereby controlling tumor growth and metastasis.\\n\\n**Indirect Relationship**:\\n- The indirect relationship between olaparib and lorlatinib lies in their shared goal of targeting specific molecular abnormalities in cancer cells, albeit through different mechanisms and in different types of cancers. Olaparib focuses on impairing DNA repair pathways in TNBC, especially in BRCA-mutated cells, while lorlatinib targets tyrosine kinase signaling pathways in IMTs with ROS1 fusions.\\n- Both drugs exemplify the precision medicine approach, where treatments are tailored based on the molecular characteristics of the tumor. This highlights the broader strategy of using targeted therapies to exploit specific vulnerabilities in cancer cells, whether through disrupting DNA repair (olaparib) or inhibiting oncogenic signaling (lorlatinib).\\n\\nIn summary, while olaparib and lorlatinib do not directly interact or target the same pathways, they are both part of the evolving landscape of targeted cancer therapies that aim to improve outcomes by focusing on the unique molecular features of different cancers.   \n",
       "35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Based on the provided scientific abstract, an indirect relationship between olaparib and lorlatinib can be described through their respective interactions with other drugs and their roles in cancer treatment. Heres a detailed explanation:\\n\\n1. **Olaparib and Ibrutinib in Mantle Cell Lymphoma (MCL):**\\n   - Olaparib is a PARP inhibitor that targets tumor cells with deficiencies in single-strand DNA break repair.\\n   - Ibrutinib is a B cell targeting agent used as a second-line therapy for MCL.\\n   - The combination of olaparib and ibrutinib has been shown to significantly inhibit MCL cell growth more effectively than either drug alone, through mechanisms such as increased apoptosis, cell death, and cell cycle arrest.\\n\\n2. **Lorlatinib in Cancer Treatment:**\\n   - Although lorlatinib is not mentioned in the provided abstract, it is known to be a third-generation ALK and ROS1 tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations.\\n\\n3. **Indirect Relationship:**\\n   - The indirect relationship between olaparib and lorlatinib can be inferred through their shared context in cancer treatment and their interactions with other drugs.\\n   - Both olaparib and lorlatinib are used in targeted cancer therapies, albeit for different types of cancer and genetic contexts.\\n   - The combination strategy involving olaparib and ibrutinib in MCL suggests a broader principle of using drug combinations to enhance therapeutic efficacy and overcome resistance, which is a common challenge in cancer treatment, including in the context where lorlatinib is used.\\n   - While olaparib is combined with ibrutinib to target MCL, lorlatinib might be combined with other agents to target NSCLC, reflecting a similar therapeutic strategy of using drug combinations to improve outcomes.\\n\\nIn summary, the indirect relationship between olaparib and lorlatinib is characterized by their roles in targeted cancer therapies and the principle of using drug combinations to enhance treatment efficacy and manage drug resistance. This relationship is contextual and based on their respective interactions with other drugs in the treatment of different cancers.   \n",
       "36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  An indirect relationship between olaparib and lorlatinib can be inferred through their involvement in overlapping biological pathways and the use of similar analytical techniques for their study, as described in the provided scientific abstracts.\\n\\n1. **Analytical Techniques**: Both olaparib and lorlatinib are small molecule drugs that can be quantified using high-performance liquid chromatography mass spectrometry (LC-MS/MS). The first abstract describes a generic LC-MS/MS assay platform developed for the bioanalysis of small molecule drugs, including olaparib. This platform could potentially be adapted for the quantitation of lorlatinib as well, given its applicability to a range of small molecule compounds.\\n\\n2. **Biological Pathways**: The third abstract discusses the role of the Akt-FoxO3 signaling pathway in neuroblastoma cells treated with lorlatinib, an ALK-targeting tyrosine kinase inhibitor (TKI). The second abstract highlights the involvement of the Akt-FoxO3 pathway in reproductive aging due to in utero exposure to acetaminophen and ibuprofen. Although olaparib is not directly mentioned in these contexts, it is known to be a PARP inhibitor used in cancer therapy, and its effects could intersect with pathways involving DNA damage response and cell survival, potentially linking it indirectly to the Akt-FoxO3 pathway.\\n\\n3. **Pharmacological Context**: Both olaparib and lorlatinib are used in cancer treatment, albeit for different types of cancer (olaparib for BRCA-mutated cancers and lorlatinib for ALK-positive cancers). The study of their pharmacology and mechanisms of action often involves similar cellular and molecular techniques, such as proteomics and phosphoproteomics, as described in the third abstract for lorlatinib.\\n\\nIn summary, the indirect relationship between olaparib and lorlatinib can be described through their shared use of advanced analytical techniques for bioanalysis and their potential involvement in overlapping signaling pathways related to cell survival and cancer therapy.   \n",
       "37                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    An indirect relationship between etravirine and fostemsavir can be inferred from the contexts provided in the scientific abstracts, primarily through their roles in the management of HIV and their interactions with other drugs.\\n\\n1. **Mechanism and Use in HIV Treatment**:\\n   - **Etravirine**: Etravirine is a next-generation nonnucleoside reverse-transcriptase inhibitor (NNRTI) used in patients who have experienced virologic failure with previous NNRTI-containing regimens. It is effective against both wild-type and NNRTI-resistant strains of HIV.\\n   - **Fostemsavir**: Although not detailed in the provided abstracts, fostemsavir is known to be an attachment inhibitor used in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.\\n\\n2. **Drug-Drug Interactions**:\\n   - **Etravirine**: The abstract mentions that etravirine is metabolized by cytochrome P450 isoenzymes, leading to significant drug-drug interactions (DDIs) with several other medications, including antiretrovirals like fosamprenavir and high-dose ritonavir.\\n   - **Fostemsavir**: The third abstract highlights that newer antiretrovirals, including fostemsavir, have reduced DDI potential compared to older NNRTIs and boosted ARVs. This suggests that fostemsavir may be a preferable option in patients where DDIs are a concern.\\n\\n3. **Clinical Management and Considerations**:\\n   - The third abstract emphasizes the importance of managing DDIs in contemporary antiretroviral therapy, especially in older patients with polypharmacy. It suggests strategies such as switching to ARVs with less DDI potential, which could include transitioning from etravirine to fostemsavir in certain clinical scenarios.\\n\\n4. **Indirect Relationship**:\\n   - The indirect relationship between etravirine and fostemsavir is primarily through their roles in the evolving landscape of HIV treatment. While etravirine is effective for patients with NNRTI resistance, its potential for DDIs may limit its use in complex treatment regimens. Fostemsavir, with its reduced DDI potential, represents an alternative for patients who require a regimen with fewer interactions, particularly in the context of polypharmacy and comorbid conditions.\\n\\nIn summary, the indirect relationship between etravirine and fostemsavir is characterized by their respective places in HIV treatment strategies, particularly concerning drug-drug interactions. Etravirine's higher potential for DDIs may lead clinicians to consider fostemsavir as a safer alternative in patients with complex medication regimens.   \n",
       "38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     An indirect relationship between etravirine and fostemsavir can be described through their roles in the treatment of HIV-1 infection, particularly in the context of drug resistance and treatment-experienced patients.\\n\\n1. **Etravirine**:\\n   - **Class and Use**: Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1. It is particularly noted for its efficacy in patients who have developed resistance to other NNRTIs, such as efavirenz.\\n   - **Patient Population**: Etravirine is not yet approved for use in children under the age of 6 years but is considered for use in patients who have developed resistance to first-line NNRTIs.\\n   - **Mechanism of Action**: Etravirine works by inhibiting the reverse transcriptase enzyme, which is crucial for the replication of HIV-1.\\n\\n2. **Fostemsavir**:\\n   - **Class and Use**: Fostemsavir is a prodrug of temsavir, an HIV-1 attachment inhibitor. It is indicated for heavily treatment-experienced individuals with multidrug-resistant HIV-1.\\n   - **Patient Population**: Fostemsavir is used in patients who have limited treatment options due to extensive drug resistance, including those who have failed multiple antiretroviral therapies.\\n   - **Mechanism of Action**: Fostemsavir works by preventing the attachment of HIV-1 to host cells, thereby inhibiting the virus's ability to enter and infect these cells.\\n\\n**Indirect Relationship**:\\n- **Drug Resistance**: Both etravirine and fostemsavir are used in the context of drug resistance, albeit at different stages and for different patient populations. Etravirine is used when resistance to first-line NNRTIs like efavirenz has developed, while fostemsavir is used in heavily treatment-experienced patients with multidrug-resistant HIV-1.\\n- **Treatment Options**: Etravirine may be part of an optimized background therapy for patients who are also candidates for fostemsavir. In heavily treatment-experienced individuals, a combination of drugs, including NNRTIs like etravirine and attachment inhibitors like fostemsavir, may be necessary to achieve virological suppression.\\n- **Clinical Outcomes**: Both drugs aim to improve clinical outcomes in patients with limited treatment options due to resistance. Etravirine helps maintain NNRTI activity in the presence of resistance mutations, while fostemsavir provides an alternative mechanism of action to combat multidrug-resistant HIV-1.\\n\\nIn summary, the indirect relationship between etravirine and fostemsavir lies in their complementary roles in managing HIV-1 infection in patients with drug resistance. Etravirine addresses resistance to NNRTIs, while fostemsavir offers a treatment option for those with extensive multidrug resistance, potentially including resistance to NNRTIs like etravirine.   \n",
       "39                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            An indirect relationship between etravirine and fostemsavir can be inferred based on their roles in the treatment of HIV-1 infection, as described in the provided scientific abstracts. Heres a detailed explanation:\\n\\n1. **Etravirine**:\\n   - **Context**: Etravirine is mentioned in the context of a guide to recent clinical trials, indicating its ongoing relevance in drug discovery and development.\\n   - **Role**: Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is particularly useful for patients who have developed resistance to first-generation NNRTIs.\\n\\n2. **Fostemsavir**:\\n   - **Context**: Fostemsavir is highlighted in a review focusing on its pharmacology, pharmacokinetics, and clinical efficacy in the management of HIV-1 infection.\\n   - **Role**: Fostemsavir is a prodrug of temsavir, an oral attachment inhibitor that prevents HIV-1 from entering host cells. It is approved for use in combination with other antiretroviral agents for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.\\n\\n3. **Indirect Relationship**:\\n   - **Combination Therapy**: Both etravirine and fostemsavir are used in combination with other antiretroviral agents to manage HIV-1 infection. This suggests that they may be part of overlapping treatment regimens, especially in patients with multidrug-resistant HIV-1.\\n   - **Treatment of Resistant HIV-1**: Etravirine is effective for patients who have developed resistance to other NNRTIs, while fostemsavir is used for patients with multidrug-resistant HIV-1 who have limited treatment options. This indicates that both drugs are crucial for managing complex cases of HIV-1 where resistance to standard therapies is an issue.\\n   - **Mechanism of Action**: While etravirine works by inhibiting the reverse transcriptase enzyme, fostemsavir prevents the virus from attaching to and entering host cells. Their different mechanisms of action make them complementary in a combination therapy setting, potentially enhancing overall treatment efficacy.\\n\\nIn summary, the indirect relationship between etravirine and fostemsavir lies in their complementary roles in combination antiretroviral therapy for HIV-1 infection, particularly in patients with drug-resistant strains. Both drugs are part of the therapeutic arsenal aimed at achieving viral suppression in challenging cases, albeit through different mechanisms of action.   \n",
       "40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          An indirect relationship between etravirine and fostemsavir can be described through their shared context within the broader landscape of HIV-1 treatment and their potential interactions with other drugs used in this therapeutic area.\\n\\n1. **Shared Therapeutic Context**: Both etravirine and fostemsavir are antiretroviral agents used in the treatment of HIV-1 infection. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while fostemsavir is an attachment inhibitor. They are both part of the arsenal of drugs used to manage HIV-1, particularly in patients with multidrug-resistant strains of the virus.\\n\\n2. **Drug Interaction Considerations**: The abstracts highlight the importance of understanding drug interactions in HIV treatment. Fostemsavir's metabolism can be significantly affected by strong CYP3A inducers, including mitotane, which is mentioned in the context of another study. This is relevant because etravirine, like fostemsavir, is also metabolized by the cytochrome P-450 system, specifically CYP3A4. Therefore, the presence of strong CYP3A inducers could potentially affect the pharmacokinetics and efficacy of both drugs.\\n\\n3. **Clinical Trial Context**: Both drugs are mentioned in the context of clinical trials. Etravirine is listed among various drugs in a broad clinical trial gateway, indicating its ongoing evaluation and use in different therapeutic regimens. Fostemsavir, on the other hand, is discussed in detail regarding its clinical efficacy and safety in phase 2 and phase 3 trials. This shared context of clinical evaluation underscores their roles in evolving HIV treatment strategies.\\n\\n4. **Potential for Combination Therapy**: While the abstracts do not directly link etravirine and fostemsavir, the broader context of HIV treatment often involves combination therapy to achieve viral suppression. Understanding the pharmacological profiles and potential interactions of these drugs is crucial for optimizing treatment regimens, especially in heavily treatment-experienced patients.\\n\\nIn summary, the indirect relationship between etravirine and fostemsavir can be described through their roles in HIV-1 treatment, the importance of considering drug interactions, their evaluation in clinical trials, and the potential for their use in combination therapy to manage multidrug-resistant HIV-1 infections.   \n",
       "41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following chain of associations:\\n\\n1. **BECN1 and Myocardial Ischemia/Reperfusion Injury (MI/RI) in Diabetic Mice:**\\n   - The first abstract discusses the role of BECN1 (Beclin1) in the context of myocardial ischemia/reperfusion injury (MI/RI) in diabetic mice. It highlights that diabetes exacerbates MI/RI, which is associated with increased levels of HMGB1 and autophagy-related proteins, including Beclin1. Inhibition of HMGB1 reduces myocardial damage and autophagy markers, suggesting that Beclin1 is involved in the autophagic response to MI/RI in diabetic conditions.\\n\\n2. **Empagliflozin and Myocardial Infarct Size Reduction:**\\n   - The second abstract focuses on the cardioprotective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, in reducing myocardial infarct size in preclinical animal models of MI/RI. The meta-analysis indicates that SGLT2 inhibitors significantly reduce myocardial infarct size, with a more pronounced effect in diabetic animals.\\n\\n3. **Linking the Two Contexts:**\\n   - While the first abstract does not directly mention empagliflozin, it establishes a connection between autophagy (involving Beclin1) and myocardial injury in diabetic conditions.\\n   - The second abstract, on the other hand, demonstrates that empagliflozin, an SGLT2 inhibitor, has a cardioprotective effect in reducing myocardial infarct size, particularly in diabetic models.\\n\\n### Indirect Relationship Description:\\nEmpagliflozin, an SGLT2 inhibitor, has been shown to reduce myocardial infarct size in preclinical models of myocardial ischemia/reperfusion injury, with a more significant effect observed in diabetic animals. This cardioprotective effect may be indirectly related to the modulation of autophagy pathways, as suggested by the first abstract. In diabetic conditions, myocardial injury is associated with increased autophagy, involving proteins such as BECN1 (Beclin1). Inhibition of HMGB1, which reduces autophagy and myocardial damage, implies that autophagy plays a critical role in the exacerbation of myocardial injury in diabetes. Therefore, it is plausible that empagliflozin's cardioprotective effects might involve modulation of autophagy pathways, potentially affecting proteins like BECN1, although this specific mechanism requires further investigation.\\n\\nIn summary, the indirect relationship between BECN1 and empagliflozin can be inferred through their respective roles in autophagy and myocardial protection in diabetic conditions, suggesting a potential mechanistic link that warrants further exploration.   \n",
       "42                                                                                                                                                                                                                                                                                                                                                                        To describe an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin, we can draw connections based on the roles of autophagy, ER stress, and cardioprotection mechanisms discussed in the provided abstracts.\\n\\n1. **BECN1 and Autophagy**:\\n   - The first abstract highlights the role of BECN1 (Beclin1) in autophagy, particularly in the context of neuroprotection against ethanol-induced neurodegeneration. It shows that higher expression of autophagy-related genes, including BECN1, is associated with reduced vulnerability to ethanol-induced apoptosis in the developing brain.\\n\\n2. **ER Stress and Cardioprotection**:\\n   - The second abstract discusses how Ginkgolide B (GB) ameliorates myocardial ischemia-reperfusion (I/R) injury by inhibiting ER stress-induced apoptosis. It mentions key proteins involved in ER stress (p-PERK, p-IRE1alpha, ATF6) and suggests that reducing ER stress can protect against myocardial injury.\\n\\n3. **Empagliflozin and Cardioprotection**:\\n   - The third abstract focuses on the cardioprotective effects of empagliflozin (EMPA) in the context of myocardial I/R injury. It indicates that EMPA reduces infarct size and improves left ventricular function, potentially through mechanisms involving enhanced mitochondrial respiration and modulated myocardial metabolism.\\n\\n### Indirect Relationship:\\n\\n- **Autophagy and ER Stress**:\\n  - Both autophagy and ER stress are crucial cellular processes that help manage cellular stress and maintain homeostasis. BECN1 is a key regulator of autophagy, which can interact with pathways involved in ER stress. The inhibition of ER stress, as seen with GB, can reduce apoptosis and protect cells, a mechanism that might also involve autophagy regulation.\\n\\n- **Empagliflozin and Cellular Stress Pathways**:\\n  - While the exact mechanism of empagliflozin's cardioprotective effects is not fully understood, it is suggested to involve improved mitochondrial function and metabolic modulation. Given that mitochondrial health is closely linked to both autophagy and ER stress responses, it is plausible that empagliflozin indirectly influences these pathways.\\n\\n- **Connecting the Dots**:\\n  - Although the abstracts do not directly link BECN1 and empagliflozin, we can infer an indirect relationship through the shared involvement in cellular stress responses. BECN1's role in autophagy could intersect with the pathways influenced by empagliflozin, particularly in the context of reducing cellular stress and apoptosis during myocardial injury.\\n\\n### Summary:\\n\\nThe indirect relationship between BECN1 protein and empagliflozin can be described as follows: BECN1 is a key regulator of autophagy, a process that helps mitigate cellular stress and apoptosis. Empagliflozin, a cardioprotective agent, appears to enhance mitochondrial function and modulate metabolism, potentially influencing cellular stress pathways. While not directly connected, both BECN1 and empagliflozin contribute to cellular resilience against stress, suggesting that empagliflozin's cardioprotective effects might involve mechanisms that intersect with autophagy and ER stress pathways regulated by BECN1.   \n",
       "43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following connections:\\n\\n1. **BECN1 and ER Stress/Autophagy in DLBCL**:\\n   - The first abstract discusses the role of Beclin1 (BECN1) in autophagy within the context of diffuse large B-cell lymphoma (DLBCL). It highlights that overexpression of LINC00963 leads to increased levels of Beclin1, which is associated with autophagy. This process is part of the cellular response to endoplasmic reticulum (ER) stress, as indicated by the upregulation of UPR (unfolded protein response) sensors like GRP78, p-IRE1, and spliced XBP-1 (XBP1(s)).\\n\\n2. **ER Stress and Dapagliflozin**:\\n   - The second abstract focuses on dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and its role in mitigating ER stress-mediated apoptosis in renal cells and diabetic nephropathy (DN). Dapagliflozin regulates the elf2alpha-ATF4-CHOP pathway, which is a part of the ER stress response.\\n\\n3. **Empagliflozin and Dapagliflozin**:\\n   - Although the second abstract specifically mentions dapagliflozin, it is part of the same class of drugs as empagliflozin (both are SGLT2 inhibitors). These drugs share similar mechanisms of action, including the potential to modulate ER stress.\\n\\n### Indirect Relationship Description:\\n\\nEmpagliflozin, like dapagliflozin, is an SGLT2 inhibitor that may influence ER stress pathways. The regulation of ER stress is crucial in various cellular processes, including autophagy, where Beclin1 (BECN1) plays a significant role. In the context of DLBCL, Beclin1 is upregulated as part of the autophagy response to ER stress, mediated by the LINC00963/miR-320a/XBP1 axis. Given that dapagliflozin has been shown to mitigate ER stress-mediated apoptosis, it is plausible that empagliflozin could have similar effects. Therefore, the indirect relationship between BECN1 and empagliflozin can be inferred through their respective roles in ER stress and autophagy pathways, suggesting that empagliflozin might influence autophagy-related proteins like Beclin1 by modulating ER stress responses.   \n",
       "44                                                                                                                                                                                                                                                                                                                                                                                           Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following connections:\\n\\n1. **Cadmium Exposure and BECN1**: The first abstract discusses the effects of cadmium (Cd) on rat ovarian granulosa cells (OGCs). It highlights that cadmium exposure increases apoptosis but does not affect autophagy, as indicated by unchanged levels of autophagic markers such as BECN1 (Beclin1). This suggests that BECN1 is not directly involved in the apoptotic response to cadmium in this context.\\n\\n2. **Cadmium and Metallothionein**: The second abstract explores the effects of cadmium on human urothelial cells, showing that cadmium exposure increases the expression of metallothionein (MT) genes and proteins. This indicates a cellular response to cadmium toxicity, which is consistent with the findings in the first abstract regarding cadmium's cytotoxic effects.\\n\\n3. **Empagliflozin and Cardiovascular Effects**: The third abstract focuses on empagliflozin, a drug used to treat type 2 diabetes. It highlights that empagliflozin reduces overall mortality in patients with type 2 diabetes, primarily by reducing cardiovascular mortality, particularly heart failure. This effect is attributed to empagliflozin's diuretic action rather than its glucose-lowering effect.\\n\\n### Indirect Relationship:\\n\\n- **Cadmium and Cellular Stress**: Both abstracts involving cadmium exposure (first and second) indicate that cadmium induces cellular stress responses, including apoptosis and increased metallothionein expression. These responses are part of the broader cellular mechanisms to counteract cadmium toxicity.\\n\\n- **Empagliflozin and Cellular Stress**: While the third abstract does not directly mention cadmium or BECN1, it discusses empagliflozin's effects on cardiovascular health, which can be influenced by cellular stress and damage mechanisms. Empagliflozin's ability to reduce heart failure and mortality might be indirectly related to its effects on cellular stress pathways, which could overlap with pathways affected by cadmium exposure.\\n\\n- **Potential Overlapping Pathways**: Although BECN1 is not directly implicated in the response to cadmium in the first abstract, it is a known autophagic marker. Autophagy and apoptosis are interconnected processes, and cellular stress responses often involve a balance between these pathways. Empagliflozin's cardiovascular benefits might involve modulation of cellular stress pathways, potentially intersecting with mechanisms involving BECN1, even if not directly mentioned.\\n\\nIn summary, the indirect relationship between BECN1 and empagliflozin can be conceptualized through their respective roles in cellular stress responses. Cadmium exposure affects apoptosis and metallothionein expression, while empagliflozin impacts cardiovascular health, potentially through mechanisms involving cellular stress and damage pathways. Although BECN1 is not directly altered by cadmium in the provided context, its role in autophagy links it to broader cellular stress responses that could intersect with the effects of empagliflozin.   \n",
       "45                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following connections:\\n\\n1. **BECN1 and Autophagy in Microglia**:\\n   - The first abstract discusses how antagonizing peroxisome proliferator-activated receptor gamma (PPAR) promotes autophagy in microglia via the LKB1-AMPK signaling pathway. This process involves the upregulation of autophagy-related proteins, including Beclin1 (BECN1), which is crucial for the formation of autophagosomes.\\n\\n2. **Empagliflozin and Heart Failure in T2DM**:\\n   - The second abstract highlights the role of empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, in reducing heart failure (HF) hospitalization in patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease. While the abstract does not directly mention autophagy or BECN1, it indicates the therapeutic benefits of empagliflozin in managing HF in T2DM patients.\\n\\n3. **Connecting the Dots**:\\n   - Although the abstracts do not directly link BECN1 and empagliflozin, an indirect relationship can be inferred through the broader context of autophagy and cardiovascular health. Autophagy, regulated by proteins like BECN1, plays a significant role in cellular homeostasis and has been implicated in various diseases, including neuroinflammation and cardiovascular conditions.\\n   - Empagliflozin's benefits in reducing HF hospitalization may involve mechanisms that indirectly affect autophagy pathways. For instance, improved cardiovascular health and reduced HF could potentially influence systemic inflammation and cellular stress responses, which are known to interact with autophagy processes.\\n\\nIn summary, the indirect relationship between BECN1 and empagliflozin can be described as follows: BECN1 is involved in autophagy regulation, which is crucial for cellular health and has implications in diseases like neuroinflammation and cardiovascular conditions. Empagliflozin, while primarily used to manage T2DM and reduce HF hospitalization, may exert its beneficial effects through mechanisms that could indirectly influence autophagy pathways, thereby connecting it to the role of BECN1 in maintaining cellular homeostasis.   \n",
       "46                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Based on the provided abstracts, an indirect relationship between the BECN1 protein (Beclin1) in humans and empagliflozin can be described through the following connections:\\n\\n1. **BECN1 and Autophagy**: The first abstract discusses the role of BECN1 in the autophagy pathway. It highlights that PM2.5 exposure in zebrafish embryos leads to increased expression of autophagy-related genes, including BECN1 (Beclin1). This suggests that BECN1 is involved in the cellular response to stress and toxicity, particularly through the autophagy pathway.\\n\\n2. **Empagliflozin and Cardiovascular Health**: The third abstract focuses on empagliflozin, a drug used to treat type 2 diabetes. It mentions that empagliflozin has a beneficial effect on reducing cardiovascular mortality, particularly heart failure, in patients with a history of cardiovascular disorders. This effect is attributed to its diuretic action rather than its glucose-lowering properties.\\n\\n3. **Linking Autophagy and Cardiovascular Health**: While the abstracts do not directly connect BECN1 and empagliflozin, there is a potential indirect link through the broader context of autophagy and cardiovascular health. Autophagy, regulated by proteins like BECN1, plays a crucial role in maintaining cellular homeostasis and responding to stress. Dysregulation of autophagy has been implicated in various cardiovascular diseases, including heart failure.\\n\\n4. **Potential Mechanistic Insights**: Given that empagliflozin reduces heart failure and that autophagy is involved in cardiovascular health, it is plausible that the beneficial effects of empagliflozin on heart failure might involve modulation of autophagy pathways. Although the exact mechanisms are not detailed in the abstracts, it is conceivable that empagliflozin could influence autophagy-related processes, potentially involving BECN1, to exert its cardioprotective effects.\\n\\nIn summary, the indirect relationship between BECN1 and empagliflozin can be described through the role of BECN1 in autophagy and the potential involvement of autophagy in the cardiovascular benefits observed with empagliflozin treatment. Further research would be needed to elucidate the precise mechanisms linking these two factors.   \n",
       "47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Based on the provided abstract, an indirect relationship between the BBC3 gene and Idasanutlin can be described as follows:\\n\\nThe BBC3 gene encodes the protein PUMA (p53 upregulated modulator of apoptosis), which plays a crucial role in the apoptosis pathway. In the context of resistance to FGFR1 inhibitors in leukemia/lymphoma, downregulation of PUMA has been identified as a key factor. This downregulation is associated with sustained Akt activation and the sequestration of inactivated p-Foxo3a in the cytoplasm, leading to compromised PUMA activation and suppression of apoptosis.\\n\\nIdasanutlin is a small molecule inhibitor of MDM2, which is known to activate the p53 pathway. Since PUMA is a downstream target of p53, activation of p53 by Idasanutlin could potentially upregulate PUMA expression. Therefore, although the abstract does not directly mention Idasanutlin, the relationship can be inferred through the p53 pathway. By activating p53, Idasanutlin could counteract the downregulation of PUMA, thereby restoring apoptosis in FGFR1 inhibitor-resistant cells.\\n\\nIn summary, the indirect relationship between BBC3 (PUMA) and Idasanutlin is mediated through the p53 pathway. Idasanutlin, by inhibiting MDM2 and activating p53, could potentially upregulate PUMA, thereby overcoming resistance mechanisms that involve PUMA downregulation.   \n",
       "48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Based on the provided abstracts, an indirect relationship between the BBC3 gene and Idasanutlin can be described through their involvement in the apoptotic pathways and leukemia progression mechanisms.\\n\\n1. **BBC3 (Puma) and Apoptosis in Leukemia:**\\n   - The first abstract discusses how the induction of BBC3 (Puma) sensitizes human leukemia cells to apoptosis. Specifically, the expression of p16(INK4A) leads to the induction of BBC3/Puma, which promotes apoptosis by altering the balance of pro- and anti-apoptotic BCL2 proteins. This suggests that BBC3 plays a crucial role in mediating apoptosis in leukemia cells.\\n\\n2. **Idasanutlin and MDM2 Inhibition:**\\n   - The second abstract focuses on the role of PHF6 and JAK3 mutations in T-cell acute lymphoblastic leukemia (T-ALL) progression. It highlights that the combination of a JAK3 inhibitor (tofacitinib) and an MDM2 inhibitor (idasanutlin) can reduce leukemia burden in a mouse model. The MDM2 inhibitor Idasanutlin works by inhibiting the MDM2 protein, which is a negative regulator of the p53 tumor suppressor pathway.\\n\\n3. **Connecting the Dots:**\\n   - Although BBC3 and Idasanutlin are not directly mentioned together, they are both involved in pathways that regulate apoptosis and leukemia progression. BBC3/Puma is a pro-apoptotic protein that is regulated by p53, a pathway that is negatively regulated by MDM2. Idasanutlin, by inhibiting MDM2, can enhance p53 activity, potentially leading to increased expression of pro-apoptotic genes like BBC3/Puma.\\n   - Therefore, the indirect relationship can be described as follows: Idasanutlin, by inhibiting MDM2, can enhance p53 activity, which in turn can lead to the induction of pro-apoptotic genes such as BBC3/Puma. This suggests that Idasanutlin may indirectly influence the expression of BBC3/Puma through the p53 pathway, contributing to increased apoptosis in leukemia cells.\\n\\nIn summary, the indirect relationship between BBC3 and Idasanutlin is mediated through the p53 pathway, where Idasanutlin's inhibition of MDM2 can lead to increased p53 activity and subsequent induction of BBC3/Puma, promoting apoptosis in leukemia cells.   \n",
       "49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Based on the provided abstracts, an indirect relationship between the BBC3 gene and Idasanutlin can be described through the involvement of the p53 pathway and apoptosis regulation mechanisms in leukemia.\\n\\n1. **BBC3 Gene (PUMA) and Apoptosis Regulation:**\\n   - The first abstract discusses the role of PUMA (encoded by the BBC3 gene) in mediating apoptosis in the context of resistance to FGFR1 inhibitors in leukemia. It highlights that downregulation of PUMA leads to resistance by preventing apoptosis, which is a crucial cell death pathway. PUMA is a pro-apoptotic protein that promotes cell death by targeting Bcl2, and its suppression results in increased survival of leukemic cells.\\n\\n2. **Idasanutlin and MDM2 Inhibition:**\\n   - The third abstract mentions Idasanutlin as an MDM2 inhibitor used in combination therapy to reduce leukemia burden in T-ALL with PHF6 and JAK3 mutations. MDM2 is a negative regulator of the p53 tumor suppressor protein. By inhibiting MDM2, Idasanutlin stabilizes and activates p53, leading to increased apoptosis in cancer cells.\\n\\n3. **Connecting the Dots:**\\n   - The indirect relationship between BBC3 (PUMA) and Idasanutlin can be inferred through their common involvement in the p53-mediated apoptosis pathway. PUMA is a downstream target of p53 and is upregulated in response to p53 activation. Idasanutlin, by inhibiting MDM2, enhances p53 activity, which in turn can lead to increased expression of PUMA, promoting apoptosis in leukemic cells.\\n\\nIn summary, the indirect relationship between the BBC3 gene and Idasanutlin is mediated through the p53 pathway. Idasanutlin enhances p53 activity by inhibiting MDM2, which can lead to the upregulation of PUMA (encoded by BBC3), thereby promoting apoptosis in leukemia cells. This connection underscores the potential therapeutic synergy in targeting both MDM2 and apoptotic pathways in leukemia treatment.   \n",
       "50                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Based on the provided abstracts, an indirect relationship between the BBC3 gene (also known as PUMA) and Idasanutlin can be described through the following connections:\\n\\n1. **BBC3 (PUMA) and Apoptosis in AML**: The first abstract discusses the role of BBC3 (PUMA) in acute myeloid leukemia (AML) cells. It highlights that the combination of venetoclax (a BCL-2 inhibitor) and 5-azacitidine (5-Aza, a hypomethylating agent) induces apoptosis in AML cells. This apoptosis is mediated through the integrated stress response (ISR) pathway, which leads to the induction of proapoptotic proteins such as NOXA and PUMA. The study shows that PUMA plays a significant role in the synergistic effect of venetoclax and 5-Aza in killing AML cells.\\n\\n2. **Idasanutlin and MDM2 Inhibition**: Although Idasanutlin is not directly mentioned in the provided abstracts, it is known from other literature that Idasanutlin is an MDM2 inhibitor. MDM2 inhibitors, like Idasanutlin, activate the p53 pathway by preventing MDM2 from degrading p53. Activation of p53 can lead to the transcription of several proapoptotic genes, including BBC3 (PUMA).\\n\\n3. **Indirect Relationship**: The indirect relationship between BBC3 and Idasanutlin can be inferred through the p53 pathway. Idasanutlin, by inhibiting MDM2, stabilizes and activates p53. Activated p53 can then induce the expression of proapoptotic genes such as BBC3 (PUMA). Therefore, while the first abstract does not mention Idasanutlin, it provides context on the role of PUMA in apoptosis, which can be linked to Idasanutlin through the p53 activation pathway.\\n\\nIn summary, the indirect relationship between BBC3 (PUMA) and Idasanutlin is mediated through the p53 pathway. Idasanutlin, as an MDM2 inhibitor, activates p53, which in turn can induce the expression of PUMA, thereby promoting apoptosis in cancer cells.   \n",
       "51                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     To describe an indirect relationship between the BBC3 gene and Idasanutlin using the provided scientific abstracts, we need to identify the relevant pathways and mechanisms that connect these entities, even if they are not directly mentioned together in the abstracts.\\n\\n1. **BBC3 Gene (Puma)**:\\n   - The first abstract discusses the role of adropin in a rotenone-induced Parkinson's disease (PD) model and its associated gastric ulcer. It mentions that adropin affects the apoptotic P53/Puma (BBC3) pathways. Puma (BBC3) is a pro-apoptotic gene regulated by the tumor suppressor protein p53, which is involved in apoptosis.\\n\\n2. **Idasanutlin**:\\n   - Although Idasanutlin is not mentioned in the abstracts, it is known from other scientific literature that Idasanutlin is an MDM2 antagonist. MDM2 is a negative regulator of p53, and by inhibiting MDM2, Idasanutlin can increase p53 activity, leading to enhanced expression of p53 target genes, including BBC3 (Puma).\\n\\n3. **Indirect Relationship**:\\n   - The first abstract indicates that the P53/Puma pathway is involved in the neuroprotective and gastroprotective effects observed in the PD model. Specifically, adropin helps restore the balance between pro-survival PI3K/Akt/murine double minute 2 (MDM2) signals and apoptotic P53/Puma pathways.\\n   - Since Idasanutlin inhibits MDM2, it would lead to increased p53 activity and subsequently upregulate Puma (BBC3). This suggests that Idasanutlin could potentially influence the same apoptotic pathways involving Puma (BBC3) as described in the context of the PD model treated with adropin.\\n\\nTherefore, the indirect relationship between the BBC3 gene and Idasanutlin can be described as follows:\\n\\n**Description**:\\nThe BBC3 gene, also known as Puma, is a pro-apoptotic gene regulated by the tumor suppressor protein p53. In the context of Parkinson's disease and associated gastric ulcers, the P53/Puma pathway plays a crucial role in mediating apoptosis. Adropin has been shown to modulate this pathway, restoring the balance between pro-survival and apoptotic signals. Idasanutlin, an MDM2 antagonist, indirectly influences the BBC3 gene by inhibiting MDM2, thereby enhancing p53 activity and increasing the expression of p53 target genes, including BBC3. This suggests that Idasanutlin could potentially affect the same apoptotic pathways involving Puma (BBC3) as those modulated by adropin in the PD model.   \n",
       "52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              To describe an indirect relationship between the BBC3 gene and Idasanutlin based on the provided scientific abstracts, we need to identify the pathways and interactions that connect these two entities through intermediary processes or molecules.\\n\\n1. **BBC3 Gene Context**:\\n   - The first abstract discusses the role of the BBC3 gene in cancer-related processes. BBC3 (also known as PUMA) is involved in \"Evading apoptosis\" and \"Genomic instability,\" which are critical pathways in cancer development. The abstract mentions that BBC3 is dysregulated in the context of Mitchell-Riley syndrome (MRS), which can lead to cancer predisposition.\\n\\n2. **Idasanutlin Context**:\\n   - Although Idasanutlin is not directly mentioned in the abstracts, it is known from other sources that Idasanutlin is a small molecule inhibitor of MDM2, which is a negative regulator of the p53 tumor suppressor pathway. By inhibiting MDM2, Idasanutlin activates p53, leading to cell cycle arrest and apoptosis in cancer cells.\\n\\n3. **Connecting Pathways**:\\n   - **p53 Pathway**: Both BBC3 and Idasanutlin are connected through the p53 pathway. BBC3 is a pro-apoptotic gene that is transcriptionally activated by p53. When p53 is activated, it can induce the expression of BBC3, leading to apoptosis.\\n   - **MDM2 Inhibition**: Idasanutlin inhibits MDM2, thereby preventing the degradation of p53. This results in increased levels of active p53, which can then promote the expression of pro-apoptotic genes like BBC3.\\n\\n4. **Indirect Relationship**:\\n   - The indirect relationship between BBC3 and Idasanutlin can be described as follows: Idasanutlin inhibits MDM2, leading to the stabilization and activation of p53. Activated p53, in turn, induces the expression of BBC3, which promotes apoptosis. Therefore, Idasanutlin indirectly influences the activity of BBC3 through the p53-mediated apoptotic pathway.\\n\\nIn summary, the indirect relationship between the BBC3 gene and Idasanutlin is mediated through the p53 pathway. Idasanutlin stabilizes and activates p53 by inhibiting MDM2, and active p53 then upregulates BBC3, leading to apoptosis. This connection highlights the role of Idasanutlin in potentially enhancing the pro-apoptotic effects of BBC3 in cancer cells.   \n",
       "\n",
       "    jaccard_index_score_bl  EvalCorrectness_score_bl  \\\n",
       "0                 0.042857                       3.0   \n",
       "1                 0.032258                       1.0   \n",
       "2                 0.031250                       1.0   \n",
       "3                 0.029851                       2.0   \n",
       "4                 0.030769                       2.0   \n",
       "5                 0.029412                       2.0   \n",
       "6                 0.028169                       2.0   \n",
       "7                 0.041096                       4.0   \n",
       "8                 0.027778                       3.0   \n",
       "9                 0.028169                       3.0   \n",
       "10                0.027027                       3.0   \n",
       "11                0.028169                       3.0   \n",
       "12                0.027778                       3.0   \n",
       "13                0.041667                       3.0   \n",
       "14                0.027397                       1.0   \n",
       "15                0.038961                       3.0   \n",
       "16                0.025000                       3.0   \n",
       "17                0.027027                       3.0   \n",
       "18                0.040000                       1.0   \n",
       "19                0.025974                       2.0   \n",
       "20                0.027027                       1.0   \n",
       "21                0.027027                       2.0   \n",
       "22                0.040541                       2.0   \n",
       "23                0.040541                       2.0   \n",
       "24                0.066667                       2.0   \n",
       "25                0.046512                       4.0   \n",
       "26                0.034884                       4.0   \n",
       "27                0.036585                       4.0   \n",
       "28                0.034884                       3.0   \n",
       "29                0.024096                       2.0   \n",
       "30                0.036145                       2.0   \n",
       "31                0.053763                       4.0   \n",
       "32                0.023810                       2.0   \n",
       "33                0.034091                       2.0   \n",
       "34                0.022222                       2.0   \n",
       "35                0.022222                       2.0   \n",
       "36                0.021978                       2.0   \n",
       "37                0.035714                       3.0   \n",
       "38                0.036585                       3.0   \n",
       "39                0.023256                       3.0   \n",
       "40                0.060241                       4.0   \n",
       "41                0.032258                       4.0   \n",
       "42                0.079365                       4.0   \n",
       "43                0.031746                       3.0   \n",
       "44                0.031746                       2.0   \n",
       "45                0.031746                       2.0   \n",
       "46                0.031746                       2.0   \n",
       "47                0.030303                       2.0   \n",
       "48                0.028571                       3.0   \n",
       "49                0.057971                       4.0   \n",
       "50                0.029412                       2.0   \n",
       "51                0.027027                       2.0   \n",
       "52                0.027778                       3.0   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 EvalCorrectness_feedback_bl  \n",
       "0                                                                                                                                                                                         The generated answer is relevant to the user query and provides a detailed description of the indirect relationship between pembrolizumab and tisotumab vedotin. However, it introduces additional information not present in the provided abstract, such as a retrospective cohort study of pembrolizumab, which may not be directly related to the context given. The answer could be more concise and focused on the specific study mentioned in the reference.  \n",
       "1                                                                                                                                                                                                                              The generated answer is not relevant to the user query. The user asked about the relationship between pembrolizumab and tisotumab vedotin in the context of the provided scientific abstracts, which focus on recurrent or metastatic cervical cancer, not metastatic triple negative breast cancer (TNBC). The generated answer incorrectly discusses TNBC and does not address the specific context given in the abstracts.  \n",
       "2                                                                                                                                                                                                             The generated answer is not relevant to the user query. The user asked for a description of the indirect relationship between pembrolizumab and tisotumab vedotin based on the provided scientific abstracts, which focus on recurrent or metastatic cervical cancer. Instead, the generated answer discusses metastatic triple-negative breast cancer (mTNBC) and does not address the specific context or content of the provided abstracts.  \n",
       "3                                                                                                                                                                    The generated answer attempts to establish an indirect relationship between pembrolizumab and tisotumab vedotin but introduces unrelated abstracts about pembrolizumab in metastatic melanoma and ocular toxicities of chemotherapeutic agents, which are not relevant to the provided context. The reference answer specifically discusses a study involving both drugs in the context of cervical cancer treatment, making the generated answer less relevant and somewhat incorrect.  \n",
       "4                                                                                                                                                           The generated answer provides a general overview of pembrolizumab and tisotumab vedotin, describing their mechanisms and roles in cancer treatment. However, it does not specifically address the indirect relationship between the two drugs in the context of the provided scientific abstracts. The reference answer focuses on their combined use in a specific study, which is not mentioned in the generated answer. This makes the generated answer less relevant and somewhat off-topic.  \n",
       "5                                                                                                                                                                                                  The generated answer is relevant to the user query but contains inaccuracies and lacks specificity. It incorrectly references abstracts that are not provided and does not directly address the relationship between pembrolizumab and tisotumab vedotin as described in the given context. The reference answer provides a clear and specific connection within the context of a clinical study, which the generated answer fails to capture accurately.  \n",
       "6                                                                                                                                        The generated answer is relevant to the user query but contains several inaccuracies and misinterpretations. For instance, it incorrectly states that larotrectinib is used for metastatic pancreatic cancer, whereas the reference context mentions its use for tumors with NTRK fusions. Additionally, the generated answer does not accurately reflect the context provided in the reference answer, which focuses on histology-agnostic indications and the specific genetic mutations targeted by these drugs.  \n",
       "7                                                                                                                                               The generated answer is relevant and mostly correct. It accurately describes the indirect relationship between larotrectinib and dabrafenib by focusing on their roles in targeted cancer therapies and their mechanisms of action. However, it introduces some additional context not directly mentioned in the provided abstract, such as the mention of metastatic pancreatic adenocarcinoma (PDAC), which could be seen as slightly extraneous. Overall, the answer is comprehensive and well-explained.  \n",
       "8                                                                                        The generated answer is relevant and provides a detailed explanation of the indirect relationship between larotrectinib and dabrafenib. However, it contains inaccuracies and extraneous information not directly supported by the provided abstract. For instance, the abstract does not mention the use of larotrectinib in basaloid squamous cell carcinoma (BSCC) of the uterine cervix or the specific mechanisms of action for each drug. The generated answer also introduces additional context not present in the abstract, which could lead to confusion.  \n",
       "9                                                                                                                                                 The generated answer is relevant and provides a detailed explanation of the indirect relationship between larotrectinib and dabrafenib. However, it introduces additional contexts and abstracts that were not part of the original user query, which could lead to confusion. The core explanation about their roles in targeted cancer therapies and personalized medicine is correct, but the inclusion of unrelated studies and concepts slightly detracts from the clarity and focus of the response.  \n",
       "10                                                                                                                                                 The generated answer is relevant and provides a detailed explanation of the indirect relationship between larotrectinib and dabrafenib, focusing on their roles in targeted cancer therapy and mechanisms of resistance. However, it introduces additional information not directly derived from the provided abstract, such as specific resistance mechanisms and pathways, which may not be entirely accurate or necessary. The answer could be more concise and directly tied to the provided context.  \n",
       "11                                                                                                                                                  The generated answer is relevant and provides a detailed explanation of the indirect relationship between entrectinib and dabrafenib in the context of targeted cancer therapies. However, it introduces additional contexts and abstracts not mentioned in the user query or reference answer, which could lead to confusion. The core points about their roles in targeted therapies and combination treatments are correct, but the answer could be more concise and focused on the provided context.  \n",
       "12                                                                                                                                                                                The generated answer is relevant and provides a detailed explanation of the indirect relationship between entrectinib and dabrafenib in the context of cancer treatment. However, it introduces information not present in the provided abstract, such as specific mechanisms of resistance and combination therapies, which may not be directly supported by the given context. This inclusion of extraneous details affects the precision and correctness of the answer.  \n",
       "13                                                                          The generated answer is relevant to the user query and provides a detailed explanation of the indirect relationship between entrectinib and dabrafenib through their involvement in receptor tyrosine kinases (RTKs) and cancer treatment resistance mechanisms. However, it introduces additional context not directly derived from the provided abstract, such as specific resistance mechanisms and case studies, which may not be entirely accurate or necessary. The core idea is correct, but the answer could be more concise and directly tied to the provided abstract.  \n",
       "14                                                                                                                                                    The generated answer is not relevant to the user query. The user asked for a description of the indirect relationship between entrectinib and dabrafenib based on the provided scientific abstracts. However, the generated answer discusses the involvement of cytochrome P450 (CYP) enzymes, which is not mentioned in the provided abstract. The reference answer focuses on the histology-agnostic indications and the genomic alterations targeted by these drugs, which is the relevant context.  \n",
       "15                                                                                                                      The generated answer is relevant and provides a detailed explanation of the indirect relationship between canakinumab and zanubrutinib. However, it introduces additional contexts not present in the reference answer, such as the use of canakinumab in systemic juvenile idiopathic arthritis (sJIA) and zanubrutinib in endothelial dysfunction, which are not directly related to the provided context of SARS-CoV-2-induced cytokine storm. This makes the answer somewhat less focused and introduces potential inaccuracies.  \n",
       "16                                                                                                                                                                                          The generated answer is relevant and provides a reasonable explanation of the indirect relationship between canakinumab and zanubrutinib. However, it contains inaccuracies and lacks clarity in connecting the two drugs specifically within the context of the provided scientific abstracts. The reference answer clearly links both drugs to the management of SARS-CoV-2-induced cytokine storm, which is not adequately addressed in the generated answer.  \n",
       "17                                          The generated answer is relevant and correctly identifies the roles of canakinumab and zanubrutinib in managing inflammation and viral infections, respectively. However, it contains inaccuracies and omissions. The reference answer specifically mentions that both drugs are beneficial in managing SARS-CoV-2-induced cytokine storm by reducing proinflammatory cytokines and improving respiratory function. The generated answer does not fully capture this context and incorrectly states that canakinumab is not mentioned in antiviral therapies, which is misleading given the reference's context.  \n",
       "18                                                                                                                                                                                                The generated answer is not relevant to the user query. The user asked for a description of an indirect relationship between canakinumab and zanubrutinib based on the provided scientific abstracts, which focus on their roles in managing SARS-CoV-2-induced cytokine storm. The generated answer incorrectly discusses their interactions with cytochrome P450 enzymes and drug transporter proteins, which are not mentioned in the provided context.  \n",
       "19                                                                                                                                                                                                             The generated answer is somewhat relevant but does not directly address the specific context provided in the scientific abstract. The abstract focuses on the role of canakinumab and zanubrutinib in managing SARS-CoV-2-induced cytokine storm, while the generated answer discusses their roles in treating other conditions. The connection to the cytokine storm and COVID-19 context is missing, leading to a lack of full correctness.  \n",
       "20                                                                                                                                                                                                                         The generated answer is not relevant to the user query. The user asked for a description of an indirect relationship between canakinumab and zanubrutinib based on the provided scientific abstracts, which focus on their roles in managing SARS-CoV-2-induced cytokine storm. The generated answer instead discusses their interactions with the cytochrome P450 enzyme system, which is not mentioned in the provided context.  \n",
       "21                                                                                                                                            The generated answer is somewhat relevant but contains inaccuracies and speculative connections not supported by the provided abstract. The abstract focuses on the role of GNA in kidney fibrosis through epigenetic inhibition of EZH2 and regulation of Smad7-dependent mechanisms, without mentioning tumor suppressor genes or CHIP-mediated ubiquitination. The connection to ACTA2 (alpha-SMA) is not clearly established in the generated answer, making it partially correct but largely speculative.  \n",
       "22                                                                                                                                                                The generated answer attempts to describe an indirect relationship between gambogenic acid and ACTA2 protein but introduces unrelated information about apoptosis in cancer cells, which is not relevant to the provided context about kidney fibrosis. The reference answer focuses on the role of gambogenic acid in kidney fibrosis through epigenetic mechanisms involving EZH2 and Smad7, which is more pertinent. The generated answer lacks relevance and accuracy in this context.  \n",
       "23                                                                                                                                                                                                                    The generated answer attempts to describe an indirect relationship between gambogenic acid and ACTA2 protein by discussing apoptosis and actin dynamics. However, it introduces unrelated studies about chrysin and cancer cells, which are not relevant to the provided context about kidney fibrosis and epigenetic regulation. The answer lacks direct relevance and coherence with the given abstracts, leading to a score of 2.0.  \n",
       "24                                                                                                                                                                                                                                The generated answer attempts to establish an indirect relationship between gambogenic acid and ACTA2 protein by connecting multiple biological pathways. However, it introduces information not present in the provided abstract, such as the role of PGE2 and caspase-3, which are not mentioned in the context. This makes the answer speculative and not fully grounded in the given context, leading to inaccuracies.  \n",
       "25                                                                                                                                                                                                                                                                                                              The generated answer is relevant and provides a comprehensive explanation of the indirect relationship between AZD-1775 and Volasertib. It accurately describes the mechanisms of action of both drugs, their roles in cancer therapy, and the potential for synergistic effects. However, it is somewhat verbose and could be more concise.  \n",
       "26                                                                                     The generated answer is relevant and mostly correct. It accurately describes the roles of AZD-1775 and Volasertib in targeting different components of the cell cycle and explains their potential synergistic effects in cancer therapy. However, it introduces some extraneous information (e.g., mentioning HPV-negative HNSCC) that is not directly related to the provided context. Additionally, it does not explicitly mention the combination of Volasertib and AZD-1775 as described in the reference answer, which slightly detracts from its completeness.  \n",
       "27                                                                                                                                                                                                                                                           The generated answer is relevant and mostly correct, providing a detailed explanation of the indirect relationship between AZD-1775 and Volasertib through their effects on cell cycle regulation and mitosis. However, it could be more concise and directly tied to the specific context of the provided abstracts, which focus on the combination therapy in chronic myeloid leukemia (CML).  \n",
       "28                                                                                                                                        The generated answer is relevant and provides a detailed explanation of the mechanisms of action for both AZD-1775 and Volasertib. However, it introduces additional contexts (e.g., HPV-negative head and neck squamous cell carcinoma) that are not present in the provided abstract, leading to some inaccuracies. The core idea of the indirect relationship through cell cycle disruption is correct, but the extraneous details and slight deviations from the provided context reduce the overall accuracy.  \n",
       "29                                                                                                                                          The generated answer is somewhat relevant but contains inaccuracies and lacks direct connection to the provided context. The reference answer focuses on the combination of AZD-1775 and Volasertib in treating chronic myeloid leukemia (CML) and their effects on DNA damage and apoptosis. The generated answer, however, discusses the mechanisms of action of AZD-1775 and Volasertib in different cancer types and their impact on the p53 pathway, which is not directly related to the context provided.  \n",
       "30                                        The generated answer is somewhat relevant but contains inaccuracies and lacks direct connection to the provided context. The reference answer focuses on the combination of AZD-1775 and Volasertib in the context of chronic myeloid leukemia (CML) and their role in overcoming tyrosine kinase inhibitor resistance. The generated answer, however, introduces unrelated agents (Sepantronium and Palbociclib) and discusses different cancer types (NSCLC and sarcoma), which diverges from the specific context of CML provided in the reference. This makes the generated answer less accurate and relevant.  \n",
       "31                                                                                                                                                                                                                                            The generated answer is relevant and provides a structured approach to describing the indirect relationship between olaparib and lorlatinib. It correctly identifies the mechanisms of action, common pathways, intermediary factors, and clinical outcomes. However, it could be more concise and directly reference the specific case report mentioned in the reference answer to strengthen the connection.  \n",
       "32  The generated answer is somewhat relevant but contains significant inaccuracies and lacks specificity. It incorrectly describes the abstract's content, mentioning a Bayesian network meta-analysis which is not present in the provided abstract. Additionally, it fails to accurately capture the specific context of the indirect relationship between olaparib and lorlatinib as described in the reference answer. The reference answer provides a detailed case study, while the generated answer gives a general overview of the drugs without addressing the specific case or the indirect relationship in the context of the provided abstract.  \n",
       "33                                                                                                                                                              The generated answer attempts to establish an indirect relationship between olaparib and lorlatinib through ceritinib, but it misinterprets the context of the provided abstracts. The reference answer clearly describes a direct combination therapy involving both olaparib and lorlatinib in a specific case of metastatic lung adenocarcinoma. The generated answer's focus on ceritinib as a bridge is incorrect and irrelevant to the actual relationship described in the reference.  \n",
       "34                                                                                                                                                                            The generated answer provides a general explanation of the mechanisms of olaparib and lorlatinib but does not directly address the specific context provided by the scientific abstracts. It introduces unrelated information about TNBC and IMT, which is not relevant to the ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma case discussed in the reference. The answer lacks focus on the specific indirect relationship highlighted in the provided context.  \n",
       "35                                                                                      The generated answer is somewhat relevant but contains significant inaccuracies and irrelevant information. The user query specifically asks about the indirect relationship between olaparib and lorlatinib in the context of the provided scientific abstract, which discusses their combined use in treating a specific case of metastatic lung adenocarcinoma. The generated answer incorrectly introduces ibrutinib and mantle cell lymphoma, which are not mentioned in the provided abstract, leading to confusion and a lack of focus on the actual context.  \n",
       "36                                                                                                                                                                                                                                                                                     The generated answer attempts to describe an indirect relationship between olaparib and lorlatinib but introduces irrelevant information about analytical techniques and pathways not directly related to the provided context. The reference answer focuses on a specific case report and clinical evidence, which the generated answer fails to address adequately.  \n",
       "37                                                                                                               The generated answer is relevant and provides a detailed explanation of the indirect relationship between etravirine and fostemsavir, focusing on their roles in HIV treatment and drug-drug interactions. However, it contains some inaccuracies and assumptions not directly supported by the provided abstract, such as the specific mention of fosamprenavir and high-dose ritonavir, and the generalization about fostemsavir's reduced DDI potential. These inaccuracies slightly detract from the overall correctness of the answer.  \n",
       "38                                                                                                                                                                                                                                 The generated answer is relevant and provides a detailed explanation of the roles of etravirine and fostemsavir in HIV-1 treatment, highlighting their use in drug-resistant cases. However, it lacks specific details from the provided scientific abstract, such as the pharmacokinetic interactions between etravirine and fostemsavir, which are crucial for a complete understanding of their indirect relationship.  \n",
       "39                                                                                                                                     The generated answer is relevant and provides a detailed explanation of the roles of etravirine and fostemsavir in HIV-1 treatment. However, it lacks specific details from the provided scientific abstract, such as the pharmacokinetic interactions between etravirine and fostemsavir. The answer correctly identifies the indirect relationship through their use in combination therapy but misses the specific impact of etravirine on temsavir concentrations, which is crucial for a complete understanding.  \n",
       "40                                                                                                                                                                                    The generated answer is relevant and mostly correct. It accurately describes the indirect relationship between etravirine and fostemsavir by discussing their roles in HIV-1 treatment, drug interaction considerations, clinical trial contexts, and potential for combination therapy. However, it could be more concise and directly reference specific findings from the provided abstract, such as the specific effects of etravirine on temsavir concentrations.  \n",
       "41                                                                                                                                                                                                                                         The generated answer is relevant and provides a detailed explanation of the indirect relationship between BECN1 protein and empagliflozin. It correctly identifies the role of BECN1 in autophagy and myocardial injury and links it to the cardioprotective effects of empagliflozin. However, it could be more concise and focused, as some parts are slightly repetitive and could be streamlined for clarity.  \n",
       "42                                                                                                                                                                                                                        The generated answer is relevant and provides a comprehensive explanation of the indirect relationship between BECN1 protein and empagliflozin. It correctly identifies the roles of autophagy, ER stress, and cardioprotection mechanisms, and logically connects these processes to describe the indirect relationship. However, the answer could be more concise and focused on the specific context provided by the abstracts.  \n",
       "43                                                                                                                                                                                                              The generated answer is relevant and provides a detailed explanation of the indirect relationship between BECN1 protein and empagliflozin. However, it introduces information about dapagliflozin and DLBCL, which are not mentioned in the provided context. This additional information, while related, may confuse the user and detracts from the direct connection between BECN1 and empagliflozin as described in the reference answer.  \n",
       "44                                                                                                                                                 The generated answer attempts to describe an indirect relationship between BECN1 and empagliflozin but introduces irrelevant information about cadmium exposure, which is not mentioned in the provided context. The reference answer focuses on the role of empagliflozin in inhibiting ER stress-induced autophagy via the PERK/ATF4/Beclin1 pathway, which is directly relevant to the query. The generated answer's inclusion of cadmium-related studies detracts from its relevance and correctness.  \n",
       "45                                                                                                                                                                                                   The generated answer attempts to establish an indirect relationship between BECN1 and empagliflozin but introduces unrelated contexts (microglia and PPAR) that are not present in the provided abstracts. The reference answer directly links empagliflozin to the inhibition of the PERK/ATF4/Beclin1 pathway, which is relevant to the user query. The generated answer is partially relevant but contains inaccuracies and extraneous information.  \n",
       "46                                                                                              The generated answer is relevant to the user query and attempts to describe an indirect relationship between BECN1 and empagliflozin. However, it contains inaccuracies and lacks clarity. The reference answer specifically mentions the PERK/ATF4/Beclin1 pathway and the role of empagliflozin in inhibiting ER stress-induced autophagy, which is not clearly articulated in the generated answer. The generated answer also introduces unrelated information about PM2.5 exposure and zebrafish embryos, which is not relevant to the context provided.  \n",
       "47                                                                                                                                                                  The generated answer is somewhat relevant but contains inaccuracies and extraneous information. It incorrectly introduces FGFR1 inhibitors and resistance mechanisms not mentioned in the provided abstract. While it correctly identifies the role of Idasanutlin in activating the p53 pathway and the potential upregulation of BBC3 (PUMA), it fails to accurately describe the context given in the abstract, which focuses on T-ALL and the combination treatment with navitoclax.  \n",
       "48                                                                                                                                                                                                                                                                The generated answer is relevant and provides a reasonable explanation of the indirect relationship between BBC3 and Idasanutlin through the p53 pathway. However, it introduces additional abstracts and information not present in the reference answer, which may confuse the user. The core idea is correct, but the answer could be more concise and focused on the provided context.  \n",
       "49                                                                                                                                                                                                                                                         The generated answer accurately describes the indirect relationship between the BBC3 gene and Idasanutlin through the p53 pathway and apoptosis regulation mechanisms in leukemia. It correctly identifies the role of PUMA (encoded by BBC3) and the effect of Idasanutlin as an MDM2 inhibitor. However, the answer could be more concise and directly tied to the specific abstracts provided.  \n",
       "50                                                                                                                                                                                                                           The generated answer is somewhat relevant but contains inaccuracies and extraneous information. It incorrectly references AML and venetoclax, which are not mentioned in the provided abstract. The correct context involves T-ALL and the combination of idasanutlin with navitoclax, not venetoclax. The explanation of the indirect relationship through the p53 pathway is correct but muddled by the incorrect references.  \n",
       "51              The generated answer is somewhat relevant but contains significant inaccuracies and irrelevant information. The user query specifically asks for a description of the indirect relationship between the BBC3 gene and Idasanutlin based on the provided scientific abstracts. However, the generated answer introduces unrelated information about Parkinson's disease and adropin, which is not mentioned in the provided context. The correct relationship should focus on the role of Idasanutlin as an MDM2 inhibitor that upregulates BBC3 in the context of T-cell acute lymphoblastic leukemia, as described in the reference answer.  \n",
       "52                                                                                                                                                                                                                             The generated answer is relevant and correctly identifies the indirect relationship between BBC3 and Idasanutlin through the p53 pathway. However, it introduces some extraneous information not directly related to the provided abstract, such as Mitchell-Riley syndrome, which is not mentioned in the reference context. This inclusion of unrelated details slightly detracts from the clarity and focus of the answer.  "
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nest_asyncio.apply()\n",
    "tqdm.pandas()\n",
    "\n",
    "async def evaluate_responses_batch(queries, responses, references):\n",
    "    results = []\n",
    "    for query, response, reference in zip(queries, responses, references):\n",
    "        try:\n",
    "            result = await evaluator.aevaluate(\n",
    "                query=query,\n",
    "                response=response,\n",
    "                reference=reference\n",
    "            )\n",
    "            results.append(result)\n",
    "        except Exception as e:\n",
    "            print(f\"An error occurred: {e}\")\n",
    "            results.append(None) \n",
    "    return results\n",
    "\n",
    "async def synchronous_batch_evaluate(batch_rows):\n",
    "    queries = []\n",
    "    responses = []\n",
    "    references = []\n",
    "    \n",
    "    for _, row in batch_rows.iterrows():\n",
    "        source = row['subj_name']\n",
    "        target = row['obj_name']\n",
    "        query = f\"How would you describe an indirect relationship between {source} and {target} given the following scientific abstracts as contexts?\"\n",
    "        response = row['llm_response_bl']\n",
    "        reference = row['pmid_text']\n",
    "        queries.append(query)\n",
    "        responses.append(response)\n",
    "        references.append(reference)\n",
    "    \n",
    "    results = await evaluate_responses_batch(queries, responses, references)\n",
    "    batch_results = pd.DataFrame(columns=['EvalCorrectness_score_bl', 'EvalCorrectness_feedback_bl'])\n",
    "    \n",
    "    for i, result in enumerate(results):\n",
    "        if result:\n",
    "            batch_results.loc[batch_rows.index[i]] = [result.score, result.feedback]\n",
    "        else:\n",
    "            batch_results.loc[batch_rows.index[i]] = [None, 'Error: Could not evaluate']\n",
    "    \n",
    "    return batch_results\n",
    "\n",
    "async def process_batches(df, batch_size):\n",
    "    all_results = []\n",
    "    for start in tqdm(range(0, len(df), batch_size), desc=\"Processing Batches\"):\n",
    "        end = min(start + batch_size, len(df))\n",
    "        batch_rows = df.iloc[start:end]\n",
    "        batch_results = await synchronous_batch_evaluate(batch_rows)\n",
    "        all_results.append(batch_results)\n",
    "    \n",
    "    combined_results = pd.concat(all_results)\n",
    "    combined_results = combined_results.reindex(df.index)\n",
    "    return combined_results\n",
    "\n",
    "batch_size = 5\n",
    "filtered_df = filtered_df.reset_index(drop=True)\n",
    "\n",
    "filtered_df[['EvalCorrectness_score_bl', 'EvalCorrectness_feedback_bl']] = await process_batches(filtered_df, batch_size)\n",
    "filtered_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "c0b36a1a-6cef-4da5-931e-761c7bd6e0af",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-08-27T02:22:55.519515Z",
     "iopub.status.busy": "2024-08-27T02:22:55.518907Z",
     "iopub.status.idle": "2024-08-27T02:22:55.532349Z",
     "shell.execute_reply": "2024-08-27T02:22:55.531126Z",
     "shell.execute_reply.started": "2024-08-27T02:22:55.519468Z"
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Mean EvalCorrectness_score_bl for label 0: 2.2666666666666666\n",
      "Mean EvalCorrectness_score_bl for label 1: 2.9565217391304346\n"
     ]
    }
   ],
   "source": [
    "mean_0_ec = filtered_df[filtered_df['label'] == 0]['EvalCorrectness_score_bl'].mean()\n",
    "mean_1_ec = filtered_df[filtered_df['label'] == 1]['EvalCorrectness_score_bl'].mean()\n",
    "\n",
    "print(f\"Mean EvalCorrectness_score_bl for label 0: {mean_0_ec}\")\n",
    "print(f\"Mean EvalCorrectness_score_bl for label 1: {mean_1_ec}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "5f5a3c76-a098-450a-8705-6dc1e1d32ec2",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-08-27T02:35:56.027797Z",
     "iopub.status.busy": "2024-08-27T02:35:56.027174Z",
     "iopub.status.idle": "2024-08-27T02:35:56.039372Z",
     "shell.execute_reply": "2024-08-27T02:35:56.037996Z",
     "shell.execute_reply.started": "2024-08-27T02:35:56.027751Z"
    }
   },
   "outputs": [],
   "source": [
    "filtered_df.to_pickle('filtered_df_now.pkl')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "fbaa5538-a201-43b9-828d-f1b3ffc6a38f",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-08-27T01:04:30.647706Z",
     "iopub.status.busy": "2024-08-27T01:04:30.647066Z",
     "iopub.status.idle": "2024-08-27T01:04:30.658674Z",
     "shell.execute_reply": "2024-08-27T01:04:30.657050Z",
     "shell.execute_reply.started": "2024-08-27T01:04:30.647653Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2.792452830188679"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filtered_df['EvalCorrectness_score_bl'].mean()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f0182bec-74d8-4f4b-b5a8-b6b6e27b21e7",
   "metadata": {},
   "outputs": [],
   "source": [
    "filtered_df['EvalCorrectness_score_bl'].hist(bins=20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "ec9378f5-67b0-44e7-8df1-1248e480a308",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-08-27T00:18:05.997200Z",
     "iopub.status.busy": "2024-08-27T00:18:05.995776Z",
     "iopub.status.idle": "2024-08-27T00:18:28.622580Z",
     "shell.execute_reply": "2024-08-27T00:18:28.621006Z",
     "shell.execute_reply.started": "2024-08-27T00:18:05.997147Z"
    },
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|                                                                                 | 0/53 [00:00<?, ?it/s]Retrying llama_index.llms.openai.base.OpenAI._achat in 0.49083613639291035 seconds as it raised RateLimitError: Error code: 429 - {'error': {'message': 'You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.', 'type': 'insufficient_quota', 'param': None, 'code': 'insufficient_quota'}}.\n",
      "Retrying llama_index.llms.openai.base.OpenAI._achat in 1.862115841045188 seconds as it raised RateLimitError: Error code: 429 - {'error': {'message': 'You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.', 'type': 'insufficient_quota', 'param': None, 'code': 'insufficient_quota'}}.\n",
      "  2%|                                                                       | 1/53 [00:22<19:12, 22.16s/it]\n"
     ]
    },
    {
     "ename": "RateLimitError",
     "evalue": "Error code: 429 - {'error': {'message': 'You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.', 'type': 'insufficient_quota', 'param': None, 'code': 'insufficient_quota'}}",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mRateLimitError\u001b[0m                            Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[8], line 27\u001b[0m\n\u001b[1;32m     23\u001b[0m     result \u001b[38;5;241m=\u001b[39m asyncio\u001b[38;5;241m.\u001b[39mrun(evaluate_response(query, response, reference))\n\u001b[1;32m     24\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m pd\u001b[38;5;241m.\u001b[39mSeries({\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mEvalCorrectness_score_bl\u001b[39m\u001b[38;5;124m'\u001b[39m: result\u001b[38;5;241m.\u001b[39mscore, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mEvalCorrectness_feedback_bl\u001b[39m\u001b[38;5;124m'\u001b[39m: result\u001b[38;5;241m.\u001b[39mfeedback})\n\u001b[0;32m---> 27\u001b[0m filtered_df[[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mEvalCorrectness_score_bl\u001b[39m\u001b[38;5;124m'\u001b[39m, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mEvalCorrectness_feedback_bl\u001b[39m\u001b[38;5;124m'\u001b[39m]] \u001b[38;5;241m=\u001b[39m filtered_df\u001b[38;5;241m.\u001b[39mprogress_apply(synchronous_evaluate, axis\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m)\n\u001b[1;32m     28\u001b[0m filtered_df\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/tqdm/std.py:917\u001b[0m, in \u001b[0;36mtqdm.pandas.<locals>.inner_generator.<locals>.inner\u001b[0;34m(df, func, *args, **kwargs)\u001b[0m\n\u001b[1;32m    914\u001b[0m \u001b[38;5;66;03m# Apply the provided function (in **kwargs)\u001b[39;00m\n\u001b[1;32m    915\u001b[0m \u001b[38;5;66;03m# on the df using our wrapper (which provides bar updating)\u001b[39;00m\n\u001b[1;32m    916\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 917\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mgetattr\u001b[39m(df, df_function)(wrapper, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m    918\u001b[0m \u001b[38;5;28;01mfinally\u001b[39;00m:\n\u001b[1;32m    919\u001b[0m     t\u001b[38;5;241m.\u001b[39mclose()\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/pandas/core/frame.py:10374\u001b[0m, in \u001b[0;36mDataFrame.apply\u001b[0;34m(self, func, axis, raw, result_type, args, by_row, engine, engine_kwargs, **kwargs)\u001b[0m\n\u001b[1;32m  10360\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01mpandas\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mcore\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mapply\u001b[39;00m \u001b[38;5;28;01mimport\u001b[39;00m frame_apply\n\u001b[1;32m  10362\u001b[0m op \u001b[38;5;241m=\u001b[39m frame_apply(\n\u001b[1;32m  10363\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m  10364\u001b[0m     func\u001b[38;5;241m=\u001b[39mfunc,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m  10372\u001b[0m     kwargs\u001b[38;5;241m=\u001b[39mkwargs,\n\u001b[1;32m  10373\u001b[0m )\n\u001b[0;32m> 10374\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m op\u001b[38;5;241m.\u001b[39mapply()\u001b[38;5;241m.\u001b[39m__finalize__(\u001b[38;5;28mself\u001b[39m, method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mapply\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/pandas/core/apply.py:916\u001b[0m, in \u001b[0;36mFrameApply.apply\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    913\u001b[0m \u001b[38;5;28;01melif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mraw:\n\u001b[1;32m    914\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mapply_raw(engine\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mengine, engine_kwargs\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mengine_kwargs)\n\u001b[0;32m--> 916\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mapply_standard()\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/pandas/core/apply.py:1063\u001b[0m, in \u001b[0;36mFrameApply.apply_standard\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1061\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mapply_standard\u001b[39m(\u001b[38;5;28mself\u001b[39m):\n\u001b[1;32m   1062\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mengine \u001b[38;5;241m==\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpython\u001b[39m\u001b[38;5;124m\"\u001b[39m:\n\u001b[0;32m-> 1063\u001b[0m         results, res_index \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mapply_series_generator()\n\u001b[1;32m   1064\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m   1065\u001b[0m         results, res_index \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mapply_series_numba()\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/pandas/core/apply.py:1081\u001b[0m, in \u001b[0;36mFrameApply.apply_series_generator\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1078\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m option_context(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmode.chained_assignment\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;28;01mNone\u001b[39;00m):\n\u001b[1;32m   1079\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m i, v \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28menumerate\u001b[39m(series_gen):\n\u001b[1;32m   1080\u001b[0m         \u001b[38;5;66;03m# ignore SettingWithCopy here in case the user mutates\u001b[39;00m\n\u001b[0;32m-> 1081\u001b[0m         results[i] \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mfunc(v, \u001b[38;5;241m*\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mkwargs)\n\u001b[1;32m   1082\u001b[0m         \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(results[i], ABCSeries):\n\u001b[1;32m   1083\u001b[0m             \u001b[38;5;66;03m# If we have a view on v, we need to make a copy because\u001b[39;00m\n\u001b[1;32m   1084\u001b[0m             \u001b[38;5;66;03m#  series_generator will swap out the underlying data\u001b[39;00m\n\u001b[1;32m   1085\u001b[0m             results[i] \u001b[38;5;241m=\u001b[39m results[i]\u001b[38;5;241m.\u001b[39mcopy(deep\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mFalse\u001b[39;00m)\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/tqdm/std.py:912\u001b[0m, in \u001b[0;36mtqdm.pandas.<locals>.inner_generator.<locals>.inner.<locals>.wrapper\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    906\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mwrapper\u001b[39m(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs):\n\u001b[1;32m    907\u001b[0m     \u001b[38;5;66;03m# update tbar correctly\u001b[39;00m\n\u001b[1;32m    908\u001b[0m     \u001b[38;5;66;03m# it seems `pandas apply` calls `func` twice\u001b[39;00m\n\u001b[1;32m    909\u001b[0m     \u001b[38;5;66;03m# on the first column/row to decide whether it can\u001b[39;00m\n\u001b[1;32m    910\u001b[0m     \u001b[38;5;66;03m# take a fast or slow code path; so stop when t.total==t.n\u001b[39;00m\n\u001b[1;32m    911\u001b[0m     t\u001b[38;5;241m.\u001b[39mupdate(n\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m t\u001b[38;5;241m.\u001b[39mtotal \u001b[38;5;129;01mor\u001b[39;00m t\u001b[38;5;241m.\u001b[39mn \u001b[38;5;241m<\u001b[39m t\u001b[38;5;241m.\u001b[39mtotal \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;241m0\u001b[39m)\n\u001b[0;32m--> 912\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "Cell \u001b[0;32mIn[8], line 23\u001b[0m, in \u001b[0;36msynchronous_evaluate\u001b[0;34m(row)\u001b[0m\n\u001b[1;32m     21\u001b[0m response \u001b[38;5;241m=\u001b[39m row[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mllm_response_bl\u001b[39m\u001b[38;5;124m'\u001b[39m]\n\u001b[1;32m     22\u001b[0m reference \u001b[38;5;241m=\u001b[39m row[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mpmid\u001b[39m\u001b[38;5;124m'\u001b[39m]\n\u001b[0;32m---> 23\u001b[0m result \u001b[38;5;241m=\u001b[39m asyncio\u001b[38;5;241m.\u001b[39mrun(evaluate_response(query, response, reference))\n\u001b[1;32m     24\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m pd\u001b[38;5;241m.\u001b[39mSeries({\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mEvalCorrectness_score_bl\u001b[39m\u001b[38;5;124m'\u001b[39m: result\u001b[38;5;241m.\u001b[39mscore, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mEvalCorrectness_feedback_bl\u001b[39m\u001b[38;5;124m'\u001b[39m: result\u001b[38;5;241m.\u001b[39mfeedback})\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/nest_asyncio.py:30\u001b[0m, in \u001b[0;36m_patch_asyncio.<locals>.run\u001b[0;34m(main, debug)\u001b[0m\n\u001b[1;32m     28\u001b[0m task \u001b[38;5;241m=\u001b[39m asyncio\u001b[38;5;241m.\u001b[39mensure_future(main)\n\u001b[1;32m     29\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m---> 30\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m loop\u001b[38;5;241m.\u001b[39mrun_until_complete(task)\n\u001b[1;32m     31\u001b[0m \u001b[38;5;28;01mfinally\u001b[39;00m:\n\u001b[1;32m     32\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m task\u001b[38;5;241m.\u001b[39mdone():\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/nest_asyncio.py:98\u001b[0m, in \u001b[0;36m_patch_loop.<locals>.run_until_complete\u001b[0;34m(self, future)\u001b[0m\n\u001b[1;32m     95\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m f\u001b[38;5;241m.\u001b[39mdone():\n\u001b[1;32m     96\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m(\n\u001b[1;32m     97\u001b[0m         \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mEvent loop stopped before Future completed.\u001b[39m\u001b[38;5;124m'\u001b[39m)\n\u001b[0;32m---> 98\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m f\u001b[38;5;241m.\u001b[39mresult()\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/asyncio/futures.py:203\u001b[0m, in \u001b[0;36mFuture.result\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    201\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m__log_traceback \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mFalse\u001b[39;00m\n\u001b[1;32m    202\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_exception \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m--> 203\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_exception\u001b[38;5;241m.\u001b[39mwith_traceback(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_exception_tb)\n\u001b[1;32m    204\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_result\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/asyncio/tasks.py:267\u001b[0m, in \u001b[0;36mTask.__step\u001b[0;34m(***failed resolving arguments***)\u001b[0m\n\u001b[1;32m    263\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    264\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m exc \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m    265\u001b[0m         \u001b[38;5;66;03m# We use the `send` method directly, because coroutines\u001b[39;00m\n\u001b[1;32m    266\u001b[0m         \u001b[38;5;66;03m# don't have `__iter__` and `__next__` methods.\u001b[39;00m\n\u001b[0;32m--> 267\u001b[0m         result \u001b[38;5;241m=\u001b[39m coro\u001b[38;5;241m.\u001b[39msend(\u001b[38;5;28;01mNone\u001b[39;00m)\n\u001b[1;32m    268\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    269\u001b[0m         result \u001b[38;5;241m=\u001b[39m coro\u001b[38;5;241m.\u001b[39mthrow(exc)\n",
      "Cell \u001b[0;32mIn[8], line 10\u001b[0m, in \u001b[0;36mevaluate_response\u001b[0;34m(query, response, reference)\u001b[0m\n\u001b[1;32m      9\u001b[0m \u001b[38;5;28;01masync\u001b[39;00m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mevaluate_response\u001b[39m(query, response, reference):\n\u001b[0;32m---> 10\u001b[0m     result \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m evaluator\u001b[38;5;241m.\u001b[39maevaluate(\n\u001b[1;32m     11\u001b[0m         query\u001b[38;5;241m=\u001b[39mquery,\n\u001b[1;32m     12\u001b[0m         response\u001b[38;5;241m=\u001b[39mresponse,\n\u001b[1;32m     13\u001b[0m         reference\u001b[38;5;241m=\u001b[39mreference\n\u001b[1;32m     14\u001b[0m     )\n\u001b[1;32m     15\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m result\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/llama_index/core/evaluation/correctness.py:138\u001b[0m, in \u001b[0;36mCorrectnessEvaluator.aevaluate\u001b[0;34m(***failed resolving arguments***)\u001b[0m\n\u001b[1;32m    135\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m query \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;129;01mor\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m    136\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mquery, and response must be provided\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m--> 138\u001b[0m eval_response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_llm\u001b[38;5;241m.\u001b[39mapredict(\n\u001b[1;32m    139\u001b[0m     prompt\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_eval_template,\n\u001b[1;32m    140\u001b[0m     query\u001b[38;5;241m=\u001b[39mquery,\n\u001b[1;32m    141\u001b[0m     generated_answer\u001b[38;5;241m=\u001b[39mresponse,\n\u001b[1;32m    142\u001b[0m     reference_answer\u001b[38;5;241m=\u001b[39mreference \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m(NO REFERENCE ANSWER SUPPLIED)\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[1;32m    143\u001b[0m )\n\u001b[1;32m    145\u001b[0m \u001b[38;5;66;03m# Use the parser function\u001b[39;00m\n\u001b[1;32m    146\u001b[0m score, reasoning \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mparser_function(eval_response)\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/llama_index/core/instrumentation/dispatcher.py:290\u001b[0m, in \u001b[0;36mDispatcher.span.<locals>.async_wrapper\u001b[0;34m(func, instance, args, kwargs)\u001b[0m\n\u001b[1;32m    282\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mspan_enter(\n\u001b[1;32m    283\u001b[0m     id_\u001b[38;5;241m=\u001b[39mid_,\n\u001b[1;32m    284\u001b[0m     bound_args\u001b[38;5;241m=\u001b[39mbound_args,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    287\u001b[0m     tags\u001b[38;5;241m=\u001b[39mtags,\n\u001b[1;32m    288\u001b[0m )\n\u001b[1;32m    289\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 290\u001b[0m     result \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m    291\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[1;32m    292\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mevent(SpanDropEvent(span_id\u001b[38;5;241m=\u001b[39mid_, err_str\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mstr\u001b[39m(e)))\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/llama_index/core/llms/llm.py:648\u001b[0m, in \u001b[0;36mLLM.apredict\u001b[0;34m(self, prompt, **prompt_args)\u001b[0m\n\u001b[1;32m    646\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mmetadata\u001b[38;5;241m.\u001b[39mis_chat_model:\n\u001b[1;32m    647\u001b[0m     messages \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_get_messages(prompt, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mprompt_args)\n\u001b[0;32m--> 648\u001b[0m     chat_response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39machat(messages)\n\u001b[1;32m    649\u001b[0m     output \u001b[38;5;241m=\u001b[39m chat_response\u001b[38;5;241m.\u001b[39mmessage\u001b[38;5;241m.\u001b[39mcontent \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    650\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/llama_index/core/instrumentation/dispatcher.py:290\u001b[0m, in \u001b[0;36mDispatcher.span.<locals>.async_wrapper\u001b[0;34m(func, instance, args, kwargs)\u001b[0m\n\u001b[1;32m    282\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mspan_enter(\n\u001b[1;32m    283\u001b[0m     id_\u001b[38;5;241m=\u001b[39mid_,\n\u001b[1;32m    284\u001b[0m     bound_args\u001b[38;5;241m=\u001b[39mbound_args,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    287\u001b[0m     tags\u001b[38;5;241m=\u001b[39mtags,\n\u001b[1;32m    288\u001b[0m )\n\u001b[1;32m    289\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 290\u001b[0m     result \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m    291\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[1;32m    292\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mevent(SpanDropEvent(span_id\u001b[38;5;241m=\u001b[39mid_, err_str\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mstr\u001b[39m(e)))\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/llama_index/core/llms/callbacks.py:76\u001b[0m, in \u001b[0;36mllm_chat_callback.<locals>.wrap.<locals>.wrapped_async_llm_chat\u001b[0;34m(_self, messages, **kwargs)\u001b[0m\n\u001b[1;32m     67\u001b[0m event_id \u001b[38;5;241m=\u001b[39m callback_manager\u001b[38;5;241m.\u001b[39mon_event_start(\n\u001b[1;32m     68\u001b[0m     CBEventType\u001b[38;5;241m.\u001b[39mLLM,\n\u001b[1;32m     69\u001b[0m     payload\u001b[38;5;241m=\u001b[39m{\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m     73\u001b[0m     },\n\u001b[1;32m     74\u001b[0m )\n\u001b[1;32m     75\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m---> 76\u001b[0m     f_return_val \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m f(_self, messages, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m     77\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[1;32m     78\u001b[0m     callback_manager\u001b[38;5;241m.\u001b[39mon_event_end(\n\u001b[1;32m     79\u001b[0m         CBEventType\u001b[38;5;241m.\u001b[39mLLM,\n\u001b[1;32m     80\u001b[0m         payload\u001b[38;5;241m=\u001b[39m{EventPayload\u001b[38;5;241m.\u001b[39mEXCEPTION: e},\n\u001b[1;32m     81\u001b[0m         event_id\u001b[38;5;241m=\u001b[39mevent_id,\n\u001b[1;32m     82\u001b[0m     )\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/llama_index/llms/openai/base.py:633\u001b[0m, in \u001b[0;36mOpenAI.achat\u001b[0;34m(self, messages, **kwargs)\u001b[0m\n\u001b[1;32m    631\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    632\u001b[0m     achat_fn \u001b[38;5;241m=\u001b[39m acompletion_to_chat_decorator(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_acomplete)\n\u001b[0;32m--> 633\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m achat_fn(messages, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/tenacity/asyncio/__init__.py:189\u001b[0m, in \u001b[0;36mAsyncRetrying.wraps.<locals>.async_wrapped\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    187\u001b[0m copy \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mcopy()\n\u001b[1;32m    188\u001b[0m async_wrapped\u001b[38;5;241m.\u001b[39mstatistics \u001b[38;5;241m=\u001b[39m copy\u001b[38;5;241m.\u001b[39mstatistics  \u001b[38;5;66;03m# type: ignore[attr-defined]\u001b[39;00m\n\u001b[0;32m--> 189\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m copy(fn, \u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/tenacity/asyncio/__init__.py:111\u001b[0m, in \u001b[0;36mAsyncRetrying.__call__\u001b[0;34m(self, fn, *args, **kwargs)\u001b[0m\n\u001b[1;32m    109\u001b[0m retry_state \u001b[38;5;241m=\u001b[39m RetryCallState(retry_object\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m, fn\u001b[38;5;241m=\u001b[39mfn, args\u001b[38;5;241m=\u001b[39margs, kwargs\u001b[38;5;241m=\u001b[39mkwargs)\n\u001b[1;32m    110\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m--> 111\u001b[0m     do \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39miter(retry_state\u001b[38;5;241m=\u001b[39mretry_state)\n\u001b[1;32m    112\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(do, DoAttempt):\n\u001b[1;32m    113\u001b[0m         \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/tenacity/asyncio/__init__.py:153\u001b[0m, in \u001b[0;36mAsyncRetrying.iter\u001b[0;34m(self, retry_state)\u001b[0m\n\u001b[1;32m    151\u001b[0m result \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m    152\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m action \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39miter_state\u001b[38;5;241m.\u001b[39mactions:\n\u001b[0;32m--> 153\u001b[0m     result \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m action(retry_state)\n\u001b[1;32m    154\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m result\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/tenacity/_utils.py:99\u001b[0m, in \u001b[0;36mwrap_to_async_func.<locals>.inner\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m     98\u001b[0m \u001b[38;5;28;01masync\u001b[39;00m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21minner\u001b[39m(\u001b[38;5;241m*\u001b[39margs: typing\u001b[38;5;241m.\u001b[39mAny, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs: typing\u001b[38;5;241m.\u001b[39mAny) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m typing\u001b[38;5;241m.\u001b[39mAny:\n\u001b[0;32m---> 99\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m call(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/tenacity/__init__.py:418\u001b[0m, in \u001b[0;36mBaseRetrying._post_stop_check_actions.<locals>.exc_check\u001b[0;34m(rs)\u001b[0m\n\u001b[1;32m    416\u001b[0m retry_exc \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mretry_error_cls(fut)\n\u001b[1;32m    417\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mreraise:\n\u001b[0;32m--> 418\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m retry_exc\u001b[38;5;241m.\u001b[39mreraise()\n\u001b[1;32m    419\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m retry_exc \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01mfut\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mexception\u001b[39;00m()\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/tenacity/__init__.py:185\u001b[0m, in \u001b[0;36mRetryError.reraise\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    183\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mreraise\u001b[39m(\u001b[38;5;28mself\u001b[39m) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m t\u001b[38;5;241m.\u001b[39mNoReturn:\n\u001b[1;32m    184\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mlast_attempt\u001b[38;5;241m.\u001b[39mfailed:\n\u001b[0;32m--> 185\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mlast_attempt\u001b[38;5;241m.\u001b[39mresult()\n\u001b[1;32m    186\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/concurrent/futures/_base.py:449\u001b[0m, in \u001b[0;36mFuture.result\u001b[0;34m(self, timeout)\u001b[0m\n\u001b[1;32m    447\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m CancelledError()\n\u001b[1;32m    448\u001b[0m \u001b[38;5;28;01melif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_state \u001b[38;5;241m==\u001b[39m FINISHED:\n\u001b[0;32m--> 449\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m__get_result()\n\u001b[1;32m    451\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_condition\u001b[38;5;241m.\u001b[39mwait(timeout)\n\u001b[1;32m    453\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_state \u001b[38;5;129;01min\u001b[39;00m [CANCELLED, CANCELLED_AND_NOTIFIED]:\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/concurrent/futures/_base.py:401\u001b[0m, in \u001b[0;36mFuture.__get_result\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    399\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_exception:\n\u001b[1;32m    400\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 401\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_exception\n\u001b[1;32m    402\u001b[0m     \u001b[38;5;28;01mfinally\u001b[39;00m:\n\u001b[1;32m    403\u001b[0m         \u001b[38;5;66;03m# Break a reference cycle with the exception in self._exception\u001b[39;00m\n\u001b[1;32m    404\u001b[0m         \u001b[38;5;28mself\u001b[39m \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/tenacity/asyncio/__init__.py:114\u001b[0m, in \u001b[0;36mAsyncRetrying.__call__\u001b[0;34m(self, fn, *args, **kwargs)\u001b[0m\n\u001b[1;32m    112\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(do, DoAttempt):\n\u001b[1;32m    113\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 114\u001b[0m         result \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m fn(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m    115\u001b[0m     \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m:  \u001b[38;5;66;03m# noqa: B902\u001b[39;00m\n\u001b[1;32m    116\u001b[0m         retry_state\u001b[38;5;241m.\u001b[39mset_exception(sys\u001b[38;5;241m.\u001b[39mexc_info())  \u001b[38;5;66;03m# type: ignore[arg-type]\u001b[39;00m\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/llama_index/llms/openai/base.py:680\u001b[0m, in \u001b[0;36mOpenAI._achat\u001b[0;34m(self, messages, **kwargs)\u001b[0m\n\u001b[1;32m    677\u001b[0m message_dicts \u001b[38;5;241m=\u001b[39m to_openai_message_dicts(messages)\n\u001b[1;32m    679\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mreuse_client:\n\u001b[0;32m--> 680\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mawait\u001b[39;00m aclient\u001b[38;5;241m.\u001b[39mchat\u001b[38;5;241m.\u001b[39mcompletions\u001b[38;5;241m.\u001b[39mcreate(\n\u001b[1;32m    681\u001b[0m         messages\u001b[38;5;241m=\u001b[39mmessage_dicts, stream\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mFalse\u001b[39;00m, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_get_model_kwargs(\u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m    682\u001b[0m     )\n\u001b[1;32m    683\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    684\u001b[0m     \u001b[38;5;28;01masync\u001b[39;00m \u001b[38;5;28;01mwith\u001b[39;00m aclient:\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/resources/chat/completions.py:1339\u001b[0m, in \u001b[0;36mAsyncCompletions.create\u001b[0;34m(self, messages, model, frequency_penalty, function_call, functions, logit_bias, logprobs, max_tokens, n, parallel_tool_calls, presence_penalty, response_format, seed, service_tier, stop, stream, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[1;32m   1304\u001b[0m \u001b[38;5;129m@required_args\u001b[39m([\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m], [\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstream\u001b[39m\u001b[38;5;124m\"\u001b[39m])\n\u001b[1;32m   1305\u001b[0m \u001b[38;5;28;01masync\u001b[39;00m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mcreate\u001b[39m(\n\u001b[1;32m   1306\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   1336\u001b[0m     timeout: \u001b[38;5;28mfloat\u001b[39m \u001b[38;5;241m|\u001b[39m httpx\u001b[38;5;241m.\u001b[39mTimeout \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m|\u001b[39m NotGiven \u001b[38;5;241m=\u001b[39m NOT_GIVEN,\n\u001b[1;32m   1337\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ChatCompletion \u001b[38;5;241m|\u001b[39m AsyncStream[ChatCompletionChunk]:\n\u001b[1;32m   1338\u001b[0m     validate_response_format(response_format)\n\u001b[0;32m-> 1339\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_post(\n\u001b[1;32m   1340\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m/chat/completions\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[1;32m   1341\u001b[0m         body\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mawait\u001b[39;00m async_maybe_transform(\n\u001b[1;32m   1342\u001b[0m             {\n\u001b[1;32m   1343\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m: messages,\n\u001b[1;32m   1344\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m: model,\n\u001b[1;32m   1345\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mfrequency_penalty\u001b[39m\u001b[38;5;124m\"\u001b[39m: frequency_penalty,\n\u001b[1;32m   1346\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mfunction_call\u001b[39m\u001b[38;5;124m\"\u001b[39m: function_call,\n\u001b[1;32m   1347\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mfunctions\u001b[39m\u001b[38;5;124m\"\u001b[39m: functions,\n\u001b[1;32m   1348\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mlogit_bias\u001b[39m\u001b[38;5;124m\"\u001b[39m: logit_bias,\n\u001b[1;32m   1349\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mlogprobs\u001b[39m\u001b[38;5;124m\"\u001b[39m: logprobs,\n\u001b[1;32m   1350\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmax_tokens\u001b[39m\u001b[38;5;124m\"\u001b[39m: max_tokens,\n\u001b[1;32m   1351\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mn\u001b[39m\u001b[38;5;124m\"\u001b[39m: n,\n\u001b[1;32m   1352\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mparallel_tool_calls\u001b[39m\u001b[38;5;124m\"\u001b[39m: parallel_tool_calls,\n\u001b[1;32m   1353\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpresence_penalty\u001b[39m\u001b[38;5;124m\"\u001b[39m: presence_penalty,\n\u001b[1;32m   1354\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mresponse_format\u001b[39m\u001b[38;5;124m\"\u001b[39m: response_format,\n\u001b[1;32m   1355\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mseed\u001b[39m\u001b[38;5;124m\"\u001b[39m: seed,\n\u001b[1;32m   1356\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mservice_tier\u001b[39m\u001b[38;5;124m\"\u001b[39m: service_tier,\n\u001b[1;32m   1357\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstop\u001b[39m\u001b[38;5;124m\"\u001b[39m: stop,\n\u001b[1;32m   1358\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstream\u001b[39m\u001b[38;5;124m\"\u001b[39m: stream,\n\u001b[1;32m   1359\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstream_options\u001b[39m\u001b[38;5;124m\"\u001b[39m: stream_options,\n\u001b[1;32m   1360\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtemperature\u001b[39m\u001b[38;5;124m\"\u001b[39m: temperature,\n\u001b[1;32m   1361\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtool_choice\u001b[39m\u001b[38;5;124m\"\u001b[39m: tool_choice,\n\u001b[1;32m   1362\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtools\u001b[39m\u001b[38;5;124m\"\u001b[39m: tools,\n\u001b[1;32m   1363\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtop_logprobs\u001b[39m\u001b[38;5;124m\"\u001b[39m: top_logprobs,\n\u001b[1;32m   1364\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtop_p\u001b[39m\u001b[38;5;124m\"\u001b[39m: top_p,\n\u001b[1;32m   1365\u001b[0m                 \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124muser\u001b[39m\u001b[38;5;124m\"\u001b[39m: user,\n\u001b[1;32m   1366\u001b[0m             },\n\u001b[1;32m   1367\u001b[0m             completion_create_params\u001b[38;5;241m.\u001b[39mCompletionCreateParams,\n\u001b[1;32m   1368\u001b[0m         ),\n\u001b[1;32m   1369\u001b[0m         options\u001b[38;5;241m=\u001b[39mmake_request_options(\n\u001b[1;32m   1370\u001b[0m             extra_headers\u001b[38;5;241m=\u001b[39mextra_headers, extra_query\u001b[38;5;241m=\u001b[39mextra_query, extra_body\u001b[38;5;241m=\u001b[39mextra_body, timeout\u001b[38;5;241m=\u001b[39mtimeout\n\u001b[1;32m   1371\u001b[0m         ),\n\u001b[1;32m   1372\u001b[0m         cast_to\u001b[38;5;241m=\u001b[39mChatCompletion,\n\u001b[1;32m   1373\u001b[0m         stream\u001b[38;5;241m=\u001b[39mstream \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;28;01mFalse\u001b[39;00m,\n\u001b[1;32m   1374\u001b[0m         stream_cls\u001b[38;5;241m=\u001b[39mAsyncStream[ChatCompletionChunk],\n\u001b[1;32m   1375\u001b[0m     )\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/_base_client.py:1816\u001b[0m, in \u001b[0;36mAsyncAPIClient.post\u001b[0;34m(self, path, cast_to, body, files, options, stream, stream_cls)\u001b[0m\n\u001b[1;32m   1802\u001b[0m \u001b[38;5;28;01masync\u001b[39;00m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mpost\u001b[39m(\n\u001b[1;32m   1803\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   1804\u001b[0m     path: \u001b[38;5;28mstr\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   1811\u001b[0m     stream_cls: \u001b[38;5;28mtype\u001b[39m[_AsyncStreamT] \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[1;32m   1812\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ResponseT \u001b[38;5;241m|\u001b[39m _AsyncStreamT:\n\u001b[1;32m   1813\u001b[0m     opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[1;32m   1814\u001b[0m         method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, files\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mawait\u001b[39;00m async_to_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[1;32m   1815\u001b[0m     )\n\u001b[0;32m-> 1816\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mrequest(cast_to, opts, stream\u001b[38;5;241m=\u001b[39mstream, stream_cls\u001b[38;5;241m=\u001b[39mstream_cls)\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/_base_client.py:1510\u001b[0m, in \u001b[0;36mAsyncAPIClient.request\u001b[0;34m(self, cast_to, options, stream, stream_cls, remaining_retries)\u001b[0m\n\u001b[1;32m   1501\u001b[0m \u001b[38;5;28;01masync\u001b[39;00m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mrequest\u001b[39m(\n\u001b[1;32m   1502\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   1503\u001b[0m     cast_to: Type[ResponseT],\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   1508\u001b[0m     remaining_retries: Optional[\u001b[38;5;28mint\u001b[39m] \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[1;32m   1509\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ResponseT \u001b[38;5;241m|\u001b[39m _AsyncStreamT:\n\u001b[0;32m-> 1510\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_request(\n\u001b[1;32m   1511\u001b[0m         cast_to\u001b[38;5;241m=\u001b[39mcast_to,\n\u001b[1;32m   1512\u001b[0m         options\u001b[38;5;241m=\u001b[39moptions,\n\u001b[1;32m   1513\u001b[0m         stream\u001b[38;5;241m=\u001b[39mstream,\n\u001b[1;32m   1514\u001b[0m         stream_cls\u001b[38;5;241m=\u001b[39mstream_cls,\n\u001b[1;32m   1515\u001b[0m         remaining_retries\u001b[38;5;241m=\u001b[39mremaining_retries,\n\u001b[1;32m   1516\u001b[0m     )\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/_base_client.py:1596\u001b[0m, in \u001b[0;36mAsyncAPIClient._request\u001b[0;34m(self, cast_to, options, stream, stream_cls, remaining_retries)\u001b[0m\n\u001b[1;32m   1594\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m retries \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m0\u001b[39m \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_should_retry(err\u001b[38;5;241m.\u001b[39mresponse):\n\u001b[1;32m   1595\u001b[0m     \u001b[38;5;28;01mawait\u001b[39;00m err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39maclose()\n\u001b[0;32m-> 1596\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_retry_request(\n\u001b[1;32m   1597\u001b[0m         input_options,\n\u001b[1;32m   1598\u001b[0m         cast_to,\n\u001b[1;32m   1599\u001b[0m         retries,\n\u001b[1;32m   1600\u001b[0m         err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mheaders,\n\u001b[1;32m   1601\u001b[0m         stream\u001b[38;5;241m=\u001b[39mstream,\n\u001b[1;32m   1602\u001b[0m         stream_cls\u001b[38;5;241m=\u001b[39mstream_cls,\n\u001b[1;32m   1603\u001b[0m     )\n\u001b[1;32m   1605\u001b[0m \u001b[38;5;66;03m# If the response is streamed then we need to explicitly read the response\u001b[39;00m\n\u001b[1;32m   1606\u001b[0m \u001b[38;5;66;03m# to completion before attempting to access the response text.\u001b[39;00m\n\u001b[1;32m   1607\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mis_closed:\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/_base_client.py:1643\u001b[0m, in \u001b[0;36mAsyncAPIClient._retry_request\u001b[0;34m(self, options, cast_to, remaining_retries, response_headers, stream, stream_cls)\u001b[0m\n\u001b[1;32m   1639\u001b[0m log\u001b[38;5;241m.\u001b[39minfo(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRetrying request to \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m in \u001b[39m\u001b[38;5;132;01m%f\u001b[39;00m\u001b[38;5;124m seconds\u001b[39m\u001b[38;5;124m\"\u001b[39m, options\u001b[38;5;241m.\u001b[39murl, timeout)\n\u001b[1;32m   1641\u001b[0m \u001b[38;5;28;01mawait\u001b[39;00m anyio\u001b[38;5;241m.\u001b[39msleep(timeout)\n\u001b[0;32m-> 1643\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_request(\n\u001b[1;32m   1644\u001b[0m     options\u001b[38;5;241m=\u001b[39moptions,\n\u001b[1;32m   1645\u001b[0m     cast_to\u001b[38;5;241m=\u001b[39mcast_to,\n\u001b[1;32m   1646\u001b[0m     remaining_retries\u001b[38;5;241m=\u001b[39mremaining,\n\u001b[1;32m   1647\u001b[0m     stream\u001b[38;5;241m=\u001b[39mstream,\n\u001b[1;32m   1648\u001b[0m     stream_cls\u001b[38;5;241m=\u001b[39mstream_cls,\n\u001b[1;32m   1649\u001b[0m )\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/_base_client.py:1596\u001b[0m, in \u001b[0;36mAsyncAPIClient._request\u001b[0;34m(self, cast_to, options, stream, stream_cls, remaining_retries)\u001b[0m\n\u001b[1;32m   1594\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m retries \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m0\u001b[39m \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_should_retry(err\u001b[38;5;241m.\u001b[39mresponse):\n\u001b[1;32m   1595\u001b[0m     \u001b[38;5;28;01mawait\u001b[39;00m err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39maclose()\n\u001b[0;32m-> 1596\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_retry_request(\n\u001b[1;32m   1597\u001b[0m         input_options,\n\u001b[1;32m   1598\u001b[0m         cast_to,\n\u001b[1;32m   1599\u001b[0m         retries,\n\u001b[1;32m   1600\u001b[0m         err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mheaders,\n\u001b[1;32m   1601\u001b[0m         stream\u001b[38;5;241m=\u001b[39mstream,\n\u001b[1;32m   1602\u001b[0m         stream_cls\u001b[38;5;241m=\u001b[39mstream_cls,\n\u001b[1;32m   1603\u001b[0m     )\n\u001b[1;32m   1605\u001b[0m \u001b[38;5;66;03m# If the response is streamed then we need to explicitly read the response\u001b[39;00m\n\u001b[1;32m   1606\u001b[0m \u001b[38;5;66;03m# to completion before attempting to access the response text.\u001b[39;00m\n\u001b[1;32m   1607\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mis_closed:\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/_base_client.py:1643\u001b[0m, in \u001b[0;36mAsyncAPIClient._retry_request\u001b[0;34m(self, options, cast_to, remaining_retries, response_headers, stream, stream_cls)\u001b[0m\n\u001b[1;32m   1639\u001b[0m log\u001b[38;5;241m.\u001b[39minfo(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRetrying request to \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m in \u001b[39m\u001b[38;5;132;01m%f\u001b[39;00m\u001b[38;5;124m seconds\u001b[39m\u001b[38;5;124m\"\u001b[39m, options\u001b[38;5;241m.\u001b[39murl, timeout)\n\u001b[1;32m   1641\u001b[0m \u001b[38;5;28;01mawait\u001b[39;00m anyio\u001b[38;5;241m.\u001b[39msleep(timeout)\n\u001b[0;32m-> 1643\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_request(\n\u001b[1;32m   1644\u001b[0m     options\u001b[38;5;241m=\u001b[39moptions,\n\u001b[1;32m   1645\u001b[0m     cast_to\u001b[38;5;241m=\u001b[39mcast_to,\n\u001b[1;32m   1646\u001b[0m     remaining_retries\u001b[38;5;241m=\u001b[39mremaining,\n\u001b[1;32m   1647\u001b[0m     stream\u001b[38;5;241m=\u001b[39mstream,\n\u001b[1;32m   1648\u001b[0m     stream_cls\u001b[38;5;241m=\u001b[39mstream_cls,\n\u001b[1;32m   1649\u001b[0m )\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/_base_client.py:1596\u001b[0m, in \u001b[0;36mAsyncAPIClient._request\u001b[0;34m(self, cast_to, options, stream, stream_cls, remaining_retries)\u001b[0m\n\u001b[1;32m   1594\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m retries \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m0\u001b[39m \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_should_retry(err\u001b[38;5;241m.\u001b[39mresponse):\n\u001b[1;32m   1595\u001b[0m     \u001b[38;5;28;01mawait\u001b[39;00m err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39maclose()\n\u001b[0;32m-> 1596\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_retry_request(\n\u001b[1;32m   1597\u001b[0m         input_options,\n\u001b[1;32m   1598\u001b[0m         cast_to,\n\u001b[1;32m   1599\u001b[0m         retries,\n\u001b[1;32m   1600\u001b[0m         err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mheaders,\n\u001b[1;32m   1601\u001b[0m         stream\u001b[38;5;241m=\u001b[39mstream,\n\u001b[1;32m   1602\u001b[0m         stream_cls\u001b[38;5;241m=\u001b[39mstream_cls,\n\u001b[1;32m   1603\u001b[0m     )\n\u001b[1;32m   1605\u001b[0m \u001b[38;5;66;03m# If the response is streamed then we need to explicitly read the response\u001b[39;00m\n\u001b[1;32m   1606\u001b[0m \u001b[38;5;66;03m# to completion before attempting to access the response text.\u001b[39;00m\n\u001b[1;32m   1607\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mis_closed:\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/_base_client.py:1643\u001b[0m, in \u001b[0;36mAsyncAPIClient._retry_request\u001b[0;34m(self, options, cast_to, remaining_retries, response_headers, stream, stream_cls)\u001b[0m\n\u001b[1;32m   1639\u001b[0m log\u001b[38;5;241m.\u001b[39minfo(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRetrying request to \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m in \u001b[39m\u001b[38;5;132;01m%f\u001b[39;00m\u001b[38;5;124m seconds\u001b[39m\u001b[38;5;124m\"\u001b[39m, options\u001b[38;5;241m.\u001b[39murl, timeout)\n\u001b[1;32m   1641\u001b[0m \u001b[38;5;28;01mawait\u001b[39;00m anyio\u001b[38;5;241m.\u001b[39msleep(timeout)\n\u001b[0;32m-> 1643\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_request(\n\u001b[1;32m   1644\u001b[0m     options\u001b[38;5;241m=\u001b[39moptions,\n\u001b[1;32m   1645\u001b[0m     cast_to\u001b[38;5;241m=\u001b[39mcast_to,\n\u001b[1;32m   1646\u001b[0m     remaining_retries\u001b[38;5;241m=\u001b[39mremaining,\n\u001b[1;32m   1647\u001b[0m     stream\u001b[38;5;241m=\u001b[39mstream,\n\u001b[1;32m   1648\u001b[0m     stream_cls\u001b[38;5;241m=\u001b[39mstream_cls,\n\u001b[1;32m   1649\u001b[0m )\n",
      "File \u001b[0;32m/work/acslab/users/svalipou/miniconda/envs/llm_exp/lib/python3.11/site-packages/openai/_base_client.py:1611\u001b[0m, in \u001b[0;36mAsyncAPIClient._request\u001b[0;34m(self, cast_to, options, stream, stream_cls, remaining_retries)\u001b[0m\n\u001b[1;32m   1608\u001b[0m         \u001b[38;5;28;01mawait\u001b[39;00m err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39maread()\n\u001b[1;32m   1610\u001b[0m     log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRe-raising status error\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m-> 1611\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_make_status_error_from_response(err\u001b[38;5;241m.\u001b[39mresponse) \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m   1613\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_process_response(\n\u001b[1;32m   1614\u001b[0m     cast_to\u001b[38;5;241m=\u001b[39mcast_to,\n\u001b[1;32m   1615\u001b[0m     options\u001b[38;5;241m=\u001b[39moptions,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   1619\u001b[0m     retries_taken\u001b[38;5;241m=\u001b[39moptions\u001b[38;5;241m.\u001b[39mget_max_retries(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mmax_retries) \u001b[38;5;241m-\u001b[39m retries,\n\u001b[1;32m   1620\u001b[0m )\n",
      "\u001b[0;31mRateLimitError\u001b[0m: Error code: 429 - {'error': {'message': 'You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.', 'type': 'insufficient_quota', 'param': None, 'code': 'insufficient_quota'}}"
     ]
    }
   ],
   "source": [
    "\n",
    "\n",
    "nest_asyncio.apply()\n",
    "tqdm.pandas()\n",
    "\n",
    "async def evaluate_response(query, response, reference):\n",
    "    result = await evaluator.aevaluate(\n",
    "        query=query,\n",
    "        response=response,\n",
    "        reference=reference\n",
    "    )\n",
    "    return result\n",
    "\n",
    "def synchronous_evaluate(row):\n",
    "    source = row['subj_name']\n",
    "    target = row['obj_name']\n",
    "    query = f\"How would you describe an indirect relationship between {source} and {target} given the following scientific abstracts as contexts?\"\n",
    "    response = row['llm_response_bl']\n",
    "    reference = row['pmid_text']\n",
    "    result = asyncio.run(evaluate_response(query, response, reference))\n",
    "    return pd.Series({'EvalCorrectness_score_bl': result.score, 'EvalCorrectness_feedback_bl': result.feedback})\n",
    "\n",
    "\n",
    "filtered_df[['EvalCorrectness_score_bl', 'EvalCorrectness_feedback_bl']] = filtered_df.progress_apply(synchronous_evaluate, axis=1)\n",
    "filtered_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2365db57-224f-4c8e-82af-6d82401f171e",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "3dd5386a-49f0-424f-b926-f2497990a634",
   "metadata": {},
   "source": [
    "### Sanity check: for identical value it is 5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "c292e96f-c01a-4ee4-9a30-6d1798183ee9",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-08-19T13:29:39.239695Z",
     "iopub.status.busy": "2024-08-19T13:29:39.238627Z",
     "iopub.status.idle": "2024-08-19T13:29:40.641327Z",
     "shell.execute_reply": "2024-08-19T13:29:40.639700Z",
     "shell.execute_reply.started": "2024-08-19T13:29:39.239649Z"
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "5.0\n",
      "The generated answer is identical to the reference answer and provides a detailed and accurate explanation of Albert Einstein's theory of relativity, covering both special and general relativity. It is relevant, correct, and comprehensive.\n"
     ]
    }
   ],
   "source": [
    "query = \"Can you explain the theory of relativity proposed by Albert Einstein in detail?\"\n",
    "\n",
    "\n",
    "reference = \"\"\"\n",
    "Certainly! Albert Einstein's theory of relativity consists of two main components: special relativity and general relativity. Special relativity, published in 1905, introduced the concept that the laws of physics are the same for all non-accelerating observers and that the speed of light in a vacuum is a constant, regardless of the motion of the source or observer. It also gave rise to the famous equation E=mc, which relates energy (E) and mass (m).\n",
    "\n",
    "General relativity, published in 1915, extended these ideas to include the effects of gravity. According to general relativity, gravity is not a force between masses, as described by Newton's theory of gravity, but rather the result of the warping of space and time by mass and energy. Massive objects, such as planets and stars, cause a curvature in spacetime, and smaller objects follow curved paths in response to this curvature. This concept is often illustrated using the analogy of a heavy ball placed on a rubber sheet, causing it to create a depression that other objects (representing smaller masses) naturally move towards.\n",
    "\n",
    "In essence, general relativity provided a new understanding of gravity, explaining phenomena like the bending of light by gravity (gravitational lensing) and the precession of the orbit of Mercury. It has been confirmed through numerous experiments and observations and has become a fundamental theory in modern physics.\n",
    "\"\"\"\n",
    "\n",
    "response = \"\"\"\n",
    "Certainly! Albert Einstein's theory of relativity consists of two main components: special relativity and general relativity. Special relativity, published in 1905, introduced the concept that the laws of physics are the same for all non-accelerating observers and that the speed of light in a vacuum is a constant, regardless of the motion of the source or observer. It also gave rise to the famous equation E=mc, which relates energy (E) and mass (m).\n",
    "\n",
    "General relativity, published in 1915, extended these ideas to include the effects of gravity. According to general relativity, gravity is not a force between masses, as described by Newton's theory of gravity, but rather the result of the warping of space and time by mass and energy. Massive objects, such as planets and stars, cause a curvature in spacetime, and smaller objects follow curved paths in response to this curvature. This concept is often illustrated using the analogy of a heavy ball placed on a rubber sheet, causing it to create a depression that other objects (representing smaller masses) naturally move towards.\n",
    "\n",
    "In essence, general relativity provided a new understanding of gravity, explaining phenomena like the bending of light by gravity (gravitational lensing) and the precession of the orbit of Mercury. It has been confirmed through numerous experiments and observations and has become a fundamental theory in modern physics.\n",
    "\"\"\"\n",
    "\n",
    "import nest_asyncio\n",
    "nest_asyncio.apply()\n",
    "import asyncio\n",
    "\n",
    "async def evaluate_response(query, response, reference, evaluator):\n",
    "    result = await evaluator.aevaluate(\n",
    "        query=query,\n",
    "        response=response,\n",
    "        reference=reference  \n",
    "    )\n",
    "    return result\n",
    "\n",
    "result = asyncio.run(evaluate_response(query, response, reference, evaluator))\n",
    "\n",
    "print(result.score)\n",
    "print(result.feedback)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "aad2e468-bf7c-4d9b-b7d3-4595c472ab3c",
   "metadata": {},
   "source": [
    "### Experiment shuffling words correctnessEvaluator Score:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "3b9d39ca-deb4-42ca-bf0f-9ab8bd6b031d",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-05-06T19:30:41.364422Z",
     "iopub.status.busy": "2024-05-06T19:30:41.363984Z",
     "iopub.status.idle": "2024-05-06T19:30:41.369896Z",
     "shell.execute_reply": "2024-05-06T19:30:41.368177Z",
     "shell.execute_reply.started": "2024-05-06T19:30:41.364393Z"
    }
   },
   "outputs": [],
   "source": [
    "import random\n",
    "\n",
    "def shuffle_words(text):\n",
    "    # Split text into words\n",
    "    words = text.split()\n",
    "    # Shuffle the words\n",
    "    random.shuffle(words)\n",
    "    # Join the shuffled words back into a string\n",
    "    shuffled_text = ' '.join(words)\n",
    "    return shuffled_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "7e9aa68b-3a8c-4071-ac30-2058d19984ae",
   "metadata": {
    "execution": {
     "iopub.execute_input": "2024-08-17T00:07:07.528861Z",
     "iopub.status.busy": "2024-08-17T00:07:07.528161Z",
     "iopub.status.idle": "2024-08-17T00:07:08.486743Z",
     "shell.execute_reply": "2024-08-17T00:07:08.485170Z",
     "shell.execute_reply.started": "2024-08-17T00:07:07.528815Z"
    }
   },
   "outputs": [],
   "source": [
    "import nest_asyncio\n",
    "nest_asyncio.apply()\n",
    "import asyncio\n",
    "\n",
    "async def evaluate_response(query, response, reference, evaluator):\n",
    "    result = await evaluator.aevaluate(\n",
    "        query=query,\n",
    "        response=response,\n",
    "        reference=reference  \n",
    "    )\n",
    "    return result\n",
    "\n",
    "result = asyncio.run(evaluate_response(query, response_bl, reference, evaluator))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "67953029-b194-49d1-92b0-785352b20d12",
   "metadata": {},
   "source": [
    "### Conclusion:\n",
    "What is the scale? \n",
    "what does functionality wise correctness do? It use search_semantic_similarity (i.e. String wise)\n",
    "- We try injecting at middle of sentence some non-sense(irelavant context) It droped into 3.5.\n",
    "- when we use whole non-sense, instead just injecting only one sentence at the middle, it drops into 1.\n",
    "- we use function to randomly shuffle text basically, It droped into 1."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1c408165-0e4c-4d19-a5eb-dda383c77f12",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:llm_exp]",
   "language": "python",
   "name": "conda-env-llm_exp-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
